assay_id,assay_subcellular_fraction,assay_organism,description,relationship_type,assay_type,doc_id,assay_test_type,assay_category,assay_tax_id,assay_strain,assay_tissue,assay_cell_type,tid
1,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,H,B,11087,,,,,,,12052
2,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,U,F,684,,,,,,,22226
3,,,,U,B,15453,,,,,,,22226
4,,Bos taurus,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,H,B,17841,,,9913.0,,,,104729
5,,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),N,F,17430,,,9606.0,,,143B,80001
6,,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),N,F,17430,,,9606.0,,,143B,80001
7,,Mus musculus,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,N,F,13799,,,10090.0,,,143B,80001
8,,Homo sapiens,In vitro cell cytotoxicity was determined against 143B cell line,N,F,17774,,,9606.0,,,143B,80001
9,,Homo sapiens,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,N,F,3801,,,9606.0,,,143B,80001
10,,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,N,F,17430,,,9606.0,,,143B,80001
11,,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,N,F,17430,,,9606.0,,,143B,80001
12,,Homo sapiens,In vitro cell cytotoxicity was determined against 143B-LTK cell line,N,F,17774,,,9606.0,,,143B,80001
13,,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,F,11324,,,1280.0,,,,50185
14,,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,F,11324,,,1280.0,,,,50185
15,,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,F,11324,,,1280.0,,,,50185
16,,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,F,11324,,,1280.0,,,,50185
17,,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,D,A,11347,,,10116.0,,,,100122
18,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),H,B,16474,,,,,,,12054
19,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,H,B,10091,,,,,,,12054
20,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),H,B,16474,,,,,,,12054
21,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),H,B,16474,,,,,,,12054
22,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),H,B,16474,,,,,,,12054
23,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,H,B,16474,,,,,,,12054
24,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,H,B,16474,,,,,,,12054
25,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",U,B,14352,,,,,,,22226
26,,Oryctolagus cuniculus,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,H,B,5646,,,9986.0,,,,12054
27,,Oryctolagus cuniculus,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),H,B,5646,,,9986.0,,,,12054
28,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,H,B,10997,,,,,,,12426
29,,soya bean,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,H,B,6309,,,3847.0,,,,12054
30,,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated,H,B,167,,,3847.0,,,,12054
31,,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,H,B,167,,,3847.0,,,,12054
32,,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,H,B,11087,,,3847.0,,,,12054
33,,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,H,B,11087,,,3847.0,,,,12054
34,,Glycine max,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,H,B,13622,,,3847.0,,,,12054
35,,Glycine max,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,H,B,13622,,,3847.0,,,,12054
36,,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,U,A,11347,,,10116.0,,,,22226
37,,Escherichia coli,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,U,B,5926,,,562.0,,,,22226
38,,,Dissociation constant with dimeric 16S rRNA RNA construct B,U,B,4567,,,,,,,22226
39,,,Dissociation constant towards 16S rRNA construct A,M,B,3782,,,,,,,22222
40,,,Dissociation constant towards 16S rRNA construct B,M,B,3782,,,,,,,22222
41,,Escherichia coli,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,M,B,4466,,,562.0,,,,100263
42,,Escherichia coli,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,M,B,6592,,,562.0,,,,100263
43,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,B,898,,,,,,,13053
44,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,B,898,,,,,,,13053
45,,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,H,B,13163,,,9606.0,,,,20001
46,,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,H,B,13163,,,9606.0,,,,20001
47,,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",D,B,10691,,,10116.0,,,,12971
48,,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",D,B,10691,,,10116.0,,,,12971
49,,Rattus norvegicus,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",D,B,10691,,,10116.0,,,,12971
50,,Rattus norvegicus,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",D,B,10691,,,10116.0,,,,12971
51,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,B,898,,,,,,,13053
52,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),H,B,912,,,,,,,11512
53,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,H,B,912,,,,,,,11512
54,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,H,B,912,,,,,,,11512
55,Membranes,Rattus norvegicus,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,D,B,15103,,,10116.0,,,,104740
56,,Homo sapiens,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,N,F,5116,,,9606.0,,,1A9,80002
57,,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,D,F,14578,,,10116.0,,,Oocytes,104835
58,,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,D,F,14578,,,10116.0,,,Oocytes,104821
59,,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,D,F,14578,,,10116.0,,,Oocytes,104848
60,,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,N,F,4787,,,9606.0,,,1A9,80002
61,,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,N,F,4787,,,9606.0,,,1A9,80002
62,,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line,N,F,3547,,,9606.0,,,1A9,80002
63,,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,N,F,3547,,,9606.0,,,1A9,80002
64,,Homo sapiens,Effective dose of compound against replication of 1A9 cell line was evaluated,N,F,6726,,,9606.0,,,1A9,80002
65,,Homo sapiens,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,N,F,3455,,,9606.0,,,1A9,80002
66,,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),N,F,5726,,,9606.0,,,1A9,80002
67,,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,N,F,5726,,,9606.0,,,1A9,80002
68,,Homo sapiens,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,N,F,5726,,,9606.0,,,1A9,80002
69,,Homo sapiens,Inhibitory activity against Taxol resistant 1A9 cell lines,N,F,3395,,,9606.0,,,1A9,80002
70,,Homo sapiens,Cytotoxicity against human ovarian cancer (1A9) cell lines.,N,F,3415,,,9606.0,,,1A9,80002
71,,Homo sapiens,Percentage inhibition of human ovarian cancer (1A9) cell lines.,N,F,3415,,,9606.0,,,1A9,80002
72,,Homo sapiens,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,N,F,17099,,,9606.0,,,1A9,80002
73,,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,N,F,17099,,,9606.0,,,1A9,80002
74,,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,N,F,17099,,,9606.0,,,1A9,80002
75,,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,N,F,17099,,,9606.0,,,1A9,80002
76,,Homo sapiens,Inhibitory concentration against Jurkat cells,N,F,17721,,,9606.0,,,Jurkat,81072
77,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,U,F,1229,,,,,,,22226
78,,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,D,A,11347,,,10116.0,,,,100121
79,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",H,B,17117,,,,,,,11231
80,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",H,B,17117,,,,,,,11231
81,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",H,B,17117,,,,,,,11231
82,Microsomes,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",H,B,11375,,,5476.0,,,,11231
83,Microsomes,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",H,B,11375,,,5476.0,,,,11231
84,Microsomes,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",H,B,11375,,,4932.0,,,,11231
85,Microsomes,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",H,B,11375,,,4932.0,,,,11231
86,Microsomes,Sus scrofa,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",H,B,11375,,,9823.0,,Liver,,12083
87,,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",H,B,791,,,10116.0,,,,11231
88,,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",H,B,791,,,10116.0,,,,11231
89,,Rattus norvegicus,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",H,B,791,,,10116.0,,,,11231
90,Microsomes,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",D,B,11375,,,10116.0,,Liver,,12083
91,Microsomes,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",D,B,11375,,,10116.0,,Liver,,12083
92,Microsomes,Rattus norvegicus,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",D,B,153,,,10116.0,,Liver,,12083
93,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),H,B,8269,,,,,,,11377
94,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,H,B,8269,,,,,,,11377
95,,Homo sapiens,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,N,F,17653,,,9606.0,,,HepG2,81020
96,,Homo sapiens,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,N,F,14277,,,9606.0,,,HepG2,81020
97,,Homo sapiens,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,N,F,1717,,,9606.0,,,HepG2,81020
98,,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,N,F,14091,,,9606.0,,,HepG2,81020
99,,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,N,F,14091,,,9606.0,,,HepG2,81020
100,,Hepatitis B virus,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,N,F,17653,,,10407.0,,,,50606
101,,Homo sapiens,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,N,F,13105,,,9606.0,,,HepG2,81020
102,,Homo sapiens,Concentration required to inhibit 50% of 2.2.15 cell line,N,F,1717,,,9606.0,,,HepG2,81020
103,,Homo sapiens,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,N,A,13105,,,9606.0,,,HepG2,81020
104,,Homo sapiens,Cytotoxic activity of compound against uninfected 2.2.15 cells.,N,F,13600,,,9606.0,,,2.2.15,50587
105,,Homo sapiens,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,N,F,13467,,,9606.0,,,2.2.15,50587
106,,Hepatitis B virus,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",N,F,17477,,,10407.0,,,2.2.15,50606
107,,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells,N,F,1593,,,9606.0,,,2.2.15,50587
108,,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells; Not determined,N,F,1593,,,9606.0,,,2.2.15,50587
109,,Homo sapiens,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,N,F,15089,,,9606.0,,,2.2.15,50587
110,,Homo sapiens,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,N,F,15089,,,9606.0,,,2.2.15,50587
111,,Homo sapiens,Cytotoxicity in 2.2.15 cells,N,F,1593,,,9606.0,,,2.2.15,50587
112,,Homo sapiens,Cytotoxicity in 2.2.15 cells; Not determined,N,F,1593,,,9606.0,,,2.2.15,50587
113,,Homo sapiens,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,N,F,13600,,,9606.0,,,2.2.15,50587
114,,Homo sapiens,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,N,F,13467,,,9606.0,,,2.2.15,50587
115,,Homo sapiens,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,N,F,13467,,,9606.0,,,2.2.15,50587
116,,Homo sapiens,Antiviral activity against HBV was determined in 2.215 cell line,N,F,14764,,,9606.0,,,HepG2,81020
117,Microsomes,Homo sapiens,Inhibition of 20-HETE synthesis in human renal microsomes,U,B,6531,,,9606.0,,,,22226
118,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,U,B,17322,,,,,,,22226
119,,Homo sapiens,Inhibitory concentration against 2008 (ovarian) cells,N,F,17072,,,9606.0,,,2008,80612
120,,Homo sapiens,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,N,F,16936,,,9606.0,,,2008,80612
121,,Homo sapiens,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),N,F,16936,,,9606.0,,,2008,80612
122,,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,N,F,17146,,,9606.0,,,2008,80612
123,,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,N,F,17146,,,9606.0,,,2008,80612
124,,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line,N,F,10797,,,9606.0,,,2008/R,80613
125,,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,N,F,10797,,,9606.0,,,2008/R,80613
126,,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line,N,F,10797,,,9606.0,,,2008/S,80614
127,,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,N,F,10797,,,9606.0,,,2008/S,80614
128,,Homo sapiens,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,S,B,4823,,,9606.0,,,,100256
129,,Homo sapiens,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,S,B,12912,,,9606.0,,,,100256
130,,,Inhibition of chymotrypsin-like activity of 20S proteasome,S,B,2957,,,,,,,100256
131,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,S,B,2957,,,,,,,100256
132,,,Inhibitory activity against 20S proteosome,S,B,3260,,,,,,,100256
133,,Homo sapiens,Compound was tested for inhibitory activity against tryptase,U,B,3451,,,9606.0,,,,22226
134,,Homo sapiens,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,N,F,13885,,,9606.0,,,HepG2,81020
135,,Homo sapiens,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,N,F,13885,,,9606.0,,,HepG2,81020
136,,,Compound was tested for the inhibition of Alpha-glucosidase,U,B,3676,,,,,,,22226
137,,,Inhibitory concentration against human neutrophil elastase (HNE),H,B,6043,,,,,,,235
138,,Rattus norvegicus,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,U,F,11140,,,10116.0,,Heart,,22226
139,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,H,F,10543,,,,,,,19640
140,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,H,F,10543,,,,,,,19640
141,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,H,B,10543,,,,,,,19640
142,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,H,F,10543,,,,,,,19640
143,,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,N,F,11365,,,10090.0,,,P338,80360
144,,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,N,F,11365,,,10090.0,,,P338,80360
145,,Homo sapiens,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,N,F,11803,,,9606.0,,,PBL,80384
146,,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,U,F,11803,,,9940.0,,,,22226
147,,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,U,F,11803,,,9940.0,,,,22226
148,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),H,B,12278,,,,,,,191
149,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,U,F,8249,,,9606.0,,,,22226
150,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,U,F,8249,,,9606.0,,,,22226
151,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,U,F,8249,,,9606.0,,,CCRF-CEM,22226
152,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,U,F,8249,,,9606.0,,,CCRF-CEM,22226
153,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,U,F,8249,,,9606.0,,,CCRF-CEM,22226
154,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,U,F,8249,,,9606.0,,,CCRF-CEM,22226
155,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,U,F,8249,,,9606.0,,,,22226
156,,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,U,F,8249,,,9606.0,,,,22226
157,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,H,B,16992,,,,,,,104290
158,,Streptococcus pyogenes,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,N,F,10543,,,1314.0,,,,50264
159,,Human herpesvirus 3,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),N,F,17833,,,10335.0,,,,50527
160,,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,N,F,17290,,,10335.0,,,HEL,50527
161,,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND: No data,N,F,17290,,,10335.0,,,,50527
162,,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND=No data,N,F,17290,,,10335.0,,,,50527
163,,escherichia cloac,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",N,F,10932,,,561.0,,,,50145
164,,,Ratio of Ki at A2 to Ki at A1 receptors,U,B,9707,,,,,,,22226
165,,Candida albicans,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",H,B,2346,,,5476.0,,,,11143
166,,Candida glabrata CBS 138,"Inhibition of 1,3-beta-glucan synthase",H,B,2205,,,284593.0,,,,18077
167,,Homo sapiens,Inhibition of growth of 1-87 human tumor cell line,N,F,11900,,,9606.0,,,1-87 tumor cell line,80609
168,,Rattus norvegicus,Inhibition of 1-lipoxygenase (LOX)in RBL cells,D,B,14864,,,10116.0,,,,12166
169,,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO),D,B,16474,,,3847.0,,,,100171
170,,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,D,B,16474,,,3847.0,,,,100171
171,,Glycine max,% inhibition against soybean 1-lipoxygenase (SLO),D,B,16474,,,3847.0,,,,100171
172,,Glycine max,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,D,B,16474,,,3847.0,,,,100171
173,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,D,B,3094,,,3847.0,,,,100171
174,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,D,B,3094,,,3847.0,,,,100171
175,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,D,B,3094,,,3847.0,,,,100171
176,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,D,B,3094,,,3847.0,,,,100171
177,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,D,B,3094,,,3847.0,,,,100171
178,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,D,B,3094,,,3847.0,,,,100171
179,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,D,B,3094,,,3847.0,,,,100171
180,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,D,B,3094,,,3847.0,,,,100171
181,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,D,B,3094,,,3847.0,,,,100171
182,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,D,B,3094,,,3847.0,,,,100171
183,,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,D,B,3094,,,3847.0,,,,100171
184,,Mus musculus,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,U,B,10413,,,10090.0,,,,22226
185,,Mus musculus,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),N,F,16929,,,10090.0,,,C3H 10T1/2,80049
186,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,U,F,1229,,,,,,,22226
187,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),H,B,16587,,,,,,,11489
188,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),H,B,16587,,,,,,,11862
189,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,H,B,16587,,,,,,,11862
190,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,H,B,16587,,,,,,,11489
191,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,H,B,16587,,,,,,,11862
192,,Bos taurus,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,D,F,8058,,,9913.0,,,,12347
193,,Rattus norvegicus,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,D,B,9065,,,10116.0,,,,100120
194,,Rattus norvegicus,Inhibition of 11 beta-hydroxylase from rat adrenal gland,D,B,8865,,,10116.0,,Adrenal gland,,100120
195,,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,D,B,9066,,,10116.0,,,,100120
196,,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,D,B,8394,,,10116.0,,,,100120
197,,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,D,B,8394,,,10116.0,,,,100120
198,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,H,B,6431,,,,,,,10328
199,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,H,B,6431,,,,,,,11490
200,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,H,B,6431,,,,,,,11490
201,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,H,F,9295,,,,,,,11134
202,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,B,10193,,,,,,,12052
203,,,Compound was tested in vitro for inhibition of 12-LO human platelet,H,B,13622,,,,,,,11134
204,,,Inhibitory concentration against human platelet 12-lipoxygenase,H,F,12079,,,,,,,11134
205,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,H,B,13622,,,,,,,11134
206,,Homo sapiens,Inhibitory concentration against human platelet 12-lipoxygenase,D,F,12079,,,9606.0,,,,11134
207,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,H,B,13500,,,,,,,11835
208,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,H,B,13723,,,,,,,11601
209,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),H,B,16474,,,,,,,11134
210,,,Inhibitory activity against human platelet 12-lipoxygenase,H,B,1630,,,,,,,11134
211,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,H,B,167,,,,,,,11134
212,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),H,B,16474,,,,,,,11134
213,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,H,B,167,,,,,,,11134
214,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,H,B,16474,,,,,,,11134
215,,,Inhibitory activity towards porcine 12-lipoxygenase,H,B,10091,,,,,,,11601
216,,,Tested for inhibition against porcine 12-LO,H,B,11966,,,,,,,11601
217,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,H,B,951,,,,,,,12052
218,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,H,B,10997,,,,,,,12052
219,,,In vitro inhibition of rat platelet 12-lipoxygenase,H,B,10193,,,,,,,12052
220,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,B,10193,,,,,,,12052
221,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,H,B,10193,,,,,,,12052
222,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,H,B,10193,,,,,,,12052
223,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,B,10193,,,,,,,12052
224,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,H,B,10193,,,,,,,12052
225,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,H,B,11087,,,,,,,12052
226,,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,N,F,15569,,,9606.0,,,41M,80007
227,,Homo sapiens,In vitro antitumor activity against 41M cell line.,N,F,12989,,,9606.0,,,41M,80007
228,,Homo sapiens,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,N,F,16745,,,9606.0,,,41M,80007
229,,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,N,F,15569,,,9606.0,,,41M,80007
230,,Homo sapiens,In vitro antitumor activity against 41McisR cell line.,N,F,12989,,,9606.0,,,41M,80007
231,,Homo sapiens,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,N,F,12989,,,9606.0,,,41M,80007
232,,Homo sapiens,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,N,F,16745,,,9606.0,,,41M,80007
233,,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),D,B,6210,,,9606.0,,,,84
234,,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),D,B,6210,,,9606.0,,,,68
235,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),H,B,6226,,,,,,,68
236,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,H,B,17855,,,,,,,10201
237,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,H,B,17855,,,,,,,10201
238,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,H,B,17855,,,,,,,10201
239,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",H,B,10413,,,,,,,12220
240,,Escherichia coli,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",H,B,10413,,,562.0,,,,11303
241,,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",H,B,10413,,,562.0,,,,11303
242,,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",H,B,10413,,,562.0,,,,11303
243,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",H,B,10413,,,,,,,12220
244,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",H,B,10413,,,,,,,12220
245,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,B,7587,,,9823.0,,,,11303
246,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",H,B,7587,,,9823.0,,,,11303
247,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",H,B,7587,,,9823.0,,,,11303
248,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",H,B,7587,,,9823.0,,,,11303
249,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,B,7587,,,9823.0,,,,11303
250,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",H,B,7587,,,9823.0,,,,11303
251,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",H,B,7587,,,9823.0,,,,11303
252,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",H,B,7587,,,9823.0,,,,11303
253,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",H,B,7587,,,9823.0,,,,11303
254,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",H,B,7587,,,9823.0,,,,11303
255,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,B,7587,,,9823.0,,,,11303
256,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",H,B,7587,,,9823.0,,,,11303
257,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",H,B,7323,,,,,,,11303
258,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",U,B,7587,,,9823.0,,,,22226
259,,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",U,B,7587,,,9823.0,,,,22226
260,,Saccharomyces cerevisiae,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,H,B,13750,,,4932.0,,,,100249
261,,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,U,B,7662,,,10116.0,,,,22226
262,,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,U,B,7662,,,10116.0,,,,22226
263,,Rattus norvegicus,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",U,B,7662,,,10116.0,,,,22226
264,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",H,F,12211,,,,,,,104698
265,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",H,F,12211,,,,,,,104698
266,,Cavia porcellus,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,D,F,12211,,,10141.0,,Ileum,,20033
267,,,Stimulatory activity of intragastric pressure was tested in the rat,H,F,12211,,,,,,,10623
268,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,H,B,15453,,,,,,,121
269,,Rattus norvegicus,Dose to reduce neuronal firing against 5-HT cells in rats (iv),U,F,11884,,,10116.0,,,,22226
270,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,H,F,7185,,,,,,,12688
271,,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,D,B,6876,,,9606.0,,,,121
272,,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,D,B,6876,,,9606.0,,,,121
273,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,H,F,11863,,,,,,,12198
274,,,Inhibition constant of high-affinity 5-HT uptake,H,B,11863,,,,,,,12198
275,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,H,F,11863,,,,,,,12198
276,,,Maximum rate was determined for high affinity transport of 5-HT,H,F,11863,,,,,,,12198
277,,,Compound was tested for agonistic activity against 5-HT uptake,H,F,4639,,,,,,,104714
278,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,H,B,15796,,,,,,,10577
279,,Bos taurus,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,H,B,15796,,,9913.0,,,,105
280,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,D,B,12801,,,10116.0,,,,104744
281,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,H,B,12801,,,,,,,104744
282,Membranes,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,H,B,12120,,,,,,,104744
283,Membranes,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,H,B,12120,,,,,,,104744
284,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,B,11963,,,,,,,104744
285,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,H,F,11701,,,,,,,51
286,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
287,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
288,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
289,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),H,F,16394,In vivo,,,,,,10576
290,,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,D,F,11574,,,10141.0,,,,105570
291,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,B,15779,,,,,,CHO,279
292,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,H,B,15363,,,,,,,107
293,,Rattus norvegicus,Efficacy against 5-hydroxytryptamine 2A receptor,D,F,15363,,,10116.0,,,,12687
294,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,H,F,15329,,,,,,,12687
295,,,Relative potency towards 5-HT2A receptor of rat tail artery,H,F,15329,,,,,,,12687
296,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,H,F,15329,,,,,,,12687
297,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,H,F,15329,,,,,,,12687
298,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,H,F,15329,,,,,,,12687
299,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,H,F,15329,,,,,,,12687
300,,Cavia porcellus,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,D,F,273,,,10141.0,,Ileum,,20033
301,,Cavia porcellus,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),D,F,273,,,10141.0,,Ileum,,20033
302,,Cavia porcellus,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,D,F,273,,,10141.0,,Ileum,,20033
303,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,H,B,12092,,,,,,,10623
304,,Rattus norvegicus,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,D,F,1317,,,10116.0,,,,10623
305,,,Binding affinity against 5-hydroxytryptamine 4 receptor,H,B,12409,,,,,,,168
306,,Gallus gallus,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,U,B,11126,,,9031.0,,,,22226
307,,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,U,F,11126,,,9606.0,,,,22226
308,,Homo sapiens,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,U,F,11126,,,9606.0,,,,22226
309,,Homo sapiens,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,N,B,11126,,,9606.0,,,HL-60,80156
310,,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,U,B,11126,,,9606.0,,,,22226
311,,Homo sapiens,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,U,B,11126,,,9606.0,,,,22226
312,,Homo sapiens,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,D,B,17807,,,9606.0,,,Oocytes,104703
313,,,Chymotryptic inhibitory activity against 26S proteasome,S,F,16575,,,,,,,100256
314,,,Inhibitory activity against 26S proteasome degradation of IkB,S,B,15407,,,,,,,100256
315,,Homo sapiens,In vitro inhibition of 2780/DOX ovarian cancer cell line,N,F,10797,,,9606.0,,,A2780,81034
316,,Homo sapiens,In vitro inhibition of 2780/S ovarian cancer cell line,N,F,10797,,,9606.0,,,A2780,81034
317,,Homo sapiens,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,U,F,3469,,,9606.0,,,,22226
318,,,Association constant for binding to AATT 28-mer AATT hairpin,M,B,16037,,,,,,,22222
319,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,M,B,16037,,,,,,,22222
320,,,Reaction Rate Parameter for 28-mer AATT hairpin,M,B,16037,,,,,,,22222
321,,,Reaction Rate Parameter for 28-mer AATT hairpin,M,B,16037,,,,,,,22222
322,,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),U,F,16524,,,9606.0,,,,22226
323,,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),U,F,16524,,,9606.0,,,,22226
324,,Homo sapiens,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,U,F,16524,,,9606.0,,,,22226
325,,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 determined by MTT test,U,F,16758,,,10029.0,,,,22226
326,,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,U,F,16758,,,10029.0,,,,22226
327,,Cricetulus griseus,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,U,F,16758,,,10029.0,,,,22226
328,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,H,B,14360,,,,,,,241
329,,Homo sapiens,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,D,B,14360,,,9606.0,,,,241
330,,Rattus norvegicus,Selectivity ratio of ID50 in liver and heart,U,B,9964,,,10116.0,,,,22226
331,,,"Selectivity, ratio of relative ID50 in liver and heart",H,B,9964,,,,,,,12132
332,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,H,B,9964,,,,,,,12132
333,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,B,9964,,,,,,,12132
334,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,B,9964,,,,,,,12132
335,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,B,9964,In vivo,,,,,,12132
336,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,F,9964,In vivo,,,,,,12132
337,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",U,B,9964,,,,,,,22226
338,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,H,B,9964,,,,,,,12132
339,,Homo sapiens,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",U,B,9964,,,9606.0,,,,22226
340,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,H,B,9964,,,,,,,12132
341,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,H,F,9964,,,,,,,12132
342,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",H,B,9964,,,,,,,12132
343,,Rattus norvegicus,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",U,B,9964,,,10116.0,,,,22226
344,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,H,B,9964,In vivo,,,,,,12132
345,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,B,9964,,,,,,,12132
346,,Rattus norvegicus,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",U,B,9964,,,10116.0,,,,22226
347,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",H,B,9964,,,,,,,12132
348,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",H,F,9964,,,,,,,12132
349,,Rattus norvegicus,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",U,B,3796,,,10116.0,,,,22226
350,,Escherichia coli,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,H,B,4251,,,562.0,,,,19690
351,,Escherichia coli,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,H,B,4251,,,562.0,,,,19690
352,,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,H,B,4251,,,562.0,,,,19690
353,,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,H,B,4251,,,562.0,,,,19690
354,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,H,B,166,,,,,,,19690
355,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,H,B,17861,,,,,,,19690
356,,,Inhibition constant against 3-dehydroquinate synthase,H,B,166,,,,,,,19690
357,,,Association rate constant against 3-dehydroquinate synthase,H,B,166,,,,,,,19690
358,,,Rate constant against 3-dehydroquinate synthase,H,B,166,,,,,,,19690
359,,,Inhibitory activity against fuc-TVII,U,B,3548,,,,,,,22226
360,Microsomes,Rattus norvegicus,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,B,9877,,,10116.0,,Liver,,12236
361,Microsomes,Rattus norvegicus,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,B,9877,,,10116.0,,Liver,,12236
362,Microsomes,Rattus norvegicus,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,B,9877,,,10116.0,,Liver,,12236
363,Microsomes,Rattus norvegicus,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,B,9877,,,10116.0,,Liver,,12236
364,Microsomes,Rattus norvegicus,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,B,9877,,,10116.0,,Liver,,12236
365,Microsomes,Rattus norvegicus,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,D,B,9877,,,10116.0,,Liver,,12236
366,Microsomes,Rattus norvegicus,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,D,B,9877,,,10116.0,,Liver,,12236
367,Microsomes,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,D,B,9877,,,10116.0,,Liver,,12236
368,Microsomes,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,D,B,9877,,,10116.0,,Liver,,12236
369,Microsomes,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,D,B,9877,,,10116.0,,Liver,,12236
370,Microsomes,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,D,B,9877,,,10116.0,,Liver,,12236
371,,,Inhibitory activity against 3-phosphoglycerate kinase.,H,B,3003,,,,,,,104832
372,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,H,B,3003,,,,,,,104832
373,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",H,B,3003,,,,,,,104832
374,,Homo sapiens,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,D,B,17185,,,9606.0,,,,10612
375,,Homo sapiens,Cytotoxicity on 3677 melanoma cells,N,F,6072,,,9606.0,,,3677 melanoma cell line,80616
376,,Homo sapiens,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,N,F,6072,,,9606.0,,,3677 melanoma cell line,80616
377,,Mus musculus,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,N,F,5018,,,10090.0,,,MC-38,80617
378,,Homo sapiens,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,U,F,2852,,,9606.0,,,,22226
379,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,U,F,8663,,,,,,B16,22226
380,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,U,F,8663,,,,,,B16,22226
381,,Human rhinovirus 14,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,D,F,3245,,,12131.0,,,,12464
382,,Human rhinovirus sp.,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,N,F,3245,,,169066.0,,,,50085
383,,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,N,F,3877,,,169066.0,,,,50679
384,,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,N,F,3877,,,169066.0,,,,50679
385,,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,F,5861,,,12131.0,,,,12464
386,,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,F,5861,,,12131.0,,,,12464
387,,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,F,5861,,,12131.0,,,,12464
388,,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,D,F,5861,,,12131.0,,,,12464
389,,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,N,F,13748,,,12059.0,,,,50665
390,,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,N,F,13748,,,12059.0,,,,50665
391,,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,N,F,13748,,,12059.0,,,,50665
392,,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,N,F,13748,,,12059.0,,,,50665
393,,Human rhinovirus B,Inhibition of human rhinovirus 3C protease,H,B,13748,,,147712.0,,,,12464
394,,Homo sapiens,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,U,B,17699,,,9606.0,,,,22226
395,,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),N,F,7145,,,10090.0,,,3EM 37,80619
396,,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),N,F,7145,,,10090.0,,,3EM 37,80619
397,,Mus musculus,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),N,F,7145,,,10090.0,,,3EM 37,80619
398,,Mus musculus,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),N,F,7145,,,10090.0,,,3EM 37,80619
399,,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,N,F,7145,,,10090.0,,,3EM 37,80619
400,,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,N,F,7145,,,10090.0,,,3EM 37,80619
401,,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,N,F,5325,,,10090.0,,,3LL cell line,80620
402,,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,N,F,5325,,,10090.0,,,3LL cell line,80620
403,,Mus musculus,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,N,F,5325,,,10090.0,,,3LL cell line,80620
404,,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,N,F,16169,,,10090.0,,,3LL cell line,80620
405,,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,N,F,16169,,,10090.0,,,3LL cell line,80620
406,,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,N,F,16169,,,10090.0,,,3LL cell line,80620
407,,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,N,F,16169,,,10090.0,,,3LL cell line,80620
408,,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,N,F,16169,,,10090.0,,,3LL cell line,80620
409,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,N,F,16169,,,10090.0,,,3LL cell line,80620
410,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,N,F,16169,,,10090.0,,,3LL cell line,80620
411,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,N,F,16169,,,10090.0,,,3LL cell line,80620
412,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,N,F,16169,,,10090.0,,,3LL cell line,80620
413,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,N,F,16169,,,10090.0,,,3LL cell line,80620
414,,Mus musculus,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,N,F,16169,,,10090.0,,,3LL cell line,80620
415,,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,N,F,16169,,,10090.0,,,3LL cell line,80620
416,,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,N,F,16169,,,10090.0,,,3LL cell line,80620
417,,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,N,F,16169,,,10090.0,,,3LL cell line,80620
418,,Mus musculus,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
419,,Mus musculus,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
420,,Mus musculus,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
421,,Mus musculus,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
422,,Mus musculus,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
423,,Mus musculus,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
424,,Mus musculus,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
425,,Mus musculus,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
426,,Mus musculus,spermine levels in 3LL cells after the treatment of 1 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
427,,Mus musculus,spermine levels in 3LL cells after the treatment of 10 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
428,,Mus musculus,spermine levels in 3LL cells after the treatment of 250 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
429,,Mus musculus,spermine levels in 3LL cells after the treatment of 50 uM of Compound,N,F,16169,,,10090.0,,,3LL cell line,80620
430,,Homo sapiens,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,N,F,15547,,,9606.0,,,3LLD122,80621
431,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,U,F,8663,,,,,,,22226
432,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,U,F,8663,,,,,,,22226
433,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,U,F,8663,,,,,,,22226
434,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,U,F,8663,,,,,,,22226
435,,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,N,F,4504,,,10090.0,,,NIH3T3,80951
436,,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,N,F,4504,,,10090.0,,,NIH3T3,80951
437,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,H,F,12695,,,,,,NIH3T3,11169
438,,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,N,F,12695,,,10090.0,,,NIH3T3,80951
439,,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,N,F,12695,,,10090.0,,,NIH3T3,80951
440,,Mus musculus,Effective dose against murine 3T3 fibroblasts cells,N,F,17642,,,10090.0,,,NIH3T3,80951
441,,Mus musculus,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,N,F,17642,,,10090.0,,,NIH3T3,80951
442,,Mus musculus,Cytotoxic effect on 3T3 cells,N,F,12340,,,10090.0,,,NIH3T3,80951
443,,Mus musculus,Cytotoxic effect on 3T3 cells,N,F,12340,,,10090.0,,,NIH3T3,80951
444,,Mus musculus,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,N,F,12716,,,10090.0,,,NIH3T3,80951
445,,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,N,F,6277,,,10090.0,,,NIH3T3,80951
446,,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,N,F,6277,,,10090.0,,,NIH3T3,80951
447,,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,N,F,6277,,,10090.0,,,NIH3T3,80951
448,,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,N,F,6277,,,10090.0,,,NIH3T3,80951
449,,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,N,F,6277,,,10090.0,,,NIH3T3,80951
450,,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,N,F,6277,,,10090.0,,,NIH3T3,80951
451,,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,N,F,6277,,,10090.0,,,NIH3T3,80951
452,,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,N,F,6277,,,10090.0,,,NIH3T3,80951
453,,Mus musculus,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,N,F,17780,,,10090.0,,,NIH3T3,80951
454,,Mus musculus,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,D,F,12751,,,10090.0,,,,104860
455,,Mus musculus,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,N,F,12380,,,10090.0,,,NIH3T3,80951
456,,Mus musculus,Inhibitory activity against 3T3 cell line,N,F,14892,,,10090.0,,,NIH3T3,80951
457,,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,N,F,12695,,,10090.0,,,NIH3T3,80951
458,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,H,F,12695,,,,,,,11169
459,,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,N,F,12695,,,10090.0,,,NIH3T3,80951
460,,Mus musculus,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,N,F,12695,,,10090.0,,,NIH3T3,80951
461,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,H,F,12695,,,,,,,11169
462,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,H,F,12695,,,,,,,11169
463,,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,N,F,6277,,,10090.0,,,NIH3T3,80951
464,,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,N,F,6277,,,10090.0,,,NIH3T3,80951
465,,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,D,F,4959,,,9606.0,,,NIH3T3,9
466,,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),D,F,4959,,,9606.0,,,NIH3T3,9
467,,Homo sapiens,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,D,F,4959,,,9606.0,,,NIH3T3,188
468,,Homo sapiens,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),D,F,4959,,,9606.0,,,NIH3T3,188
469,,Mus musculus,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,N,F,12082,,,10090.0,,,NIH3T3,80951
470,,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,N,F,12082,,,10090.0,,,NIH3T3,80951
471,,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,N,F,12082,,,10090.0,,,NIH3T3,80951
472,,Mus musculus,Inhibitory concentration was calculated on 3T3 cells by using growth assay,N,F,12082,,,10090.0,,,NIH3T3,80951
473,,Mus musculus,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,N,F,2643,,,10090.0,,,NIH3T3,80951
474,,Mus musculus,Inhibition of Swiss 3T3 mouse fibroblast proliferation,N,F,11926,,,10090.0,,,NIH3T3,80951
475,,Mus musculus,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,N,A,15204,,,10090.0,,,NIH3T3,80951
476,,Mus musculus,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,N,F,15992,,,10090.0,,,NIH3T3,80951
477,,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,N,F,16279,,,10090.0,,,NIH3T3,80951
478,,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,F,16279,,,10090.0,,,NIH3T3,80951
479,,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,F,16279,,,10090.0,,,NIH3T3,80951
480,,Mus musculus,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,F,16279,,,10090.0,,,NIH3T3,80951
481,,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,F,16279,,,10090.0,,,NIH3T3,80951
482,,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,F,16279,,,10090.0,,,NIH3T3,80951
483,,Mus musculus,Inhibition of swiss 3T3 mouse fibroblast proliferation,N,F,12831,,,10090.0,,,NIH3T3,80951
484,,Mus musculus,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,N,F,13497,,,10090.0,,,NIH3T3,80951
485,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,F,13715,,,,,,3T3-L1,80006
486,,Mus musculus,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,N,F,13618,,,10090.0,,,3T3-L1,80006
487,,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,N,F,11902,,,10090.0,,,3T3-L1,80006
488,,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,N,F,11902,,,10090.0,,,3T3-L1,80006
489,,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,N,F,11902,,,10090.0,,,3T3-L1,80006
490,,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",N,F,14840,,,10090.0,,,3T3-L1,80006
491,,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",N,F,14840,,,10090.0,,,3T3-L1,80006
492,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,N,F,13715,,,,,,3T3-L1,80006
493,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,N,F,13715,,,,,,3T3-L1,80006
494,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,F,13715,,,,,,3T3-L1,80006
495,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,N,F,13715,,,,,,3T3-L1,80006
496,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,F,13715,,,,,,3T3-L1,80006
497,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,N,F,13715,,,,,,3T3-L1,80006
498,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,N,F,13715,,,,,,3T3-L1,80006
499,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,N,F,13715,,,,,,3T3-L1,80006
500,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,F,13715,,,,,,3T3-L1,80006
501,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,N,F,13715,,,,,,3T3-L1,80006
502,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,F,13715,,,,,,3T3-L1,80006
503,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,N,F,13715,,,,,,3T3-L1,80006
504,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,F,13715,,,,,,3T3-L1,80006
505,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,N,F,13715,,,,,,3T3-L1,80006
506,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,F,13715,,,,,,3T3-L1,80006
507,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,F,13715,,,,,,3T3-L1,80006
508,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,N,F,13715,,,,,,3T3-L1,80006
509,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,N,F,13715,,,,,,3T3-L1,80006
510,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,F,13715,,,,,,3T3-L1,80006
511,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,N,F,13715,,,,,,3T3-L1,80006
512,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,N,F,13715,,,,,,3T3-L1,80006
513,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,F,13715,,,,,,3T3-L1,80006
514,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,F,13715,,,,,,3T3-L1,80006
515,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,F,13715,,,,,,3T3-L1,80006
516,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,N,F,13715,,,,,,3T3-L1,80006
517,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,H,F,6411,,,,,,3T3-L1,11214
518,,Mus musculus,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,N,F,6411,,,10090.0,,,3T3-L1,80006
519,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,H,F,6411,,,,,,3T3-L1,11214
520,,Mus musculus,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,N,F,3966,,,10090.0,,,3T3-L1,80006
521,,Mus musculus,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,N,F,3966,,,10090.0,,,3T3-L1,80006
522,,Mus musculus,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,N,F,15556,,,10090.0,,,3T3-L1,80006
523,,Mus musculus,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,N,F,5845,,,10090.0,,,3T3-L1,80006
524,,Mus musculus,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,N,F,14422,,,10090.0,,,3T3-L1,80006
525,,Mus musculus,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,N,F,5845,,,10090.0,,,3T3-L1,80006
526,,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,N,F,14508,,,10090.0,,,3T3-L1,80006
527,,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,N,F,14508,,,10090.0,,,3T3-L1,80006
528,,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,N,F,14508,,,10090.0,,,3T3-L1,80006
529,,Rattus norvegicus,Inhibitory activity against rat fibroblast (3Y1) cell line,N,F,6349,,,10116.0,,,3Y1 cell line,80622
530,,Rattus norvegicus,Mean concentration causing inhibition of cell growth in 3Y1 cells.,N,F,15899,,,10116.0,,,3Y1 cell line,80622
531,,Rattus norvegicus,Cytotoxicity in 3Y1 cells.,N,F,15899,,,10116.0,,,3Y1 cell line,80622
532,,Rattus norvegicus,Cytostatic effect in 3Y1 cells.,N,F,15899,,,10116.0,,,3Y1 cell line,80622
533,,Rattus norvegicus,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",N,F,15899,,,10116.0,,,3Y1 cell line,80622
534,,Rattus norvegicus,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,N,F,17038,,,10116.0,,,3Y1 cell line,80622
535,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,U,B,12421,,,,,,,22226
536,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,U,B,12947,,,,,,,22226
537,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,U,B,12947,,,,,,,22226
538,,Sus scrofa,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,D,B,4896,,,9823.0,,,,11607
539,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,H,B,6148,,,,,,,11607
540,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,H,B,16432,,,,,,,11607
541,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,H,B,4978,,,,,,,11607
542,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),H,B,4978,,,,,,,11607
543,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,H,B,3723,,,,,,,11607
544,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),H,B,3518,,,,,,,11607
545,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,H,B,4164,,,,,,,11607
546,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,H,B,3518,,,,,,,11607
547,,Sus scrofa,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,D,B,4164,,,9823.0,,,,11607
548,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,H,B,3518,,,,,,,11607
549,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),H,B,3518,,,,,,,11607
550,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,H,B,4978,,,,,,,11607
551,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),H,B,4978,,,,,,,11607
552,,,Binding affinity against melatonin (MT1) receptor (pC1),H,B,6455,,,,,,,104733
553,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,U,B,2222,,,,,,,22226
554,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,U,B,13020,,,,,,,22226
555,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,U,B,13021,,,,,,,22226
556,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,H,B,14532,,,,,,,10619
557,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,H,B,14118,,,,,,,10619
558,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,H,B,11884,,,,,Hippocampus,,51
559,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,H,B,13969,,,,,,,51
560,,,Binding affinity for 5-hydroxytryptamine 1A receptor,H,B,13392,,,,,,,51
561,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,H,B,14430,,,,,,,51
562,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,B,12248,,,,,Hippocampus,,51
563,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,B,12249,,,,,Hippocampus,,51
564,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
565,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
566,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
567,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
568,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
569,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,B,12249,,,,,Hippocampus,,51
570,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",H,B,11799,,,,,Hippocampus,,51
571,Membranes,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,D,B,14331,,,10116.0,,,,10576
572,,Bos taurus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,H,B,11884,,,9913.0,,Hippocampus,,51
573,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,H,B,14331,,,,,Hippocampus,,51
574,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,H,B,11701,,,,,Hippocampus,,51
575,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,H,B,11701,,,,,Hippocampus,,51
576,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,H,B,12248,,,,,Hippocampus,,51
577,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,H,B,12248,,,,,,CHO,51
578,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,B,12248,,,,,Hippocampus,,51
579,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,B,12249,,,,,Hippocampus,,51
580,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,B,12248,,,,,,CHO,51
581,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",H,B,11799,,,,,Hippocampus,,51
582,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,H,B,634,,,,,,,51
583,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
584,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
585,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
586,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
587,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,B,9995,,,,,Hippocampus,,51
588,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,H,B,12210,,,,,Hippocampus,,51
589,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,B,13311,,,,,Hippocampus,,51
590,,Homo sapiens,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",D,B,2331,,,9606.0,,,CHO,51
591,,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,H,F,1375,,,10141.0,,,,51
592,,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,H,F,1375,,,10141.0,,,,51
593,,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,H,F,11574,,,10141.0,,Hippocampus,,51
594,,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,H,B,12867,,,10141.0,,Ileum,,51
595,,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,B,12867,,,10141.0,,Ileum,,51
596,,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,H,B,12867,,,10141.0,,Ileum,,51
597,,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,B,12867,,,10141.0,,Ileum,,51
598,,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,B,12867,,,10141.0,,Ileum,,51
599,,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,H,B,12867,,,10141.0,,Ileum,,51
600,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1A receptor,H,B,11574,,,10141.0,,,,51
601,,Cavia porcellus,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,H,B,13114,,,10141.0,,,,51
602,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,H,B,13181,,,10141.0,,,,51
603,,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,H,B,10639,,,10141.0,,Hippocampus,,106
604,,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,H,F,10639,,,10141.0,,Hippocampus,,106
605,,Cricetulus griseus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),H,B,11883,,,10029.0,,,CHO,11863
606,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,H,B,17785,,,,,,,51
607,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,H,F,1558,,,,,,HeLa,51
608,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,H,F,1558,,,,,,HeLa,51
609,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,H,F,15740,,,,,,,51
610,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,H,F,17624,,,,,,CHO,51
611,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,H,F,17624,,,,,,CHO,51
612,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,H,F,17624,,,,,,CHO,51
613,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,H,F,17624,,,,,,CHO,51
614,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,B,17624,,,,,,CHO,51
615,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,B,17624,,,,,,CHO,51
616,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,H,B,17624,,,,,,CHO,51
617,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,H,F,14256,,,,,,,51
618,,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,D,B,3445,,,9606.0,,,HeLa,51
619,,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,D,B,3445,,,9606.0,,,HeLa,51
620,,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,D,B,17200,,,9606.0,,,CHO,51
621,,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,D,B,17200,,,9606.0,,,CHO,51
622,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,H,F,15180,,,,,,,51
623,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,H,F,15180,,,,,,,51
624,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,F,16026,,,,,,,51
625,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,F,2759,,,,,,CHO,51
626,,Homo sapiens,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),D,F,2759,,,9606.0,,,CHO,51
627,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),H,F,2759,,,,,,CHO,51
628,,Homo sapiens,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),D,F,2759,,,9606.0,,,CHO,51
629,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,F,2759,,,,,,CHO,51
630,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),H,F,2759,,,,,,CHO,51
631,,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),D,F,2759,,,9606.0,,,CHO,51
632,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),H,F,2759,,,,,,CHO,51
633,,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),D,F,2759,,,9606.0,,,CHO,51
634,,Homo sapiens,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,D,F,3445,,,9606.0,,,,51
635,,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,F,5272,,,9606.0,,,,51
636,,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",D,F,5272,,,9606.0,,,,51
637,,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",D,F,5272,,,9606.0,,,,51
638,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,F,17624,,,,,,CHO,51
639,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,F,17624,,,,,,CHO,51
640,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,H,F,17624,,,,,,CHO,51
641,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,F,17624,,,,,,CHO,51
642,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,H,F,17624,,,,,,CHO,51
643,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,H,F,17624,,,,,,CHO,51
644,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,F,17624,,,,,,CHO,51
645,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,H,F,17624,,,,,,CHO,51
646,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,F,17624,,,,,,CHO,51
647,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,H,F,17624,,,,,,CHO,51
648,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,F,17624,,,,,,CHO,51
649,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,H,F,17624,,,,,,CHO,51
650,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,F,6563,,,,,,,51
651,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,F,6563,,,,,,,51
652,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,H,F,6563,,,,,,,51
653,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,F,17296,,,,,,HEK293,51
654,,Homo sapiens,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",D,F,6876,,,9606.0,,,,51
655,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",H,F,6876,,,,,,,51
656,,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,D,F,5272,,,9606.0,,,,51
657,,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,D,F,5272,,,9606.0,,,,51
658,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,F,5548,,,,,,,51
659,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",H,F,5548,,,,,,,51
660,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,F,5548,,,,,,,51
661,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,F,5548,,,,,,,51
662,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",H,F,5929,,,,,,,51
663,,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",D,F,5929,,,9606.0,,,,51
664,,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",D,F,5929,,,9606.0,,,,51
665,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",H,F,16245,,,,,,,51
666,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",H,F,5640,,,,,,,51
667,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",H,F,5640,,,,,,,51
668,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,H,F,14509,,,,,,CHO,51
669,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,H,F,14509,,,,,,CHO,51
670,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,B,15331,,,,,,,51
671,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,B,15331,,,,,,,51
672,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,F,6563,,,,,,,51
673,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",H,F,6563,,,,,,,51
674,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,H,F,6563,,,,,,,51
675,,Homo sapiens,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,D,F,6563,,,9606.0,,,,51
676,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,F,6563,,,,,,,51
677,,Homo sapiens,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,D,F,5272,,,9606.0,,,,51
678,,Homo sapiens,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,F,5272,,,9606.0,,,,51
679,,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",D,F,5272,,,9606.0,,,,51
680,,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,D,F,5272,,,9606.0,,,,51
681,,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,D,F,5272,,,9606.0,,,,51
682,,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,F,5272,,,9606.0,,,,51
683,,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",D,F,5272,,,9606.0,,,,51
684,,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,D,F,5272,,,9606.0,,,,51
685,,Homo sapiens,Inhibition of human 5-hydroxytryptamine 1A receptor,D,B,16146,,,9606.0,,,,51
686,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,B,17624,,,,,,CHO,51
687,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,D,B,13706,,,,,,HEK293,105
688,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,H,B,15250,,,,,,CHO,51
689,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,F,17624,,,,,,CHO,51
690,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,H,B,6861,,,,,,,51
691,,Homo sapiens,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,D,B,17200,,,9606.0,,,,51
692,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,H,B,17624,,,,,,CHO,51
693,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,B,17624,,,,,,CHO,51
694,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,U,F,12058,In vivo,,10116.0,,,,22226
695,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,U,F,12058,In vivo,,10116.0,,,,22226
696,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,U,F,12058,In vivo,,10116.0,,,,22226
697,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,U,F,12058,In vivo,,10116.0,,,,22226
698,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,U,F,12058,In vivo,,10116.0,,,,22226
699,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,U,F,12058,In vivo,,10116.0,,,,22226
700,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,U,F,12058,In vivo,,10116.0,,,,22226
701,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,U,F,12058,In vivo,,10116.0,,,,22226
702,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,U,F,12058,In vivo,,10116.0,,,,22226
703,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,U,F,12058,In vivo,,10116.0,,,,22226
704,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,U,F,12058,In vivo,,10116.0,,,,22226
705,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,U,F,12058,In vivo,,10116.0,,,,22226
706,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,U,F,12058,In vivo,,10116.0,,,,22226
707,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,U,F,12058,In vivo,,10116.0,,,,22226
708,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,U,F,12058,In vivo,,10116.0,,,,22226
709,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,U,F,12058,In vivo,,10116.0,,,,22226
710,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,U,F,12058,In vivo,,10116.0,,,,22226
711,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,U,F,12058,In vivo,,10116.0,,,,22226
712,,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,U,F,12058,In vivo,,10116.0,,,,22226
713,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,H,B,11440,,,,,,,105093
714,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,H,B,6238,,,,,Hypothalamus,,11923
715,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,H,B,10046,,,,,,,10577
716,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,H,B,10046,,,,,,,10577
717,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,H,B,10046,,,,,,,10577
718,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",H,B,167,,,,,,,55
719,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",H,B,167,,,,,,,55
720,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),H,F,11520,,,,,,,12166
721,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,F,11520,,,,,,,12166
722,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,F,11520,,,,,,,12166
723,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,F,11520,,,,,,,12166
724,,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,H,F,135,,,10141.0,,,,55
725,,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,H,F,135,,,10141.0,,,,55
726,,Cavia porcellus,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,H,B,11311,,,10141.0,,,,55
727,,Cavia porcellus,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,H,B,10193,,,10141.0,,,,55
728,,Homo sapiens,Inhibitory concentration against 5-lipoxygenase from human whole blood,D,B,12281,,,9606.0,,,,55
729,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],H,B,11311,,,,,,,55
730,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,H,F,12576,,,,,,,17087
731,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,H,B,12281,,,,,,,17087
732,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,H,F,12576,,,,,,,17087
733,,Sus scrofa,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,H,B,11089,,,9823.0,,,,55
734,,,In vitro inhibition of rat 5-Lipoxygenase,H,B,11006,,,,,,,12166
735,,Rattus norvegicus,Inhibitory activity against 5-Lipoxygenase,D,B,11481,,,10116.0,,,,12166
736,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,H,B,10864,,,,,,RBL-1,12166
737,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,B,3595,,,,,,RBL-1,12166
738,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,H,B,11311,,,,,,RBL-1,12166
739,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,H,B,11311,,,,,,,12166
740,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],H,B,11311,,,,,,,12166
741,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,H,B,11006,,,,,,,12166
742,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,H,B,3595,,,,,,RBL-1,12166
743,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,H,B,11311,,,,,,,12166
744,,Rattus norvegicus,Ratio of IC50 against 5-LO and COX,U,B,11481,,,10116.0,,,,22226
745,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,H,B,11006,,,,,,,12166
746,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,H,B,11006,,,,,,,12166
747,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,H,B,11311,,,,,,,12166
748,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,H,F,11006,,,,,,,12166
749,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,H,B,4288,,,,,Prostate gland,,120
750,,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,U,B,7587,,,8932.0,,,,22226
751,,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,U,B,7587,,,8932.0,,,,22226
752,,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,U,B,7587,,,8932.0,,,,22226
753,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,H,B,11249,,,,,,,10732
754,,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,D,F,8003,,,10116.0,,,,12198
755,,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),D,F,8003,,,10116.0,,,,12198
756,,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),D,F,8003,,,10116.0,,,,12198
757,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,H,B,12416,,,,,Hippocampus,,10576
758,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,H,B,16293,,,,,,,51
759,,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,U,B,13047,,,9986.0,,,,22226
760,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,U,B,13047,,,9986.0,,,,22226
761,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,U,B,13047,,,9986.0,,,,22226
762,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,U,B,13047,,,9986.0,,,,22226
763,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,B,10085,,,,,Hippocampus,,104744
764,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,B,10085,,,,,Hippocampus,,104744
765,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,B,10085,,,,,Hippocampus,,104744
766,Membranes,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,H,B,9841,,,,,,,104744
767,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,D,B,8822,,,10116.0,,,,104744
768,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,D,B,9806,,,10116.0,,,,104744
769,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,D,B,9806,,,10116.0,,,,104744
770,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,H,B,8868,,,,,,,104744
771,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,H,B,9036,,,,,Hippocampus,,104744
772,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,H,B,11374,,,,,Hippocampus,,104744
773,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,H,B,10881,,,,,,,104744
774,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,H,B,8822,,,,,,,104744
775,,Rattus norvegicus,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,D,B,9806,,,10116.0,,,,104744
776,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,B,15463,,,,,,,104744
777,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,B,15463,,,,,,,104744
778,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,B,14542,,,,,Brain,,104744
779,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,B,14542,,,,,Brain,,104744
780,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,H,B,8569,,,,,,,104744
781,,Rattus norvegicus,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,D,B,10062,,,10116.0,,,,104744
782,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,H,B,4771,,,,,,,104744
783,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,B,10062,,,,,,,104744
784,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,B,10062,,,,,,,104744
785,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,B,10062,,,,,,,104744
786,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,H,B,15463,,,,,,,104744
787,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,H,B,15463,,,,,,,104744
788,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,H,B,9098,,,,,,,104744
789,,Rattus norvegicus,Affinity for 5-hydroxytryptamine 1 receptor,U,B,3070,,,10116.0,,,,22226
790,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,H,B,14542,,,,,Brain,,104744
791,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,B,14542,,,,,Brain,,104744
792,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,H,B,6398,,,,,,,104744
793,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,H,B,1344,,,,,Brain,,104744
794,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,B,11963,,,,,,,104744
795,,Rattus norvegicus,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,U,B,8908,,,10116.0,,,,22226
796,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,H,B,9098,,,,,,,104744
797,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,D,B,8841,,,10116.0,,,,104744
798,,Rattus norvegicus,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,U,B,8814,,,10116.0,,,,22226
799,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,H,B,11752,,,,,,,104744
800,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,H,B,11642,,,,,Brain,,104744
801,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,H,B,11642,,,,,,,104744
802,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,H,B,9231,,,,,Brain,,104744
803,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,H,B,11351,,,,,Brain,,104744
804,,,Compound was tested for binding affinity against 5-HT1 receptor,U,B,4639,,,,,,,22226
805,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,U,B,1205,,,,,,,22226
806,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,H,B,10025,,,,,,,10576
807,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",H,F,13241,,,,,,,10576
808,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,H,F,16245,In vivo,,,,,,10576
809,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,H,F,16245,In vivo,,,,,,10576
810,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,H,F,12438,,,,,,,10576
811,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,H,F,16245,In vivo,,,,,,10576
812,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,H,F,16245,In vivo,,,,,,10576
813,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,H,F,15740,,,,,,,10576
814,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,H,F,15535,,,,,,,10576
815,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,H,F,15535,,,,,,,51
816,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,H,F,15535,,,,,,,10576
817,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,H,B,9888,,,,,,,10576
818,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,H,B,10085,,,,,Hippocampus,,10576
819,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,H,B,10085,,,,,Hippocampus,,10576
820,Membranes,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,H,B,17331,,,,,,,10576
821,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,D,B,10845,,,10116.0,,Hippocampus,,10576
822,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,D,B,10845,,,10116.0,,Hippocampus,,10576
823,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,H,B,10845,,,,,Hippocampus,,10576
824,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,D,B,10845,,,10116.0,,Hippocampus,,10576
825,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,D,B,10845,,,10116.0,,Hippocampus,,10576
826,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,H,B,13730,,,,,,,10576
827,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,H,B,13508,,,,,,,10576
828,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,H,B,13508,,,,,Hippocampus,,10576
829,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,B,12073,,,,,Hippocampus,,10576
830,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,H,B,4671,,,,,Hippocampus,,10576
831,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,H,B,13631,,,,,Hippocampus,,10576
832,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,H,B,12438,,,,,,,10576
833,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,H,B,10483,,,,,,,10576
834,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,H,B,10483,,,,,Hippocampus,,10576
835,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,H,B,12352,,,,,,,10576
836,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,H,B,14732,,,,,Hippocampus,,10576
837,,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,D,B,11049,,,10116.0,,,,10576
838,,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,D,B,11049,,,10116.0,,,,10576
839,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",H,B,13657,,,,,,,10576
840,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,H,B,11473,,,,,,,10576
841,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,H,B,2014,,,,,,,10576
842,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,B,3086,,,,,Hippocampus,,10576
843,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,B,15854,,,,,,,10576
844,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,H,B,10922,,,,,Hippocampus,,10576
845,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,H,B,13346,,,,,Hippocampus,,10576
846,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,H,B,15311,,,,,,,10576
847,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,H,B,10922,,,,,Hippocampus,,10576
848,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,H,B,10025,,,,,,,10576
849,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,H,B,10025,,,,,,,10576
850,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,H,B,9742,,,,,,,10576
851,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,H,F,9742,,,,,,,10576
852,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,B,12304,,,,,,,10576
853,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,H,B,15789,,,,,Hippocampus,,10576
854,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",H,B,9912,,,,,,,10576
855,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",H,B,9912,,,,,,,10576
856,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",H,B,9912,,,,,,,10576
857,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,H,B,16693,,,,,,,10576
858,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,B,13276,,,,,,,10576
859,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,H,B,12678,,,,,Hippocampus,,10576
860,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,H,B,11825,,,,,,,10576
861,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,H,B,12443,,,,,,,10576
862,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,H,B,13830,,,,,,,10576
863,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,H,B,14286,,,,,Hippocampus,,10576
864,,Rattus norvegicus,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,D,B,14356,,,10116.0,,Hippocampus,,10576
865,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,H,B,15306,,,,,,,10576
866,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),H,B,15306,,,,,,,10576
867,,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",D,F,16616,,,10116.0,,,,10576
868,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",H,B,3651,,,,,Hippocampus,,10576
869,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,H,F,14331,,,,,Hippocampus,,10576
870,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,H,F,14331,,,,,Hippocampus,,10576
871,,Rattus norvegicus,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,D,B,14178,,,10116.0,,,,10576
872,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,D,B,10639,,,10116.0,,,,10576
873,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,B,12306,,,,,Hippocampus,,10576
874,,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,D,B,1348,,,10116.0,,,,10576
875,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,H,B,13605,,,,,Hippocampus,,10576
876,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,B,17624,,,,,,CHO,51
877,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,F,17624,,,,,,CHO,51
878,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,F,17624,,,,,,CHO,51
879,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,H,B,15267,,,,,,,51
880,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,H,B,16532,,,,,,,51
881,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,F,6563,,,,,,,51
882,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,H,B,4751,,,,,,CHO,51
883,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,H,B,15463,,,,,,,51
884,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),H,B,3805,,,,,,,51
885,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,B,5640,,,,,,,51
886,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,H,B,6563,,,,,,,51
887,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,H,B,5548,,,,,,,51
888,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,H,B,6347,,,,,,,51
889,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,F,17296,,,,,,HEK293,51
890,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,H,B,13047,,,,,,,51
891,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,H,B,15740,,,,,,,51
892,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",H,F,5640,,,,,,,51
893,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",H,F,5640,,,,,,,51
894,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,H,B,17211,,,,,,HeLa,51
895,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,H,B,4751,,,,,,CHO,51
896,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,D,B,6491,,,9606.0,,,,51
897,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,H,B,4707,,,,,,,51
898,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1A receptor,D,B,13910,,,9606.0,,,,51
899,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,H,B,16190,,,,,,HeLa,51
900,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,B,16633,,,,,,,51
901,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,H,B,11898,,,,,,CHO,51
902,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,B,11898,,,,,,CHO,51
903,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,H,B,14331,,,,,,,51
904,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,H,B,17624,,,,,,CHO,51
905,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,H,B,17624,,,,,,CHO,51
906,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,H,B,3307,,,,,,,51
907,,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,D,B,6563,,,9606.0,,,CHO,51
908,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,H,B,14165,,,,,,,51
909,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,H,B,5732,,,,,,,51
910,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,H,B,13366,,,,,,,51
911,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,H,B,17626,,,,,,,51
912,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,H,B,6588,,,,,,HeLa,51
913,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,H,B,16209,,,,,,,51
914,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,B,15463,,,,,,,51
915,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,B,15463,,,,,,,51
916,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,H,B,14770,,,,,,,51
917,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),H,B,16245,,,,,,Cell line,51
918,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),H,B,16245,,,,,,,51
919,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,H,B,5548,,,,,,,51
920,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,B,5548,,,,,,,51
921,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,B,5548,,,,,,,51
922,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,H,B,6876,,,,,,,51
923,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,B,2598,,,,,,,51
924,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,H,B,17785,,,,,,,51
925,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,B,6013,,,,,,,51
926,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,H,B,5929,,,,,,,51
927,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,B,16633,,,,,,,51
928,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,H,B,1558,,,,,,,51
929,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,B,16026,,,,,,,51
930,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,H,B,12469,,,,,,,51
931,,Homo sapiens,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,D,B,15874,,,9606.0,,,,51
932,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,H,B,15874,,,,,,,51
933,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,H,B,3935,,,,,,,51
934,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,H,B,15818,,,,,,,51
935,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,H,B,13706,,,,,,CHO-K1,51
936,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,H,F,13729,,,,,,CHO-K1,51
937,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,H,B,15413,,,,,,,51
938,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),H,B,15413,,,,,,,51
939,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),H,B,15413,,,,,,,51
940,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,H,B,15413,,,,,,,51
941,,Homo sapiens,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,D,B,3445,,,9606.0,,,HeLa,51
942,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,H,B,15740,,,,,,,51
943,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,H,B,15740,,,,,,,51
944,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,H,B,17626,,,,,,,51
945,,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,D,B,4234,,,9606.0,,,,51
946,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,H,B,5640,,,,,,,51
947,,Rattus norvegicus,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,H,B,5272,,,10116.0,,,,51
948,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,H,B,4622,,,,,,CHO,51
949,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,H,B,17085,,,,,,,51
950,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,H,B,3025,,,,,,,51
951,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,H,B,15315,,,,,,,51
952,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,H,B,15267,,,,,,,51
953,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,H,B,17158,,,,,,HeLa,51
954,,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,D,B,14214,,,9606.0,,,HeLa,51
955,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,B,17133,,,,,,,51
956,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,H,B,16532,,,,,,,51
957,,Homo sapiens,Affinity for 5-hydroxytryptamine 1A receptor subtype,D,B,2391,,,9606.0,,,,51
958,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,H,B,14447,,,,,,,51
959,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,H,B,14447,,,,,,,51
960,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,H,B,15086,,,,,,,51
961,,Homo sapiens,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,D,B,13051,,,9606.0,,,,51
962,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",H,F,16026,,,,,,,51
963,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,H,B,17085,,,,,,,51
964,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,B,17133,,,,,,,51
965,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,H,B,17133,,,,,,,51
966,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,B,17211,,,,,,HeLa,51
967,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,H,B,17211,,,,,,HeLa,51
968,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,B,17211,,,,,,HeLa,51
969,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,B,17211,,,,,,HeLa,51
970,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,F,16394,,,,,,,51
971,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,F,16394,,,,,,,51
972,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,F,16394,,,,,,,51
973,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,H,F,16394,In vivo,,,,,,51
974,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,H,B,16394,,,,,,,51
975,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,H,F,15740,,,,,,,51
976,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,H,F,15740,,,,,,,51
977,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,H,B,15740,,,,,,,51
978,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,F,17296,,,,,,HEK293,51
979,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",H,F,5640,,,,,,,51
980,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",H,F,5640,,,,,,,51
981,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",H,F,5640,,,,,,,51
982,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",H,F,5640,,,,,,,51
983,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,F,2759,,,,,,CHO,51
984,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",H,F,16394,,,,,,,51
985,,Homo sapiens,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",D,F,16394,,,9606.0,,,,51
986,,Homo sapiens,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,D,F,3445,,,9606.0,,,,51
987,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,H,B,4316,,,,,,CHO,51
988,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,H,B,4316,,,,,,,51
989,,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,D,F,15180,,,9606.0,,,,51
990,,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,D,F,15180,,,9606.0,,,,51
991,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,F,15042,,,,,,,51
992,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,F,15042,,,,,,,51
993,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,H,F,15042,,,,,,,51
994,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,F,15042,,,,,,,51
995,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,F,15042,,,,,,,51
996,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,F,15042,,,,,,,51
997,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,H,F,15042,,,,,,,51
998,,Homo sapiens,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,F,15180,,,9606.0,,,HeLa,51
999,,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,F,15180,,,9606.0,,,HeLa,51
1000,,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,F,15180,,,9606.0,,,HeLa,51
1001,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",H,F,16245,,,,,,,51
1002,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,F,16026,,,,,,,51
1003,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,F,17296,,,,,,HEK293,51
1004,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),H,F,2759,,,,,,CHO,51
1005,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,H,F,2759,,,,,,CHO,51
1006,,Homo sapiens,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),D,F,2759,,,9606.0,,,CHO,51
1007,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),H,F,2759,,,,,,CHO,51
1008,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,H,F,15419,,,,,,,51
1009,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,H,F,15419,,,,,,,51
1010,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,F,16026,,,,,,,51
1011,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,H,B,1414,In vitro,,,,,,51
1012,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,H,B,1414,In vitro,,,,,,51
1013,,,Binding activity radioligand.,H,B,12861,,,,,,,51
1014,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,B,12861,,,,,,,51
1015,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,H,B,5104,,,,,,,51
1016,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,H,B,5105,,,,,,,51
1017,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,H,B,16312,,,,,,,51
1018,,Homo sapiens,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,D,B,15180,,,9606.0,,,,51
1019,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,H,B,5033,,,,,,,51
1020,,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,D,B,16909,,,9606.0,,,CHO,51
1021,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,H,F,2590,,,,,,,51
1022,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,H,F,2590,,,,,,,51
1023,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,H,B,16394,,,,,,,51
1024,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,D,B,4540,,,9606.0,,,HEK293,51
1025,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,H,B,17296,,,,,,HEK293,51
1026,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,H,B,17296,,,,,,HEK293,51
1027,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,H,B,15779,,,,,,HEK293,51
1028,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,H,B,15779,,,,,,HEK293,51
1029,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,H,B,15779,,,,,,HEK293,51
1030,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,H,B,6166,,,,,,,51
1031,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,H,B,15779,,,,,,HEK293,51
1032,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,H,B,4199,,,,,,HEK293,51
1033,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,H,B,15316,,,,,,,51
1034,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,H,B,14875,,,,,,,51
1035,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,H,B,14727,,,,,,HeLa,51
1036,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,H,B,14727,,,,,,,51
1037,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,H,B,15146,,,,,,HEK293,51
1038,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,H,B,5213,,,,,,HEK293,51
1039,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,H,B,16429,,,,,,,51
1040,,Homo sapiens,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,D,B,15042,,,9606.0,,,HeLa,51
1041,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,H,B,14818,,,,,,HEK293,51
1042,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",H,B,4829,,,,,,HEK293,51
1043,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,D,B,17200,,,,,,,51
1044,,Homo sapiens,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,D,B,13051,,,9606.0,,,,51
1045,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,H,B,5486,,,,,,,106
1046,,,Binding affinity against 5-HT1D receptor,H,B,5254,,,,,,,105
1047,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,B,5254,,,,,,,105
1048,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,B,15331,,,,,,,107
1049,,Homo sapiens,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,H,B,13506,,,9606.0,,,,10576
1050,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,H,B,15267,,,,,,,51
1051,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,H,F,16616,In vivo,,,,,,11863
1052,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,H,F,16616,In vivo,,,,,,11863
1053,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,H,F,16616,In vivo,,,,,,11863
1054,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,D,F,16616,,,10090.0,,,,11863
1055,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,D,F,16616,,,10090.0,,,,11863
1056,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,D,F,16616,,,10090.0,,,,11863
1057,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,D,F,16616,,,10090.0,,,,11863
1058,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,D,F,16616,,,10090.0,,,,11863
1059,,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,D,F,16616,,,10090.0,,,,11863
1060,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,H,B,10297,,,,,Hippocampus,,11863
1061,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,H,B,13704,,,,,,,11863
1062,,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,D,B,10297,,,10090.0,,Hippocampus,,11863
1063,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,H,B,10297,,,,,Hippocampus,,11863
1064,,Mus musculus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,D,B,10297,,,10090.0,,Hippocampus,,11863
1065,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,H,B,10297,,,,,Hippocampus,,11863
1066,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,H,B,217,,,,,,,11863
1067,,Mus musculus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,D,B,10297,,,10090.0,,Hippocampus,,11863
1068,,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,H,B,4921,,,9823.0,,,,51
1069,,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,H,B,4921,,,9823.0,,,,51
1070,,Sus scrofa,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,H,B,4996,,,9823.0,,,,51
1071,,Sus scrofa,Compound was evaluated for the binding affinity at 5- HT1A receptor,H,B,12918,,,9823.0,,,,51
1072,,Sus scrofa,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,H,B,5333,,,9823.0,,,,51
1073,,Sus scrofa,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,H,B,4437,,,9823.0,,,,51
1074,,Sus scrofa,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,H,B,1742,,,9823.0,,,,51
1075,,Sus scrofa,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,H,B,16688,,,9823.0,,,,51
1076,,Sus scrofa,Binding activity radioligand.,H,B,12861,,,9823.0,,,,51
1077,,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,H,B,12861,,,9823.0,,,,51
1078,,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,H,B,12861,,,9823.0,,,,51
1079,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,H,B,12490,,,,,,,10624
1080,,Sus scrofa,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,H,B,11828,,,9823.0,,,,51
1081,,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,H,B,11866,,,9823.0,,Hippocampus,,51
1082,,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,H,B,12827,,,9823.0,,,,51
1083,,Sus scrofa,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,H,B,12918,,,9823.0,,,,51
1084,,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,H,F,12919,,,9823.0,,,,51
1085,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,H,B,13047,,,9986.0,,,,51
1086,,Rattus norvegicus,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,D,B,15796,,,10116.0,,,,10576
1087,,Rattus norvegicus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",D,B,3651,,,10116.0,,Hippocampus,,10576
1088,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,H,B,188,,,,,,,10576
1089,Membranes,Rattus norvegicus,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",D,F,16616,,,10116.0,,,,10576
1090,Membranes,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",D,F,16616,,,10116.0,,Hippocampus,,10576
1091,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,B,12306,,,,,Hippocampus,,10576
1092,,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,D,B,17167,,,10116.0,,Hippocampus,,10576
1093,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,H,B,14776,,,,,,,10576
1094,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,H,B,12158,,,,,,,10576
1095,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,H,B,13481,,,,,,,10576
1096,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,B,13427,In vitro,,,,,,10576
1097,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,H,B,10210,,,,,,,10576
1098,Membranes,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,H,B,10205,,,,,,,10576
1099,Membranes,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,H,B,10205,,,,,,,10576
1100,Membranes,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,H,B,10205,,,,,,,10576
1101,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,D,B,12280,,,10116.0,,,,10576
1102,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,H,B,17386,,,,,,,10576
1103,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,H,B,13654,,,,,,,10576
1104,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,H,B,14423,,,,,Hippocampus,,10576
1105,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,H,B,15412,,,,,Hippocampus,,10576
1106,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,B,12073,,,,,Hippocampus,,10576
1107,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,D,B,4101,,,10116.0,,,,10576
1108,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,H,B,10062,,,,,,,10576
1109,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,H,B,6238,,,,,,,10576
1110,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,B,16273,,,,,,,10576
1111,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,H,B,11139,,,,,,,10576
1112,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,H,B,16796,,,,,,,10576
1113,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,D,B,9548,,,10116.0,,Brain,,10576
1114,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,H,B,10381,,,,,Brain,,10576
1115,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,H,B,13408,,,,,,,10576
1116,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,D,B,13825,,,10116.0,,Hippocampus,,10576
1117,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,H,B,11147,,,,,Hippocampus,,10576
1118,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,H,B,10552,,,,,,,10576
1119,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",H,B,10552,,,,,Striatum,,10576
1120,Membranes,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,D,B,17136,,,10116.0,,,,10576
1121,Membranes,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,D,B,5778,,,10116.0,,,,10576
1122,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,B,13481,,,,,Hippocampus,,10576
1123,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,H,B,13481,,,,,Hippocampus,,10576
1124,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,H,B,13630,,,,,Hippocampus,,10576
1125,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,B,16245,,,,,,,10576
1126,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,H,B,14509,,,,,Hippocampus,,10576
1127,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,H,B,14509,,,,,Hippocampus,,10576
1128,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,H,B,14509,,,,,Hippocampus,,10576
1129,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,H,B,14509,,,,,Hippocampus,,10576
1130,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,H,B,14256,,,,,,,10576
1131,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,H,B,11139,,,,,,,10576
1132,,Rattus norvegicus,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,D,B,11047,,,10116.0,,,,10576
1133,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,D,B,11047,,,10116.0,,,,10576
1134,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,D,B,11047,,,10116.0,,,,10576
1135,,Rattus norvegicus,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,D,B,2395,,,10116.0,,,CHO-K1,10576
1136,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,B,9699,,,,,,,10576
1137,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,D,B,12028,,,10116.0,,Hippocampus,,10576
1138,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,H,B,12028,,,,,Hippocampus,,10576
1139,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,B,5815,,,,,,,10576
1140,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,H,B,16616,,,,,,,10576
1141,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,H,B,5815,,,,,,,10576
1142,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",H,B,2761,,,,,Hippocampus,,10576
1143,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,H,B,13133,,,,,,,10576
1144,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,H,B,10444,,,,,,,10576
1145,,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,D,B,13278,,,10116.0,,,,10576
1146,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,H,B,15874,,,,,,,10576
1147,Membranes,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",H,B,10552,,,,,Striatum,,10576
1148,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),H,B,11130,,,,,,,10576
1149,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),H,B,11130,In vivo,,,,,,10576
1150,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,H,B,14542,,,,,Brain,,10576
1151,,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,D,B,13670,,,10116.0,,,,10576
1152,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,H,B,9888,,,,,,,10576
1153,Membranes,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,D,B,3678,,,10116.0,,,,10576
1154,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,H,B,11332,,,,,Hippocampus,,10576
1155,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,H,B,11332,,,,,Hippocampus,,10576
1156,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,H,B,1185,,,,,,,10576
1157,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,H,B,2014,,,,,,,10576
1158,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,H,B,1185,,,,,,,10576
1159,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,H,B,14429,,,,,,,10576
1160,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",H,B,16288,,,,,,,10576
1161,,Rattus norvegicus,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,D,B,5432,,,10116.0,,,,10576
1162,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,H,B,14429,,,,,,,10576
1163,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,H,B,13672,,,,,,,10576
1164,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,B,11296,,,,,Hippocampus,,10576
1165,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,H,B,11296,,,,,,,10576
1166,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,H,B,14749,,,,,,CHO,10576
1167,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,H,B,15086,,,,,,,10576
1168,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,H,B,13462,,,,,Hippocampus,,10576
1169,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,H,B,15363,,,,,,,10576
1170,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,H,B,15363,,,,,,,10576
1171,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,H,B,10796,,,,,,,10576
1172,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,H,B,12816,,,,,Brain,,10576
1173,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,B,13542,,,,,Hippocampus,,10576
1174,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,H,B,13308,,,,,,,10576
1175,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,H,B,13541,,,,,Hippocampus,,10576
1176,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,H,B,10058,,,,,Hippocampus,,10576
1177,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,H,B,10058,,,,,Hippocampus,,10576
1178,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,H,B,10058,,,,,Hippocampus,,10576
1179,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,H,B,10058,,,,,Hippocampus,,10576
1180,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,H,B,10058,,,,,Hippocampus,,10576
1181,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,H,B,10058,,,,,Hippocampus,,10576
1182,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,H,B,10058,,,,,Hippocampus,,10576
1183,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,H,B,10058,,,,,Hippocampus,,10576
1184,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,H,B,10058,,,,,Hippocampus,,10576
1185,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,H,B,10058,,,,,Hippocampus,,10576
1186,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,H,B,10058,,,,,Hippocampus,,10576
1187,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,H,B,10058,,,,,Hippocampus,,10576
1188,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,H,B,10058,,,,,Hippocampus,,10576
1189,,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,D,B,10058,,,10116.0,,Hippocampus,,10576
1190,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,H,B,10058,,,,,Hippocampus,,10576
1191,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,H,B,10058,,,,,Hippocampus,,10576
1192,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,H,B,12879,,,,,,,10576
1193,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,H,B,11964,,,,,,,10576
1194,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),H,B,11964,,,,,,,10576
1195,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),H,B,11964,,,,,,,10576
1196,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,H,B,9548,,,,,Brain,,10576
1197,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,H,B,9098,,,,,,,10576
1198,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,H,B,9098,,,,,,,10576
1199,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,H,B,9098,,,,,,,10576
1200,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,H,B,13248,,,,,,CHO,10576
1201,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,H,B,3147,,,,,,,10576
1202,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,H,B,13949,,,,,,,10576
1203,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),H,B,11883,,,,,,CHO,10576
1204,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),H,B,11883,,,,,,,10576
1205,,Rattus norvegicus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,D,B,11883,,,10116.0,,,,10576
1206,Membranes,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,B,15535,,,,,,,10576
1207,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,H,B,15535,,,,,,,10576
1208,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,H,B,15535,,,,,,,10576
1209,,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,D,B,16372,,,9606.0,,,CHO,51
1210,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,H,B,14608,,,,,,,10576
1211,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,D,B,4795,,,10116.0,,Hippocampus,,10576
1212,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,B,13863,,,,,,,10576
1213,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,H,B,13863,,,,,,,10576
1214,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,H,B,13863,,,,,,,10576
1215,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,H,B,13863,,,,,,,10576
1216,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,H,B,13863,,,,,,,10576
1217,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,H,B,13863,,,,,,,10576
1218,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,H,B,13863,,,,,,,10576
1219,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,H,B,13863,,,,,,,10576
1220,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,H,B,13863,,,,,,,10576
1221,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,H,B,13863,,,,,,,10576
1222,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,H,B,13863,,,,,,,10576
1223,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,H,B,13863,,,,,,,10576
1224,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,H,B,13863,,,,,,,10576
1225,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,H,B,13863,,,,,,,10576
1226,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,H,B,13863,,,,,,,10576
1227,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,H,B,9742,,,,,,,10576
1228,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,H,B,12073,,,,,,,10576
1229,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,H,B,4101,,,,,,,10576
1230,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,H,B,15360,,,,,,,10576
1231,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,B,11576,,,,,Hippocampus,,10576
1232,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,H,B,5834,,,,,,,10576
1233,,Rattus norvegicus,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,D,B,2395,,,10116.0,,,CHO-K1,10576
1234,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,H,B,1375,,,,,,,10576
1235,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,H,B,1375,,,,,,,10576
1236,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),H,B,3967,,,,,,,10576
1237,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,H,B,12884,,,,,,,10576
1238,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,H,B,2343,,,,,,,10576
1239,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",H,B,11511,,,,,,,10576
1240,,Rattus norvegicus,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",D,B,11511,,,10116.0,,,,10576
1241,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,H,F,16394,In vivo,,,,,,10576
1242,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),H,F,16394,In vivo,,,,,,10576
1243,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),H,F,16394,In vivo,,,,,,10576
1244,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),H,F,16394,In vivo,,,,,,10576
1245,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),H,F,16394,In vivo,,,,,,10576
1246,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),H,F,16394,In vivo,,,,,,10576
1247,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),H,F,16394,In vivo,,,,,,10576
1248,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),H,F,16394,In vivo,,,,,,10576
1249,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),H,F,16394,In vivo,,,,,,10576
1250,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),H,F,16394,In vivo,,,,,,10576
1251,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),H,F,16394,In vivo,,,,,,10576
1252,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),H,F,16394,In vivo,,,,,,10576
1253,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),H,F,16394,In vivo,,,,,,10576
1254,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),H,F,16394,In vivo,,,,,,10576
1255,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,H,F,16394,In vivo,,,,,,10576
1256,Membranes,Rattus norvegicus,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",D,F,16616,,,10116.0,,,,10576
1257,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,H,B,16796,,,,,,,10576
1258,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,H,B,16796,,,,,,,10576
1259,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,H,B,15629,,,,,,,10576
1260,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",H,F,13241,,,,,,,10576
1261,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,B,12073,,,,,Hippocampus,,10576
1262,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,H,B,14286,,,,,Hippocampus,,10576
1263,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,H,B,14542,,,,,Brain,,10576
1264,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,H,F,13630,,,,,,,10576
1265,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,H,F,13630,,,,,,,10576
1266,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,H,F,13630,,,,,,,10576
1267,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,H,F,13630,,,,,,,10576
1268,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,H,F,13630,,,,,,,10576
1269,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,H,F,13630,,,,,,,10576
1270,,Rattus norvegicus,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,D,F,13630,,,10116.0,,,,10576
1271,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,H,F,13630,,,,,,,10576
1272,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,H,F,13630,,,,,,,10576
1273,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,H,F,13630,,,,,,,10576
1274,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,H,F,13630,,,,,,,10576
1275,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,H,F,13630,,,,,,,10576
1276,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,H,F,13630,,,,,,,10576
1277,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,H,F,13630,,,,,,,10576
1278,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,H,F,13630,,,,,,,10576
1279,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,H,F,13630,,,,,,,10576
1280,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,H,F,13630,,,,,,,10576
1281,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,H,F,13630,,,,,,,10576
1282,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,H,F,13630,,,,,,,10576
1283,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,H,F,13630,,,,,,,10576
1284,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,H,F,13630,,,,,,,10576
1285,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,H,F,13630,,,,,,,10576
1286,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,H,F,13630,,,,,,,10576
1287,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,H,F,13630,,,,,,,10576
1288,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,H,B,9783,,,,,Hippocampus,,10576
1289,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,H,B,9783,,,,,Hippocampus,,10576
1290,Membranes,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,D,B,14331,,,10116.0,,,,10576
1291,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,H,B,15260,,,,,Hippocampus,,10576
1292,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,H,B,15260,,,,,Hippocampus,,10576
1293,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,H,B,15260,,,,,Hippocampus,,10576
1294,,Rattus norvegicus,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",D,F,16616,,,10116.0,,,,10576
1295,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,H,B,15629,,,,,,,10576
1296,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,H,B,15086,,,,,,,10576
1297,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,H,F,5717,,,,,,,10576
1298,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,H,B,12652,,,,,,,10576
1299,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,H,B,14608,,,,,Hippocampus,,10576
1300,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,B,12306,,,,,Hippocampus,,10576
1301,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,B,12306,,,,,Hippocampus,,10576
1302,,Rattus norvegicus,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,D,B,15247,,,10116.0,,,,10576
1303,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,H,B,17529,,,,,Hippocampus,,10576
1304,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,H,B,14826,,,,,Hippocampus,,10576
1305,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,H,B,14826,,,,,Hippocampus,,10576
1306,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,B,13241,,,,,Hippocampus,,10576
1307,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,H,B,14093,,,,,Hippocampus,,10576
1308,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,H,B,14093,,,,,Hippocampus,,10576
1309,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,H,B,14442,,,,,Brain,,10576
1310,,,Affinity for 5-hydroxytryptamine 1A receptor site,H,B,9919,,,,,,,10576
1311,,,Affinity for 5-hydroxytryptamine 1A receptor site,H,B,9919,,,,,,,10576
1312,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,H,B,11440,,,,,Hippocampus,,10576
1313,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,H,B,11257,,,,,,,10576
1314,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,H,B,10330,,,,,,,10576
1315,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,D,B,17331,,,10116.0,,Hippocampus,,10576
1316,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,H,B,16567,,,,,,,10576
1317,,Rattus norvegicus,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",D,B,12058,,,10116.0,,,,10576
1318,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,H,B,9699,,,,,Hippocampus,,10576
1319,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,H,B,9547,,,,,,,10576
1320,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,H,B,10330,,,,,,,10576
1321,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,H,B,14331,,,,,,,10576
1322,,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,D,B,14060,,,10116.0,,,,10576
1323,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,H,B,14744,,,,,Hippocampus,,10576
1324,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,H,B,13506,,,,,,,10576
1325,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,B,10862,,,,,Brain,,10576
1326,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,B,10862,,,,,Brain,,10576
1327,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,H,B,10062,,,,,,,10576
1328,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,H,B,12073,,,,,,,10576
1329,,,GTPgammaS radioligand binding assay,H,B,14875,,,,,,,106
1330,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,H,B,2391,,,,,,,106
1331,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,H,F,2391,,,,,,,106
1332,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,H,F,2391,,,,,,,106
1333,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,H,B,2391,,,,,,,106
1334,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,H,B,2391,,,,,,,106
1335,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,H,F,2391,,,,,,,106
1336,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,H,B,17211,,,,,,HeLa,106
1337,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,H,B,17211,,,,,,HeLa,106
1338,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,D,B,6491,,,9606.0,,,,106
1339,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,H,B,16190,,,,,,CHO,106
1340,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,H,B,14165,,,,,,,106
1341,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,H,B,14165,,,,,,,106
1342,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,D,B,4234,,,9606.0,,,,106
1343,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,H,B,6328,,,,,,,106
1344,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,B,14770,,,,,,,106
1345,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,H,B,2598,,,,,,,106
1346,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,H,B,6897,,,,,,,106
1347,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,H,B,6897,,,,,,,106
1348,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,H,B,6013,,,,,,,106
1349,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,H,B,5843,,,,,,,106
1350,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,H,B,14454,,,,,,,106
1351,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,H,B,16209,,,,,,,106
1352,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,H,B,3935,,,,,,,106
1353,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,H,F,13729,,,,,,CHO-K1,106
1354,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,H,F,14251,,,,,,,106
1355,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,H,B,17085,,,,,,,106
1356,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,H,B,3025,,,,,,,106
1357,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,H,B,15315,,,,,,,106
1358,,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,D,B,14214,,,9606.0,,,,106
1359,,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,D,B,3804,,,9606.0,,,,106
1360,,Homo sapiens,Affinity for 5-hydroxytryptamine 1B receptor subtype,D,B,2391,,,9606.0,,,,106
1361,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,D,B,4175,,,9606.0,,,,106
1362,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,H,B,17296,,,,,,CHO,106
1363,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,H,B,17085,,,,,,,106
1364,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,H,B,17211,,,,,,HeLa,106
1365,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,H,B,17211,,,,,,HeLa,106
1366,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,H,B,17211,,,,,,HeLa,106
1367,,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,D,B,15926,,,9606.0,,,,106
1368,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,H,B,16312,,,,,,CHO-K1,106
1369,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,H,B,5843,,,,,,,106
1370,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,H,B,5843,,,,,,,106
1371,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,H,B,16312,,,,,,CHO-K1,106
1372,,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,D,B,15926,,,9606.0,,,,106
1373,,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,D,B,15926,,,9606.0,,,,106
1374,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,D,B,4540,,,9606.0,,,CHO,106
1375,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,H,B,6166,,,,,,,106
1376,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,H,B,17296,,,,,,CHO,106
1377,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,H,B,17296,,,,,,CHO,106
1378,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,H,B,17296,,,,,,CHO,106
1379,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,B,15779,,,,,,CHO,106
1380,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,B,15779,,,,,,CHO,106
1381,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,H,B,15779,,,,,,CHO,106
1382,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,H,B,4199,,,,,,CHO,106
1383,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,D,B,14875,,,9606.0,,,,106
1384,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,H,B,15146,,,,,,CHO,106
1385,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,H,B,5213,,,,,,,106
1386,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,H,B,14818,,,,,,CHO,106
1387,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",H,B,4829,,,,,,CHO,106
1388,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,H,F,14454,,,,,,,106
1389,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,H,F,14454,,,,,,,106
1390,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",H,F,14875,,,,,,CHO,106
1391,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",H,F,14875,,,,,,CHO,106
1392,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",H,F,15250,,,,,,,105
1393,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,H,B,15250,,,,,,CHO,105
1394,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,H,B,15086,,,,,,,17105
1395,,Oryctolagus cuniculus,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,H,F,3025,,,9986.0,,,,106
1396,,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,H,B,14998,,,9986.0,,,,106
1397,,Oryctolagus cuniculus,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",H,B,14998,,,9986.0,,,,106
1398,,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,H,B,14998,,,9986.0,,,,106
1399,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,H,B,13969,,,,,,,10577
1400,,,Binding affinity for 5-hydroxytryptamine 1B receptor,D,B,13392,,,,,,,10577
1401,,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,D,B,3651,,,10116.0,,Striatum,,10577
1402,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,H,B,10025,,,,,,,10577
1403,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,H,B,13863,,,,,,,10576
1404,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,H,B,13863,,,,,,,10576
1405,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,H,B,13863,,,,,,,10576
1406,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,H,B,13863,,,,,,,10576
1407,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,H,B,13863,,,,,,,10576
1408,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,H,B,13863,,,,,,,10576
1409,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,H,B,4622,,,,,Hippocampus,,10576
1410,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,H,B,14911,,,,,,,10576
1411,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,H,B,12678,,,,,Hippocampus,,10576
1412,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,H,B,12678,,,,,Hippocampus,,10576
1413,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,B,14235,,,,,Hippocampus,,10576
1414,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,H,B,14949,,,,,Hippocampus,,10576
1415,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,H,B,14949,,,,,Hippocampus,,10576
1416,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,H,B,14949,,,,,Hippocampus,,10576
1417,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,H,B,14949,,,,,Hippocampus,,10576
1418,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,H,B,14949,,,,,Hippocampus,,10576
1419,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,H,B,16118,,,,,,,10576
1420,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,H,B,3268,,,,,,,10576
1421,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,H,B,3268,,,,,,,10576
1422,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,H,B,16117,,,,,,,10576
1423,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,H,B,9783,,,,,Hippocampus,,10576
1424,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,H,B,9783,,,,,Hippocampus,,10576
1425,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,D,B,14356,,,10116.0,,Hippocampus,,10576
1426,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,H,F,15740,,,,,,,10576
1427,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,B,12306,,,,,Hippocampus,,10576
1428,,Rattus norvegicus,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,D,B,13348,,,10116.0,,Hippocampus,,10576
1429,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,H,B,10394,,,,,,,10576
1430,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,H,B,15260,,,,,Hippocampus,,10576
1431,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,B,10046,,,,,Hippocampus,,10576
1432,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,H,F,15260,,,,,Hippocampus,,10576
1433,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,H,B,12851,,,,,,,10576
1434,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,D,B,2148,,,10116.0,,Hippocampus,,10576
1435,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,H,B,13134,,,,,,,10576
1436,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,H,B,12462,,,,,,,10576
1437,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,H,B,12462,,,,,,,10576
1438,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,H,B,12462,,,,,,CHO,10576
1439,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,H,B,11933,,,,,,,10576
1440,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,H,B,11933,,,,,,,10576
1441,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,D,B,403,,,10116.0,,Hippocampus,,10576
1442,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,H,B,15538,,,,,Hippocampus,,10576
1443,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,H,B,15538,,,,,Hippocampus,,10576
1444,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,H,B,15538,,,,,Hippocampus,,10576
1445,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,H,B,12464,,,,,,,10576
1446,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,H,B,1455,,,,,,,10576
1447,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,H,B,12652,,,,,,,10576
1448,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,H,B,12639,,,,,Hippocampus,,10576
1449,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,H,B,13949,,,,,,,10576
1450,,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,D,B,12463,,,10116.0,,,,10576
1451,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,H,B,14829,,,,,Hippocampus,,10576
1452,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,H,B,14829,,,,,Hippocampus,,10576
1453,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,H,B,12092,,,,,,,10576
1454,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,H,B,403,,,,,,,10576
1455,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,H,B,403,,,,,,,10576
1456,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,H,B,3967,,,,,,,10576
1457,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,D,B,12771,,,10116.0,,,,10576
1458,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,H,B,15086,,,,,,,10576
1459,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,H,B,14909,,,,,Hippocampus,,10576
1460,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,H,B,14949,,,,,Hippocampus,,10576
1461,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,D,B,2309,,,10116.0,,Hippocampus,,10576
1462,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,B,4170,,,,,,,10576
1463,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,D,B,11642,,,10116.0,,Hippocampus,,10576
1464,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,H,B,11642,,,,,Hippocampus,,10576
1465,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,H,B,12953,,,,,Hippocampus,,10576
1466,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,H,B,12953,,,,,Hippocampus,,10576
1467,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,H,B,12953,,,,,Hippocampus,,10576
1468,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",H,B,12903,,,,,,CHO,10576
1469,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,H,B,12536,,,,,,,10576
1470,,,The inhibition activity of 5-HT1A at 1 uM,H,B,10058,,,,,,,10576
1471,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",H,B,12902,,,,,,CHO-K1,10576
1472,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,H,B,14057,,,,,,,10576
1473,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,H,B,11296,,,,,,,10576
1474,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,B,11296,,,,,Hippocampus,,10576
1475,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,B,11296,,,,,Hippocampus,,10576
1476,Membranes,Rattus norvegicus,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,D,F,16616,,,10116.0,,,,10576
1477,Membranes,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",D,F,16616,,,10116.0,,Hippocampus,,10576
1478,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,H,B,16567,,,,,,,10576
1479,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,H,B,16567,,,,,,,10576
1480,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,H,B,16567,,,,,,,10576
1481,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,H,B,16567,,,,,,,10576
1482,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,H,B,17136,,,,,,,10576
1483,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,H,B,17136,,,,,,,10576
1484,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,D,B,16616,,,10116.0,,,,10576
1485,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,H,B,17331,,,,,Hippocampus,,10576
1486,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,H,B,17331,,,,,Hippocampus,,10576
1487,,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,D,B,17167,,,10116.0,,Hippocampus,,10576
1488,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,H,F,15740,,,,,,,10576
1489,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,H,F,15740,,,,,,,10576
1490,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,H,B,4671,,,,,,,10576
1491,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,H,B,10058,,,,,Hippocampus,,10576
1492,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,H,B,10058,,,,,Hippocampus,,10576
1493,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,H,B,10058,,,,,Hippocampus,,10576
1494,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,H,B,12073,,,,,,,10576
1495,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),H,B,2759,,,,,,,10576
1496,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),H,F,2759,,,,,,,10576
1497,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),H,B,2759,,,,,,,10576
1498,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),H,F,2759,,,,,,,10576
1499,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,H,F,2759,,,,,,,10576
1500,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,B,9737,,,,,Brain,,10576
1501,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,H,B,9737,,,,,,,10576
1502,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,H,F,5717,,,,,,,10576
1503,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,H,B,12253,,,,,Hippocampus,,10576
1504,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,H,B,14025,,,,,,,10576
1505,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,H,B,10425,,,,,,,10576
1506,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,H,B,14998,,,,,,,10576
1507,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,H,B,13694,,,,,Hippocampus,,10576
1508,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,H,B,13694,,,,,Hippocampus,,10576
1509,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,H,B,4342,,,,,,,10576
1510,,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 1A receptor,D,B,12936,,,10116.0,,,,10576
1511,,Rattus norvegicus,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,D,B,13144,,,10116.0,,,,10576
1512,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,H,B,13343,,,,,,,10576
1513,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,B,12132,,,,,,,10576
1514,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,H,B,15419,,,,,,,10576
1515,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,H,B,1479,,,,,Hippocampus,,10576
1516,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,H,B,14287,,,,,,,10576
1517,,,Binding affinity at 5-hydroxytryptamine 1A receptor,H,B,13116,,,,,,,10576
1518,Membranes,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,D,B,2759,,,10116.0,,,,10576
1519,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,H,B,2759,,,,,,,10576
1520,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",H,B,14748,,,,,,,10576
1521,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,B,12304,,,,,,,10576
1522,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,D,B,12409,,,10116.0,,Hippocampus,,10576
1523,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,D,B,12409,,,10116.0,,Hippocampus,,10576
1524,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,H,B,13267,,,,,Hippocampus,,10576
1525,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,B,15194,,,,,,,10576
1526,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,H,B,14256,,,,,,,10576
1527,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,H,B,16567,,,,,,,10576
1528,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,H,F,15740,,,,,,,10576
1529,,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,D,B,13278,,,10116.0,,,,12687
1530,Membranes,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,B,1970,,,,,,,10626
1531,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,H,B,10034,,,,,Brain,,10576
1532,,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,H,B,13348,,,10116.0,,,,51
1533,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,H,F,13630,,,,,,,10576
1534,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,B,10862,,,,,Brain,,10576
1535,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",H,B,12058,,,,,,,10576
1536,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,H,B,4639,,,,,,,51
1537,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,H,B,15453,,,,,,,51
1538,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,B,4820,,,,,,,51
1539,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,H,B,1089,,,,,,,51
1540,Brain membranes,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,H,B,386,,,,,,,51
1541,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,H,B,6011,,,,,,,51
1542,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,H,B,5014,,,,,,,51
1543,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,H,B,4402,,,,,,,51
1544,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,B,17066,,,,,,,51
1545,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,H,B,17515,,,,,,,51
1546,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,B,2474,,,,,,,51
1547,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,H,B,4775,,,,,,,51
1548,,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,D,B,14294,,,9606.0,,,,51
1549,,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,D,B,14294,,,9606.0,,,,51
1550,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,B,12249,,,,,,CHO,51
1551,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,H,B,11376,,,,,,,51
1552,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,B,2474,In vivo,,,,,,51
1553,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,B,13311,,,,,Hippocampus,,51
1554,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,H,B,4373,,,,,,,51
1555,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,H,B,1633,,,,,,,51
1556,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,H,B,11866,,,,,,,51
1557,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,H,B,4373,,,,,,,51
1558,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,H,B,4687,,,,,,,51
1559,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,H,B,16946,,,,,,,11863
1560,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,H,B,13291,,,,,,,11863
1561,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,H,B,14159,,,,,,,11863
1562,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,H,B,10812,,,,,,,11863
1563,,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,D,B,3032,,,10090.0,,,CHO,11863
1564,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,H,B,16655,,,,,,,11863
1565,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,H,B,14532,,,,,,,11863
1566,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,B,13944,,,,,,,11863
1567,,,Binding affinity against serotonergic 5-HT1a receptor,H,B,13033,,,,,,,11863
1568,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,H,B,10321,,,,,,,11863
1569,,Mus musculus,Binding affinity for 5-hydroxytryptamine 1A receptor,D,B,2968,,,10090.0,,,,11863
1570,,,Binding affinity at 5-hydroxytryptamine 1A receptor,H,B,13964,,,,,,,11863
1571,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",H,B,15527,,,,,,,11863
1572,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,B,12248,,,,,,CHO,11863
1573,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,B,12249,,,,,,CHO,11863
1574,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,H,B,15120,,,,,,,11863
1575,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,H,B,13313,,,,,,,11863
1576,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,H,B,2613,,,,,,,11863
1577,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,H,B,16700,,,,,,,11863
1578,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,H,B,2201,,,,,,,11863
1579,,Mus musculus,Binding affinity against 5-hydroxytryptamine 1A receptor,D,B,1274,,,10090.0,,,,11863
1580,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,H,B,1317,,,,,,,11863
1581,,,Tested against 5-hydroxytryptamine 1A receptor,H,B,12146,,,,,,,11863
1582,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,H,B,14059,,,,,,,11863
1583,,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,H,B,14025,,,9986.0,,,,106
1584,,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,H,B,14025,,,9986.0,,,,106
1585,,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,D,B,14447,,,9593.0,,,HEK293,105571
1586,,Cavia porcellus,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,H,F,3025,In vivo,,10141.0,,,,106
1587,,Cavia porcellus,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,H,F,3025,In vivo,,10141.0,,,,106
1588,,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,H,F,15329,,,10141.0,,,,106
1589,,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,H,F,15329,,,10141.0,,,,106
1590,,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,H,F,15847,,,10141.0,,,,106
1591,,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,H,F,15847,,,10141.0,,,,106
1592,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,H,F,14165,,,,,,,106
1593,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),H,F,14214,,,,,,,106
1594,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),H,F,14214,,,,,,,106
1595,,Homo sapiens,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,D,F,14214,,,9606.0,,,,106
1596,,Homo sapiens,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,D,F,13729,,,9606.0,,,CHO-K1,106
1597,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,H,F,3025,,,,,,CHO,106
1598,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,H,B,2391,,,,,,,106
1599,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,H,F,2391,,,,,,,106
1600,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",H,F,14956,,,,,,CHO,106
1601,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,H,F,2598,,,,,,CHO,106
1602,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,H,F,2598,,,,,,CHO,106
1603,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,H,F,2598,,,,,,CHO,106
1604,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,H,F,2598,,,,,,CHO,106
1605,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",H,F,14956,,,,,,,106
1606,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",H,F,14956,,,,,,,106
1607,,Homo sapiens,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,D,B,14214,,,9606.0,,,,106
1608,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,H,B,3463,,,,,,CHO,106
1609,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,H,B,15331,,,,,,,106
1610,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1B receptor,D,B,16146,,,9606.0,,,,106
1611,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,D,B,14159,,,9606.0,,,CHO,106
1612,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,H,B,14158,,,,,,CHO,106
1613,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,H,B,14159,,,,,,,106
1614,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,H,B,15250,,,,,,CHO,106
1615,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,H,B,15250,,,,,,CHO,106
1616,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,H,B,15331,,,,,,CHO,106
1617,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,H,B,15332,,,,,,CHO,106
1618,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,H,B,14956,,,,,,CHO,106
1619,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),H,B,3805,,,,,,,106
1620,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,H,B,14875,,,,,,,106
1621,,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,F,14454,,,9986.0,,,,105
1622,,Oryctolagus cuniculus,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,F,14454,,,9986.0,,,,105
1623,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),H,B,16288,,,,,,,105
1624,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),H,B,16288,,,,,,,105
1625,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,H,B,16312,,,,,,,105
1626,,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,H,B,1348,,,9913.0,,,,105
1627,,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,H,B,5834,,,9913.0,,,,105
1628,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,H,B,13366,,,9913.0,,Striatum,,105
1629,,Bos taurus,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,H,B,1414,,,9913.0,,,,105
1630,,Bos taurus,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,H,B,14998,,,9913.0,,,,105
1631,,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,H,B,11473,,,9913.0,,,,105
1632,,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,H,B,11473,,,9913.0,,,,105
1633,,Bos taurus,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,H,B,10639,,,9913.0,,,,105
1634,,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,H,B,10639,,,9913.0,,,,105
1635,,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,H,B,1375,,,9913.0,,,,105
1636,,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,H,B,1375,,,9913.0,,,,105
1637,,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,H,B,16532,,,9913.0,,,,105
1638,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,H,B,11147,,,9913.0,,,,105
1639,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,H,B,13366,,,9913.0,,Striatum,,105
1640,,Bos taurus,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,H,B,10444,,,9913.0,,,,105
1641,,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,H,B,16532,,,9913.0,,,,105
1642,,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,H,B,16532,,,9913.0,,,,105
1643,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,H,B,12827,,,9913.0,,,,105
1644,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,H,B,12827,,,9913.0,,,,105
1645,,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,F,12919,,,9913.0,,,,105
1646,,Bos taurus,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,H,B,14025,,,9913.0,,,,105
1647,,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,F,12919,,,9913.0,,,,105
1648,,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,F,12919,,,9913.0,,,,105
1649,,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,F,12919,,,9913.0,,,,105
1650,,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,H,B,14447,,,9593.0,,,HEK293,105
1651,,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,D,B,1375,,,10141.0,,,,105570
1652,,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,D,B,1375,,,10141.0,,,,105570
1653,,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,D,F,12409,,,10141.0,,,,105570
1654,,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,F,12409,,,10141.0,,,,105570
1655,,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,D,F,12409,,,10141.0,,,,105570
1656,,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,D,F,12409,,,10141.0,,,,105570
1657,,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,D,F,12409,,,10141.0,,,,105570
1658,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1D receptor,D,B,11574,,,10141.0,,,,105570
1659,,Cavia porcellus,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,D,B,1558,,,10141.0,,,,105570
1660,,Cavia porcellus,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,F,12409,,,10141.0,,,,105570
1661,,Cavia porcellus,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,F,12409,,,10141.0,,,,105570
1662,,Cavia porcellus,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,F,12409,,,10141.0,,,,105570
1663,,Cavia porcellus,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,D,F,12409,,,10141.0,,,,105570
1664,,Cavia porcellus,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,D,B,12253,,,10141.0,,,,105570
1665,,Cavia porcellus,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,D,B,12936,,,10141.0,,,,105570
1666,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,H,B,13181,,,10141.0,,,,105
1667,,Cavia porcellus,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,D,B,12409,,,10141.0,,Striatum,,105570
1668,,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,D,B,10639,,,10141.0,,,,105570
1669,,,Binding affinity against 5-hydroxytryptamine 1D receptor,H,B,5254,,,,,,,51
1670,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,H,B,13051,,,,,,,106
1671,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,H,F,3463,,,,,,,105
1672,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,H,F,15315,,,,,,,105
1673,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,H,F,6011,,,,,,,105
1674,,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",D,F,14159,,,9606.0,,,CHO,105
1675,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",H,F,14159,,,,,,CHO,105
1676,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,H,B,15250,,,,,,CHO,105
1677,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,H,B,15250,,,,,,CHO,105
1678,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",H,F,15331,,,,,,CHO,105
1679,,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",D,F,15332,,,9606.0,,,CHO,105
1680,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",H,F,15332,,,,,,CHO,105
1681,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",H,F,3294,,,,,,CHO,105
1682,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",H,F,14158,,,,,,CHO,105
1683,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",H,F,14956,,,,,,CHO,105
1684,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,H,F,12469,,,,,,,105
1685,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,H,F,3463,,,,,,CHO,105
1686,,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",D,F,15250,,,9606.0,,,CHO,105
1687,,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",D,F,15250,,,9606.0,,,CHO,105
1688,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",H,F,14956,,,,,,,105
1689,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",H,F,14159,,,,,,,105
1690,,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",D,F,14159,,,9606.0,,,,105
1691,,Homo sapiens,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,D,F,14499,,,9606.0,,,CHO,105
1692,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,H,F,15315,,,,,,,105
1693,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),H,B,3294,In vitro,,,,,,105
1694,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,H,B,3463,,,,,,CHO,105
1695,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,H,B,15331,,,,,,,105
1696,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,B,14159,,,9606.0,,,CHO,105
1697,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,H,B,14158,,,,,,CHO,105
1698,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,H,B,14159,,,,,,,105
1699,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,H,B,15250,,,,,,CHO,105
1700,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,B,15250,,,,,,CHO,105
1701,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,B,15331,,,,,,CHO,105
1702,,Homo sapiens,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,B,15332,,,9606.0,,,CHO,105
1703,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,B,14499,,,9606.0,,,CHO,105
1704,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,B,15332,,,,,,CHO,105
1705,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,H,B,14956,,,,,,CHO,105
1706,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),H,B,3805,,,,,,,105
1707,,Homo sapiens,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,D,B,6011,,,9606.0,,,CHO,105
1708,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,H,B,16190,,,,,,CHO,105
1709,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,H,B,14165,,,,,,,105
1710,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,D,B,4234,,,9606.0,,,,105
1711,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",H,B,15527,,,,,,,105
1712,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,H,B,6328,,,,,,,105
1713,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,H,B,16209,,,,,,,105
1714,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,H,B,14770,,,,,,,105
1715,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,H,B,2598,,,,,,,105
1716,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,H,B,6897,,,,,,,105
1717,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,H,B,6013,,,,,,,105
1718,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,H,B,5843,,,,,,,105
1719,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,H,B,14454,,,,,,,105
1720,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,H,B,14454,,,,,,,105
1721,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,H,B,14454,,,,,,,105
1722,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,H,B,15818,,,,,,,105
1723,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,H,F,13729,,,,,,CHO-K1,105
1724,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),D,B,6011,In vitro,,9606.0,,,,105
1725,,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,D,B,4234,,,9606.0,,,,105
1726,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,H,B,17085,,,,,,,105
1727,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,H,B,3025,,,,,,,105
1728,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,H,B,15315,,,,,,,105
1729,,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,D,B,14214,,,9606.0,,,,105
1730,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,B,3804,,,9606.0,,,,105
1731,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,H,B,16700,,,,,,,105
1732,,Homo sapiens,Affinity for 5-hydroxytryptamine 1D receptor subtype,D,B,2391,,,9606.0,,,,105
1733,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,B,4175,,,9606.0,,,,105
1734,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,H,B,17085,,,,,,,105
1735,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,H,B,17085,,,,,,,105
1736,,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,D,B,15926,,,9606.0,,,,105
1737,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,H,B,16312,,,,,,CHO-K1,105
1738,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,H,B,16312,,,,,,CHO-K1,105
1739,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,H,B,14956,,,,,,CHO,104802
1740,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",H,F,3294,,,,,,,105
1741,,,Binding activity radioligand.,H,B,12861,,,,,,,105
1742,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,B,12861,,,,,,,105
1743,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,H,B,16312,,,,,,CHO-K1,105
1744,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,H,B,5104,,,,,,,105
1745,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,H,B,5105,,,,,,,105
1746,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,H,B,14499,,,,,,,105
1747,,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor,D,B,15926,,,9606.0,,,,105
1748,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,D,B,4540,,,9606.0,,,CHO,105
1749,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,H,B,15779,,,,,,CHO,105
1750,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,B,15779,,,,,,CHO,105
1751,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,H,B,6166,,,,,,,105
1752,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,H,B,15779,,,,,,CHO,105
1753,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,H,B,15779,,,,,,CHO,105
1754,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,H,B,17451,,,,,,HEK293,105
1755,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,H,B,17451,,,,,,HEK293,105
1756,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,H,B,17451,,,,,,HEK293,105
1757,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,H,B,4199,,,,,,CHO,105
1758,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,B,14875,,,9606.0,,,,105
1759,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,H,B,15146,,,,,,CHO,105
1760,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,H,B,5213,,,,,,,105
1761,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,H,B,14818,,,,,,CHO,105
1762,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",H,B,4829,,,,,,CHO,105
1763,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,H,F,14454,,,,,,,105
1764,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,H,F,14454,,,,,,,105
1765,,,Binding affinity against 5-HT2C receptor,H,B,5254,,,,,,,108
1766,,,Binding affinity against 5-hydroxytryptamine 1D receptor,H,B,5254,,,,,,,108
1767,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,H,B,10639,,,,,,,10577
1768,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,H,F,10639,,,,,,,10577
1769,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",H,B,12352,,,,,,,10577
1770,,,Binding affinity towards 5-HT1B was determined,H,B,9098,,,,,,,10577
1771,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,H,B,14430,,,,,,,10577
1772,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",H,B,13657,,,,,,,10577
1773,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",H,B,13657,,,,,,,10577
1774,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,B,15854,,,,,,,10577
1775,,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,D,B,10639,,,10116.0,,,,10577
1776,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,H,B,10025,,,,,,,10577
1777,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",H,B,10025,,,,,,,10577
1778,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,H,B,14286,,,,,,,10577
1779,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,H,B,3651,,,,,Striatum,,10577
1780,,Rattus norvegicus,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,D,B,14178,,,10116.0,,,,10577
1781,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,H,B,10639,,,,,,,10577
1782,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,H,B,13605,,,,,Striatum,,10577
1783,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,H,B,5834,,,,,Striatum,,10577
1784,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,H,B,10922,,,,,Striatum,,10577
1785,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,H,B,14286,,,,,,,10577
1786,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,H,B,11825,,,,,,,10577
1787,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,H,B,14826,,,,,Striatum,,10577
1788,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,H,B,9699,,,,,Striatum,,10577
1789,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,H,B,14423,,,,,,,10577
1790,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,H,B,10062,,,,,,,10577
1791,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,H,B,10062,,,,,,,10577
1792,,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,D,B,12280,,,10116.0,,,,10577
1793,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,H,B,15412,,,,,Striatum,,10577
1794,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,H,B,15412,,,,,Striatum,,10577
1795,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,H,B,10062,,,,,,,10577
1796,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,H,B,11147,,,,,,,10577
1797,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,H,B,9547,,,,,,,10577
1798,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,H,B,10444,,,,,,,10577
1799,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,H,B,12469,,,,,Striatum,,10577
1800,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,H,B,9098,,,,,,,10577
1801,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,H,B,9098,,,,,,,10577
1802,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,H,B,9699,,,,,,,10577
1803,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,H,B,10394,,,,,,,10577
1804,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,H,B,12092,,,,,,,10577
1805,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,H,B,16700,,,,,,,10577
1806,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,D,B,403,,,10116.0,,,,10577
1807,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1B receptor,D,B,12771,,,10116.0,,,,10577
1808,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,H,B,11642,,,,,,,10577
1809,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,H,B,12953,,,,,,,10577
1810,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,H,B,12953,,,,,,,10577
1811,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,H,B,12953,,,,,Striatum,,10577
1812,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,H,B,12953,,,,,,,10577
1813,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,B,9737,,,,,Brain,,10577
1814,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,H,B,9737,,,,,,,10577
1815,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,B,9737,,,,,Brain,,10577
1816,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,H,B,12827,,,,,,,10577
1817,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,H,B,5033,,,,,,,10577
1818,,Rattus norvegicus,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,D,B,9786,,,10116.0,,,,10577
1819,,,Binding affinity at 5-hydroxytryptamine 1B receptor,H,B,13116,,,,,,,10577
1820,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,H,B,16429,,,,,,,10577
1821,,Rattus norvegicus,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,D,B,12409,,,10116.0,,,,10577
1822,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,H,B,15194,,,,,,,10577
1823,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,B,15194,,,,,,,10577
1824,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,H,B,5486,,,,,,,104686
1825,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,H,B,4639,,,,,,,106
1826,Brain membranes,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,H,B,386,,,,,,,106
1827,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,H,B,2474,,,,,,,106
1828,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,H,B,6011,,,,,,,106
1829,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,H,B,5014,,,,,,,106
1830,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,H,B,17515,,,,,,,106
1831,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,H,B,4373,,,,,,,106
1832,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,H,B,1633,,,,,,,106
1833,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,H,B,1633,,,,,,,106
1834,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,H,B,4373,,,,,,,106
1835,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,H,B,4687,,,,,,,106
1836,,,Binding affinity against 5-hydroxytryptamine 1B receptor,H,B,11574,,,,,,,106
1837,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,H,B,10321,,,,,,,106
1838,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,B,15527,,,,,,,106
1839,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,H,B,17200,,,,,,,106
1840,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,H,B,14423,,,,,,,104802
1841,,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,H,B,5834,,,9913.0,,,,108
1842,,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,H,B,11473,,,9823.0,,,,108
1843,,Sus scrofa,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,H,B,11473,,,9823.0,,,,108
1844,,Sus scrofa,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,H,B,10639,,,9823.0,,,,108
1845,,Sus scrofa,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,H,B,10639,,,9823.0,,,,108
1846,,Sus scrofa,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,H,B,14331,,,9823.0,,,,108
1847,,Sus scrofa,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,H,B,10796,,,9823.0,,,,108
1848,,Sus scrofa,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,H,B,9098,,,9823.0,,,,108
1849,,Sus scrofa,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,H,B,14331,,,9823.0,,,,108
1850,,Sus scrofa,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,H,B,11828,,,9823.0,,,,108
1851,,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,H,B,11866,,,9823.0,,,,108
1852,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,H,B,13047,,,9986.0,,,,108
1853,,Rattus norvegicus,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,D,B,188,,,10116.0,,,,12689
1854,,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,D,B,11825,,,10116.0,,,,12689
1855,,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,D,B,11825,,,10116.0,,,,12689
1856,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,D,B,11624,,,10116.0,,,,12689
1857,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,D,B,11139,,,10116.0,,,,12689
1858,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,D,B,11147,,,10116.0,,,,12689
1859,,Rattus norvegicus,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,D,B,10444,,,10116.0,,,,12689
1860,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor,D,B,11624,,,10116.0,,,,12689
1861,,Rattus norvegicus,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,B,11662,,,10116.0,,,,12689
1862,,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,B,11662,,,10116.0,,,,12689
1863,,Rattus norvegicus,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,B,11662,,,10116.0,,,,12689
1864,,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,B,11662,,,10116.0,,,,12689
1865,,Rattus norvegicus,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,D,B,9098,,,10116.0,,,,12689
1866,,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,D,B,10394,,,10116.0,,,,12689
1867,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,H,B,11933,,,,,,,12689
1868,,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,D,B,12092,,,10116.0,,,,12689
1869,,Rattus norvegicus,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,D,B,12253,,,10116.0,,,,12689
1870,,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,D,B,12253,,,10116.0,,,HEK293,12689
1871,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,H,B,1558,,,,,,,108
1872,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,H,B,2474,,,,,,,108
1873,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,H,B,2474,,,,,,,108
1874,,,Binding affinity against 5-hydroxytryptamine 1C receptor,H,B,11574,,,,,,,12689
1875,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,H,B,1558,,,,,,,12689
1876,,,Binding affinity against 5-hydroxytryptamine 1C receptor,H,B,13944,,,,,,,12689
1877,,,Binding affinity against serotonergic 5-HT1c receptor,H,B,13033,,,,,,,12689
1878,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,H,B,10321,,,,,,,12689
1879,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,H,B,11866,,,,,,,12689
1880,,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,B,14454,,,9986.0,,,,105
1881,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,H,B,11574,,,,,,,104686
1882,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,H,B,11574,,,,,,,104686
1883,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,H,B,13631,,,,,,,104686
1884,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,D,B,9630,,,10116.0,,,,104686
1885,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,D,B,8822,,,10116.0,,,,104686
1886,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,D,B,9064,,,10116.0,,Brain,,104686
1887,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,H,B,8868,,,,,,,104686
1888,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,H,B,9064,,,,,,,104686
1889,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,H,B,9806,,,,,,,104686
1890,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,B,9098,,,,,,,104686
1891,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,H,B,8868,,,,,,,104686
1892,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,H,B,12765,,,,,,,104686
1893,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,B,11049,,,,,,,104686
1894,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,B,11049,,,,,,,104686
1895,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,H,B,11049,,,,,,,104686
1896,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,H,B,11049,,,,,,,104686
1897,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,B,11049,,,,,,,104686
1898,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,H,B,11473,,,,,,,104686
1899,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,H,B,11473,,,,,,,104686
1900,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,H,B,3086,,,,,,,104686
1901,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,B,11049,,,,,,,104686
1902,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,B,11049,,,,,,,104686
1903,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,H,B,10639,,,,,,,104686
1904,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,H,B,10922,,,,,,,104686
1905,,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,D,B,9064,,,10116.0,,Brain,,104686
1906,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,H,B,10748,,,,,Brain,,104686
1907,Membranes,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,H,B,11614,,,,,,,104686
1908,Membranes,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,H,B,11615,,,,,,,104686
1909,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,H,B,11615,,,,,,,104686
1910,Membranes,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,H,B,11614,,,,,,,104686
1911,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,H,B,11702,,,,,,,104686
1912,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,H,B,11702,,,,,,,104686
1913,,Rattus norvegicus,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,D,B,11702,,,10116.0,,,,104686
1914,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,H,B,11702,,,,,,,104686
1915,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,H,B,13346,,,,,,,104686
1916,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,H,B,10025,,,,,,,104686
1917,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,H,B,10025,,,,,,,104686
1918,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",H,B,10025,,,,,,,104686
1919,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,H,B,9036,,,,,,,104686
1920,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,H,B,9036,,,,,,,104686
1921,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,H,B,9161,,,,,,,104686
1922,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,H,B,12304,,,,,,,104686
1923,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,H,B,13276,,,,,,,104686
1924,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,H,B,11825,,,,,,,104686
1925,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,H,B,12443,,,,,,,104686
1926,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,H,B,13830,,,,,,,104686
1927,Membranes,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,H,B,9592,,,,,,,104686
1928,Membranes,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,H,B,9592,,,,,,,104686
1929,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,H,B,10881,,,,,,,104686
1930,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,H,B,13605,,,,,,,104686
1931,,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 2 receptor,D,B,11624,,,10116.0,,,,104686
1932,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,H,B,4101,,,,,,,104686
1933,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,H,B,4101,,,,,,,104686
1934,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,H,B,15360,,,,,,,104686
1935,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,H,B,11576,,,,,,,104686
1936,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,H,B,5834,,,,,,,104686
1937,,Rattus norvegicus,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,B,2395,,,10116.0,,,CHO-K1,104686
1938,Membranes,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,H,B,11965,,,,,,,104686
1939,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),H,B,3967,,,,,,,104686
1940,Brain membranes,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),H,B,11130,,,,,,,104686
1941,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,B,13427,In vitro,,,,,,104686
1942,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,B,9443,,,,,,,104686
1943,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,H,B,9443,,,,,,,104686
1944,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,H,B,11825,,,,,,,104686
1945,Membranes,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,H,B,12120,,,,,,,104686
1946,Membranes,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,H,B,12120,,,,,,,104686
1947,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,H,F,11963,,,,,Thoracic aorta,,104686
1948,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,H,B,9069,,,,,,,104686
1949,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,H,B,8868,,,,,,,104686
1950,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,H,B,17200,,,,,,,10624
1951,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,H,B,17200,,,,,,,10624
1952,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,H,B,13969,,,,,,,17106
1953,,,Binding affinity for 5-hydroxytryptamine 1D receptor,D,B,13392,,,,,,,17106
1954,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,B,1742,,,,,,,17106
1955,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,B,1742,,,,,,,17106
1956,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,H,B,14331,,,,,Striatum,,17106
1957,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,H,F,12861,,,,,,,17106
1958,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,H,B,12861,,,,,,,17106
1959,,,Binding activity radioligand.,H,B,12861,,,,,,,17106
1960,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,B,12861,,,,,,,17106
1961,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,B,12861,,,,,,,17106
1962,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,H,B,12861,,,,,,,17106
1963,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,B,675,,,,,,,17106
1964,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,H,B,12490,,,,,,,17106
1965,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,H,B,11828,,,,,,,17106
1966,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,H,B,11866,,,,,,,17106
1967,,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,H,B,773,,,9823.0,,,,105
1968,,Oryctolagus cuniculus,The compound was tested for intrinsic activity against 5-HT1D receptor,H,B,13047,,,9986.0,,,,105
1969,,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,H,B,13047,,,9986.0,,,,105
1970,,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT1D receptor,H,B,13047,,,9986.0,,,,105
1971,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,H,B,188,,,,,,,10578
1972,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,H,F,10639,,,,,,,10578
1973,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,H,F,12438,,,,,,,10578
1974,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,H,B,12438,,,,,,,10578
1975,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,B,15854,,,,,,,10578
1976,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,H,B,10394,,,,,,,10578
1977,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,H,B,12092,,,,,,,10578
1978,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,H,B,3389,,,,,,,10578
1979,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,H,B,6011,,,,,,,105
1980,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,H,B,4639,,,,,,,105
1981,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,H,B,2474,,,,,,,105
1982,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,H,B,5014,,,,,,,105
1983,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,H,B,17515,,,,,,,105
1984,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,H,B,11866,,,,,,,105
1985,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,H,B,4687,,,,,,,105
1986,,,Tested against 5-hydroxytryptamine 1D receptor,H,B,12146,,,,,,,105
1987,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,H,B,10321,,,,,,,105
1988,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,H,B,13267,,,,,,HEK293,105
1989,,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 1D receptor,D,B,1274,,,9606.0,,,,105
1990,,,,H,B,15250,,,,,,,105
1991,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,B,13706,,,,,,CHO-K1,106
1992,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,B,13706,,,,,,CHO-K1,105
1993,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,H,B,13706,,,,,,HEK293,105
1994,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,H,B,13706,,,,,,HEK293,105
1995,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,H,B,13047,,,,,,,105
1996,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,H,B,13366,,,,,,,105
1997,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,H,B,13366,,,,,,,105
1998,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,H,B,1558,,,,,,,105
1999,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",H,B,12902,,,,,,CHO-K1,105
2000,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,B,13706,,,,,,CHO-K1,105
2001,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,H,F,13706,,,,,,,105
2002,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,F,13706,,,,,,,105
2003,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,F,14251,,,,,,,105
2004,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,F,14251,,,,,,,105
2005,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,F,14251,,,,,,,105
2006,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,H,B,13313,,,,,,,105
2007,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,H,B,13313,,,,,,,105
2008,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,H,B,13366,,,,,,,105
2009,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,H,B,13051,,,,,,,105
2010,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",H,B,12903,,,,,,CHO,105
2011,,Homo sapiens,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,D,B,12469,,,9606.0,,,,105
2012,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,H,B,5619,,,,,,,17106
2013,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,H,B,13047,,,9986.0,,,,105
2014,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,H,B,16633,,,,,,,105
2015,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,H,B,16633,,,,,,,105
2016,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,H,B,16633,,,,,,,105
2017,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,H,B,16633,,,,,,,105
2018,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,H,B,3269,,,,,,,105
2019,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,H,B,12409,,,,,,,105
2020,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,F,13706,,,,,,,106
2021,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,H,B,13706,,,,,,HEK293,106
2022,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,H,B,13706,,,,,,HEK293,106
2023,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",H,B,12903,,,,,,CHO,106
2024,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,H,B,13047,,,,,,,106
2025,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,B,13366,,,,,,,106
2026,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,B,13366,,,,,,,106
2027,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,B,13366,,,,,,,106
2028,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,H,B,13366,,,,,,,106
2029,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,H,B,13366,,,,,,,106
2030,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,H,B,12469,,,,,,CHO,106
2031,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,H,B,13706,,,,,,CHO-K1,106
2032,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,H,B,13706,,,,,,CHO-K1,106
2033,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,F,13706,,,,,,,106
2034,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",H,B,12902,,,,,,CHO-K1,106
2035,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,H,B,13051,,,,,,,105
2036,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",H,B,12903,,,,,,CHO,106
2037,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,H,F,1558,,,,,,CHO-K1,105
2038,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,H,F,1558,,,,,,CHO-K1,105
2039,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,H,F,1558,,,,,,CHO-K1,105
2040,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,H,F,1558,,,,,,CHO-K1,105
2041,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,H,B,1558,,,,,,,105
2042,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,H,B,13047,,,9986.0,,,,106
2043,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,H,B,13313,,,,,,,105
2044,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,H,B,13313,,,,,,,105
2045,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,H,B,12409,,,,,,,105
2046,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,H,B,15250,,,,,,CHO,10618
2047,,Homo sapiens,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,D,B,1348,,,9606.0,,,,10618
2048,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,H,B,1348,,,,,,,10618
2049,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,D,B,4234,,,9606.0,,,,10618
2050,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,H,B,16209,,,,,,,10618
2051,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,H,B,10444,,,,,,,10618
2052,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,H,B,3935,,,,,,,10618
2053,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,H,B,15818,,,,,,,10618
2054,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,H,B,17085,,,,,,,10618
2055,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,D,B,12936,,,9606.0,,,CHO,10618
2056,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,H,B,6166,,,,,,,10618
2057,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,B,15779,,,,,,CHO,10618
2058,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,H,B,15779,,,,,,CHO,10618
2059,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,H,B,15779,,,,,,CHO,10618
2060,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,H,B,13181,,,,,,,10618
2061,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,H,B,4199,,,,,,CHO,10618
2062,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,H,B,14875,,,,,,,10618
2063,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,H,B,15146,,,,,,CHO,10618
2064,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,H,B,5213,,,,,,,10618
2065,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,H,B,12146,,,,,,,10618
2066,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,H,B,13267,,,,,,CHO,10618
2067,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,H,B,14818,,,,,,CHO,10618
2068,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",H,B,4829,,,,,,CHO,10618
2069,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,H,B,4373,,,,,,,10618
2070,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,H,B,4373,,,,,,,10618
2071,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,H,B,14159,,,,,,,10618
2072,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,H,B,16633,,,,,,,10618
2073,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",H,F,17085,,,,,,,279
2074,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",H,F,17085,,,,,,,279
2075,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,H,F,16209,,,,,,,279
2076,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,H,F,16209,,,,,,,279
2077,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",H,F,17085,,,,,,,279
2078,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,H,B,14159,,,,,,,279
2079,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,H,B,15250,,,,,,CHO,279
2080,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),H,B,3805,,,,,,,279
2081,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,H,B,16190,,,,,,CHO,279
2082,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,H,B,16190,,,,,,,279
2083,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,H,B,16209,,,,,,,279
2084,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,H,B,16209,,,,,,,279
2085,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,H,B,16209,,,,,,,279
2086,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,H,B,6866,,,,,,,279
2087,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,H,B,17085,,,,,,,279
2088,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,H,B,16312,,,,,,,279
2089,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,H,B,6166,,,,,,,279
2090,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,B,15779,,,,,,CHO,279
2091,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,H,B,4199,,,,,,CHO,279
2092,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,H,B,14875,,,,,,,279
2093,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,H,B,15146,,,,,,CHO,279
2094,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,H,B,5213,,,,,,,279
2095,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,H,B,14818,,,,,,CHO,279
2096,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",H,B,4829,,,,,,CHO,279
2097,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",H,B,4829,,,,,,CHO,279
2098,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,H,B,4373,,,,,,,279
2099,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,H,B,4373,,,,,,,279
2100,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,H,B,5014,,,,,,,279
2101,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",H,B,11662,,,,,,,104686
2102,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",H,B,11662,,,,,,,104686
2103,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,B,11662,,,,,,,104686
2104,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,H,B,14093,,,,,,,12687
2105,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",H,F,11200,In vivo,,,,,,104686
2106,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,F,11200,,,,,,,104686
2107,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,H,B,12352,,,,,,,17005
2108,,Bos taurus,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",U,B,13657,,,9913.0,,,,22226
2109,,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,U,B,14331,,,9913.0,,,,22226
2110,,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,U,B,14331,,,9913.0,,,,22226
2111,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,U,B,14331,,,,,,,22226
2112,,Cavia porcellus,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,H,B,12685,,,10141.0,,,,104784
2113,,Cavia porcellus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,H,B,14389,,,10141.0,,,,104784
2114,,Cavia porcellus,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,H,B,14386,,,10141.0,,,,104784
2115,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,H,B,5732,,,,,,,104784
2116,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,B,16293,,,,,,,104784
2117,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,H,B,2078,,,,,,,104784
2118,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,H,B,5486,,,,,,,10209
2119,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,H,B,11820,In vivo,,,,,,104826
2120,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,H,B,10297,,,,,,,104826
2121,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,H,B,13704,,,,,,,104826
2122,,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,D,B,10297,,,10090.0,,,,104826
2123,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,H,B,11820,In vivo,,,,,,104826
2124,,Mus musculus,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,D,B,10297,,,10090.0,,,,104826
2125,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,H,B,11555,,,,,,,104826
2126,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,H,B,11555,,,,,,,104826
2127,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,H,B,11555,,,,,,,104826
2128,,Mus musculus,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,D,B,10297,,,10090.0,,,,104826
2129,,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,H,B,16688,,,9823.0,,,,104784
2130,,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,H,B,16688,,,9823.0,,,,104784
2131,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,U,B,5333,,,,,,,22226
2132,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,U,B,4437,,,,,,,22226
2133,,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,H,B,5033,,,9823.0,,,,17005
2134,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,H,B,15267,,,,,,,104686
2135,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,H,B,15267,,,,,,,104686
2136,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,H,B,11820,,,,,,,104826
2137,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,H,B,9069,,,,,,,104686
2138,,Rattus norvegicus,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,D,B,9162,,,10116.0,,,,104686
2139,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,H,B,9162,,,,,,,104686
2140,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,H,B,9162,,,,,,,104686
2141,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,H,F,10428,,,,,,,104686
2142,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,H,B,9628,,,,,,,104686
2143,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,H,B,12704,,,,,,,104686
2144,,Rattus norvegicus,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,D,B,15453,,,10116.0,,,,104686
2145,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,H,B,188,,,,,,,104686
2146,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,H,B,10349,,,,,,,104686
2147,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,H,B,10349,,,,,,,104686
2148,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,H,B,8868,,,,,,,104686
2149,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,H,B,10025,,,,,,,104686
2150,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",H,B,10025,,,,,,,104686
2151,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,H,B,11702,,,,,,,104686
2152,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,H,B,11702,,,,,,,104686
2153,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,H,B,11702,,,,,,,104686
2154,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,H,F,11702,,,,,,,104686
2155,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,H,F,11702,,,,,,,104686
2156,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,H,B,10085,,,,,Hippocampus,,104686
2157,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,H,B,10085,,,,,Hippocampus,,104686
2158,,Rattus norvegicus,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,D,B,9630,,,10116.0,,Brain,,104686
2159,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,H,B,11070,,,,,,,104686
2160,Membranes,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,H,B,9841,,,,,,,104686
2161,Membranes,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,H,B,9841,,,,,,,104686
2162,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,H,B,13291,,,,,,,104686
2163,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,H,F,10590,,,,,,,104686
2164,,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,D,B,9064,,,10116.0,,Brain,,104686
2165,Membranes,Rattus norvegicus,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,D,B,12268,,,10116.0,,,,104686
2166,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,H,B,13508,,,,,Brain,,104686
2167,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,H,F,11279,,,,,,,104686
2168,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,H,F,11200,,,,,,,104686
2169,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,F,11200,,,,,,,104686
2170,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,H,F,11200,,,,,,,104686
2171,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,H,F,11200,,,,,,,104686
2172,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,F,11200,,,,,,,104686
2173,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,H,B,9231,,,,,Brain,,104686
2174,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,H,B,9737,,,,,,,104686
2175,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,B,9737,,,,,Brain,,104686
2176,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,H,B,9737,,,,,,,104686
2177,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,H,B,9737,,,,,,,104686
2178,,Rattus norvegicus,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,D,B,11828,,,10116.0,,,,104686
2179,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,H,B,12253,,,,,,,104686
2180,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,H,B,12253,,,,,,,104686
2181,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",H,F,11279,,,,,,,104686
2182,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,H,B,11866,,,,,,,104686
2183,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,D,B,14424,,,10116.0,,,,104686
2184,,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,D,B,15180,,,10116.0,,,,104686
2185,,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,D,B,15180,,,10116.0,,,,104686
2186,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,D,B,9786,,,10116.0,,,,104686
2187,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,H,B,12132,,,,,,,104686
2188,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,H,B,5486,,,,,,,104686
2189,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,H,B,15316,,,,,,,104686
2190,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,H,B,16429,,,,,,,104686
2191,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,H,B,14617,,,,,,,104686
2192,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,H,B,11351,,,,,Brain,,104686
2193,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,H,F,11279,,,,,,,104686
2194,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,B,9523,,,,,,,105075
2195,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,B,9523,,,,,,,105075
2196,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,B,9523,,,,,,,105075
2197,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,B,9523,,,,,,,105075
2198,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,B,9523,,,,,,,105075
2199,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,B,9523,,,,,,,105075
2200,,,Hill coefficient of compound was determined,H,B,9523,,,,,,,105075
2201,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,U,B,4771,,,,,,,22226
2202,,Rattus norvegicus,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,D,B,5033,,,10116.0,,,,104686
2203,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,H,B,10845,,,,,,,12687
2204,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,H,B,10845,,,,,,,12687
2205,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),H,B,16288,,,,,,,12687
2206,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),H,B,16288,,,,,,,12687
2207,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,H,B,16190,,,,,,,12687
2208,,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,D,B,12463,,,10116.0,,,,104686
2209,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",H,B,9699,,,,,,,104686
2210,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,H,B,9699,,,,,,,104686
2211,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,B,11662,,,,,,,104686
2212,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,H,B,1205,,,,,,,104784
2213,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,U,B,11376,,,,,,,22226
2214,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",H,B,11376,,,,,,,104784
2215,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,H,B,4639,,,,,,,104784
2216,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,H,B,2222,,,,,,,104784
2217,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,H,B,1558,,,,,,,104784
2218,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,H,B,1089,,,,,,,104784
2219,Brain membranes,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,H,B,386,,,,,,,104784
2220,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,H,B,2474,,,,,,,104784
2221,,,Binding affinity towards 5-HT2 receptor,H,B,17066,,,,,,,104784
2222,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,H,B,959,,,,,,,104784
2223,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,H,B,6398,,,,,,,104784
2224,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,H,B,11889,,,,,,,104686
2225,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,H,B,4221,,,,,,,104784
2226,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,H,B,11026,,,,,,,104784
2227,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,H,B,11866,,,,,,,104784
2228,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,H,B,4221,,,,,,,104784
2229,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,U,B,13950,,,,,,,22226
2230,,,5-hydroxytryptamine 2 receptor binding affinity,H,B,1263,,,,,,,104784
2231,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,H,B,13291,,,,,,,17005
2232,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,H,B,10812,,,,,,,17005
2233,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,H,B,13020,,,,,,,104784
2234,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,H,B,13021,,,,,,,104784
2235,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,H,B,13020,,,,,,,104784
2236,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,H,B,14532,,,,,,,17005
2237,,,Binding affinity against 5-hydroxytryptamine 2 receptor,H,B,13944,,,,,,,17005
2238,,,Binding affinity against 5-hydroxytryptamine 2 receptor,H,B,14331,,,,,,,17005
2239,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,H,B,14118,,,,,,,17005
2240,,,Binding affinity against serotonergic 5-HT2 receptor,H,B,13033,,,,,,,17005
2241,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,H,B,10321,,,,,,,17005
2242,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,H,B,12918,,,,,,,17005
2243,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,H,B,15120,,,,,,,17005
2244,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,H,B,2613,,,,,,,17005
2245,,Homo sapiens,Inhibitory activity against cloned human 5-HT2 receptor,D,B,13378,,,9606.0,,,,104784
2246,,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",D,B,2331,,,9606.0,,,CHO,104784
2247,,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",D,B,2331,,,9606.0,,,CHO,104784
2248,,Homo sapiens,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",D,B,2331,,,9606.0,,,CHO,104784
2249,,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",D,B,2331,,,9606.0,,,CHO,104784
2250,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,B,4170,,,,,,,104784
2251,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,H,B,15453,,,,,,,104784
2252,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,B,1479,,,,,,,17005
2253,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,H,B,11139,,,,,,,104686
2254,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,H,B,13969,,,,,,,17005
2255,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,B,13392,,,,,,,17005
2256,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,H,B,14430,,,,,,,17005
2257,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,H,B,13181,,,10141.0,,,,107
2258,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,B,17200,,,,,,,51
2259,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,B,17200,,,,,,,107
2260,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,B,17200,,,,,,,51
2261,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,H,B,13463,,,,,,,107
2262,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,H,B,6347,,,,,,CHO,107
2263,,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,D,F,6857,,,9606.0,,,CHO,107
2264,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,H,F,4176,,,,,,,107
2265,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,H,F,4176,,,,,,,107
2266,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,H,F,4176,,,,,,,107
2267,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",H,B,6347,,,,,,CHO,107
2268,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",H,B,6347,,,,,,CHO,107
2269,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,H,B,15331,,,,,,,107
2270,,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2A receptor,D,B,16146,,,9606.0,,,,107
2271,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,B,15250,,,,,,CHO,107
2272,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,H,B,13631,,,,,,,107
2273,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),H,B,3805,,,,,,,107
2274,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,H,B,4011,,,,,,CHO,107
2275,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,H,B,4012,,,,,,CHO,107
2276,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,H,B,6366,,,,,,L929,107
2277,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,B,15949,,,,,,CHO,107
2278,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,H,F,14093,,,,,,,107
2279,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,F,13481,,,,,,,107
2280,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,H,B,6347,,,,,,CHO,107
2281,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,H,B,6347,,,,,,CHO,107
2282,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,H,F,14093,,,,,,,107
2283,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,H,F,14093,,,,,,,107
2284,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,F,13481,,,,,,,107
2285,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,H,B,14442,,,,,,,107
2286,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,B,14442,,,,,,,107
2287,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,H,B,14755,,,,,,,107
2288,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,H,B,16441,,,,,,,107
2289,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,H,B,14744,,,,,,,107
2290,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,B,16659,,,,,,CHO,107
2291,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,H,B,3307,,,,,,,107
2292,,Homo sapiens,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,D,B,6857,,,9606.0,,,,107
2293,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,H,B,5635,,,,,,,107
2294,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,D,B,4234,,,9606.0,,,,107
2295,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,H,B,15527,,,,,,,107
2296,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,H,B,6588,,,,,,CHO,107
2297,,,Binding affinity towards human 5-HT2A receptor in BEK cells,H,B,13631,,,,,,,107
2298,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,H,B,17723,,,,,,,107
2299,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,H,B,14770,,,,,,,107
2300,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,D,B,16293,,,9606.0,,,,107
2301,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,B,16209,,,,,,,107
2302,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,H,B,12469,,,,,,,107
2303,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,H,B,15363,,,,,,,107
2304,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,H,B,15363,,,,,,,107
2305,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",H,B,16441,,,,,,,107
2306,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,H,B,8,,,,,,,107
2307,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,H,B,4176,,,,,,HEK293,107
2308,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,H,B,17085,,,,,,,107
2309,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,B,17200,,,,,,,107
2310,,Homo sapiens,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,D,B,17200,,,9606.0,,,,107
2311,,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,D,B,4013,,,9606.0,,,CHO,107
2312,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,H,B,5088,,,,,,,107
2313,,Homo sapiens,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,D,B,5088,,,9606.0,,,,107
2314,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,H,B,5088,,,,,,,107
2315,,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,D,B,5088,,,9606.0,,,,107
2316,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,H,B,5088,,,,,,,107
2317,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,B,5088,,,,,,,107
2318,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,H,B,9786,,,,,,,104686
2319,,Rattus norvegicus,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,D,B,9205,,,10116.0,,,,104686
2320,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,H,B,11257,,,,,,,104686
2321,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,H,B,9362,,,,,,,104686
2322,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,H,B,9362,,,,,,,104686
2323,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,H,B,10590,,,,,,,104686
2324,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,H,B,10468,,,,,,,104686
2325,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,H,B,13050,,,,,,,104686
2326,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,H,B,11624,,,,,,,104686
2327,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,H,B,10468,,,,,,,104686
2328,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,H,B,10330,,,,,,,104686
2329,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,H,B,10062,,,,,,,104686
2330,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,H,B,11642,,,,,,,104686
2331,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,H,B,10062,,,,,,,104686
2332,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,B,13427,In vitro,,,,,,104686
2333,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,D,B,12280,,,10116.0,,,,104686
2334,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,D,B,4101,,,10116.0,,,,104686
2335,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,H,B,10062,,,,,,,104686
2336,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,H,B,11147,,,,,,,104686
2337,,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,B,2395,,,10116.0,,,CHO-K1,104686
2338,,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,B,2395,,,10116.0,,,CHO-K1,104686
2339,,Rattus norvegicus,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,D,B,9098,,,10116.0,,,,104686
2340,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,H,B,9098,,,,,,,104686
2341,,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,D,B,9098,,,10116.0,,,,104686
2342,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,B,9443,,,,,,,104686
2343,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,H,B,9443,,,,,,,104686
2344,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",H,B,9699,,,,,,,104686
2345,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,H,B,9699,,,,,,,104686
2346,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,B,9098,,,,,,,104686
2347,,Rattus norvegicus,Affinity for 5-hydroxytryptamine 2 receptor,D,B,3070,,,10116.0,,,,104686
2348,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,H,B,9547,,,,,,,104686
2349,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,H,B,10444,,,,,,,104686
2350,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,H,B,14617,,,,,,,104686
2351,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,H,B,14617,,,,,,,104686
2352,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),H,B,11130,,,,,,,104686
2353,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),H,B,11130,In vivo,,,,,,104686
2354,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,H,B,14542,,,,,Brain,,104686
2355,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,H,B,2797,,,,,,,104686
2356,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,H,B,11332,,,,,,,104686
2357,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,H,B,11332,,,,,,,104686
2358,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,H,B,10752,,,,,Frontal cortex,,104686
2359,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,H,B,1185,,,,,,,104686
2360,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,H,B,1185,,,,,,,104686
2361,,Rattus norvegicus,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,D,B,11624,,,10116.0,,,,104686
2362,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,H,B,1344,,,,,,,104686
2363,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,D,B,15453,,,10116.0,,Striatum,,104686
2364,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",H,B,11662,,,,,,,104686
2365,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,B,11662,,,,,,,104686
2366,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,H,B,10796,,,,,,,104686
2367,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,H,B,9069,,,,,,,104686
2368,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,D,B,8814,,,10116.0,,,,104686
2369,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,D,B,8908,,,10116.0,,,,104686
2370,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,H,B,9098,,,,,,,104686
2371,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,H,B,9098,,,,,,,104686
2372,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,H,B,9098,,,,,,,104686
2373,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,H,B,9098,,,,,,,104686
2374,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,H,B,9098,,,,,,,104686
2375,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,H,B,9098,,,,,,,104686
2376,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,H,B,9098,,,,,,,104686
2377,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,H,B,9161,,,,,,,104686
2378,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,H,B,9161,,,,,,,104686
2379,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,H,B,9161,,,,,,,104686
2380,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,H,B,9161,,,,,,,104686
2381,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,H,B,9161,,,,,,,104686
2382,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,H,B,9161,,,,,,,104686
2383,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,H,B,9161,,,,,,,104686
2384,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,H,B,9161,,,,,,,104686
2385,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,H,B,9161,,,,,,,104686
2386,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,H,B,9161,,,,,,,104686
2387,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,H,B,9161,,,,,,,104686
2388,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,H,B,9161,,,,,,,104686
2389,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,H,B,12094,,,,,,,104686
2390,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,H,B,12018,,,,,,,104686
2391,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,H,B,10394,,,,,,,104686
2392,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,H,B,15260,,,,,,,104686
2393,,Rattus norvegicus,Inhibitory constant against 5-hydroxytryptamine 2 receptor,D,B,11624,,,10116.0,,,,104686
2394,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,H,B,13654,,,,,,,104686
2395,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,H,B,9541,,,,,,,104686
2396,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,H,B,11933,,,,,,,104686
2397,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,H,B,15538,,,,,,,104686
2398,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,H,B,15538,,,,,,,104686
2399,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,H,B,15538,,,,,,,104686
2400,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,D,B,8841,,,,,,,104686
2401,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,H,B,1455,,,,,,,104686
2402,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,H,B,1455,,,,,,,104686
2403,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,H,B,11752,,,,,,,104686
2404,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,H,B,11642,,,,,Brain,,104686
2405,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,H,B,12092,,,,,,,104686
2406,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,H,B,3967,,,,,,,104686
2407,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor,D,B,12771,,,10116.0,,,,104686
2408,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,H,B,11642,,,,,,,104686
2409,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,H,B,11628,,,,,,,104686
2410,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,H,B,13654,,,,,,,104686
2411,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,F,11200,,,,,,,104686
2412,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,F,11200,,,,,,,104686
2413,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",H,F,11200,In vivo,,,,,,104686
2414,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",H,F,11200,In vivo,,,,,,104686
2415,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",H,F,11200,In vivo,,,,,,104686
2416,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",H,F,11200,In vivo,,,,,,104686
2417,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,H,B,15436,,,,,Brain,,12687
2418,,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,B,15436,,,10116.0,,,,12687
2419,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,H,B,14025,,,,,,,12687
2420,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,H,B,4342,,,,,,,12687
2421,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,D,B,13735,,,10116.0,,,,12687
2422,,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,D,B,5816,,,10116.0,,,,12687
2423,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,H,B,14287,,,,,,,12687
2424,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,H,B,15738,,,,,,,12687
2425,,Rattus norvegicus,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,D,B,15738,,,10116.0,,,,12687
2426,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,H,B,15026,,,,,,,12687
2427,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,H,B,16647,,,,,,,12687
2428,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,H,B,16647,,,,,,,12687
2429,,Rattus norvegicus,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,D,B,13345,,,10116.0,,,,12687
2430,Membranes,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,H,B,1543,,,,,,,12687
2431,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,H,B,12444,,,,,,,12687
2432,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,H,B,16404,,,,,,,12687
2433,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,H,B,16404,,,,,,CHO,12687
2434,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,H,B,15577,,,,,,,12687
2435,,,Serotonergic activity of the compound.,H,B,15577,,,,,,,12687
2436,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,H,B,2495,,,,,,,12687
2437,,Rattus norvegicus,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,D,B,15042,,,10116.0,,,,12687
2438,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,H,B,15026,,,,,,,12687
2439,,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,F,12919,,,10116.0,,,,12687
2440,,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,F,12919,,,10116.0,,,,12687
2441,,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,F,12919,,,10116.0,,,,12687
2442,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,B,15194,,,,,,,12687
2443,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,H,B,15194,,,,,,,12687
2444,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,B,4820,,,,,,,107
2445,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,H,B,6736,,,,,,,107
2446,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,H,B,5163,,,,,,,107
2447,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,H,B,5163,,,,,,,107
2448,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,H,B,6011,,,,,,,107
2449,,Homo sapiens,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,D,B,14294,,,9606.0,,,,107
2450,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,H,B,5014,,,,,,,107
2451,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,B,17066,,,,,,,107
2452,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,H,B,17515,,,,,,,107
2453,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,H,B,6736,,,,,,,107
2454,,,Affinity for 5-hydroxytryptamine 2A receptor,H,B,5163,,,,,,,107
2455,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,H,B,16911,,,,,,NIH3T3,107
2456,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,H,B,6841,,,,,,,107
2457,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,H,B,6119,,,,,,,107
2458,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,H,B,3962,,,,,,,107
2459,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,H,B,4373,,,,,,,107
2460,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,H,B,4373,,,,,,,107
2461,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,H,F,3962,,,,,,,107
2462,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,H,B,1633,,,,,,,107
2463,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,H,B,4373,,,,,,,107
2464,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,H,B,6576,,,,,,,107
2465,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,H,B,4687,,,,,,,107
2466,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,H,B,16946,,,,,,,107
2467,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,H,B,14159,,,,,,,107
2468,,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,H,B,3032,,,10090.0,,,CHO,107
2469,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,H,B,16655,,,,,,,107
2470,,,Binding affinity at 5-hydroxytryptamine 2A receptor,H,B,13964,,,,,,,107
2471,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,H,B,16989,,,,,,,107
2472,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,H,B,16117,,,,,,,107
2473,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,H,B,16700,,,,,,,107
2474,,,Affinity against 5-hydroxytryptamine 2A receptor,H,B,3269,,,,,,,107
2475,,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 2A receptor,D,B,1274,,,9606.0,,,,107
2476,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,H,B,1317,,,,,,,107
2477,,,Tested against 5-hydroxytryptamine 2A receptor,H,B,12146,,,,,,,107
2478,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,H,B,12652,,,,,,,105075
2479,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,H,B,12652,,,,,,,105075
2480,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,H,B,12652,,,,,,,105075
2481,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,H,B,12652,,,,,,,105075
2482,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),H,B,16647,,,,,,,107
2483,,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,D,B,15851,,,9606.0,,,HEK293,227
2484,,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,D,F,6857,,,9606.0,,,CHO,227
2485,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),H,B,3805,,,,,,,227
2486,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,D,B,6491,,,9606.0,,,,227
2487,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,H,F,14093,,,,,,,227
2488,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,H,F,13481,,,,,,,227
2489,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,H,F,14093,,,,,,,227
2490,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,H,F,14093,,,,,,,227
2491,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,H,F,14093,,,,,,,227
2492,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,H,F,13481,,,,,,,227
2493,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,H,B,14442,,,,,,,227
2494,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,H,B,14442,,,,,,,227
2495,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,H,B,14442,,,,,,,227
2496,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,H,B,12369,,,,,,,107
2497,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,H,B,12369,,,,,,,107
2498,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,H,B,12369,,,,,,,107
2499,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,H,B,14447,,,,,,,107
2500,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,H,B,14447,,,,,,,107
2501,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,B,17451,,,,,,NIH3T3,107
2502,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,H,F,6857,,,,,,CHO,107
2503,,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,F,6857,,,9606.0,,,CHO,107
2504,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,H,B,5635,,,,,,,104817
2505,,,Binding activity radioligand.,H,B,12861,,,,,,,107
2506,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,B,12861,,,,,,,107
2507,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,H,B,5105,,,,,,L929,107
2508,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,H,B,5104,,,,,,L929,107
2509,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,H,B,5105,,,,,,L929,107
2510,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,H,B,5105,,,,,,L929,107
2511,,,Binding affinity against 5-HT2A receptor,H,B,5254,,,,,,,107
2512,,,Binding affinity against 5-hydroxytryptamine 2A receptor,H,B,5254,,,,,,,107
2513,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,H,B,13267,,,,,,HEK293,107
2514,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,H,B,13267,,,,,,HEK293,107
2515,,Homo sapiens,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,D,B,14157,,,9606.0,,,HEK293,107
2516,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,B,12936,,,9606.0,,,HEK293,107
2517,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,H,B,14068,,,,,,,107
2518,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,B,12936,,,9606.0,,,HEK293,107
2519,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,B,12936,,,9606.0,,,HEK293,107
2520,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,D,B,4540,,,9606.0,,,HEK293,107
2521,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,H,B,6166,,,,,,,107
2522,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,H,B,17296,,,,,,HEK293,107
2523,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,H,B,17296,,,,,,HEK293,107
2524,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,H,B,17296,,,,,,HEK293,107
2525,,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,D,B,15779,,,9606.0,,,HEK293,107
2526,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,H,B,14391,,,,,,HEK293,107
2527,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",H,B,15851,,,,,,HEK293,107
2528,,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,D,B,15851,,,9606.0,,,HEK293,107
2529,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,H,B,3832,,,,,,HEK293,107
2530,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,H,B,3833,,,,,,HEK293,107
2531,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,B,12936,,,9606.0,,,HEK293,107
2532,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,H,B,17451,,,,,,NIH3T3,107
2533,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,B,17451,,,,,,NIH3T3,107
2534,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,B,17451,,,,,,NIH3T3,107
2535,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,H,B,4199,,,,,,HEK293,107
2536,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,H,B,1883,,,,,,CHO-K1,107
2537,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,H,B,1883,,,,,,CHO-K1,107
2538,,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,D,B,14875,,,9606.0,,,,107
2539,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,H,B,15146,,,,,,HEK293,107
2540,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,H,B,5213,,,,,,HEK293,107
2541,,Homo sapiens,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,D,B,16404,,,9606.0,,,CHO,107
2542,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,H,B,14818,,,,,,HEK293,107
2543,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",H,B,4829,,,,,,HEK293,107
2544,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,H,F,12652,,,,,,NIH3T3,10620
2545,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,H,B,4682,,,,,,NIH3T3,107
2546,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,H,F,12652,,,,,,,10620
2547,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,H,B,4921,,,,,,,10621
2548,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,H,B,4921,,,,,,,10621
2549,,Oryctolagus cuniculus,Binding affinity against rabbit aorta 5-HT2A receptor,H,B,16312,,,9986.0,,,,107
2550,,Oryctolagus cuniculus,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,H,B,14998,,,9986.0,,,,107
2551,,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,H,B,14025,,,9986.0,,,,107
2552,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,H,B,13047,,,9986.0,,,,107
2553,,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT2A receptor,H,B,13047,,,9986.0,,,,107
2554,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,H,B,1883,,,,,,CHO-K1,10576
2555,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,H,B,13463,,,,,,,12687
2556,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,H,B,13463,,,,,,,12687
2557,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,H,B,13463,,,,,Stomach,,12687
2558,,Rattus norvegicus,Binding affinity for 5-HT 2A in rat stomach fundus,D,B,13463,,,10116.0,,Stomach,,12687
2559,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,H,B,13463,,,,,,,12687
2560,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,H,B,16326,,,,,,NIH3T3,12687
2561,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,H,F,14093,,,,,,,12687
2562,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,H,F,14093,,,,,,,12687
2563,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,H,B,15740,,,,,,,12687
2564,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,H,B,16633,,,,,,,12687
2565,,Rattus norvegicus,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,D,F,17200,,,10116.0,,,,12687
2566,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,B,17133,,,,,,,12687
2567,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,B,17133,,,,,,,12687
2568,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,B,17133,,,,,,,12687
2569,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,H,F,17200,,,,,,,12687
2570,,,Efficacy at 5-hydroxytryptamine 2A receptor,H,F,15363,,,,,,,12687
2571,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),H,B,17200,,,,,,,12687
2572,,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),D,B,17200,,,10116.0,,,,12687
2573,,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),D,B,17200,,,10116.0,,,,12687
2574,,Rattus norvegicus,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,D,F,17200,,,10116.0,,,,12687
2575,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,H,F,17200,,,,,,,12687
2576,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,H,B,17211,,,,,,,12687
2577,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,H,B,17331,,,,,,,12687
2578,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,H,B,13565,,,,,,,12687
2579,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,H,B,13730,,,,,,,12687
2580,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,H,B,12416,,,,,,,12687
2581,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,H,B,15295,,,,,,,12687
2582,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,H,B,1742,,,,,,,12687
2583,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,H,B,15295,,,,,,,12687
2584,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,H,B,14970,,,,,,,12687
2585,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,H,B,16693,,,,,,,12687
2586,,Rattus norvegicus,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,D,B,14776,,,10116.0,,,,12687
2587,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,B,14286,,,,,,,12687
2588,,Rattus norvegicus,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,D,B,17200,,,10116.0,,,,12687
2589,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),H,B,15306,,,,,,,12687
2590,,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,D,B,14178,,,10116.0,,,,12687
2591,,Rattus norvegicus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,D,B,14229,,,10116.0,,,,12687
2592,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,H,B,12884,,,,,,,12687
2593,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",H,B,13149,,,,,,,12687
2594,,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,D,B,15295,,,10116.0,,,,12687
2595,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,H,B,15740,,,,,,,12687
2596,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",H,B,15185,,,,,,,12687
2597,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",H,B,15185,,,,,,,12687
2598,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,H,B,17529,,,,,,,12687
2599,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,H,B,14826,,,,,,,12687
2600,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,H,B,17211,,,,,,,12687
2601,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,H,B,14826,,,,,,,12687
2602,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,H,B,14093,,,,,,,12687
2603,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,H,B,14093,,,,,,,12687
2604,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,H,B,13246,,,,,,NIH3T3,12687
2605,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,H,B,13246,,,,,,,12687
2606,,Rattus norvegicus,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,B,15436,,,10116.0,,,,12687
2607,,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,B,15436,,,10116.0,,,,12687
2608,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,H,B,14442,,,,,Brain,,12687
2609,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,H,B,12457,,,,,,,12687
2610,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,H,B,12457,,,,,,NIH3T3,12687
2611,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",H,F,14755,,,,,,,12687
2612,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,H,B,4707,,,,,,,12687
2613,,,Binding affinity against 5-hydroxytryptamine 2A receptor,H,B,13297,,,,,,,12687
2614,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,H,B,17331,,,,,,,12687
2615,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,H,B,4664,,,,,,,12687
2616,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,B,16633,,,,,,,12687
2617,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,D,B,4664,,,10116.0,,,NIH3T3,12687
2618,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,B,16133,,,,,,,12687
2619,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,B,16133,,,,,,,12687
2620,,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,D,B,14060,,,10116.0,,,,12687
2621,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,B,16326,,,,,,,12687
2622,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,B,16659,,,,,,CHO,12687
2623,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,H,B,14776,,,,,,,12687
2624,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,H,B,13481,,,,,,,12687
2625,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,H,B,17386,,,,,,,12687
2626,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor,D,B,6611,,,10116.0,,,,12687
2627,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,H,B,14423,,,,,,,12687
2628,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,H,B,15412,,,,,,,12687
2629,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,H,B,15412,,,,,,,12687
2630,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,H,B,6238,,,,,,,12687
2631,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,H,B,6648,,,,,,,12687
2632,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,H,B,5667,,,,,,,12687
2633,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,D,B,6611,,,10116.0,,,,12687
2634,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,B,13481,,,,,,,12687
2635,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,H,B,13481,,,,,,,12687
2636,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,H,B,15558,,,,,,NIH3T3,12687
2637,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,B,6013,,,,,,,12687
2638,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,B,16633,,,,,,,12687
2639,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,H,B,6013,,,,,,,12687
2640,,Rattus norvegicus,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,D,B,6013,,,10116.0,,,,12687
2641,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,H,B,6013,,,,,,,12687
2642,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,H,B,6013,,,,,,,12687
2643,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,H,B,6013,,,,,,,12687
2644,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,H,B,6013,,,,,,,12687
2645,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,H,B,16293,,,,,,,12687
2646,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,H,B,17175,,,,,,NIH3T3,12687
2647,,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,D,B,13278,,,10116.0,,,,12687
2648,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,H,B,3682,,,,,Caudate-putamen,,12687
2649,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,H,B,2014,,,,,,,12687
2650,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,H,B,2014,,,,,,,12687
2651,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,H,B,4932,,,,,,,12687
2652,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,H,B,4932,,,,,,,12687
2653,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,H,B,3935,,,,,,,12687
2654,,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,D,B,5432,,,10116.0,,Hippocampus,,12687
2655,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,H,B,15818,,,,,,,12687
2656,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,H,B,13672,,,,,,,12687
2657,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,H,B,13672,,,,,,,12687
2658,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,H,B,14749,,,,,,NIH3T3,12687
2659,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,H,B,13462,,,,,,,12687
2660,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,H,B,15740,,,,,,,12687
2661,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,H,B,16647,,,,,,,12687
2662,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,H,B,13345,,,,,Brain,,12687
2663,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,B,16740,,,,,,,12687
2664,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,B,16740,,,,,,,12687
2665,,Rattus norvegicus,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,D,B,15535,,,10116.0,,,,12687
2666,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,B,16740,,,,,,,12687
2667,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,B,16740,,,,,,,12687
2668,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,B,16740,,,,,,,12687
2669,,Rattus norvegicus,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,D,B,4795,,,10116.0,,,,12687
2670,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,H,B,8,,,,,,,12687
2671,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,H,B,8,,,,,,,12687
2672,,Rattus norvegicus,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,D,B,17200,,,10116.0,,,,12687
2673,,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,D,B,2148,,,10116.0,,,,12687
2674,,Rattus norvegicus,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",D,B,13345,,,10116.0,,,,105102
2675,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,B,5088,,,,,,,12687
2676,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,B,5088,,,,,,,12687
2677,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,H,B,17133,,,,,,,12687
2678,,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,D,B,17133,,,10116.0,,,,12687
2679,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,H,B,16532,,,,,,,12687
2680,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,H,B,15086,,,,,,,12687
2681,,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,B,2309,,,10116.0,,,,12687
2682,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,H,B,12953,,,,,,,12687
2683,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,H,B,12953,,,,,,,12687
2684,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,H,B,12953,,,,,,,12687
2685,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,H,B,16659,,,,,,CHO,12687
2686,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,H,B,16740,,,,,,,12687
2687,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,H,B,16740,,,,,,,12687
2688,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,H,B,17133,,,,,,,12687
2689,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,H,B,17211,,,,,,,12687
2690,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,H,B,17331,,,,,,,12687
2691,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,H,B,16633,,,,,,,12687
2692,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,H,B,16633,,,,,,,12687
2693,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,H,B,16633,,,,,,,12687
2694,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,H,B,15026,,,,,,,12687
2695,,,Ratio of pKi of 5-HT2A to that of D2 receptor,H,B,15026,,,,,,,12687
2696,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,H,B,16404,,,,,,,105093
2697,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,H,B,16404,,,,,,,105093
2698,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,H,B,16404,,,,,,,105075
2699,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,H,B,16404,,,,,,,12687
2700,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,H,B,16326,,,,,,,12687
2701,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,H,F,15847,,,,,,,12687
2702,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,H,F,15847,,,,,,,12687
2703,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,H,F,15329,,,,,,,12687
2704,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,H,F,16404,,,,,Thoracic aorta,,12687
2705,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,H,F,16404,,,,,Thoracic aorta,,12687
2706,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,H,F,16404,,,,,Thoracic aorta,,12687
2707,,,Binding activity radioligand.,H,B,12861,,,,,,,12687
2708,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,B,12861,,,,,,,12687
2709,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,H,B,12861,,,,,,,12687
2710,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,H,B,12490,,,,,,,12687
2711,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,H,B,12827,,,,,,N1E-115,12687
2712,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,H,B,12827,,,,,,N1E-115,12687
2713,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,H,B,12918,,,,,,,12687
2714,,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,D,F,12919,,,10116.0,,,,12687
2715,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,H,B,17723,,,,,,,108
2716,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,B,6013,,,,,,,108
2717,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,H,B,16293,,,,,,,108
2718,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,H,B,3857,,,,,,,108
2719,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,H,B,3857,,,,,,,108
2720,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,H,B,3857,,,,,,,108
2721,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,H,B,15363,,,,,,,108
2722,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,H,B,15363,,,,,,,108
2723,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,H,B,16441,,,,,,,108
2724,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,H,B,16441,,,,,,,108
2725,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,H,B,4176,,,,,,HEK293,108
2726,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,H,B,17085,,,,,,,108
2727,,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,D,B,17200,,,9606.0,,,,108
2728,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,H,B,5088,,,,,,,108
2729,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,H,B,5088,,,,,,,108
2730,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,B,5088,,,,,,,108
2731,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,H,B,5088,,,,,,,108
2732,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,B,16659,,,,,,CHO,108
2733,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,H,B,16659,,,,,,CHO,108
2734,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,B,17451,,,,,,NIH3T3,108
2735,,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,F,6857,,,9606.0,,,CHO,108
2736,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,H,B,3857,,,,,,,108
2737,,,Binding activity radioligand.,H,B,12861,,,,,,,108
2738,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,B,12861,,,,,,,108
2739,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,H,B,5104,,,,,,CHO,108
2740,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,H,B,5105,,,,,,CHO,108
2741,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,H,B,5105,,,,,,CHO,108
2742,,,Binding affinity against 5-HT2C receptor,H,B,5254,,,,,,,108
2743,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,H,B,13267,,,,,,HEK293,108
2744,,Homo sapiens,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,D,B,14157,,,9606.0,,,HEK293,108
2745,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,D,B,12936,,,9606.0,,,HEK293,108
2746,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,H,B,14068,,,,,,,108
2747,,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,D,B,12936,,,9606.0,,,HEK293,108
2748,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,D,B,4540,,,9606.0,,,HEK293,108
2749,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,D,B,4540,,,9606.0,,,HEK293,108
2750,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,H,B,6166,,,,,,,108
2751,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,H,B,17296,,,,,,HEK293,108
2752,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,H,B,17296,,,,,,HEK293,108
2753,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,B,15779,,,,,,HEK293,108
2754,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,B,15779,,,,,,HEK293,108
2755,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,H,B,14391,,,,,,HEK293,108
2756,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",H,B,15779,,,,,,HEK293,108
2757,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",H,B,15851,,,,,,HEK293,108
2758,,Homo sapiens,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,D,B,15851,,,9606.0,,,HEK293,108
2759,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",H,B,15779,,,,,,HEK293,108
2760,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,H,B,3832,,,,,,HEK293,108
2761,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,H,B,3833,,,,,,HEK293,108
2762,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,H,B,17451,,,,,,NIH3T3,108
2763,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,H,B,4199,,,,,,HEK293,108
2764,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,H,B,1883,,,,,,CHO-K1,108
2765,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,D,B,4321,,,9606.0,,,,108
2766,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,H,B,14875,,,,,,,108
2767,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,H,B,15146,,,,,,HEK293,108
2768,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,H,B,5213,,,,,,HEK293,108
2769,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,H,B,16404,,,,,,HeLa,108
2770,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,H,F,13267,,,,,,,108
2771,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,H,F,13267,,,,,Hippocampus,,108
2772,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,H,B,14818,,,,,,HEK293,108
2773,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",H,B,4829,,,,,,HEK293,108
2774,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,H,B,13463,,,,,,,11864
2775,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,H,B,13463,,,,,Stomach,,11864
2776,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,H,B,13463,,,,,Stomach,,11864
2777,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,H,F,12652,,,,,,A9,11864
2778,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,H,B,4682,,,,,,NIH3T3,11864
2779,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,H,B,4682,,,,,,NIH3T3,11864
2780,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,H,B,4682,,,,,,NIH3T3,11864
2781,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,H,F,12652,,,,,,,11864
2782,,Mus musculus,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,H,B,13463,,,10090.0,,Stomach,,12689
2783,,Rattus norvegicus,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,D,B,13463,,,10116.0,,Stomach,,12689
2784,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,H,B,13969,,,,,,,108
2785,,Sus scrofa,Binding affinity for 5-hydroxytryptamine 2C receptor,H,B,13392,,,9823.0,,,,108
2786,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,B,13392,,,,,,,108
2787,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,H,B,14430,,,,,,,108
2788,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,H,B,1742,,,,,,,108
2789,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,H,B,14286,,,,,,,108
2790,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,H,B,5619,,,,,,,108
2791,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,H,B,15086,,,,,,,108
2792,,,Binding activity radioligand.,H,B,12861,,,,,,,108
2793,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,B,12861,,,,,,,108
2794,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,H,B,12861,,,,,,,108
2795,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,H,B,12827,,,,,,,108
2796,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,H,B,12827,,,,,,,108
2797,,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,H,F,12919,,,9823.0,,,,108
2798,,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,H,F,12919,,,9823.0,,,,108
2799,,Sus scrofa,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,H,B,16429,,,9823.0,,,,108
2800,,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,H,B,773,,,9823.0,,,,108
2801,,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,H,B,5033,,,9823.0,,,,108
2802,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,B,12861,,,,,,,12687
2803,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,H,F,14093,,,,,,,12689
2804,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,H,B,14970,,,,,,,12689
2805,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,H,B,14970,,,,,,,12689
2806,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,H,B,14970,,,,,,,12689
2807,,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,D,B,14178,,,10116.0,,,,12689
2808,,Rattus norvegicus,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,D,B,14178,,,10116.0,,,,12689
2809,Brain membranes,Rattus norvegicus,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,D,B,14229,,,10116.0,,,,12689
2810,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,H,B,16532,,,,,,,12689
2811,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,H,B,14826,,,,,,,12689
2812,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,H,B,17211,,,,,,,12689
2813,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,H,B,17211,In vitro,,,,,,12689
2814,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,H,B,13246,,,,,,NIH3T3,12689
2815,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,H,B,13246,,,,,,,12689
2816,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,H,B,12457,,,,,,,12689
2817,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,H,B,12457,,,,,,NIH3T3,12689
2818,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,H,B,4707,,,,,,,12689
2819,,,Binding affinity against 5-hydroxytryptamine 2C receptor,H,B,13297,,,,,,,12689
2820,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,B,16633,,,,,,,12689
2821,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,B,16133,,,,,,,12689
2822,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,H,B,16326,,,,,,,12689
2823,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,H,B,14423,,,,,,,12689
2824,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,H,B,15412,,,,,,,12689
2825,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,H,B,15412,,,,,,,12689
2826,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,H,B,15558,,,,,,A9,12689
2827,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,B,16633,,,,,,,12689
2828,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,H,B,6013,,,,,,,12689
2829,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,H,B,17175,In vitro,,,,,,12689
2830,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,H,B,12469,,,,,,,12689
2831,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,H,B,3682,,,,,Caudate-putamen,,12689
2832,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,H,B,4932,,,,,,,12689
2833,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,H,B,4932,,,,,,,12689
2834,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,H,B,3935,,,,,,,12689
2835,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,H,B,15818,,,,,,,12689
2836,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,H,B,15818,,,,,,,12689
2837,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,H,B,14749,,,,,,,12689
2838,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,H,B,15740,,,,,,,12689
2839,,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,D,B,17133,,,10116.0,,,,12689
2840,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,H,B,16532,,,,,,,12689
2841,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,H,B,12369,,,,,,,12689
2842,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,H,B,12369,,,,,,,12689
2843,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,D,B,2309,,,10116.0,,,,12689
2844,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,H,B,12953,,,,,,,12689
2845,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,H,B,12953,,,,,,,12689
2846,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,H,B,12953,,,,,,,12689
2847,,,Binding affinity for 5-hydroxytryptamine 2C receptor,H,B,12953,,,,,,,12689
2848,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,H,B,17133,,,,,,,12689
2849,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,H,B,17211,,,,,,,12689
2850,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,H,B,17211,,,,,,,12689
2851,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,H,B,14025,,,,,,,12689
2852,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,H,B,14998,,,,,,,12689
2853,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,H,B,4342,,,,,,,12689
2854,,Rattus norvegicus,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,D,B,13735,,,10116.0,,,,12689
2855,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,H,B,13181,,,,,,,12689
2856,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,H,B,1883,,,,,,CHO-K1,12689
2857,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,B,15194,,,,,,,12689
2858,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,H,B,15194,,,,,,,12689
2859,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,H,F,14579,,,,,,,12689
2860,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,H,B,4639,,,,,,,108
2861,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,B,4820,,,,,,,108
2862,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,H,B,14442,,,,,,,227
2863,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,H,B,14755,,,,,,,227
2864,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,H,B,14744,,,,,,,227
2865,,Homo sapiens,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,D,B,6857,,,9606.0,,,,227
2866,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,H,B,16209,,,,,,,227
2867,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,H,B,15363,,,,,,,227
2868,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,H,B,15363,,,,,,,227
2869,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,H,B,15363,,,,,,,227
2870,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,H,B,17085,,,,,,,227
2871,,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,D,B,17200,,,9606.0,,,,227
2872,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,D,B,15851,,,9606.0,,,HEK293,227
2873,,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,D,B,15851,,,9606.0,,,HEK293,227
2874,,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,F,6857,,,9606.0,,,CHO,227
2875,,Homo sapiens,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,F,6857,,,9606.0,,,CHO,227
2876,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,B,15779,,,,,,HEK293,227
2877,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,H,B,15851,,,,,,HEK293,227
2878,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",H,B,15779,,,,,,HEK293,227
2879,,Homo sapiens,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,D,B,14157,,,9606.0,,,HEK293,227
2880,,Homo sapiens,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,D,B,4540,,,9606.0,,,HEK293,227
2881,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,H,B,6166,,,,,,,227
2882,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,H,B,15779,,,,,,HEK293,227
2883,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,H,B,14391,,,,,,HEK293,227
2884,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,H,B,3832,,,,,,HEK293,227
2885,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,H,B,3833,,,,,,HEK293,227
2886,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,D,B,15851,,,9606.0,,,HEK293,227
2887,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,D,B,15851,,,9606.0,,,HEK293,227
2888,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,H,B,4199,,,,,,HEK293,227
2889,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,H,B,1883,,,,,,CHO-K1,227
2890,,,Binding affinity against 5-hydroxytryptamine 2B receptor,H,B,4321,,,,,,,227
2891,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,H,B,15146,,,,,,HEK293,227
2892,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,H,B,5213,,,,,,HEK293,227
2893,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,H,B,14818,,,,,,HEK293,227
2894,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,B,4829,,,,,,HEK293,227
2895,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,B,4829,,,,,,HEK293,227
2896,,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,H,B,14025,,,9986.0,,,,227
2897,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,H,B,13463,,,,,Stomach,,12688
2898,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,H,B,7259,,,,,Stomach,,12688
2899,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,H,B,7259,,,,,Stomach,,12688
2900,,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,D,F,7185,,,10116.0,,Stomach,,12688
2901,,Rattus norvegicus,Antagonistic against 5-hydroxytryptamine 2B receptor,D,F,7185,,,10116.0,,,,12688
2902,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,H,F,13267,,,,,Stomach,,12688
2903,,Rattus norvegicus,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,D,B,13735,,,10116.0,,Stomach,,12688
2904,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,H,F,15738,,,,,,,12688
2905,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,H,F,15738,,,,,,,12688
2906,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,H,F,15738,,,,,,,12688
2907,,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,B,12936,,,10116.0,,Stomach,,12688
2908,,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,B,12936,,,10116.0,,Stomach,,12688
2909,,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,B,12936,,,10116.0,,Stomach,,12688
2910,,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,B,12936,,,10116.0,,Stomach,,12688
2911,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,H,F,16404,,,,,Stomach,,12688
2912,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,H,F,16404,,,,,Stomach,,12688
2913,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,H,F,16404,,,,,Stomach,,12688
2914,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,H,F,16404,,,,,Stomach,,12688
2915,,Rattus norvegicus,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,D,F,16404,,,10116.0,,Stomach,,12688
2916,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,H,F,16404,,,,,Thoracic aorta,,12688
2917,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,H,B,7483,,,,,,,12688
2918,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,H,B,7483,,,,,,,12688
2919,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,H,B,7483,,,,,,,12688
2920,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,H,B,7483,,,,,,,12688
2922,,Rattus norvegicus,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,D,F,16404,,,10116.0,,Stomach,,12688
2923,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,B,6347,,,,,,,227
2924,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,H,B,4373,,,,,,,227
2925,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,H,B,4373,,,,,,,227
2926,,,Evaluated for the binding affinity to 5-HT 2B receptor,H,B,4687,,,,,,,227
2927,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,H,B,16946,,,,,,,227
2928,,,Binding affinities against 5-hydroxytryptamine 2B receptor,H,B,16633,,,,,,,227
2929,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,H,B,16633,,,,,,,227
2930,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,H,B,16633,,,,,,,227
2931,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,H,B,15026,,,,,,,108
2932,,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,H,B,15738,,,9913.0,,,,108
2933,,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,H,B,15738,,,9913.0,,,,108
2934,,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,H,B,15738,,,9913.0,,,,108
2935,,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,H,B,15738,,,9913.0,,,,108
2936,,Bos taurus,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,H,B,16404,,,9913.0,,,,108
2937,,Bos taurus,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,H,B,15026,,,9913.0,,,,108
2938,,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,H,B,15738,,,9913.0,,,,108
2939,,Cavia porcellus,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,H,B,16312,,,10141.0,,,,108
2940,,Cavia porcellus,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,D,B,5486,,,10141.0,,Striatum,,20033
2941,,,Binding affinity against 5-HT1A receptor,H,B,5254,,,,,,,51
2942,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,H,F,3857,,,,,,CHO,108
2943,,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,D,F,6857,,,9606.0,,,CHO,108
2944,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,H,F,4176,,,,,,,108
2945,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,H,B,6347,,,,,,CHO,108
2946,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",H,B,6347,,,,,,CHO,108
2947,,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2C receptor,D,B,16146,,,9606.0,,,,108
2948,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),H,B,3805,,,,,,,108
2949,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,H,B,3857,,,,,,,108
2950,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,H,B,5635,,,,,,,108
2951,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,H,B,5635,,,,,,,108
2952,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,H,B,5635,,,,,,,108
2953,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,H,B,4012,,,,,,CHO,108
2954,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,H,B,6366,,,,,,CHO,108
2955,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,B,15949,,,,,,CHO,108
2956,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,H,B,17211,,,,,,CHO,108
2957,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,D,B,6491,,,9606.0,,,,108
2958,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,H,F,14093,,,,,,,108
2959,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,F,13481,,,,,,,108
2960,,Rattus norvegicus,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,H,B,6347,,,10116.0,,,CHO,108
2961,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,H,F,14093,,,,,,,108
2962,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,H,F,14093,,,,,,,108
2963,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,F,13481,,,,,,,108
2964,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,H,B,14442,,,,,,,108
2965,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,H,B,14442,,,,,,,108
2966,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,H,B,14442,,,,,,,108
2967,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,H,B,14755,,,,,,,108
2968,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,H,B,14744,,,,,,,108
2969,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,B,16659,,,,,,CHO,108
2970,,Homo sapiens,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,D,B,6857,,,9606.0,,,,108
2971,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,H,B,5635,,,,,,,108
2972,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,D,B,4234,,,9606.0,,,,108
2973,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,H,B,16209,,,,,,,108
2974,Membranes,Rattus norvegicus,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,D,B,5778,,,10116.0,,,,104698
2975,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,H,B,5094,,,,,,,104698
2976,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,D,B,809,,,10116.0,,,,104698
2977,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,H,B,1578,,,,,,,104698
2978,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,H,B,809,,,,,,,104698
2979,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,H,B,12469,,,,,,,104698
2980,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,H,B,14290,,,,,,,104698
2981,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,H,B,14290,,,,,,,104698
2982,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,H,B,10609,,,,,,,104698
2983,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,H,B,10609,,,,,,,104698
2984,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,H,B,10609,,,,,,,104698
2985,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",H,B,15253,,,,,,,104698
2986,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",H,B,15253,,,,,,,104698
2987,Membranes,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,H,B,11683,,,,,,,104698
2988,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,H,B,12092,,,,,,,104698
2989,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,H,B,1946,,,,,,,104698
2990,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,H,B,11623,,,,,,,104698
2991,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,H,B,11623,,,,,,,104698
2992,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,H,B,14788,,,,,,,104698
2993,,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,D,B,5432,,,10116.0,,,,104698
2994,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,B,14826,,,,,,,104698
2995,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,H,B,2222,,,,,,,104698
2996,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,H,B,11963,,,,,,,104698
2997,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,H,B,14145,,,,,,,104698
2998,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,H,B,17819,,,,,,,104698
2999,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,H,B,10394,,,,,,,104698
3000,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,H,B,10394,,,,,,,104698
3001,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,H,B,15034,,,,,,,104698
3002,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,H,B,691,,,,,,,104698
3003,Membranes,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,H,B,12092,,,,,,,104698
3004,,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,D,B,11752,,,10116.0,,,,104698
3005,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,H,B,11752,,,,,Brain,,104698
3006,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,H,B,301,,,,,,,104698
3007,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,H,B,16532,,,,,,,104698
3008,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,H,B,16532,,,,,,,104698
3009,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,H,B,12092,,,,,,,104698
3010,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,H,B,11684,,,,,,,104698
3011,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,H,B,11684,,,,,,,104698
3012,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,H,B,12953,,,,,,,104698
3013,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,H,B,12953,,,,,,,104698
3014,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,H,B,12953,,,,,,,104698
3015,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,H,B,12861,,,,,,,104698
3016,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3017,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3018,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3019,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3020,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3021,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3022,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3023,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3024,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3025,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3026,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3027,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3028,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3029,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3030,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3031,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3032,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3033,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3034,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,H,F,10609,,,,,,,104698
3035,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,H,B,12861,,,,,,,104698
3036,,Rattus norvegicus,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,D,B,12861,,,10116.0,,,,104698
3037,,,Binding activity radioligand.,H,B,12861,,,,,,,104698
3038,Brain membranes,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,H,B,10728,,,,,,,104698
3039,Brain membranes,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,H,B,10728,,,,,,,104698
3040,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,H,B,5163,,,,,,,108
3041,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,H,B,5163,,,,,,,108
3042,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,H,B,6011,,,,,,,108
3043,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,H,B,5014,,,,,,,108
3044,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,H,B,5635,,,,,,,108
3045,,,Affinity for 5-hydroxytryptamine 2C receptor,H,B,5163,,,,,,,108
3046,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,B,6841,,,,,,,108
3047,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,H,B,6119,,,,,,,108
3048,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,H,B,4373,,,,,,,108
3049,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,H,B,1633,,,,,,,108
3050,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,H,B,1633,,,,,,,108
3051,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,H,B,4373,,,,,,,108
3052,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,H,B,6576,,,,,,,108
3053,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,H,B,4687,,,,,,,108
3054,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,H,B,12146,,,,,,,108
3055,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,H,B,12146,,,,,,,108
3056,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,H,B,16946,,,,,,,108
3057,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,H,B,14159,,,,,,,108
3058,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,H,B,16700,,,,,,,108
3059,,,Affinity against 5-hydroxytryptamine 2C receptor,H,B,3269,,,,,,,108
3060,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,D,B,1274,,,9606.0,,,,108
3061,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,H,B,1317,,,,,,,108
3062,,Bos taurus,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,H,B,5834,,,9913.0,,,,144
3063,,Bos taurus,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,H,B,11147,,,9913.0,,,,144
3064,,Cavia porcellus,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,H,F,14145,,,10141.0,,,,104714
3065,,Cavia porcellus,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,H,B,10561,,,10141.0,,Ileum,,104714
3066,,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,H,F,15847,,,10141.0,,,,104714
3067,,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,H,F,15847,,,10141.0,,,,104714
3068,,Cavia porcellus,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,H,B,10561,,,10141.0,,Ileum,,104714
3069,,Cavia porcellus,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,H,B,11454,,,10141.0,,Ileum,,104714
3070,,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,H,F,4639,,,10141.0,,,,104714
3071,,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,H,F,4639,,,10141.0,,,,104714
3072,,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,H,F,4639,,,10141.0,,,,104714
3073,,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,H,F,4639,,,10141.0,,,,104714
3074,,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,H,F,4639,,,10141.0,,,,104714
3075,,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,H,F,4639,,,10141.0,,,,104714
3076,,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",H,F,15253,,,10141.0,,Ileum,,104714
3077,,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",H,F,15253,,,10141.0,,Ileum,,104714
3078,,Cavia porcellus,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,H,F,11963,,,10141.0,,Ileum,,104714
3079,,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,H,B,1946,,,10141.0,,Ileum,,104714
3080,,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,H,B,1946,,,10141.0,,Ileum,,104714
3081,,Cavia porcellus,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,H,B,12045,,,10141.0,,,,104714
3082,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,B,1559,,,10141.0,,Ileum,,104714
3083,,Cavia porcellus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,F,273,,,10141.0,,Ileum,,104714
3084,,Cavia porcellus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),H,F,273,,,10141.0,,Ileum,,104714
3085,,Cavia porcellus,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,H,F,188,,,10141.0,,Ileum,,104714
3086,,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,H,F,12919,,,10141.0,,Ileum,,104714
3087,,Cavia porcellus,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,H,F,12918,,,10141.0,,Ileum,,104714
3088,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,B,1559,,,10141.0,,Ileum,,104714
3089,,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,F,273,,,10141.0,,Ileum,,104714
3090,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,B,1559,,,10141.0,,Ileum,,104714
3091,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,H,B,1559,,,10141.0,,Ileum,,104714
3092,,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,H,B,1559,,,10141.0,,Ileum,,104714
3093,,Cavia porcellus,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,H,B,14424,,,10141.0,,Ileum,,104714
3094,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,U,B,13181,,,10141.0,,,,22226
3095,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,H,B,5486,,,,,,,51
3096,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,D,B,6491,,,9606.0,,,,104714
3097,,,Binding affinity towards 5-HT3 receptor,H,B,6013,,,,,,,104714
3098,,,Binding activity radioligand.,H,B,12861,,,,,,,104714
3099,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,H,B,12861,,,,,,,104714
3100,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,H,B,5104,,,,,,,104714
3101,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,H,B,5105,,,,,,,104714
3102,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,H,B,5104,,,,,,,104714
3103,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,U,B,3935,,,,,,,22226
3104,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,H,B,13657,,,,,,NG108-15,105030
3105,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",H,B,10369,In vivo,,,,,,105030
3106,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),H,B,10369,,,,,,,105030
3107,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,H,B,12918,,,,,,,105030
3108,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,H,B,12918,,,,,,,105030
3109,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),H,B,10369,,,,,,,105030
3110,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,H,B,773,,,,,,,105030
3111,,,5-hydroxytryptamine 3 receptor agonism in mouse,H,F,12918,,,,,,,105030
3112,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,H,B,10561,,,,,,,105030
3113,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,H,B,12827,,,,,,,105030
3114,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,H,B,12827,,,,,,,105030
3115,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,H,B,12918,,,,,,,105030
3116,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,H,B,273,,,,,,,105030
3117,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,H,B,273,,,,,,,105030
3118,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,H,B,10561,,,,,,,105030
3119,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,H,B,5033,In vitro,,,,,,105030
3120,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,H,B,16429,,,,,,N1E-115,105030
3121,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,H,B,10322,,,,,,,11765
3122,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,H,B,14331,,,,,,,11765
3123,,Mus musculus,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,D,B,13462,,,10090.0,,,,10630
3124,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,B,12861,,,,,,,17106
3125,,Sus scrofa,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,H,B,15086,,,9823.0,,,,144
3126,,Sus scrofa,Binding activity radioligand.,H,B,12861,,,9823.0,,,,144
3127,,Oryctolagus cuniculus,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,H,B,10561,,,9986.0,,,,104714
3128,,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,H,B,10561,,,9986.0,,,,104714
3129,,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,H,B,10561,,,9986.0,,,,104714
3130,,Oryctolagus cuniculus,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,H,B,10561,,,9986.0,,,,104714
3131,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,F,273,,,9986.0,,,,104714
3132,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,F,273,,,9986.0,,,,104714
3133,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,F,273,,,9986.0,,Ileum,,104714
3134,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,F,273,,,9986.0,,,,104714
3135,,Oryctolagus cuniculus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,F,273,,,9986.0,,,,104714
3136,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,F,273,,,9986.0,,,,104714
3137,,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,F,273,,,9986.0,,,,104714
3138,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,H,B,13047,,,9986.0,,,CHO,104714
3139,,Rattus norvegicus,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,D,B,1650,,,10116.0,,,,104698
3140,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),H,B,16288,,,,,,,12020
3141,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),H,B,16288,,,,,,,12020
3142,,Rattus norvegicus,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,D,B,10254,,,10116.0,,,,104698
3143,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",H,B,14532,,,,,,,104698
3144,,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",H,F,13392,In vivo,,,,Heart,,104698
3145,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",H,F,13392,,,,,Heart,,104698
3146,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",H,F,13392,,,,,Heart,,104698
3147,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",H,F,13392,,,,,Heart,,104698
3148,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",H,F,13392,,,,,Heart,,104698
3149,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",H,F,13392,,,,,,,104698
3150,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",H,F,13392,,,,,,,104698
3151,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",H,F,13392,,,,,,,104698
3152,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",H,F,13392,,,,,,,104698
3153,,Rattus norvegicus,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),D,F,1089,In vivo,,10116.0,,,,104698
3154,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),H,F,1089,In vivo,,,,,,104698
3155,,Rattus norvegicus,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,D,F,11454,In vivo,,10116.0,,,,104698
3156,,Rattus norvegicus,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,D,F,11454,,,10116.0,,,,104698
3157,,Rattus norvegicus,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,D,F,12205,In vivo,,10116.0,,,,104698
3158,,Rattus norvegicus,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),D,F,1089,,,10116.0,,,,104698
3159,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,H,B,5094,,,,,,,104698
3160,,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,D,B,2622,,,10116.0,,,,104698
3161,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,H,B,245,,,,,,,104698
3162,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,H,B,14788,,,,,,,104698
3163,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,H,B,14788,,,,,,,104698
3164,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,H,B,3020,,,,,,,104698
3165,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,H,B,1742,,,,,,,104698
3166,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,H,B,17394,,,,,Brain,,104698
3167,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,H,B,17394,,,,,Brain,,104698
3168,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,B,17394,,,,,,,104698
3169,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,B,14286,,,,,,,104698
3170,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,H,B,14178,,,,,,,104698
3171,,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,D,B,14178,,,10116.0,,,,104698
3172,,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,D,B,14178,,,10116.0,,,,104698
3173,,Rattus norvegicus,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,D,B,14178,,,10116.0,,,,104698
3174,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,H,B,15034,,,,,,,104698
3175,Membranes,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",H,B,1089,,,,,,,104698
3176,,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,D,B,1089,,,10116.0,,,,104698
3177,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,H,B,16532,,,,,,,104698
3178,,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,D,B,12801,,,10116.0,,,,104698
3179,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),H,B,15194,,,,,,NG108-15,104698
3180,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,H,B,15194,,,,,,NG108-15,104698
3181,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,H,B,15194,,,,,,,104698
3182,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,H,B,15194,,,,,,,104698
3183,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,H,B,15194,,,,,,,104698
3184,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,H,B,15194,,,,,,,104698
3185,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,H,F,10610,,,,,,,104698
3186,,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,D,F,10355,,,10116.0,,,,104698
3187,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",H,F,691,,,,,,,104698
3188,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,H,F,10611,,,,,,,104698
3189,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,H,F,12801,In vivo,,,,,,104698
3190,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,H,F,10609,,,,,,,104698
3191,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3192,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3193,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),H,F,11454,In vivo,,,,,,104698
3194,,Rattus norvegicus,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,D,F,11454,In vivo,,10116.0,,,,104698
3195,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3196,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,H,F,11454,In vivo,,,,,,104698
3197,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3198,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3199,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3200,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3201,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3202,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3203,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3204,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3205,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3206,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3207,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3208,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,H,F,11454,In vivo,,,,,,104698
3209,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,H,F,11454,In vivo,,,,,,104698
3210,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,H,F,11454,In vivo,,,,,,104698
3211,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,H,F,11454,In vivo,,,,,,104698
3212,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,H,F,11454,In vivo,,,,,,104698
3213,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3214,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3215,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3216,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3217,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3219,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,H,F,11454,In vivo,,,,,,104698
3220,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",H,F,670,,,,,,,104698
3221,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",H,F,670,,,,,,,104698
3222,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,H,F,10321,In vivo,,,,,,104698
3223,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,H,F,10321,In vivo,,,,,,104698
3224,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,H,F,10321,In vivo,,,,,,104698
3225,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,H,F,10321,In vivo,,,,,,104698
3226,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,H,F,10321,In vivo,,,,,,104698
3227,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),H,F,10322,In vivo,,,,,,104698
3228,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,H,F,15412,,,,,,,104698
3229,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,H,F,15412,,,,,,,104698
3230,,Rattus norvegicus,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,D,B,15412,,,10116.0,,,,104698
3231,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,H,F,15412,,,,,,,104698
3232,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,D,B,15412,,,,,Hippocampus,,104698
3233,,Rattus norvegicus,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,D,B,15412,,,10116.0,,,,104698
3234,,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,D,B,17394,,,10116.0,,,,104698
3235,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,H,B,12457,,,,,,,104698
3236,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,H,B,12457,,,,,,,104698
3237,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,H,B,12205,,,,,,,104698
3238,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,H,B,14532,,,,,,,104698
3239,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,H,B,1122,,,,,,,104698
3240,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,H,B,5094,,,,,,,104698
3241,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,D,F,809,,,10141.0,,Ileum,,20033
3242,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,D,F,809,,,10141.0,,Ileum,,20033
3243,,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",D,F,14290,,,10141.0,,Ileum,,20033
3244,,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",D,F,14290,,,10141.0,,Ileum,,20033
3245,,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",D,F,14290,,,10141.0,,Ileum,,20033
3246,,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",D,F,14290,,,10141.0,,Ileum,,20033
3247,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",D,F,14290,,,10141.0,,Ileum,,20033
3248,,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,D,F,13961,,,10141.0,,Ileum,,20033
3249,,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,D,F,13961,,,10141.0,,Ileum,,20033
3250,,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,D,F,809,,,10141.0,,Ileum,,20033
3251,,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,D,F,809,,,10141.0,,Ileum,,20033
3252,,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,D,F,809,,,10141.0,,Ileum,,20033
3253,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",D,F,14290,,,10141.0,,Ileum,,20033
3254,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",D,F,14290,,,10141.0,,Ileum,,20033
3255,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",D,F,14290,,,10141.0,,Ileum,,20033
3256,,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,D,F,14290,,,10141.0,,Ileum,,20033
3257,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",D,F,14290,,,10141.0,,Ileum,,20033
3258,,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",D,F,14290,,,10141.0,,Ileum,,20033
3259,,Cavia porcellus,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,D,B,15034,,,10141.0,,,,20033
3260,,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,D,B,5094,,,10141.0,,Striatum,,20033
3261,,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,D,B,5094,,,10141.0,,Striatum,,20033
3262,,Cavia porcellus,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,D,B,5399,,,10141.0,,Striatum,,20033
3263,,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,D,B,17394,,,10141.0,,Striatum,,20033
3264,,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,D,B,17394,,,10141.0,,Striatum,,20033
3265,,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,D,B,17394,,,10141.0,,Striatum,,20033
3266,,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,D,F,13961,,,10141.0,,Ileum,,20033
3267,,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,D,F,13961,,,10141.0,,Ileum,,20033
3268,,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,D,F,13961,,,10141.0,,Ileum,,20033
3269,,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,D,B,16946,,,10141.0,,,,20033
3270,,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,D,B,16946,,,10141.0,,,,20033
3271,,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor,D,F,15034,,,10141.0,,,,20033
3272,,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,D,F,15034,,,10141.0,,,,20033
3273,,Cavia porcellus,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,D,F,12918,,,10141.0,,,,20033
3274,,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,D,B,16946,,,10141.0,,,,20033
3275,,Cavia porcellus,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,D,B,17394,,,10141.0,,Striatum,,20033
3276,,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,D,B,15034,,,10141.0,,Striatum,,20033
3277,,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,D,B,5094,,,10141.0,,Striatum,,20033
3278,,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,D,B,5094,,,10141.0,,Striatum,,20033
3279,,Cavia porcellus,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,D,B,17358,,,10141.0,,Ileum,,20033
3280,,Cavia porcellus,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,D,B,12953,,,10141.0,,,,20033
3281,,Cavia porcellus,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,D,B,12953,,,10141.0,,,,20033
3282,,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,D,B,12953,,,10141.0,,,,20033
3283,,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,D,B,12953,,,10141.0,,,,20033
3284,,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,D,F,273,,,10141.0,,Ileum,,20033
3285,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,D,F,12918,,,10141.0,,Ileum,,20033
3286,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,D,F,12919,,,10141.0,,Ileum,,20033
3287,,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,D,F,273,,,10141.0,,Ileum,,20033
3288,,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,D,F,273,,,10141.0,,Ileum,,20033
3289,,Cavia porcellus,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,D,B,13181,,,10141.0,,,,20033
3290,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,H,B,13181,,,10141.0,,,,168
3291,,Cavia porcellus,Antagonistic activity against 5-hydroxytryptamine 4 receptor,D,F,15034,,,10141.0,,,,20033
3292,,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,D,B,5033,,,10141.0,,,,20033
3293,,Cavia porcellus,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,D,B,1980,,,10141.0,,,,20033
3294,,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,H,B,13181,,,10141.0,,,HEK293,168
3295,,Cavia porcellus,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,D,B,14287,,,10141.0,,,,20033
3296,,Cavia porcellus,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,D,B,1317,,,10141.0,,,,20033
3297,,Cavia porcellus,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,D,B,15316,,,10141.0,,,,20033
3298,,Cavia porcellus,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,D,B,16429,,,10141.0,,Striatum,,20033
3299,,Cavia porcellus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,D,B,14818,,,10141.0,,Hippocampus,,20033
3300,,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,D,B,15194,,,10141.0,,,,20033
3301,,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,D,B,15194,,,10141.0,,,,20033
3302,,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,D,F,13961,,,10141.0,,Ileum,,20033
3303,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,H,B,5486,,,,,,,108
3304,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,H,B,16209,,,,,,,168
3305,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,H,B,17085,,,,,,,168
3306,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,H,B,4199,,,,,,HeLa,168
3307,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,H,B,15146,,,,,,,168
3308,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,H,B,5213,,,,,,,168
3309,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",H,B,4829,,,,,,HeLa,168
3310,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,H,B,17358,,,,,,,10622
3311,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,H,B,17358,,,,,,,10622
3312,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,H,B,16946,,,,,,,10622
3313,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,H,B,17358,,,,,,,10622
3314,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,H,F,268,,,,,Cardiac atrium,,11249
3315,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,H,F,268,,,,,Cardiac atrium,,11249
3316,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,H,B,15086,,,,,,,11249
3317,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,H,B,14875,,,,,Hippocampus,,11249
3318,,Sus scrofa,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,H,B,13267,,,9823.0,,Hippocampus,,168
3319,,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,H,B,13047,,,9986.0,,,,168
3320,,Rattus norvegicus,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,D,B,1650,,,10116.0,,,,10623
3321,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,H,F,567,,,,,,,10623
3322,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,H,B,17358,,,,,,,10623
3323,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,H,B,188,,,,,,,10623
3324,,,lntrinsic activity relative to 5-HT receptor,H,F,670,,,,,,,10623
3325,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,H,F,204,,,,,,,10623
3326,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,H,F,1946,,,,,,,10623
3327,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,H,F,6398,,,,,,,10623
3328,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,H,F,6398,,,,,,,10623
3329,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,H,F,17358,,,,,,,10623
3330,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,H,F,6398,,,,,,,10623
3331,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,H,B,11752,,,,,,,10623
3332,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,H,F,809,,,,,,,10623
3333,,Rattus norvegicus,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,D,B,14178,,,10116.0,,,,10623
3334,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,H,B,567,,,,,,,10623
3335,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,H,B,1946,,,,,,,10623
3336,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,H,B,1946,,,,,,,10623
3337,,Rattus norvegicus,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,D,B,13961,,,10116.0,,,,10623
3338,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,H,B,6238,,,,,Striatum,,10623
3339,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,H,B,14290,,,,,,,10623
3340,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,H,B,14290,,,,,,,10623
3341,,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,D,B,809,,,10116.0,,Striatum,,10623
3342,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,H,B,1578,,,,,Striatum,,10623
3343,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,H,B,16709,,,,,Striatum,,10623
3344,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,H,B,1946,,,,,Striatum,,10623
3345,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,H,B,15253,,,,,Striatum,,10623
3346,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,H,B,4535,,,,,Striatum,,10623
3347,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,H,B,13961,,,,,,,10623
3348,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,H,F,17358,,,,,Brain,,10623
3349,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,H,F,15847,,,,,,,10623
3350,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,H,F,15847,,,,,,,10623
3351,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,H,F,670,,,,,,,10623
3352,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,H,F,670,,,,,,,10623
3353,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,H,F,1317,,,,,,,10623
3354,,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 4 receptor,D,B,12936,,,10116.0,,,,10623
3355,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,H,B,4535,,,,,Striatum,,10623
3356,,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,D,F,14424,,,10116.0,,,,10623
3357,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,H,F,14424,,,,,,,10623
3358,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,H,F,14424,,,,,,,10623
3359,,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,D,F,14424,,,10116.0,,,,10623
3360,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,H,F,14424,,,,,,,10623
3361,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,H,F,14424,,,,,,,10623
3362,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),H,F,14424,,,,,,,10623
3363,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,H,F,14424,,,,,,,10623
3364,,Rattus norvegicus,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,H,F,1980,,,10116.0,,,,168
3365,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,H,F,4639,,,,,,,168
3366,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,H,B,17358,,,,,,,168
3367,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,H,B,17358,,,,,,,168
3368,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,H,B,17358,,,,,,,168
3369,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,H,B,1558,,,,,,,168
3370,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,F,17358,,,,,,,168
3371,,,In vitro binding affinity towards 5-HT4 receptor was determined,H,B,16117,,,,,,,168
3372,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,F,17358,,,,,,,168
3373,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,H,F,17358,,,,,,,168
3374,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,H,B,17358,,,,,,,168
3375,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,H,B,17358,,,,,,,168
3376,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,H,B,17358,,,,,,,168
3377,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,H,B,17358,,,,,,,168
3378,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,H,B,1274,,,,,,,168
3379,Brain membranes,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,H,B,10728,,,,,,,104698
3380,Brain membranes,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,H,B,11695,,,,,,,104698
3381,Brain membranes,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,H,B,11695,,,,,,,104698
3382,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,H,B,12490,,,,,,,104698
3383,,Rattus norvegicus,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,D,B,11828,,,10116.0,,,,104698
3384,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,H,B,12253,,,,,Hippocampus,,104698
3385,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,H,B,10561,,,,,,,104698
3386,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,H,B,10561,,,,,,,104698
3387,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,H,F,14432,,,,,,,104698
3388,,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 3 receptor,D,B,12936,,,10116.0,,,,104698
3389,,Rattus norvegicus,Binding affinity against 5-Hydroxytryptamine 3 receptor,D,B,1274,,,10116.0,,,,104698
3390,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,H,B,1980,,,,,,,104698
3391,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,H,B,670,,,,,,,104698
3392,,Rattus norvegicus,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,D,B,968,,,10116.0,,,,104698
3393,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,H,B,14287,,,,,,,104698
3394,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,H,B,567,,,,,,,104698
3395,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,H,B,13267,,,,,,,104698
3396,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,H,B,14826,,,,,,,104698
3397,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,H,B,15194,,,,,,,104698
3398,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,H,B,15194,,,,,,,104698
3399,,Rattus norvegicus,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,D,B,10394,,,10116.0,,,,104698
3400,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",D,B,13657,,,,,,,10576
3401,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,H,F,1879,,,,,Brain,,12020
3402,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,H,F,1879,,,,,,,12020
3403,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,H,F,1879,,,,,,,12020
3404,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,H,F,204,In vivo,,,,,,12020
3405,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,H,B,1879,,,,,,,12020
3406,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,B,1879,,,,,,,12020
3407,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,H,B,1879,,,,,,,12020
3408,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,H,B,1879,,,,,,,12020
3409,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",H,B,10641,,,,,,,104698
3410,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,H,B,773,,,,,,,12020
3411,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,H,B,11952,,,,,,,104698
3412,,Rattus norvegicus,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,D,F,14145,,,10116.0,,,,12020
3413,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,B,17066,,,,,,,144
3414,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,H,B,6398,,,,,,,104714
3415,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,U,B,10321,,,,,,,22226
3416,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,H,F,511,,,,,,,104714
3417,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,H,B,4639,,,,,,,104714
3418,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,B,4639,,,,,,,104714
3419,,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,H,F,4639,,,10141.0,,,,104714
3420,,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,H,F,4639,,,10141.0,,,,104714
3421,,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,H,F,4639,,,10141.0,,,,104714
3422,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,H,B,1558,,,,,,,104714
3423,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,H,F,268,,,,,,,104714
3424,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,H,B,2474,,,,,,,104714
3425,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,H,F,5067,,,,,,,104714
3426,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,H,F,5067,,,,,,,104714
3427,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,H,F,5067,,,,,,,104714
3428,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,H,B,5067,,,,,,,104714
3429,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,H,F,5067,,,,,,,104714
3430,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,H,F,5067,,,,,,,104714
3431,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,H,F,5067,,,,,,,104714
3432,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,H,B,5067,,,,,,,104714
3433,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,H,B,5067,,,,,,,104714
3434,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,H,F,5067,,,,,,,104714
3435,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,H,B,5067,,,,,,,104714
3436,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,B,5067,,,,,,,104714
3437,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,H,B,14331,,,,,,,104714
3438,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,H,B,5067,,,,,,,104714
3439,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,H,B,6179,,,,,,NG108-15,104714
3440,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,H,B,4265,,,,,,,104714
3441,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,H,B,4265,,,,,,NG108-15,104714
3442,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,H,B,17358,,,,,,,104714
3443,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,H,B,17358,,,,,,,104714
3444,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,H,B,13628,In vitro,,,,,,104714
3445,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,H,B,4612,,,,,,,104714
3446,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,H,F,17358,,,,,,,104714
3447,,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,H,F,4639,,,10141.0,,,,104714
3448,,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,H,F,4639,,,10141.0,,,,104714
3449,,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,H,F,4639,,,10141.0,,,,104714
3450,,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,H,F,4639,,,10141.0,,,,104714
3451,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,H,B,511,,,,,,,104714
3452,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,B,1479,,,,,,,104714
3453,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,H,B,1317,,,,,,,104714
3454,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,H,B,12146,,,,,,,104714
3455,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,H,B,12146,,,,,,,104714
3456,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,H,B,13969,,,,,,,104714
3457,,,Binding affinity for 5-hydroxytryptamine 2C receptor,H,B,13392,,,,,,,108
3458,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,B,13392,,,,,,,104698
3459,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,H,B,14159,,,,,,,144
3460,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,H,B,1558,,,,,,,144
3461,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,H,B,16655,,,,,,,144
3462,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,H,B,13020,,,,,,,104714
3463,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,H,B,13021,,,,,,,104714
3464,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,H,B,13020,,,,,,,104714
3465,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,H,B,10321,,,,,,,144
3466,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,B,15818,,,,,,,144
3467,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,B,15818,,,,,,,144
3468,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,H,B,17358,,,,,,,144
3469,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,H,B,2222,,,,,,,144
3470,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,H,B,10322,,,,,,,144
3471,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,H,B,16117,,,,,,,144
3472,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,H,B,17200,,,,,,,144
3473,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,H,F,17358,,,,,,,144
3474,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,H,B,16700,,,,,,,144
3475,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,H,B,1980,,,,,,,144
3476,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,H,B,1980,,,,,,,144
3477,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,H,B,12409,,,,,,,104714
3478,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,H,B,4365,,,,,,,144
3479,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,H,F,4365,,,,,,,144
3480,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,H,B,4365,,,,,,,144
3481,,Rattus norvegicus,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,D,F,6769,,,10116.0,,,Oocytes,12020
3482,,Rattus norvegicus,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,D,F,6769,,,10116.0,,,Oocytes,12020
3483,,Rattus norvegicus,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,D,F,6769,,,10116.0,,,Oocytes,12020
3484,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,D,F,809,,,10141.0,,Ileum,,20033
3485,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,D,F,809,,,10141.0,,Ileum,,20033
3486,,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,D,F,14290,,,10141.0,,,,20033
3487,,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,D,B,17358,,,10141.0,,Ileum,,20033
3488,,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,D,B,17358,,,10141.0,,,,20033
3489,,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,D,B,17358,,,10141.0,,Ileum,,20033
3490,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,H,B,17386,,,,,Ileum,,10209
3491,,,Affinity against 5-hydroxytryptamine 7 receptor,H,B,3269,,,,,,,10209
3492,,Cavia porcellus,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,H,B,7721,,,10141.0,,,,104841
3493,,Cavia porcellus,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,H,B,7721,,,10141.0,,,,104841
3494,,Cavia porcellus,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,H,B,9117,,,10141.0,,Ileum,,104841
3495,,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",H,B,7721,,,10141.0,,,,104841
3496,,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",H,B,7721,,,10141.0,,,,104841
3497,,Cavia porcellus,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,H,F,15796,,,10141.0,,,,104841
3498,,Cavia porcellus,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,H,F,15796,,,10141.0,,,,104841
3499,,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,D,B,15650,,,9606.0,,Cardiac atrium,,168
3500,,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,D,B,15650,,,9606.0,,Cardiac atrium,,168
3501,,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",D,F,6866,,,9606.0,,,,104841
3502,,Homo sapiens,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",D,F,15650,,,9606.0,,Cardiac atrium,,168
3503,,Mus musculus,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,U,B,10063,,,10090.0,,,,22226
3504,,Mus musculus,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,U,B,12665,,,10090.0,,,,22226
3505,,,5-hydroxytryptamine receptor binding affinity was determined in rats,H,B,7504,,,,,,,104705
3506,,,Binding affinity at rat 5-hydroxytryptamine receptor.,H,B,7504,,,,,,,104705
3507,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,H,B,7038,,,,,,,104705
3508,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,H,B,7626,,,,,,,104705
3509,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,H,B,7626,,,,,,,104705
3510,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,H,F,7185,,,,,Stomach,,104705
3511,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,H,F,7185,,,,,Stomach,,104705
3512,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,H,F,7185,,,,,,,104705
3513,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,H,B,6960,,,,,,,104705
3514,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",H,B,6960,,,,,,,104705
3515,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,H,B,12416,,,,,Hippocampus,,10576
3516,,,Binding affinity for rat 5-hydroxytryptamine transporter.,H,B,15753,,,,,,,12198
3517,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,H,B,8062,,,,,,,104705
3518,,Rattus norvegicus,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,D,B,9036,,,10116.0,,,,104705
3519,,Rattus norvegicus,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,D,B,15067,,,10116.0,,,,104705
3520,,Rattus norvegicus,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,D,F,15753,,,10116.0,,Brain,,12198
3521,,Rattus norvegicus,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,D,F,15753,,,10116.0,,Cerebellum,,12198
3522,,Rattus norvegicus,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,D,B,15295,,,10116.0,,,,104705
3523,,Rattus norvegicus,Percent binding affinity against 5-hydroxytryptamine receptor,D,B,6347,,,10116.0,,,,104705
3524,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,U,B,6763,,,,,,,22226
3525,,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,D,B,12092,,,10116.0,,,,104705
3526,,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined,D,B,1579,,,10116.0,,,,104705
3527,,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,D,B,1579,,,10116.0,,Stomach,,104705
3528,,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,D,B,5963,In vitro,,9606.0,,,,121
3529,,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,D,B,5963,In vitro,,9606.0,,,,121
3530,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,H,B,5030,,,,,,,18065
3531,,,Inhibition of 5-hydroxytryptamine reuptake,H,B,15796,,,,,,,121
3532,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",H,F,15413,,,,,,,18065
3533,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",H,F,15413,,,,,,,18065
3534,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",H,F,15413,,,,,,,18065
3535,,,Tested for 5-hydroxytryptamine receptor uptake,H,F,12409,,,,,,,18065
3536,,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,D,B,16909,,,9606.0,,,CHO,51
3537,,Homo sapiens,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,D,F,16909,,,9606.0,,,,51
3538,,Homo sapiens,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,H,B,15629,,,9606.0,,,,10576
3539,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,H,B,15629,,,,,,,10576
3540,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,H,B,15629,,,,,,,10576
3541,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,H,F,10034,,,,,Striatum,,10825
3542,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,H,F,10034,,,,,Striatum,,10825
3543,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,H,F,10034,,,,,Striatum,,10825
3544,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,H,F,10034,,,,,Striatum,,10825
3545,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,H,F,10034,,,,,Striatum,,10825
3546,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,H,F,10034,,,,,Striatum,,10825
3547,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,H,F,10034,,,,,Striatum,,10825
3548,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,H,F,10034,,,,,Striatum,,10825
3549,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,H,F,10034,,,,,Striatum,,10825
3550,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,H,F,10034,,,,,Striatum,,10825
3551,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,H,F,10034,,,,,Striatum,,10825
3552,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,H,F,10034,,,,,Limbic system,,10825
3553,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,H,F,10034,,,,,Limbic system,,10825
3554,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,H,F,10034,,,,,Limbic system,,10825
3555,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,H,F,10034,,,,,Limbic system,,10825
3556,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,H,F,10034,,,,,Limbic system,,10825
3557,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,H,F,10034,,,,,Limbic system,,10825
3558,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,H,F,10034,,,,,Limbic system,,10825
3559,,,Binding affinity against 5-hydroxytryptamine 4 receptor,H,B,1274,,,,,,,168
3560,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,F,17358,,,,,,,168
3561,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,H,B,14532,,,,,,,168
3562,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,H,B,16989,,,,,,,168
3563,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,H,B,17200,,,,,,,168
3564,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,H,B,15779,,,,,,,168
3565,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,H,B,15779,,,,,,,168
3566,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,H,B,15779,,,,,,,168
3567,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,H,B,15650,,,,,,COS-7,168
3568,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,H,B,15650,,,,,,COS-7,168
3569,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,H,B,15650,,,,,,COS-7,168
3570,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,H,B,15650,,,,,,COS-7,168
3571,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,H,B,17046,,,,,,C6,168
3572,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,H,B,17046,,,,,,C6,168
3573,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,H,B,15650,,,,,,C6,168
3574,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,H,B,17046,,,,,,C6,168
3575,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,H,B,17066,,,,,,,10624
3576,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,H,B,17200,,,,,,,105
3577,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 5A receptor,D,B,16146,,,9606.0,,,,10624
3578,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,H,B,15250,,,,,,CHO,10624
3579,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,D,B,6491,,,9606.0,,,,10624
3580,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor,D,B,17066,,,9606.0,,,,10624
3581,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,D,B,17066,,,9606.0,,,,10624
3582,,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,D,B,4234,,,9606.0,,,,10624
3583,,,Binding affinity towards 5-HT5A receptor,H,B,6013,,,,,,,10624
3584,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,H,B,17175,,,,,,,10624
3585,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,H,B,15818,,,,,,,10624
3586,,,Binding affinity towards cloned human 5-HT5A receptor was determined,H,B,6166,,,,,,,10624
3587,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,B,15779,,,,,,HEK293,10624
3588,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,H,B,15779,,,,,,HEK293,10624
3589,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),H,B,5213,,,,,,HEK293,10624
3590,,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,D,B,17066,,,10090.0,,,,10625
3591,,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,D,B,17066,,,10090.0,,,,10625
3592,,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,D,B,17066,,,10090.0,,,,10625
3593,,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,D,B,17066,,,10090.0,,,,10625
3594,,Mus musculus,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,D,B,17066,,,10090.0,,,,10625
3595,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,H,B,17175,,,,,,,10625
3596,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,H,B,16190,,,,,,HEK293,10576
3597,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,H,B,16190,,,,,,HEK293,10626
3598,,,Binding affinity towards 5-HT5a receptor,H,B,4820,,,,,,,10624
3599,,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 5A receptor,D,B,17066,,,9606.0,,,,10624
3600,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,H,B,17066,,,,,,,10624
3601,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,H,B,17175,,,,,,,10624
3602,,,Binding affinities against 5-hydroxytryptamine 5A receptor,H,B,16633,,,,,,,10624
3603,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,H,B,16633,,,,,,,10624
3604,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,H,B,16700,,,,,,,10624
3605,,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,H,F,4639,,,10141.0,,,,104714
3606,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,H,B,5486,,,,,,,104714
3607,,Homo sapiens,Inhibition of human 5-hydroxytryptamine 6 receptor,D,B,16146,,,9606.0,,,,10627
3608,,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,D,B,17273,,,9606.0,,,,10627
3609,,,Inhibition against human 5-hydroxytryptamine 6 receptor,H,B,17687,,,,,,,10627
3610,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,D,B,6491,,,9606.0,,,,10627
3611,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,H,B,16190,,,,,,HeLa,10627
3612,,Homo sapiens,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,D,B,17066,,,9606.0,,,,10627
3613,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor,D,B,17066,,,9606.0,,,,10627
3614,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,D,B,17066,,,9606.0,,,,10627
3615,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,D,B,17066,,,9606.0,,,,10627
3616,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 6 receptor,D,B,3555,,,9606.0,,,,10627
3617,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,B,5808,,,,,,,10627
3618,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,B,6013,,,,,,,10627
3619,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",H,B,15818,,,,,,HEK293,10627
3620,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,H,B,16209,,,,,,,10627
3621,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,H,B,3935,,,,,,HEK293,10627
3622,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,H,B,15818,,,,,,,10627
3623,,Homo sapiens,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,D,B,3805,,,9606.0,,,HEK293,10627
3624,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,H,B,16441,,,,,,,10627
3625,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,H,B,16441,,,,,,,10627
3626,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,H,B,6786,,,,,,COS-7,10627
3627,,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,D,B,4234,,,9606.0,,,,10627
3628,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,H,B,17085,,,,,,,10627
3629,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,H,B,17200,,,,,,,10627
3630,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,H,B,17451,,,,,,HEK293,10627
3631,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,H,F,3935,,,,,,,10627
3632,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,H,B,5033,,,,,,,10627
3633,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,H,B,4540,,,,,,,10627
3634,,Homo sapiens,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,D,B,4540,,,9606.0,,,HeLa,10627
3635,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,D,B,4540,,,9606.0,,,HeLa,10627
3636,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,H,B,17296,,,,,,HeLa,10627
3637,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,H,B,17296,,,,,,HeLa,10627
3638,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,H,B,17296,,,,,,HeLa,10627
3639,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,B,15779,,,,,,CHO,10627
3640,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,B,15779,,,,,,HEK293,10627
3641,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,H,B,15779,,,,,,HEK293,10627
3642,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,H,B,15779,,,,,,HEK293,10627
3643,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,H,B,15779,,,,,,HeLa,10627
3644,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,B,6166,,,,,,,10627
3645,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,H,B,17451,,,,,,HeLa,10627
3646,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,H,B,15316,,,,,,,10627
3647,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,H,B,4199,,,,,,,10627
3648,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,H,B,15146,,,,,,HeLa,10627
3649,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),H,B,5213,,,,,,,10627
3650,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,H,B,16429,,,,,,,10627
3651,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,H,B,14818,,,,,,HeLa,10627
3652,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",H,B,4829,,,,,,HeLa,10627
3653,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",H,B,4829,,,,,,HeLa,10627
3654,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",H,B,4829,,,,,,HeLa,10627
3655,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,H,B,15250,,,,,,CHO,10628
3656,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,H,B,14423,,,,,,,10628
3657,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,H,B,15086,,,,,,,10628
3658,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,H,B,4342,,,,,,,10628
3659,,Homo sapiens,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,D,B,16190,,,9606.0,,,HeLa,10627
3660,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,B,4820,,,,,,,10627
3661,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,H,B,4639,,,,,,,10627
3662,,Homo sapiens,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,D,F,17066,,,9606.0,,,,10627
3663,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,H,B,6011,,,,,,,10627
3664,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,B,17066,,,,,,,10627
3665,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,H,B,17515,,,,,,,10627
3666,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,H,B,5014,,,,,,,10627
3667,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,H,B,4373,,,,,,,10627
3668,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,H,F,17066,,,,,,,10627
3669,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,H,F,17066,,,,,,,10627
3670,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,H,B,4373,,,,,,,10627
3671,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,H,B,4687,,,,,,,10627
3672,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,H,B,16946,,,,,,,10627
3673,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,H,B,16946,,,,,,,10627
3674,,,Binding affinities against 5-hydroxytryptamine 6 receptor,H,B,16633,,,,,,,10627
3675,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,H,B,16633,,,,,,,10627
3676,,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor,D,B,17066,,,9606.0,,,,10627
3677,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,H,B,16700,,,,,,,10627
3678,,,Affinity against 5-hydroxytryptamine 6 receptor,H,B,3269,,,,,,,10627
3679,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],H,B,5486,,,,,,,10627
3680,,Homo sapiens,Inhibition of human 5-hydroxytryptamine 7 receptor,D,B,16146,,,9606.0,,,,10209
3681,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,H,B,5014,,,,,,HEK293,10209
3682,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,H,B,15463,,,,,,,10209
3683,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),H,B,3805,,,,,,,10209
3684,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,H,B,5014,,,,,,HEK293,10209
3685,,Homo sapiens,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,D,B,6491,,,9606.0,,,,10209
3686,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,H,B,16190,,,,,,CHO,10209
3687,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,D,B,17066,,,9606.0,,,,10209
3688,,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,D,B,17066,,,9606.0,,,,10209
3689,,Homo sapiens,Binding affinity against 5-hydroxytryptamine 7 receptor,D,B,3555,,,9606.0,,,,10209
3690,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,H,B,6588,,,,,,CHO,10209
3691,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,H,B,15463,,,,,,,10209
3692,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,B,6013,,,,,,,10209
3693,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,H,B,16209,,,,,,,10209
3694,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,H,B,3935,,,,,,,10209
3695,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,H,B,15818,,,,,,,10209
3696,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,H,B,5014,,,,,,HEK293,10209
3697,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,H,B,16441,,,,,,,10209
3698,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,H,B,16441,,,,,,,10209
3699,,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,D,B,4234,,,9606.0,,,,10209
3700,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,H,B,17085,,,,,,,10209
3701,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,H,B,17200,,,,,,,10209
3702,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,H,B,17451,,,,,,CHO,10209
3703,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,H,B,17085,,,,,,,10209
3704,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,H,B,5104,,,,,,,10209
3705,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,H,B,5104,,,,,,,10209
3706,,Homo sapiens,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,D,B,5033,,,9606.0,,,COS-7,10209
3707,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,H,B,5486,,,,,,COS-7,10209
3708,,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,D,B,4540,,,9606.0,,,HEK293,10209
3709,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,H,B,6166,,,,,,,10209
3710,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,H,B,17342,,,,,,HEK293,10209
3711,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,H,B,17342,,,,,,,10209
3712,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,H,B,17296,,,,,,,10209
3713,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,H,B,16429,,,,,,,10209
3714,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,H,B,15779,,,,,,HEK293,10209
3715,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,B,15779,,,,,,HEK293,10209
3716,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,B,15779,,,,,,HEK293,10209
3717,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,B,15779,,,,,,HEK293,10209
3718,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,H,B,15779,,,,,,HEK293,10209
3719,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,H,B,17451,,,,,,CHO,10209
3720,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),H,B,4199,,,,,,HEK293,10209
3721,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,D,B,4199,,,,,,HEK293,10209
3722,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),H,B,4199,,,,,,HEK293,10209
3723,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,D,B,3680,,,,,,HEK293,10209
3724,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,D,B,3680,,,,,,,10209
3725,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,H,B,15316,,,,,,COS-7,10209
3726,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,H,B,15146,,,,,,HEK293,10209
3727,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,H,B,5213,,,,,,HEK293,10209
3728,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),H,B,5213,,,,,,HEK293,10209
3729,,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,D,B,14818,,,9606.0,,,HEK293,10209
3730,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,H,B,14818,,,,,,HEK293,10209
3731,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,H,B,14818,,,,,,HEK293,10209
3732,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",H,B,4829,,,,,,HEK293,10209
3733,,Homo sapiens,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,D,B,17200,,,9606.0,,,,10209
3734,,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,D,B,17066,,,10090.0,,,,10022
3735,,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,H,B,14025,,,9986.0,,,,10209
3736,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,H,B,15250,,,,,,CHO,11923
3737,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,H,B,16372,,,,,,CHO,11923
3738,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,H,B,16372,,,,,,CHO,11923
3739,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,H,B,16372,,,,,,CHO,11923
3740,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,H,B,16372,,,,,,CHO,11923
3741,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,H,B,16372,,,,,,CHO,11923
3742,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,H,B,16372,,,,,,CHO,11923
3743,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,H,B,16372,,,,,,CHO,11923
3744,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,H,B,16372,,,,,,CHO,11923
3745,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,H,B,16372,,,,,,CHO,11923
3746,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,H,B,16372,,,,,,CHO,11923
3747,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,H,B,16372,,,,,,CHO,11923
3748,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,H,B,16372,,,,,,CHO,11923
3749,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,H,B,17066,,,,,,,11923
3750,,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,D,B,17066,,,10116.0,,,,11923
3751,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,H,B,17386,,,,,,,11923
3752,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,H,B,14423,,,,,,,11923
3753,,Rattus norvegicus,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,D,B,15874,,,10116.0,,,,11923
3754,,Rattus norvegicus,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,D,B,15874,,,10116.0,,,,11923
3755,,Rattus norvegicus,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,D,B,16372,,,10116.0,,,CHO,11923
3756,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,H,B,4622,,,,,,,11923
3757,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,H,B,15086,,,,,,,11923
3758,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",H,B,16372,,,,,,CHO,11923
3759,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",H,B,16372,,,,,,CHO,11923
3760,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,H,B,16372,,,,,,CHO,11923
3761,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,H,B,16372,,,,,,CHO,11923
3762,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,H,F,17386,,,,,Ileum,,11923
3763,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,H,F,17386,,,,,Ileum,,11923
3764,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,H,F,17386,,,,,Ileum,,11923
3765,Membranes,Rattus norvegicus,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,D,B,5831,,,10116.0,,,,11923
3766,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,H,B,4342,,,,,,,11923
3767,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,H,B,17319,,,,,,,11923
3768,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,H,B,17342,,,,,Hypothalamus,,11923
3769,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,H,B,17342,,,,,,,11923
3770,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,H,B,3680,,,,,Hypothalamus,,11923
3771,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,B,3680,,,,,,,11923
3772,,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,D,F,17319,,,10116.0,,,HEK293,11923
3773,,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,D,F,17319,,,10116.0,,,HEK293,11923
3774,,Rattus norvegicus,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,D,F,17319,,,10116.0,,,HEK293,11923
3775,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,B,4820,,,,,,,10209
3776,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,H,B,4639,,,,,,,10209
3777,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,H,B,6011,,,,,,,10209
3778,,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,D,B,17066,,,9606.0,,,,10209
3779,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,H,B,17066,,,,,,,10209
3780,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,H,B,17515,,,,,,,10209
3781,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,H,B,4373,,,,,,,10209
3782,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,H,F,17066,,,,,,,10209
3783,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,H,B,4373,,,,,,,10209
3784,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,H,B,4373,,,,,,,10209
3785,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,H,B,4687,,,,,,,10209
3786,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,H,B,17342,,,,,,,10209
3787,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,H,B,16946,,,,,,,10209
3788,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,H,B,16946,,,,,,,10209
3789,,,Binding affinities against 5-hydroxytryptamine 7 receptor,H,B,16633,,,,,,,10209
3790,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,H,B,16633,,,,,,,10209
3791,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,H,B,17066,,,,,,,10209
3792,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,H,B,16700,,,,,,,10209
3793,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,H,B,17386,,,,,Ileum,,10209
3794,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,H,F,14080,,,,,,,55
3795,,Homo sapiens,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,D,F,14080,,,9606.0,,,,55
3796,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,H,B,409,,,,,,,55
3797,,,In vitro inhibition of human recombinant lipoxygenase enzyme,H,B,409,,,,,,,55
3798,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,H,B,409,,,,,,,55
3799,,,Inhibition of 5-lipoxygenase in human whole blood.,H,B,11090,,,,,Blood,,55
3800,,,Inhibition of 5-lipoxygenase in human whole blood.,H,B,11090,,,,,Blood,,55
3801,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,H,B,948,,,,,,,55
3802,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),H,B,948,,,,,,,55
3803,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,H,F,13622,,,,,,,55
3804,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,H,F,13622,,,,,Blood,,55
3805,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,H,B,9637,,,,,,,55
3806,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),H,B,11320,,,,,,,55
3807,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,H,B,11320,,,,,,,55
3808,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,H,B,6838,,,,,,,55
3809,,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),D,B,17667,,,9606.0,,Blood,,55
3810,,,In vitro potency against human 5-Lipoxygenase,H,B,12703,,,,,,,55
3811,,Homo sapiens,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,D,F,14312,,,9606.0,,,,55
3812,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,H,F,14312,,,,,Blood,,55
3813,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,H,F,5364,,,,,,,55
3814,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,H,B,951,,,,,,,55
3815,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,H,B,951,,,,,,,55
3816,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,H,B,951,,,,,,,55
3817,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,H,B,951,,,,,,,55
3818,,,Inhibition of human 5-lipoxygenase in human cells,H,B,12365,,,,,,,55
3819,,,Inhibition of human neutrophil 5-lipoxygenase,H,B,10603,,,,,,,55
3820,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,H,B,10501,,,,,,,55
3821,,,Inhibition of 5-lipoxygenase from human whole blood,H,B,12281,,,,,Blood,,55
3822,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,H,B,2567,,,,,,,55
3823,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,H,B,2567,,,,,,,55
3824,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,H,B,10193,,,,,,,55
3825,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,B,10193,,,,,,,55
3826,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,H,B,13623,,,,,,,55
3827,,,Tested against 5-lipoxygenase,H,B,12780,,,,,,,55
3828,,,Tested for activity against 5-Lipoxygenase (5-LO),H,B,12780,,,,,,,55
3829,,,Tested for activity against 5-lipoxygenase,H,B,12780,,,,,,,55
3830,,,Tested for inhibition of 5-HPETE production by human 5-LO,H,B,11966,,,,,,,55
3831,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,H,F,5364,,,,,,,55
3832,,,Inhibition of Human 5-lipoxygenase,H,B,13165,,,,,,,55
3833,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,H,B,5364,,,,,,,55
3834,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],H,B,11311,,,,,,,55
3835,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],H,B,11311,,,,,,,55
3836,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,H,B,14863,,,,,,,55
3837,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,H,B,14863,,,,,,,55
3838,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),H,B,11087,,,,,Blood,,55
3839,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,H,B,455,,,,,,,55
3840,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,B,13183,,,,,,,55
3841,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,H,B,10319,,,,,,,55
3842,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,B,10193,,,,,,,55
3843,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,H,B,951,,,,,,,55
3844,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,H,B,951,,,,,,,55
3845,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,H,B,951,,,,,,,55
3846,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,H,B,951,,,,,,,55
3847,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,H,B,9859,,,,,,,55
3848,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,H,B,9859,,,,,,,55
3849,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,H,B,9859,,,,,,,55
3850,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,H,B,2567,,,,,,,55
3851,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,H,B,10193,,,,,,,55
3852,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,B,10193,,,,,,,55
3853,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,H,B,949,,,,,,,55
3854,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,H,B,949,,,,,,,55
3855,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,H,B,10603,,,,,,,55
3856,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,H,B,10603,,,,,,,55
3857,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,H,F,10603,,,,,,,55
3858,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,H,B,10603,,,,,,,55
3859,,,Inhibition of lipoxygenase at the concentration of 1 uM,H,B,10603,,,,,,,55
3860,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,H,B,10193,,,,,,,55
3861,,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LOX),D,B,14580,,,9606.0,,,,55
3862,,,Inhibition of 5-lipoxygenase in mouse macrophages.,H,B,11090,,,,,,,17087
3863,,,Inhibition of 5-lipoxygenase in mouse macrophages.,H,B,11090,,,,,,,17087
3864,,,Inhibitory activity against lipoxygenase-2 in mice,H,B,6339,,,,,,,17087
3865,,,Inhibitory activity against murine lipoxygenase-2.,H,B,6339,,,,,,,17087
3866,,Mus musculus,Inhibition of 5-lipoxygenase from mouse macrophage,D,B,12281,,,10090.0,,,,17087
3867,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,H,B,11311,,,,,,,17087
3868,,Sus scrofa,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,H,B,11089,,,9823.0,,,,55
3869,,Sus scrofa,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,H,B,10091,,,9823.0,,,,55
3870,,Oryctolagus cuniculus,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,H,B,14352,,,9986.0,,,,55
3871,,Rattus norvegicus,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,D,B,13329,,,10116.0,,,,12166
3872,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",H,B,13329,,,,,,,12166
3873,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",H,B,13329,,,,,,,12166
3874,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",H,B,13329,,,,,,,12166
3875,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),H,B,13329,,,,,,,12166
3876,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",H,B,13329,,,,,,,12166
3877,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,H,B,13329,,,,,,,12166
3878,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),H,B,11311,,,,,,,12166
3879,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,H,B,11311,,,,,,,12166
3880,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",H,B,105,,,,,,RBL-1,12166
3881,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",H,B,105,,,,,,RBL-1,12166
3882,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),H,B,9138,,,,,,,12166
3883,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",H,B,9138,,,,,,,12166
3884,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",H,B,9138,,,,,,,12166
3885,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,H,B,14427,,,,,,,12166
3886,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",H,B,13329,,,,,,,12166
3887,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",H,B,13329,,,,,,,12166
3888,,Rattus norvegicus,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,D,B,14427,,,10116.0,,,RBL-2H3,12166
3889,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,H,B,14427,,,,,,,12166
3890,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,H,B,14427,,,,,,,12166
3891,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,H,B,10293,,,,,,RBL-1,12166
3892,,Rattus norvegicus,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,D,B,338,,,10116.0,,,RBL-1,12166
3893,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),H,B,303,,,,,,,12166
3894,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,H,B,303,,,,,,RBL-1,12166
3895,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,H,B,9247,,,,,,RBL-1,12166
3896,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,H,B,9247,,,,,,RBL-1,12166
3897,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,H,B,137,,,,,,RBL-1,12166
3898,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,H,B,11481,,,,,,,12166
3899,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",H,B,11481,,,,,,,12166
3900,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,H,B,9029,,,,,,,12166
3901,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,H,B,1701,,,,,,,12166
3902,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,H,B,1701,,,,,,,12166
3903,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,H,B,1701,,,,,,,12166
3904,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,H,B,1701,,,,,,,12166
3905,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,H,F,13358,,,,,,RBL-1,12166
3906,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,H,B,1175,,,,,,RBL-1,12166
3907,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,H,B,8797,,,,,,RBL-1,12166
3908,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,H,B,8797,,,,,,,12166
3909,,Rattus norvegicus,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,D,B,577,,,10116.0,,,,12166
3910,,,In vitro inhibitory activity against RBL-1 5-LO,H,B,9295,,,,,,RBL-1,12166
3911,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),H,B,9295,,,,,,RBL-1,12166
3912,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),H,B,9295,,,,,,RBL-1,12166
3913,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,H,B,9295,,,,,,,12166
3914,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,H,B,9295,,,,,,,12166
3915,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,H,B,216,,,,,,,12166
3916,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,H,B,11090,,,,,,RBL-1,12166
3917,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,H,B,11090,,,,,Blood,,12166
3918,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,H,B,10091,,,,,,,12166
3919,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,H,F,10274,,,,,,,12166
3920,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,H,F,13622,,,,,,,12166
3921,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,H,B,12118,,,,,,RBL-1,12166
3922,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,H,B,12576,,,,,,,12166
3923,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,H,B,9546,,,,,,RBL-1,12166
3924,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,H,B,9521,,,,,,RBL-1,12166
3925,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,H,B,10626,,,,,,RBL-1,12166
3926,,,In vitro inhibition of RBL-1 5-lipoxygenase,H,B,9225,,,,,,RBL-1,12166
3927,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,H,B,9225,,,,,,RBL-1,12166
3928,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,H,B,9225,,,,,,RBL-1,12166
3929,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,H,B,9225,,,,,,RBL-1,12166
3930,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,H,B,9225,,,,,,RBL-1,12166
3931,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,H,B,9225,,,,,,RBL-1,12166
3932,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,H,B,9225,,,,,,RBL-1,12166
3933,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,H,B,9225,,,,,,RBL-1,12166
3934,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,H,B,9225,,,,,,RBL-1,12166
3935,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,H,B,9225,,,,,,RBL-1,12166
3936,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,H,B,9225,,,,,,RBL-1,12166
3937,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,H,B,9225,,,,,,RBL-1,12166
3938,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,H,B,9225,,,,,,RBL-1,12166
3939,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,H,B,9225,,,,,,RBL-1,12166
3940,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,H,B,9225,,,,,,RBL-1,12166
3941,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,H,B,9225,,,,,,RBL-1,12166
3942,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,H,B,9225,,,,,,RBL-1,12166
3943,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,H,B,9225,,,,,,RBL-1,12166
3944,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,H,B,9225,,,,,,RBL-1,12166
3945,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,H,B,9225,,,,,,RBL-1,12166
3946,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,H,B,9225,,,,,,RBL-1,12166
3947,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,H,B,9225,,,,,,RBL-1,12166
3948,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,H,B,9225,,,,,,RBL-1,12166
3949,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,H,B,9225,,,,,,RBL-1,12166
3950,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,H,B,9401,,,,,,,12166
3951,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,H,B,10325,,,,,,,12166
3952,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,H,F,1556,,,,,,RBL-2H3,12166
3953,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,H,F,1556,,,,,,RBL-2H3,12166
3954,,Rattus norvegicus,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,D,B,961,,,10116.0,,,RBL-1,12166
3955,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,H,B,6838,,,,,,,12166
3956,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),H,B,10325,,,,,,,12166
3957,,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,D,B,9209,,,10116.0,,,RBL-1,12166
3958,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,H,B,11520,,,,,,RBL-1,12166
3959,,,In vitro inhibitory activity against 5-lipoxygenase was determined,H,B,137,,,,,,,12166
3960,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,H,B,4717,,,,,,RBL-1,12166
3961,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,H,B,10636,,,,,,RBL-1,12166
3962,,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,D,F,14312,,,10116.0,,,,12166
3963,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,H,B,1203,,,,,,RBL-1,12166
3964,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,H,B,1203,,,,,,,12166
3965,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,H,B,13622,,,,,,RBL-1,12166
3966,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,H,B,9793,,,,,,,12166
3967,,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,D,B,1143,,,10116.0,,,RBL-1,12166
3968,,Rattus norvegicus,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,D,B,11854,,,10116.0,,,RBL-1,12166
3969,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,B,3595,,,,,,RBL-1,12166
3970,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),H,B,3595,,,,,,RBL-1,12166
3971,,Rattus norvegicus,Inhibition of 5-lipoxygenase in rat RBL-1 cells,D,B,10501,,,10116.0,,,RBL-1,12166
3972,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,B,12526,,,,,,RBL-1,12166
3973,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,H,F,10034,,,,,Limbic system,,10825
3974,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,H,F,10034,,,,,Limbic system,,10825
3975,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,H,F,10034,,,,,,,10825
3976,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,B,10046,,,,,Hippocampus,,10576
3977,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,B,10046,,,,,Hippocampus,,10576
3978,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,H,B,10046,,,,,,,10577
3979,,Canis lupus familiaris,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,H,F,12079,,,9615.0,,Blood,,55
3980,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,H,F,12079,,,,,Blood,,55
3981,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],H,B,11311,,,,,,,12166
3982,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,H,B,12338,,,,,,,17140
3983,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,H,B,12143,,,,,,,17140
3984,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),H,B,12143,,,,,,,17140
3985,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,H,B,12143,,,,,,,17140
3986,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,H,B,12143,,,,,,,17140
3987,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,H,B,12365,,,,,,,17140
3988,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,H,B,13500,,,,,,,17140
3989,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
3990,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
3991,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
3992,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
3993,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
3994,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
3995,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
3996,,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
3997,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
3998,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
3999,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4000,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4001,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4002,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4003,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4004,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4005,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4006,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4007,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4008,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4009,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4010,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4011,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4012,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4013,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4014,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4015,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4016,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4017,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4018,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4019,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4020,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4021,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4022,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4023,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4024,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4025,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4026,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4027,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4028,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4029,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4030,,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4031,,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4032,,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4033,,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4034,,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,F,12832,In vivo,,9615.0,,Blood,,55
4035,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,H,B,3595,,,9615.0,,,,55
4036,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,H,B,3595,,,9615.0,,,,55
4037,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,H,B,3595,,,9615.0,,,,55
4038,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,H,B,3595,,,9615.0,,,,55
4039,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,H,B,3595,,,9615.0,,,,55
4040,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,H,B,3595,,,9615.0,,,,55
4041,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,H,B,3595,,,9615.0,,,,55
4042,,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,H,B,3595,,,9615.0,,,,55
4043,,Cavia porcellus,Ability to inhibit 5-lipoxygenase in guinea pig,H,B,9203,,,10141.0,,,,55
4044,,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),H,B,82,,,10141.0,,,,55
4045,,Cavia porcellus,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,H,B,11090,,,10141.0,,,,55
4046,,Cavia porcellus,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",H,B,12832,,,10141.0,,Blood,,55
4047,,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,H,B,1065,,,10141.0,,,,55
4048,,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,H,B,1065,,,10141.0,,,,55
4049,,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,H,B,12832,,,10141.0,,,,55
4050,,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,H,B,12832,,,10141.0,,,,55
4051,,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,H,B,12832,,,10141.0,,,,55
4052,,Cavia porcellus,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,H,B,10504,,,10141.0,,,,55
4053,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase,H,B,7788,,,10141.0,,,,55
4054,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,H,B,10001,,,10141.0,,,,55
4055,,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,H,B,10193,,,10141.0,,,,55
4056,,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,H,B,13243,,,10141.0,,,,55
4057,,Cavia porcellus,Inhibitory activity uM,H,B,13243,,,10141.0,,,,55
4058,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,H,B,969,,,10141.0,,,,55
4059,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at 10 uM,H,B,10001,,,10141.0,,,,55
4060,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,H,B,7788,,,10141.0,,,,55
4061,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,H,B,10001,,,10141.0,,,,55
4062,,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,H,B,10193,,,10141.0,,,,55
4063,,Cavia porcellus,Inhibitory activity uM,H,B,13243,,,10141.0,,,,55
4064,,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,H,B,13243,,,10141.0,,,,55
4065,,Cavia porcellus,Inhibitory activity uM,H,B,13243,,,10141.0,,,,55
4066,,Cavia porcellus,Inhibitory activity uM,H,F,13243,,,10141.0,,,,55
4067,,Cavia porcellus,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,H,B,10504,,,10141.0,,,,55
4068,,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,H,B,7788,,,10141.0,,,,55
4069,,Cavia porcellus,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,H,F,10546,,,10141.0,,Ileum,,55
4070,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,B,13183,,,,,,,55
4071,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,B,13183,,,,,,,55
4072,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),H,B,2578,,,,,,,55
4073,,,In vitro inhibition of human 5-Lipoxygenase.,H,B,12780,,,,,,,55
4074,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,U,B,7411,,,10116.0,,Liver,,22226
4075,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,U,B,7411,,,10116.0,,Liver,,22226
4076,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,U,B,7411,,,10116.0,,Liver,,22226
4077,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,U,B,7411,,,10116.0,,Liver,,22226
4078,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,U,B,7411,,,10116.0,,Liver,,22226
4079,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,B,7411,,,10116.0,,Liver,,22226
4080,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,B,7411,,,10116.0,,Liver,,22226
4081,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,U,B,7411,,,10116.0,,Liver,,22226
4082,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,U,B,7411,,,10116.0,,Liver,,22226
4083,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,U,B,7411,,,10116.0,,Liver,,22226
4084,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,U,B,7411,,,10116.0,,Liver,,22226
4085,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,U,B,7411,,,10116.0,,Liver,,22226
4086,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,U,B,7411,,,10116.0,,Liver,,22226
4087,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,B,7411,,,10116.0,,Liver,,22226
4088,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,U,B,7411,,,10116.0,,Liver,,22226
4089,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,U,B,7411,,,10116.0,,Liver,,22226
4090,Microsomes,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,B,7411,,,10116.0,,Liver,,22226
4091,Microsomes,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,B,7411,,,10116.0,,Liver,,22226
4092,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,U,B,7411,,,10116.0,,Liver,,22226
4093,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,U,B,7411,,,10116.0,,Liver,,22226
4094,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,U,B,7411,,,10116.0,,Liver,,22226
4095,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,U,B,7411,,,10116.0,,Liver,,22226
4096,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,U,B,7411,,,10116.0,,Liver,,22226
4097,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,U,B,7411,,,10116.0,,Liver,,22226
4098,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,U,B,7411,,,10116.0,,Liver,,22226
4099,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,U,B,7411,,,10116.0,,Liver,,22226
4100,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,U,B,7411,,,10116.0,,Liver,,22226
4101,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,U,B,7411,,,10116.0,,Liver,,22226
4102,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,U,B,7411,,,10116.0,,Liver,,22226
4103,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,U,B,7411,,,10116.0,,Liver,,22226
4104,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,U,B,7411,,,10116.0,,Liver,,22226
4105,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,U,B,7411,,,10116.0,,Liver,,22226
4106,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,U,B,7411,,,10116.0,,Liver,,22226
4107,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,U,B,7411,,,10116.0,,Liver,,22226
4108,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,B,7411,,,10116.0,,Liver,,22226
4109,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,U,B,7411,,,10116.0,,Liver,,22226
4110,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,U,B,7411,,,10116.0,,Liver,,22226
4111,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,U,B,7411,,,10116.0,,Liver,,22226
4112,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,U,B,7411,,,10116.0,,Liver,,22226
4113,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,U,B,7411,,,10116.0,,Liver,,22226
4114,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,B,7411,,,10116.0,,Liver,,22226
4115,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,U,B,7411,,,10116.0,,Liver,,22226
4116,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,U,B,7411,,,10116.0,,Liver,,22226
4117,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,U,B,7411,,,10116.0,,Liver,,22226
4118,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,U,B,7411,,,10116.0,,Liver,,22226
4119,Microsomes,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,U,B,7411,,,10116.0,,Liver,,22226
4120,Microsomes,Rattus norvegicus,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,B,7411,,,10116.0,,Liver,,22226
4121,Microsomes,Rattus norvegicus,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,U,B,7411,,,10116.0,,,,22226
4122,Microsomes,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,B,7411,,,10116.0,,Liver,,22226
4123,Microsomes,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,B,7411,,,10116.0,,Liver,,22226
4124,Microsomes,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",U,B,7411,,,10116.0,,Liver,,22226
4125,Microsomes,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,B,7411,,,10116.0,,Liver,,22226
4126,Microsomes,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,B,7411,,,10116.0,,Liver,,22226
4127,,Homo sapiens,In vitro inhibition of 7226/S myeloma cancer cell line,N,F,10797,,,9606.0,,,RPMI-8226,80433
4128,,Homo sapiens,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),N,F,6881,,,9606.0,,,BEL-7404 tumor cell line,80698
4129,,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,N,F,3838,,,9606.0,,,786-0,80640
4130,,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,N,F,3838,,,9606.0,,,786-0,80640
4131,,Cricetulus griseus,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,N,F,12981,,,10029.0,,,V79,81264
4132,,Cricetulus griseus,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,N,F,12981,,,10029.0,,,V79,81264
4133,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,N,F,7653,,,10116.0,,,7800C1 cell line,80635
4134,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,N,F,7653,,,10116.0,,,7800C1 cell line,80635
4135,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,N,F,7653,,,10116.0,,,7800C1 cell line,80635
4136,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,N,F,7653,,,10116.0,,,7800C1 cell line,80635
4137,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,N,F,7653,,,10116.0,,,7800C1 cell line,80635
4138,,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,N,F,7653,,,10116.0,,,7800C1 cell line,80635
4139,,Homo sapiens,In vitro antitumor activity against renal 786-0 tumor cell lines,N,F,17229,,,9606.0,,,786-0,80640
4140,,Homo sapiens,Cytotoxic activity against 786-0 Renal cancer cell line,N,F,12858,,,9606.0,,,786-0,80640
4141,,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,N,F,16325,,,9606.0,,,786-0,80640
4142,,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,N,F,16325,,,9606.0,,,786-0,80640
4143,,Homo sapiens,In vitro antitumor activity against human renal 786-0 cell line,N,F,5858,,,9606.0,,,786-0,80640
4144,,Homo sapiens,Inhibition of Renal cancer in 786-0 cancer cell lines,N,F,16325,,,9606.0,,,786-0,80640
4145,,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,N,F,14696,,,9606.0,,,786-0,80640
4146,,Homo sapiens,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,N,F,3786,,,9606.0,,,786-0,80640
4147,,Homo sapiens,inhibition of the growth of renal cancer(786-0) cell line,N,F,14696,,,9606.0,,,786-0,80640
4148,,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),N,F,14769,,,9606.0,,,786-0,80640
4149,,Homo sapiens,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,N,F,15354,,,9606.0,,,786-0,80640
4150,,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor,N,F,14255,,,9606.0,,,786-0,80640
4151,,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor t,N,F,14255,,,9606.0,,,786-0,80640
4152,,Homo sapiens,The IC50 value was measured on 786-0 cell line in renal tumor type.,N,F,14255,,,9606.0,,,786-0,80640
4153,,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,N,F,14696,,,9606.0,,,786-0,80640
4154,,Homo sapiens,Tested for cytotoxic activity against renal cancer 786-0 cell line,N,F,12016,,,9606.0,,,786-0,80640
4155,,Homo sapiens,Compound was tested for growth inhibitory activity against 786-0 cell line,N,F,2597,,,9606.0,,,786-0,80640
4156,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,H,B,12526,,,,,,RBL-1,12166
4157,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,H,B,12526,,,,,,RBL-1,12166
4158,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,H,B,14799,,,,,,,12166
4159,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,B,3595,,,,,,RBL-1,12166
4160,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),H,B,3595,,,,,,RBL-1,12166
4161,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,H,B,12767,,,,,,,12166
4162,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,H,B,10997,,,,,,,12166
4163,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,H,B,11388,,,,,,RBL-1,12166
4164,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,H,B,167,,,,,,,12166
4165,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",H,B,167,,,,,,,12166
4166,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,H,B,13744,,,,,,,12166
4167,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,H,B,1630,,,,,,,12166
4168,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),H,B,1630,,,,,,,12166
4169,,Rattus norvegicus,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",D,B,969,,,10116.0,,,,12166
4170,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,H,B,13621,,,,,,RBL-1,12166
4171,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,H,B,10089,,,,,,,12166
4172,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,H,B,10193,,,,,,,12166
4173,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,H,B,11966,,,,,,,12166
4174,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,H,B,12251,,,,,,,12166
4175,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),H,B,211,,,,,,RBL-1,12166
4176,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,H,F,12251,,,,,,,12166
4177,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,H,B,12495,,,,,,RBL-1,12166
4178,,,Tested for its inhibitory activity against 5-lipoxygenase,H,B,414,,,,,,,12166
4179,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,H,B,414,,,,,,,12166
4180,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",H,B,10325,,,,,,,12166
4181,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,H,B,11966,,,,,,,12166
4182,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,B,165,,,,,,RBL-1,12166
4183,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,H,B,165,,,,,,RBL-1,12166
4184,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,B,165,,,,,,RBL-1,12166
4185,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,B,165,,,,,,RBL-1,12166
4186,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,H,B,11311,,,,,,,12166
4187,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,H,B,11311,,,,,,RBL-1,12166
4188,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,H,B,11311,,,,,,RBL-1,12166
4189,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],H,B,11311,,,,,,,12166
4190,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),H,B,11311,,,,,,,12166
4191,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),H,B,11311,In vivo,,,,,,12166
4192,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,H,F,11311,,,,,,RBL-2H3,12166
4193,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,H,F,11311,,,,,,RBL-2H3,12166
4194,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],H,B,11311,,,,,,,12166
4195,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,H,B,11732,,,,,,,12166
4196,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,H,B,11732,,,,,,,12166
4197,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,H,B,11087,,,,,,,12166
4198,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,H,B,11087,,,,,,,12166
4199,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,H,B,11087,,,,,,RBL-1,12166
4200,,Rattus norvegicus,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,D,B,11087,,,10116.0,,,,12166
4201,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,H,B,496,,,,,,RBL-1,12166
4202,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,H,F,13986,,,,,,RBL-1,12166
4203,,,Compound was evaluated for the inhibition of 5-lipoxygenase,H,B,11520,,,,,,,12166
4204,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,H,B,10293,,,,,,RBL-1,12166
4205,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,H,B,303,,,,,,RBL-1,12166
4206,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,H,B,303,,,,,,RBL-1,12166
4207,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,H,B,9247,,,,,,RBL-1,12166
4208,,Rattus norvegicus,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,D,B,9247,,,10116.0,,,RBL-1,12166
4209,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,H,B,9247,,,,,,RBL-1,12166
4210,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,H,B,9247,,,,,,RBL-1,12166
4211,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,H,B,9247,,,,,,RBL-1,12166
4212,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,H,B,9247,,,,,,RBL-1,12166
4213,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,H,B,9247,,,,,,RBL-1,12166
4214,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,H,B,9247,,,,,,RBL-1,12166
4215,,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase at 10 uM,D,B,11481,,,10116.0,,,,12166
4216,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,H,B,105,,,,,,,12166
4217,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,H,B,9029,,,,,,,12166
4218,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,H,B,1175,,,,,,RBL-1,12166
4219,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,H,B,12118,,,,,,RBL-1,12166
4220,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,H,B,12118,,,,,,RBL-1,12166
4221,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,H,B,12118,,,,,,RBL-1,12166
4222,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,H,B,9225,,,,,,RBL-1,12166
4223,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,H,B,9401,,,,,,,12166
4224,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,H,B,137,,,,,,,12166
4225,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,H,B,137,,,,,,,12166
4226,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,H,B,4717,,,,,,RBL-1,12166
4227,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,H,B,3595,,,,,,RBL-1,12166
4228,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,H,B,10501,,,,,,RBL-1,12166
4229,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,H,B,10501,,,,,,RBL-1,12166
4230,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,H,B,10501,,,,,,RBL-1,12166
4231,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,B,12526,,,,,,RBL-1,12166
4232,,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,D,B,14799,,,10116.0,,,RBL-1,12166
4233,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,H,B,14799,,,,,,,12166
4234,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,H,B,3595,,,,,,RBL-1,12166
4235,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,H,B,3595,,,,,,RBL-1,12166
4236,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,B,12526,,,,,,RBL-1,12166
4237,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,B,12526,,,,,,RBL-1,12166
4238,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,H,B,10193,,,,,,,12166
4239,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,H,B,10193,,,,,,,12166
4240,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,H,B,10193,,,,,,,12166
4241,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,H,B,10193,,,,,,,12166
4242,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),H,B,9138,,,,,,,12166
4243,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,H,B,9138,,,,,,,12166
4244,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,H,B,11966,,,,,,,12166
4245,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,H,B,165,,,,,,RBL-1,12166
4246,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,H,B,165,,,,,,RBL-1,12166
4247,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,H,B,11311,,,,,,RBL-2H3,12166
4248,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,H,B,11311,,,,,,RBL-2H3,12166
4249,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,H,F,11311,,,,,,RBL-2H3,12166
4250,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,H,F,11311,,,,,,,12166
4251,,,The compound was tested for inhibition of isolated 5-lipoxygenase,H,B,11311,,,,,,,12166
4252,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,H,F,11311,,,,,,RBL-2H3,12166
4253,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,H,B,11087,,,,,,,12166
4254,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,H,B,11087,,,,,,,12166
4255,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,H,B,11087,,,,,,,12166
4256,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,H,B,11087,,,,,,,12166
4257,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,H,B,11087,,,,,,,12166
4258,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,H,B,496,,,,,,RBL-1,12166
4259,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,H,B,496,,,,,,RBL-1,12166
4260,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,H,F,13986,,,,,,RBL-1,12166
4261,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,H,F,13986,,,,,,RBL-1,12166
4262,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,H,F,13986,,,,,,RBL-1,12166
4263,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,H,F,13986,,,,,,RBL-1,12166
4264,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,H,F,13986,,,,,,RBL-1,12166
4265,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,H,F,13986,,,,,,RBL-1,12166
4266,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,H,F,13986,,,,,,RBL-1,12166
4267,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,H,F,13986,,,,,,RBL-1,12166
4268,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,H,F,13986,,,,,,RBL-1,12166
4269,,Rattus norvegicus,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,D,F,13986,,,10116.0,,,,12166
4270,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,H,B,10193,,,,,,,12166
4271,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,H,B,9295,,,,,,,12166
4272,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,H,B,4717,,,,,,RBL-1,12166
4273,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,H,B,4717,,,,,,RBL-1,12166
4274,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,H,B,11854,,,,,,RBL-1,12166
4275,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,H,B,11854,,,,,,RBL-1,12166
4276,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,H,B,11854,,,,,,RBL-1,12166
4277,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,H,B,10193,,,,,,,12166
4278,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,H,B,9295,,,,,,RBL-1,12166
4279,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,H,B,9295,,,,,,RBL-1,12166
4280,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,H,B,9295,,,,,,RBL-1,12166
4281,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,H,B,9295,,,,,,RBL-1,12166
4282,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,H,B,165,,,,,,RBL-1,12166
4283,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,H,B,11311,,,,,,,12166
4284,,Homo sapiens,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),H,B,10489,,,9606.0,,,RBL-1,12166
4285,,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),D,B,10489,,,10116.0,,,RBL-1,12166
4286,,Rattus norvegicus,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),D,B,10489,,,10116.0,,,RBL-1,12166
4287,,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,D,B,14799,,,10116.0,,,,12166
4288,,Glycine max,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),H,B,9295,,,3847.0,,,,12054
4289,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",U,B,16811,,,,,,,22226
4290,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,H,B,168,,,,,,,55
4291,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,H,B,6309,,,,,,,55
4292,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,H,B,6309,,,,,,,55
4293,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,H,B,3092,,,,,,RBL-1,55
4294,,,Inhibitory activity against 5-lipoxygenase.,H,B,168,,,,,,,55
4295,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,H,B,168,,,,,,,55
4296,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,H,B,168,,,,,,,55
4297,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,H,B,168,,,,,,,55
4298,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,H,F,12338,,,,,,,55
4299,,,Tested for the inhibitory activity against 5-lipoxygenase,H,B,4501,,,,,,,55
4300,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,H,B,1132,,,,,,,55
4301,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,H,B,2117,,,,,,,55
4302,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,H,B,168,,,,,,,55
4303,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,H,B,168,,,,,,,55
4304,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,H,B,13575,,,,,,RBL-1,12166
4305,,,,H,B,11089,,,,,,,12166
4306,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),H,B,216,,,,,,,10102
4307,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,H,B,13165,,,,,,,10102
4308,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,H,B,3278,,,,,,,10102
4309,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,H,B,3278,,,,,,,10102
4310,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,H,B,11966,,,,,,,10102
4311,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",H,B,175,,,,,,,10102
4312,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",H,B,175,,,,,,,10102
4313,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,H,B,13449,,,,,,,10102
4314,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,H,B,12014,,,,,,,11238
4315,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),H,B,12014,,,,,,,11238
4316,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),H,B,12014,,,,,,,11238
4317,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,S,B,99,,,,,,,100284
4318,,Homo sapiens,The dark toxicity against 543 human galactophore carcinoma cells,U,F,4349,,,9606.0,,,,22226
4319,,Homo sapiens,Tested in vitro for cytotoxicity against 56 human tumor cell lines,N,F,4071,,,9606.0,,,Panel (56 tumour cell lines),80623
4320,,Homo sapiens,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,N,F,17589,,,9606.0,,,5637,80008
4321,,Homo sapiens,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,N,F,15002,,,9606.0,,,5637,80008
4322,,Homo sapiens,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",N,F,13958,,,9606.0,,,5637,80008
4323,,Homo sapiens,Growth inhibition against human 5637 cell lines,N,F,17589,,,9606.0,,,5637,80008
4324,,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells.,N,F,16748,,,9606.0,,,5637,80008
4325,,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,N,F,16747,,,9606.0,,,5637,80008
4326,,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,N,F,16747,,,9606.0,,,5637,80008
4327,,Bos taurus,In vitro inhibition of bovine trypsin(Trp).,D,B,15285,,,9913.0,,,,10443
4328,,Cercopithecidae,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,H,B,3726,,,9527.0,,,CV-1,240
4329,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,H,B,5033,,,,,,,10577
4330,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,H,F,11756,,,,,,,104698
4331,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,U,F,11953,In vivo,,,,,,22226
4332,,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,D,B,5033,,,10141.0,,,,20033
4333,Microsomes,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,H,A,11347,,,10116.0,,,,17045
4334,Microsomes,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,H,A,11347,,,10116.0,,,,17045
4335,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,U,F,1229,,,,,,,22226
4336,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,U,F,1229,,,,,,,22226
4337,,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,H,B,17588,,,5691.0,,,,11938
4338,,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,H,B,17588,,,5691.0,,,,11938
4339,,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,H,B,17588,,,9940.0,,,,11938
4340,,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,H,B,17588,,,9940.0,,,,11938
4341,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,H,B,16485,,,,,,,11938
4342,,Homo sapiens,Average inhibitory concentration against 60 human cell lines was reported,U,F,4337,,,9606.0,,,,22226
4343,,Homo sapiens,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,U,F,4112,,,9606.0,,,,22226
4344,,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,N,F,16160,,,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),80315
4345,,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,N,F,16160,,,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),80315
4346,,,In vitro mean growth inhibitory activity against 60-cell panel,N,F,17376,,,,,,Panel NCI-60 (60 carcinoma cell lines),80315
4347,,,In vitro mean growth lethal concentration against 60-cell panel,N,F,17376,,,,,,Panel NCI-60 (60 carcinoma cell lines),80315
4348,,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,N,F,17376,,,,,,Panel NCI-60 (60 carcinoma cell lines),80315
4349,,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,N,F,17376,,,,,,Panel NCI-60 (60 carcinoma cell lines),80315
4350,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,H,F,3241,,,,,,,104775
4351,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,H,F,3241,,,,,,,104775
4352,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,H,B,3725,,,,,,,275
4353,,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,N,F,10805,,,5833.0,,,,50425
4354,,Plasmodium falciparum,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,N,F,10805,,,5833.0,,,,50425
4355,,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,N,F,10805,,,5833.0,,,,50425
4356,,Plasmodium falciparum,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,N,F,10805,,,5833.0,,,,50425
4357,,Plasmodium falciparum,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,N,F,10805,,,5833.0,,,,50425
4358,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,N,F,10144,,,10090.0,,,6C3HED,80628
4359,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,N,F,10144,,,10090.0,,,6C3HED,80628
4360,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,N,F,10144,,,10090.0,,,6C3HED,80628
4361,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,N,F,10144,,,10090.0,,,6C3HED,80628
4362,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,N,F,10144,,,10090.0,,,6C3HED,80628
4363,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,N,F,10144,,,10090.0,,,6C3HED,80628
4364,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,U,F,10685,In vivo,,10090.0,,,,22224
4365,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,U,F,10685,In vivo,,10090.0,,,,22224
4366,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),U,F,10685,In vivo,,10090.0,,,,22224
4367,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,U,F,10685,In vivo,,10090.0,,,,22224
4368,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,U,F,10685,In vivo,,10090.0,,,,22224
4369,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,U,F,10685,In vivo,,10090.0,,,,22224
4370,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,U,F,10685,In vivo,,10090.0,,,,22224
4371,,Mus musculus,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",U,F,10685,In vivo,,10090.0,,,,22224
4372,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),U,F,10685,In vivo,,10090.0,,,,22224
4373,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),U,F,10685,In vivo,,10090.0,,,,22224
4374,,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,U,F,10685,In vivo,,10090.0,,,,22224
4375,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,U,F,10144,,,10090.0,,,,22224
4376,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,U,F,10144,,,10090.0,,,,22224
4377,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,U,F,10144,,,10090.0,,,,22224
4378,,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,U,F,10144,,,10090.0,,,,22224
4379,,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,U,F,10685,,,10090.0,,,,22224
4380,,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,U,F,10685,,,10090.0,,,,22224
4381,,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,U,F,10685,,,10090.0,,,,22224
4382,,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,U,F,10685,,,10090.0,,,,22224
4383,,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,U,A,10685,,,10090.0,,,,22224
4384,,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,U,A,10685,,,10090.0,,,,22224
4385,,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,U,A,10685,,,10090.0,,,,22224
4386,,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,U,A,10685,,,10090.0,,,,22224
4387,,Mus musculus,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",N,F,8831,,,10090.0,,,6C3HED,80628
4388,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,U,F,11704,In vivo,,,,,,22224
4389,,Mus musculus,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,N,A,11704,,,10090.0,,,,50594
4390,,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,N,F,10685,In vivo,,10090.0,,,6C3HED,80628
4391,,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,N,F,10685,In vivo,,10090.0,,,6C3HED,80628
4392,,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),N,F,11368,,,10090.0,,,6C3HED,80628
4393,,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),N,F,11368,,,10090.0,,,6C3HED,80628
4394,,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),N,F,11368,,,10090.0,,,6C3HED,80628
4395,,Staphylococcus aureus,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",U,B,17763,,,1280.0,,,,22226
4396,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,U,B,7411,,,10116.0,,Liver,,22226
4397,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,U,B,7411,,,10116.0,,Liver,,22226
4398,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,U,B,7411,,,10116.0,,Liver,,22226
4399,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,U,B,7411,,,10116.0,,Liver,,22226
4400,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,U,B,7411,,,10116.0,,Liver,,22226
4401,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,U,B,7411,,,10116.0,,Liver,,22226
4402,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,U,B,7411,,,10116.0,,Liver,,22226
4403,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,U,B,7411,,,10116.0,,Liver,,22226
4404,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,U,B,7411,,,10116.0,,Liver,,22226
4405,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,U,B,7411,,,10116.0,,Liver,,22226
4406,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,U,B,7411,,,10116.0,,Liver,,22226
4407,Microsomes,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,U,B,7411,,,10116.0,,Liver,,22226
4408,,Cercopithecidae,The apparent total plasma clearance in monkey,U,A,347,In vivo,,9527.0,,Plasma,,22224
4409,,Cercopithecidae,Compound was evaluated for Hepatic clearance in monkey,U,A,3341,In vivo,,9527.0,,,,22224
4410,,Cercopithecidae,Lower clearance in monkey (i.v.) at 0.5 mpk,U,A,17853,In vivo,,9527.0,,,,22224
4411,,Cercopithecidae,Plasma clearance in rhesus monkey,U,A,4514,In vivo,,9527.0,,,,22224
4412,,Cercopithecidae,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,U,A,6062,In vivo,,9527.0,,,,22224
4413,,Cercopithecidae,Plasma clearance of compound was determined in monkey,U,A,6821,In vivo,,9527.0,,,,22224
4414,,Cercopithecidae,Plasma clearance was calculated in rhesus monkey,U,A,6057,In vivo,,9527.0,,,,22224
4415,,Cercopithecidae,Plasma clearance in rhesus monkey,U,A,5145,In vivo,,9527.0,,,,22224
4416,,Cercopithecidae,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,A,6641,In vivo,,9527.0,,,,22224
4417,,Cercopithecidae,Plasma clearance was evaluated in rhesus,U,A,5472,In vivo,,9527.0,,,,22224
4418,,Cercopithecidae,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,U,A,4257,In vivo,,9527.0,,,,22224
4419,,Cercopithecidae,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,A,5546,In vivo,,9527.0,,,,22224
4420,,Cercopithecidae,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,A,5334,In vivo,,9527.0,,,,22224
4421,,Cercopithecidae,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,A,5334,In vivo,,9527.0,,,,22224
4422,,Cercopithecidae,Cmax 24 hr after 2 mg/kg oral administration in monkeys,U,A,17509,In vivo,,9527.0,,,,22224
4423,,Cercopithecidae,Cmax in monkey after administration of 1 mg/kg iv,U,A,6535,In vivo,,9527.0,,,,22224
4424,,Cercopithecidae,Cmax was determine after peroral administration at 10 mpk in Rhesus,U,A,5668,In vivo,,9527.0,,,,22224
4425,,Cercopithecidae,Cmax in cynomolgus monkey by iv administration,U,A,5922,In vivo,,9527.0,,,,22224
4426,,Cercopithecidae,Cmax in cynomolgus monkey by po administration,U,A,5922,In vivo,,9527.0,,,,22224
4427,,Cercopithecidae,Cmax value evaluated in monkey,U,A,6078,In vivo,,9527.0,,,,22224
4428,,Cercopithecidae,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,A,2661,In vivo,,9527.0,,,,22224
4429,,Cercopithecidae,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,U,A,3249,In vivo,,9527.0,,Plasma,,22224
4430,,Cercopithecidae,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,U,A,3249,In vivo,,9527.0,,Plasma,,22224
4431,,Cercopithecidae,Maximal plasma concentration in squirrel monkeys,U,A,5553,In vivo,,9527.0,,Plasma,,22224
4432,,Cercopithecidae,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,A,1916,In vivo,,9527.0,,,,22224
4433,,Cercopithecidae,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,U,A,6227,In vivo,,9527.0,,Plasma,,22224
4434,,Cercopithecidae,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,A,4809,In vivo,,9527.0,,,,22224
4435,,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,U,A,5355,In vivo,,9527.0,,,,22224
4436,,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,U,A,5355,In vivo,,9527.0,,,,22224
4437,,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,U,A,5355,In vivo,,9527.0,,,,22224
4438,,Cercopithecidae,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,U,A,5355,In vivo,,9527.0,,,,22224
4439,,Cercopithecidae,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,U,A,6221,In vivo,,9527.0,,Plasma,,22224
4440,,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,U,A,167,,,9527.0,,,,22224
4441,,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,U,A,167,,,9527.0,,,,22224
4442,,monkey,Absolute bioavailability was evaluated in monkey,U,A,4257,In vivo,,9443.0,,,,22224
4443,,monkey,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,U,A,6221,In vivo,,9443.0,,,,22224
4444,,monkey,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,U,A,17667,In vivo,,9443.0,,,,22224
4445,,Macaca mulatta,Bioavailability of compound was determined in rhesus monkey,U,A,17267,In vivo,,9544.0,,,,22224
4446,,marmosets,Bioavailability determined after oral administration in marmoset,U,A,4256,In vivo,,38020.0,,,,22224
4447,,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,U,A,4256,In vivo,,9541.0,,,,22224
4448,,monkey,Bioavailability in monkey (p.o.) at 2.0 mpk,U,A,17853,In vivo,,9443.0,,,,22224
4449,,monkey,Bioavailability was evaluated after oral administration in monkey,U,A,16365,In vivo,,9443.0,,,,22224
4450,,Macaca fascicularis,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,A,1916,In vivo,,9541.0,,,,22224
4451,,Macaca mulatta,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,A,5334,In vivo,,9544.0,,,,22224
4452,,Macaca mulatta,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,A,5334,In vivo,,9544.0,,,,22224
4453,,monkey,Bioavailability of the compound was determined in monkey,U,A,17592,In vivo,,9443.0,,,,22224
4454,,Saimiri sciureus,Bioavailability in squirrel monkey (dose 5 mg/kg),U,A,1399,In vivo,,9521.0,,,,22224
4455,,monkey,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,A,4809,In vivo,,9443.0,,,,22224
4456,,monkey,Oral bioavailability in monkey,U,A,3341,In vivo,,9443.0,,,,22224
4457,,Saimiri sciureus,Compound was tested for bioavailability in squirrel monkey,U,A,64,In vivo,,9521.0,,,,22224
4458,,Macaca mulatta,Oral bioavailability in Rhesus monkey,U,A,5005,In vivo,,9544.0,,,,22224
4459,,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),U,A,5005,In vivo,,9544.0,,,,22224
4460,,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,U,A,5237,In vivo,,9541.0,,,,22224
4461,,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,U,A,5237,In vivo,,9541.0,,,,22224
4462,,monkey,Oral bioavailability in monkey (dose 5 mg/kg),U,A,5302,In vivo,,9443.0,,,,22224
4463,,monkey,Oral bioavailability of compound at 5 mg/kg in monkey,U,A,17667,In vivo,,9443.0,,,,22224
4464,,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,N,A,6161,In vivo,,9615.0,,,,50588
4465,,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,N,A,6161,In vivo,,9615.0,,,,50588
4466,,Canis lupus familiaris,Plasma half life determined,N,A,3854,,,9615.0,,Plasma,,50588
4467,,Canis lupus familiaris,Plasma half life in dog,N,A,993,,,9615.0,,Plasma,,50588
4468,,Canis lupus familiaris,Plasma half-life in Beagle dogs,N,A,4514,,,9615.0,,Plasma,,50588
4469,,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,A,5334,In vivo,,9615.0,,Plasma,,50588
4470,,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),N,A,5334,In vivo,,9615.0,,Plasma,,50588
4471,,Canis lupus familiaris,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,N,A,1466,In vivo,,9615.0,,,,50588
4472,,Canis lupus familiaris,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,N,A,1466,In vivo,,9615.0,,,,50588
4473,,Canis lupus familiaris,Tested for the half life period in dog,N,A,5313,,,9615.0,,,,50588
4474,,Canis lupus familiaris,Tested for the half life period in dog at dosage of 10 mpk,N,A,5313,In vivo,,9615.0,,,,50588
4475,,Canis lupus familiaris,The compound was tested for half life in dog,N,A,3880,,,9615.0,,,,50588
4476,,Canis lupus familiaris,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",N,A,3639,,,9615.0,,Plasma,,50588
4477,,Canis lupus familiaris,The half life was determined,N,A,3880,,,9615.0,,,,50588
4478,,Canis lupus familiaris,The plasma half-life in dogs,N,A,3918,,,9615.0,,Plasma,,50588
4479,,Canis lupus familiaris,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,N,A,16452,,,9615.0,,Plasma,,50588
4480,,Canis lupus familiaris,Half life in dog,N,A,17796,,,9615.0,,,,50588
4481,,Canis lupus familiaris,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,N,A,5983,In vivo,,9615.0,,,,50588
4482,,Canis lupus familiaris,tmax upon peroral administration of 10.0 mg/Kg dose in dog,N,A,1466,In vivo,,9615.0,,,,50588
4483,,Canis lupus familiaris,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,A,16456,In vivo,,9615.0,,,,50588
4484,,Mustela putorius furo,Cmax in ferrets after 30 mg/kg oral dose,N,A,6113,In vivo,,9669.0,,,,50506
4485,,Mustela putorius furo,Emesis in ferrets at 30 mg/kg oral dose,N,F,6113,In vivo,,9669.0,,,,50506
4486,,Macaca fascicularis,Bioavailability in cynomolgus monkey,U,A,17796,In vivo,,9541.0,,,,22224
4487,,Macaca fascicularis,Volume of distribution in cynomolgus,N,A,17796,In vivo,,9541.0,,,,100710
4488,,Cavia porcellus,AUC tested in guinea pig when 3 mg/kg dose was given perorally,U,A,5308,,,10141.0,,Plasma,,22224
4489,,Cavia porcellus,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,U,A,4877,,,10141.0,,,,22224
4490,,Cavia porcellus,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",U,A,4876,,,10141.0,,,,22224
4491,,Cavia porcellus,AUC in guinea pig after 3mg/kg oral dose,U,A,4878,In vivo,,10141.0,,Plasma,,22224
4492,,Cavia porcellus,Bioavailability in guinea pig was tested,U,A,5308,In vivo,,10141.0,,,,22224
4493,,Cavia porcellus,Tested for oral bioavailability in guinea pig at 5 mg/kg,U,A,4877,In vivo,,10141.0,,,,22224
4494,,Cavia porcellus,Tested for the oral bioavailability of the compound,U,A,4876,In vivo,,10141.0,,,,22224
4495,,Cavia porcellus,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,U,A,4876,In vivo,,10141.0,,,,22224
4496,,Cavia porcellus,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,U,A,5308,In vivo,,10141.0,,,,22224
4497,,Cavia porcellus,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,U,A,4877,In vivo,,10141.0,,Lung,,22224
4498,,Cavia porcellus,Cmax in guinea pig after 3mg/kg oral dose,U,A,4878,In vivo,,10141.0,,,,22224
4499,,Cavia porcellus,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,U,A,5689,,,10141.0,,Blood,,22224
4500,,Cavia porcellus,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,U,A,5689,,,10141.0,,Brain,,22224
4501,,Cavia porcellus,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,U,A,5689,,,10141.0,,,,22224
4502,,Cavia porcellus,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,U,A,5689,,,10141.0,,Intestine,,22224
4503,,Cavia porcellus,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,U,A,5689,,,10141.0,,Kidney,,22224
4504,,Cavia porcellus,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,U,A,5689,,,10141.0,,Liver,,22224
4505,,Cavia porcellus,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,U,A,5689,,,10141.0,,,,22224
4506,,Cavia porcellus,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,U,A,5689,,,10141.0,,Spleen,,22224
4507,,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),U,A,14465,In vivo,,10141.0,,,,22224
4508,,Cavia porcellus,Partition coefficient was measured as -log (counts per min ),U,A,5689,,,10141.0,,,,22224
4509,,Cavia porcellus,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,U,A,611,In vivo,,10141.0,,,,22224
4510,,Cavia porcellus,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,U,A,611,In vivo,,10141.0,,,,22224
4511,,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),U,A,14465,In vivo,,10141.0,,,,22224
4512,,Cavia porcellus,"Tested for the half life period of the compound, intravenously",U,A,4876,In vivo,,10141.0,,,,22224
4513,,Cavia porcellus,Half-life was measured,U,A,5689,,,10141.0,,,,22224
4514,,Cavia porcellus,The time required for onset of inotropy after addition of a single dose of delta F75,U,A,7515,,,10141.0,,,,22224
4515,,Cavia porcellus,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,U,A,17667,In vivo,,10141.0,,,,22224
4516,,Cavia porcellus,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,U,A,17667,In vivo,,10141.0,,,,22224
4517,,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,U,A,4727,In vivo,,10029.0,,,,22224
4518,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,,,50594
4519,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,A,10107,In vivo,,10090.0,,,,50594
4520,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,,,50594
4521,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,,,50594
4522,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,N,A,10107,In vivo,,10090.0,,,,50594
4523,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,,,50594
4524,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,,,50594
4525,,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,N,A,3655,In vivo,,10090.0,,Blood,,50594
4526,,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,N,A,3655,In vivo,,10090.0,,Blood,,50594
4527,,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,N,A,3655,In vivo,,10090.0,,Blood,,50594
4528,,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,N,A,3655,In vivo,,10090.0,,Bone,,50594
4529,,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,N,A,3655,In vivo,,10090.0,,Bone,,50594
4530,,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,N,A,3655,In vivo,,10090.0,,Bone,,50594
4531,,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,N,A,3655,In vivo,,10090.0,,Brain,,50594
4532,,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,N,A,3655,In vivo,,10090.0,,Brain,,50594
4533,,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,N,A,3655,In vivo,,10090.0,,Brain,,50594
4534,,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,N,A,3655,In vivo,,10090.0,,Heart,,50594
4535,,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,N,A,3655,In vivo,,10090.0,,Heart,,50594
4536,,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,N,A,3655,In vivo,,10090.0,,Heart,,50594
4537,,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,N,A,3655,In vivo,,10090.0,,Intestine,,50594
4538,,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,N,A,3655,In vivo,,10090.0,,Intestine,,50594
4539,,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,N,A,3655,In vivo,,10090.0,,Intestine,,50594
4540,,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,N,A,3655,In vivo,,10090.0,,Kidney,,50594
4541,,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,N,A,3655,In vivo,,10090.0,,Kidney,,50594
4542,,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,N,A,3655,In vivo,,10090.0,,Kidney,,50594
4543,,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,N,A,3655,In vivo,,10090.0,,Liver,,50594
4544,,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,N,A,3655,In vivo,,10090.0,,Liver,,50594
4545,,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,N,A,3655,In vivo,,10090.0,,Liver,,50594
4546,,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,N,A,3655,In vivo,,10090.0,,Lung,,50594
4547,,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,N,A,3655,In vivo,,10090.0,,Lung,,50594
4548,,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,N,A,3655,In vivo,,10090.0,,Lung,,50594
4549,,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,N,A,3655,In vivo,,10090.0,,Muscle tissue,,50594
4550,,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,N,A,3655,In vivo,,10090.0,,Muscle tissue,,50594
4551,,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,N,A,3655,In vivo,,10090.0,,Muscle tissue,,50594
4552,,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,N,A,3655,In vivo,,10090.0,,Spleen,,50594
4553,,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,N,A,3655,In vivo,,10090.0,,Spleen,,50594
4554,,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,N,A,3655,In vivo,,10090.0,,Spleen,,50594
4555,,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,N,A,3655,In vivo,,10090.0,,Stomach,,50594
4556,,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,N,A,3655,In vivo,,10090.0,,Stomach,,50594
4557,,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,N,A,3655,In vivo,,10090.0,,Stomach,,50594
4558,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,N,A,16597,In vivo,,10090.0,,,,50594
4559,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,N,F,16597,In vivo,,10090.0,,,,50594
4560,,Mus musculus,MRT value at a dose of 10 mg/kg intravenous administration in mice.,N,A,16597,In vivo,,10090.0,,,,50594
4561,,Mus musculus,MRT value at a dose of 10 mg/kg peroral administration in mice.,N,A,16597,In vivo,,10090.0,,,,50594
4562,,Mus musculus,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,N,A,17764,In vivo,,10090.0,,,,50594
4563,,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,N,F,17764,In vivo,,10090.0,,,,50594
4564,,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,N,F,3830,,,9606.0,,,A2780,81034
4565,,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,N,F,3829,,,9606.0,,,A2780,81034
4566,,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell lines.,N,F,2040,,,9606.0,,,A2780,81034
4567,,Homo sapiens,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,N,F,15684,,,9606.0,,,A2780,81034
4568,,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,N,F,15684,,,9606.0,,,A2780,81034
4569,,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,N,F,15684,,,9606.0,,,A2780,81034
4570,,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,N,F,15684,,,9606.0,,,A2780,81034
4571,,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,N,F,15684,,,9606.0,,,A2780,81034
4572,,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,N,F,15684,,,9606.0,,,A2780,81034
4573,,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,N,F,2859,,,9606.0,,,A2780,81034
4574,,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780,N,F,5618,,,9606.0,,,A2780,81034
4575,,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,N,F,15684,,,9606.0,,,A2780,81034
4576,,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,N,F,15684,,,9606.0,,,A2780,81034
4577,,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,N,F,15684,,,9606.0,,,A2780,81034
4578,,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,N,F,15684,,,9606.0,,,A2780,81034
4579,,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,N,F,2113,,,9606.0,,,A2780,81034
4580,,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,N,F,2113,,,9606.0,,,A2780,81034
4581,,Homo sapiens,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,N,F,16745,,,9606.0,,,A2780,81034
4582,,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,F,16597,,,9606.0,,,A2780,81034
4583,,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,N,F,15684,,,9606.0,,,A2780,81034
4584,,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,N,F,15684,,,9606.0,,,A2780,81034
4585,,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,N,F,2040,,,9606.0,,,A2780,81034
4586,,Homo sapiens,Relative resistance factor in A2780 cisplatin-resistant line,N,F,2040,,,9606.0,,,A2780,81034
4587,,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,N,F,16165,,,9606.0,,,A2780,81034
4588,,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,N,F,16165,,,9606.0,,,A2780,81034
4589,,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,F,16597,,,9606.0,,,A2780,81034
4590,,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,F,16597,,,9606.0,,,A2780,81034
4591,,Homo sapiens,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,N,F,3992,,,9606.0,,,A2780,81034
4592,,Homo sapiens,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,N,F,10553,,,9606.0,,,A2780,81034
4593,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,N,F,15608,,,9606.0,,,A2780,81034
4594,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,N,F,15608,,,9606.0,,,A2780,81034
4595,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,N,F,15608,,,9606.0,,,A2780,81034
4596,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,N,F,15608,,,9606.0,,,A2780,81034
4597,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,N,F,15608,,,9606.0,,,A2780,81034
4598,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,N,F,15608,,,9606.0,,,A2780,81034
4599,,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,N,F,15569,,,9606.0,,,A2780,81034
4600,,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line,N,F,17420,,,9606.0,,,A2780,81034
4601,,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,N,F,17420,,,9606.0,,,A2780,81034
4602,,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),N,F,15099,,,9606.0,,,A2780,81034
4603,,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),N,F,15099,,,9606.0,,,A2780,81034
4604,,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,N,F,17672,,,9606.0,,,A2780,81034
4605,,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,N,F,17672,,,9606.0,,,A2780,81034
4606,,Homo sapiens,In vitro cytotoxicity against A2780ADR cell line,N,F,17270,,,9606.0,,,A2780,81034
4607,,Homo sapiens,In vitro cytotoxicity against A2780CIS cell line,N,F,17270,,,9606.0,,,A2780,81034
4608,,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,N,F,5574,,,9606.0,,,A2780,81034
4609,,Homo sapiens,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,N,F,2113,,,9606.0,,,A2780,81034
4610,,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",N,F,16913,,,9606.0,,,A2780,81034
4611,,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",N,F,16913,,,9606.0,,,A2780,81034
4612,,Macaca mulatta,Oral bioavailability of compound in rhesus macaques,U,A,17839,In vivo,,9544.0,,,,22224
4613,,monkey,Oral bioavailability in monkey,U,A,6821,In vivo,,9443.0,,,,22224
4614,,monkey,Oral bioavailability evaluated in monkey,U,A,6078,In vivo,,9443.0,,,,22224
4615,,monkey,Oral bioavailability in monkey (dose 1 mg/kg p.o.),U,A,6535,In vivo,,9443.0,,,,22224
4616,,Macaca mulatta,Oral bioavailability in Rhesus monkey,U,A,4449,In vivo,,9544.0,,,,22224
4617,,Macaca mulatta,Oral bioavailability was calculated in rhesus monkey,U,A,6057,In vivo,,9544.0,,,,22224
4618,,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,U,A,5922,In vivo,,9541.0,,,,22224
4619,,monkey,Oral bioavailability in monkey,U,A,5940,In vivo,,9443.0,,,,22224
4620,,monkey,Oral bioavailability in monkey,U,A,6265,In vivo,,9443.0,,,,22224
4621,,monkey,Oral bioavailability in monkey (dose 1 mg/kg),U,A,6265,In vivo,,9443.0,,,,22224
4622,,monkey,Oral bioavailability in monkey (dose 5 mg/kg),U,A,6265,In vivo,,9443.0,,,,22224
4623,,monkey,Oral bioavailability in monkey,U,A,5940,In vivo,,9443.0,,,,22224
4624,,monkey,Oral bioavailability in monkey,U,A,5940,In vivo,,9443.0,,,,22224
4625,,Macaca mulatta,Oral bioavailability in rhesus monkey,U,A,4514,In vivo,,9544.0,,,,22224
4626,,Macaca mulatta,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,U,A,5546,In vivo,,9544.0,,,,22224
4627,,Saimiri sciureus,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,U,A,5553,In vivo,,9521.0,,,,22224
4628,,monkey,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,A,6641,In vivo,,9443.0,,,,22224
4629,,Macaca mulatta,Oral bioavailability in Rhesus monkey,U,A,5472,In vivo,,9544.0,,,,22224
4630,,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),U,A,5668,In vivo,,9544.0,,,,22224
4631,,monkey,Oral bioavailability in monkey at 10 mg/kg of the compound,U,A,5711,In vivo,,9443.0,,,,22224
4632,,Macaca mulatta,Bioavailability in Rhesus monkey,U,A,5145,In vivo,,9544.0,,,,22224
4633,,Cercopithecidae,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,,,9527.0,,,,22224
4634,,Cercopithecidae,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,,,9527.0,,,,22224
4635,,Cercopithecidae,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,U,A,3249,In vivo,,9527.0,,,,22224
4636,,Cercopithecidae,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,U,A,3249,In vivo,,9527.0,,,,22224
4637,,Cercopithecidae,Mean residence time was determined after intravenous administration in cynomolgus monkeys,U,A,5355,In vivo,,9527.0,,,,22224
4638,,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,U,A,5355,In vivo,,9527.0,,,,22224
4639,,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,U,A,5355,In vivo,,9527.0,,,,22224
4640,,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,A,4809,In vivo,,9527.0,,,,22224
4641,,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,A,4809,In vivo,,9527.0,,,,22224
4642,Microsomes,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),U,A,14294,,,9527.0,,,,22224
4643,Microsomes,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),U,A,14294,,,9527.0,,,,22224
4644,Microsomes,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),U,A,14294,,,9527.0,,,,22224
4645,Microsomes,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),U,A,14294,,,9527.0,,,,22224
4646,,Cercopithecidae,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,In vivo,,9527.0,,,,22224
4647,,Cercopithecidae,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,In vivo,,9527.0,,,,22224
4648,,Cercopithecidae,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,U,A,11271,,,9527.0,,,,22224
4649,,Cercopithecidae,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,,,9527.0,,,,22224
4650,,Cercopithecidae,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,,,9527.0,,,,22224
4651,,Cercopithecidae,Elimination Half-life of compound was determined in monkey,U,A,6821,,,9527.0,,,,22224
4652,,Cercopithecidae,Half life of compound was determined in rhesus monkey,U,A,17267,,,9527.0,,,,22224
4653,,Cercopithecidae,Half life in monkey plasma,U,A,5819,,,9527.0,,Plasma,,22224
4654,,Cercopithecidae,Half life in monkey plasma; Not detected,U,A,5819,,,9527.0,,Plasma,,22224
4655,,Cercopithecidae,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,A,1916,In vivo,,9527.0,,,,22224
4656,,Cercopithecidae,Half-life 24 hr after 2 mg/kg iv administration in monkeys,U,A,17509,In vivo,,9527.0,,,,22224
4657,,Cercopithecidae,Terminal half life of the compound.,U,A,1399,,,9527.0,,,,22224
4658,,Cercopithecidae,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,A,1916,In vivo,,9527.0,,,,22224
4659,,Cercopithecidae,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,A,4809,In vivo,,9527.0,,,,22224
4660,,Cercopithecidae,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,A,5546,,,9527.0,,,,22224
4661,,Cercopithecidae,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,,,9527.0,,Urine,,22224
4662,,Cercopithecidae,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,,,9527.0,,Urine,,22224
4663,,Cercopithecidae,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,U,A,4257,In vivo,,9527.0,,,,22224
4664,,Cercopithecidae,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,U,A,6221,In vivo,,9527.0,,,,22224
4665,,Cercopithecidae,Volume of distribution was evaluated in rhesus,U,A,5472,In vivo,,9527.0,,,,22224
4666,,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,U,A,4727,In vivo,,10029.0,,,,22224
4667,,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,U,A,4727,In vivo,,10029.0,,,,22224
4668,,Cricetulus griseus,Bioavailability in hamster was determined,U,A,4727,In vivo,,10029.0,,,,22224
4669,,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,U,A,4727,In vivo,,10029.0,,,,22224
4670,,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,U,A,4727,In vivo,,10029.0,,,,22224
4671,,Cricetulus griseus,Half life of compound was determined in hamster blood,U,A,4727,,,10029.0,,Blood,,22224
4672,,Sus scrofa,Michaelis-Menten constant of the compound.,U,A,1452,,,9823.0,,,,22224
4673,,Sus scrofa,Vmax value was measured at 0 uM concentration of silyl ether.,U,A,1452,,,9823.0,,,,22224
4674,,Sus scrofa,Vmax value was measured at 10 uM concentration of silyl ether.,U,A,1452,,,9823.0,,,,22224
4675,,Sus scrofa,Vmax value was measured at 5 uM concentration of silyl ether.,U,A,1452,,,9823.0,,,,22224
4676,,Homo sapiens,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,D,B,11706,,,9606.0,,,,235
4677,,Homo sapiens,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,U,A,1916,,,9606.0,,,,22224
4678,,Homo sapiens,Compound was evaluated for area under the curve expressed as (h*ug/ml),U,A,17791,,,9606.0,,,,22224
4679,,Homo sapiens,Active metabolite of ifosfamide determined in humans; A-Active,U,A,7766,,,9606.0,,,,22224
4680,,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,U,A,6567,,,9606.0,,,,22224
4681,,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,U,A,6567,,,9606.0,,,,22224
4682,,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,U,A,6567,,,9606.0,,,,22224
4683,,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,U,A,6567,,,9606.0,,,,22224
4684,,Homo sapiens,Compound was evaluated for oral bioavailability in human,U,A,17791,,,9606.0,,,,22224
4685,,Homo sapiens,Metabolite of ifosfamide determined in urine; NF-Not found,U,A,7766,,,9606.0,,Urine,,22224
4686,,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),U,A,6852,,,9606.0,,,,22224
4687,,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,U,A,6852,,,9606.0,,,,22224
4688,,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,U,A,6852,,,9606.0,,,,22224
4689,,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,U,A,6852,,,9606.0,,,,22224
4690,,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,U,A,6852,,,9606.0,,,,22224
4691,,Homo sapiens,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),U,A,6852,,,9606.0,,,,22224
4692,,Homo sapiens,Percent of compound in healthy individuals (Group D),U,A,6852,,,9606.0,,,,22224
4693,Microsomes,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,U,A,4397,,,9606.0,,Liver,,22224
4694,,Homo sapiens,Binding towards human plasma protein at 10 uM,U,A,17409,,,9606.0,,,,22224
4695,,Homo sapiens,Binding towards human plasma protein at 100 uM,U,A,17409,,,9606.0,,,,22224
4696,,Homo sapiens,Human plasma protein binding activity was determined,U,A,17176,,,9606.0,,,,22224
4697,,Homo sapiens,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),U,A,15444,,,9606.0,,,,22224
4698,,Homo sapiens,Percent binding of compound towards human plasma protein was determined,U,A,17267,,,9606.0,,,,22224
4699,Microsomes,Homo sapiens,Plasma clearance in human liver microsomes,U,A,5944,In vitro,,9606.0,,Liver,,22224
4700,Microsomes,Homo sapiens,In vitro intrinsic clearance in human liver microsome,U,A,5668,In vitro,,9606.0,,Liver,,22224
4701,Microsomes,Homo sapiens,In vitro intrinsic clearance in human liver microsome,U,A,5669,In vitro,,9606.0,,Liver,,22224
4702,Microsomes,Homo sapiens,In vitro microsome metabolism clearance in human was determined,U,A,5041,In vitro,,9606.0,,,,22224
4703,Microsomes,Homo sapiens,In vitro microsome metabolism clearance in human was determined; High,U,A,5041,In vitro,,9606.0,,,,22224
4704,Microsomes,Homo sapiens,In vitro microsome metabolism clearance in human was determined; ND denotes no data,U,A,5041,In vitro,,9606.0,,,,22224
4705,Microsomes,Homo sapiens,Pharmacokinetic property (clearance) in human liver microsome,U,A,5676,In vitro,,9606.0,,Liver,,22224
4706,Microsomes,Homo sapiens,Plasma clearance in human liver microsomes,U,A,5944,In vitro,,9606.0,,Liver,,22224
4707,Microsomes,Homo sapiens,In vitro clearance in human liver microsomes,U,A,17538,In vitro,,9606.0,,Liver,,22224
4708,Microsomes,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,U,A,6331,In vitro,,9606.0,,Liver,,22224
4709,Microsomes,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,U,A,5948,In vitro,,9606.0,,Liver,,22224
4710,,Homo sapiens,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,U,A,5965,In vivo,,9606.0,,,,22224
4711,,Homo sapiens,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,U,A,1916,In vivo,,9606.0,,,,22224
4712,,Homo sapiens,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,U,A,5965,,,9606.0,,,,22224
4713,,Homo sapiens,Stability in human plasma 2 hr after incubation expressed as percent concentration,U,A,1299,,,9606.0,,,,22224
4714,,Homo sapiens,Stability in human plasma 4 hr after incubation expressed as percent concentration,U,A,1299,,,9606.0,,,,22224
4715,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,A,7766,,,9606.0,,Urine,,22224
4716,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,A,7766,,,9606.0,,Urine,,22224
4717,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,A,7766,,,9606.0,,Urine,,22224
4718,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,A,7766,,,9606.0,,Urine,,22224
4719,,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,N,F,17764,In vivo,,10090.0,,,,50594
4720,,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,N,F,17764,In vivo,,10090.0,,,,50594
4721,,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,N,F,17764,In vivo,,10090.0,,,,50594
4722,,Mus musculus,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,N,F,17764,In vivo,,10090.0,,,,50594
4723,,Mus musculus,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),N,A,14294,,,10090.0,,,,50594
4724,,Mus musculus,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),N,A,14294,,,10090.0,,,,50594
4725,,Mus musculus,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),N,A,14294,,,10090.0,,,,50594
4726,,Mus musculus,In vitro metabolic potential in mouse liver microsomes,N,A,6251,,,10090.0,,Liver,,50594
4727,,Mus musculus,Ability of compound to bind to plasma protein was evaluated in HSA cells,N,A,17582,,,10090.0,,,,50594
4728,,Mus musculus,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),N,A,17811,,,10090.0,,Adrenal gland,,50594
4729,,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,N,A,17811,,,10090.0,,Brain,,50594
4730,,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,N,A,17811,,,10090.0,,Brain,,50594
4731,,Mus musculus,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),N,A,17811,,,10090.0,,,,50594
4732,,Mus musculus,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),N,A,17811,,,10090.0,,Kidney,,50594
4733,,Mus musculus,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),N,A,17811,,,10090.0,,,,50594
4734,,Mus musculus,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,N,A,5288,,,10090.0,,,,50594
4735,,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,N,A,2717,,,10090.0,,Serum,,50594
4736,,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,N,A,2717,,,10090.0,,Serum,,50594
4737,,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,N,A,2717,,,10090.0,,Serum,,50594
4738,,Mus musculus,Half life of compound was determined in plasma of mice at 24 mg/Kg,N,A,17753,In vivo,,10090.0,,Plasma,,50594
4739,,Mus musculus,Half life of compound was determined in plasma of mice at 40 mg/Kg,N,A,17753,In vivo,,10090.0,,Plasma,,50594
4740,,Mus musculus,Half life of compound was determined in plasma of mice at 5 mg/Kg,N,A,17753,In vivo,,10090.0,,Plasma,,50594
4741,,Mus musculus,Half life after intraperitoneal administration in mice at 18 uM/kg,N,F,17764,In vivo,,10090.0,,,,50594
4742,,Mus musculus,Half life after intraperitoneal administration in mice at 23 uM/kg,N,F,17764,In vivo,,10090.0,,,,50594
4743,,Mus musculus,Half life after intraperitoneal administration in mice at 25 uM/kg,N,F,17764,In vivo,,10090.0,,,,50594
4744,,Mus musculus,Half life after intraperitoneal administration in mice at 26 uM/kg,N,F,17764,In vivo,,10090.0,,,,50594
4745,,Mus musculus,Half life after intravenous administration in mice at 23 uM/kg,N,F,17764,In vivo,,10090.0,,,,50594
4746,,Mus musculus,Half life after intravenous administration in mice at 24 uM/kg,N,A,17764,In vivo,,10090.0,,,,50594
4747,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,N,A,16597,In vivo,,10090.0,,,,50594
4748,,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,N,A,2675,In vivo,,10090.0,,,,50594
4749,,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after oral administration,N,A,2675,In vivo,,10090.0,,,,50594
4750,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),N,A,16597,In vivo,,10090.0,,,,50594
4751,,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",N,A,4890,In vivo,,10090.0,,,,50594
4752,,Mus musculus,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,N,A,429,In vivo,,10090.0,,,,50594
4753,,Mus musculus,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,N,A,17837,In vivo,,10090.0,,Blood,,50594
4754,,Mus musculus,Half life at a dose of 10 mg/kg intravenous administration in mice.,N,A,16597,In vivo,,10090.0,,,,50594
4755,,Mus musculus,Half life at a dose of 10 mg/kg peroral administration in mice.,N,A,16597,In vivo,,10090.0,,,,50594
4756,,Mus musculus,Half life in ob/ob mice,N,A,6619,,,10090.0,,,,50594
4757,,Mus musculus,Half-life at a single subcutaneous administration of 40 mg/kg in mice,N,A,4066,In vivo,,10090.0,,,,50594
4758,,Mus musculus,Half-life was measured in mouse,N,A,4239,,,10090.0,,,,50594
4759,,Mus musculus,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,N,A,5969,In vivo,,10090.0,,,,50594
4760,,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,N,A,8999,,,10090.0,,,,50594
4761,,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,N,A,8999,,,10090.0,,,,50594
4762,,Mus musculus,T2 in brain of mice at the oral dose of 50 mg/kg,N,A,17641,,,10090.0,,Brain,,50594
4763,,Mus musculus,T2 in kidney of mice at the oral dose of 50 mg/kg,N,A,17641,,,10090.0,,Kidney,,50594
4764,,Mus musculus,T2 in liver of mice at the oral dose of 50 mg/kg,N,A,17641,,,10090.0,,Liver,,50594
4765,,Mus musculus,T2 in lungs of mice at the oral dose of 50 mg/kg,N,A,17641,,,10090.0,,Lung,,50594
4766,,Mus musculus,T2 in spleen of mice at the oral dose of 50 mg/kg,N,A,17641,,,10090.0,,Spleen,,50594
4767,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,N,A,16597,In vivo,,10090.0,,,,50594
4768,,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",N,A,4890,In vivo,,10090.0,,,,50594
4769,,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,N,A,429,In vivo,,10090.0,,,,50594
4770,,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,N,A,429,In vivo,,10090.0,,,,50594
4771,,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,N,A,5969,In vivo,,10090.0,,,,50594
4772,,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",N,F,16913,,,9606.0,,,A2780,81034
4773,,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",N,F,16913,,,9606.0,,,A2780,81034
4774,,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,F,16913,,,9606.0,,,A2780,81034
4775,,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,F,16913,,,9606.0,,,A2780,81034
4776,,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,F,16913,,,9606.0,,,A2780,81034
4777,,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,F,16913,,,9606.0,,,A2780,81034
4778,,Homo sapiens,In vitro cytotoxicity against A2780TAX cell line,N,F,17270,,,9606.0,,,A2780,81034
4779,,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780cis,N,F,5618,,,9606.0,,,A2780cisR,80017
4780,,Homo sapiens,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,N,F,17777,,,9606.0,,,A2780,81034
4781,,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,N,F,16112,,,9606.0,,,A2780cisR,80017
4782,,Homo sapiens,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),N,F,15748,,,9606.0,,,A2780cisR,80017
4783,,Homo sapiens,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,N,F,6633,,,9606.0,,,A2780,81034
4784,,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,N,F,16930,,,9606.0,,,A2780,81034
4785,,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,N,F,17496,,,9606.0,,,A2780,81034
4786,,Homo sapiens,In vitro antitumor activity against A2780cisR cell line.,N,F,12989,,,9606.0,,,A2780,81034
4787,,Homo sapiens,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),N,F,4840,,,9606.0,,,A2780,81034
4788,,Homo sapiens,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,N,F,12989,,,9606.0,,,A2780,81034
4789,,Homo sapiens,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,N,F,16745,,,9606.0,,,A2780cisR,80017
4790,,Homo sapiens,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,N,F,16597,,,9606.0,,,A2780,81034
4791,,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,D,B,16547,,,10116.0,,,,11736
4792,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),H,F,16547,,,,,,,11736
4793,,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),D,F,16547,,,10116.0,,,,11736
4794,,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,D,F,15856,,,9606.0,,,HEK293,278
4795,,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,D,F,15856,,,9606.0,,,HEK293,278
4796,,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,D,B,16547,,,10090.0,,,,11831
4797,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),H,F,16547,,,,,,,11831
4798,,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),D,F,16547,,,10090.0,,,,11831
4799,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,H,B,17402,,,,,,,280
4800,,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),U,F,11746,,,9606.0,,,T-cells,22226
4801,,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,U,F,11746,,,9606.0,,,T-cells,22226
4802,,Homo sapiens,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,N,F,5455,,,9606.0,,,A-375,80018
4803,,Homo sapiens,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,N,F,2068,,,9606.0,,,A-375,80018
4804,,Homo sapiens,In vitro antitumor activity against A375cell line extracted form melanoma,N,F,2683,,,9606.0,,,A-375,80018
4805,,Homo sapiens,Inhibition of cell growth in (A375) melan cell line,N,F,15313,,,9606.0,,,A-375,80018
4806,,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,N,F,13739,,,9606.0,,,A-375,80018
4807,,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,N,F,13739,,,9606.0,,,A-375,80018
4808,,Homo sapiens,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,N,F,14750,,,9606.0,,,A-375,80018
4809,,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,N,F,14777,,,9606.0,,,A-427,80019
4810,,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,N,F,14777,,,9606.0,,,A-427,80019
4811,,Homo sapiens,Cytotoxicity against lung carcinoma A427 tumor cell lines,N,F,17672,,,9606.0,,,A-427,80019
4812,,Homo sapiens,Inhibition of large cell lung carcinoma (A427),N,F,14368,,,9606.0,,,A-427,80019
4813,,Homo sapiens,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,N,F,14368,,,9606.0,,,A-427,80019
4814,,Homo sapiens,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,N,F,13866,,,9606.0,,,A-427,80019
4815,,Homo sapiens,Inhibitory concentration in human lung carcinoma A427 cell line,N,F,2545,,,9606.0,,,A-427,80019
4816,,Homo sapiens,Inhibitory concentration in human lung carcinoma A427/VCR cell line,N,F,2545,,,9606.0,,,A-427,80019
4817,,Cercopithecidae,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,U,A,6062,In vivo,,9527.0,,,,22224
4818,,Cercopithecidae,Tested for volume of distribution upon iv administration to african green monkey,U,A,4578,In vivo,,9527.0,,,,22224
4819,,Cercopithecidae,Volume of distribution in monkey,U,A,17592,In vivo,,9527.0,,,,22224
4820,,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,A,5005,In vivo,,9544.0,,,,22224
4821,,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,U,A,5005,In vivo,,9544.0,,,,22224
4822,,Cercopithecidae,Pharmacokinetic property(Vdss) in cynomolgus monkey,U,A,5922,In vivo,,9527.0,,,,22224
4823,,Cercopithecidae,The distribution volume after intravenous administration in cynomolgus monkeys,U,A,5355,In vivo,,9527.0,,,,22224
4824,,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,U,A,5355,In vivo,,9527.0,,,,22224
4825,,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,U,A,5355,In vivo,,9527.0,,,,22224
4826,,Cercopithecidae,Volume displacement was calculated in rhesus monkey,U,A,6057,In vivo,,9527.0,,,,22224
4827,,Cercopithecidae,Volume of distribution in steady state was determined in rhesus monkey,U,A,5145,In vivo,,9527.0,,,,22224
4828,,Cercopithecidae,Volume of distribution of compound was determined in monkey,U,A,6821,In vivo,,9527.0,,,,22224
4829,,Cercopithecidae,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,A,5334,In vivo,,9527.0,,,,22224
4830,,Cercopithecidae,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,A,5334,In vivo,,9527.0,,,,22224
4831,,Cercopithecidae,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,A,6641,In vivo,,9527.0,,,,22224
4832,,Cercopithecidae,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,A,2661,In vivo,,9527.0,,,,22224
4833,,Cercopithecidae,Volume distribution in monkey after administration of 1 mg/kg iv,U,A,6535,In vivo,,9527.0,,,,22224
4834,,Cercopithecidae,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,A,4809,In vivo,,9527.0,,,,22224
4835,,Cercopithecidae,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,U,A,6062,In vivo,,9527.0,,,,22224
4836,,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,In vivo,,9527.0,,,,22224
4837,,Cercopithecidae,Oral systemic bioavailability upon iv administration to african green monkey,U,A,4578,In vivo,,9527.0,,,,22224
4838,,Cercopithecidae,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,A,4809,In vivo,,9527.0,,,,22224
4839,,Cercopithecidae,Baboon plasma free fraction. ,U,A,11271,,,9527.0,,,,22224
4840,,Cercopithecidae,Area under the curve was calculated in rhesus monkey after iv administration,U,A,6057,,,9527.0,,,,22224
4841,,Cercopithecidae,Area under the curve was calculated in rhesus monkey after peroral administration,U,A,6057,,,9527.0,,,,22224
4842,,Cercopithecidae,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,U,A,17853,,,9527.0,,,,22224
4843,,Cercopithecidae,Half life period in monkey after 5 mg/kg dose,U,A,5302,In vivo,,9527.0,,,,22224
4844,,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose,U,A,4257,In vivo,,9527.0,,,,22224
4845,,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,U,A,4257,In vivo,,9527.0,,,,22224
4846,,Cercopithecidae,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,U,A,13501,In vivo,,9527.0,,Plasma,,22224
4847,,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,U,A,5394,In vivo,,9527.0,,,,22224
4848,,Cercopithecidae,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,A,2661,In vivo,,9527.0,,,,22224
4849,,Cercopithecidae,Compound was evaluated for terminal half life in monkey,U,A,3341,,,9527.0,,,,22224
4850,,Cercopithecidae,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,U,A,3045,In vivo,,9527.0,,,,22224
4851,,Macaca mulatta,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,A,5005,In vivo,,9544.0,,Plasma,,22224
4852,,Cercopithecidae,Half life of compound was determined in squirrel monkey,U,A,4847,,,9527.0,,,,22224
4853,,Macaca fascicularis,Half life after iv administration in cynomolgus monkey,U,A,4256,In vivo,,9541.0,,,,22224
4854,,Cercopithecidae,Half life in monkey plasma after administration of 1 mg/kg iv,U,A,6535,In vivo,,9527.0,,Plasma,,22224
4855,,Cercopithecidae,Half life was calculated in rhesus monkey,U,A,6057,,,9527.0,,,,22224
4856,,Cercopithecidae,Half life in monkey,U,A,17592,,,9527.0,,,,22224
4857,,Cercopithecidae,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,A,6641,In vivo,,9527.0,,,,22224
4858,,Cercopithecidae,Half life was evaluated in rhesus,U,A,5472,,,9527.0,,,,22224
4859,,Cercopithecidae,Half life period after oral administration (2.5 mg/kg) in monkey was determined,U,A,6221,In vivo,,9527.0,,,,22224
4860,,Cercopithecidae,Half life period was determine after peroral administration at 10 mpk in Rhesus,U,A,5668,In vivo,,9527.0,,,,22224
4861,,Cercopithecidae,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,A,4809,In vivo,,9527.0,,,,22224
4862,,Cercopithecidae,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,A,5546,In vivo,,9527.0,,,,22224
4863,,Cercopithecidae,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,U,A,5553,In vivo,,9527.0,,,,22224
4864,,Cercopithecidae,Half-life was calculated in monkey,U,A,6078,,,9527.0,,,,22224
4865,,Cercopithecidae,Half-life in Squirrel monkey,U,A,5147,,,9527.0,,,,22224
4866,,Cercopithecidae,Half-life in rhesus monkey,U,A,5145,,,9527.0,,,,22224
4867,,Cercopithecidae,Half-life was measured in monkey after an iv dose of 1 mg/kg,U,A,6062,In vivo,,9527.0,,,,22224
4868,,Cercopithecidae,Half-life period after intravenous administration in cynomolgus monkeys,U,A,5355,In vivo,,9527.0,,,,22224
4869,,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys,U,A,5355,In vivo,,9527.0,,,,22224
4870,,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,U,A,5355,In vivo,,9527.0,,,,22224
4871,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,A,7766,,,9606.0,,Urine,,22224
4872,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,A,7766,,,9606.0,,Urine,,22224
4873,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,A,7766,,,9606.0,,Urine,,22224
4874,,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,A,7766,,,9606.0,,Urine,,22224
4875,,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,U,A,7766,,,9606.0,,Urine,,22224
4876,,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,U,A,7766,,,9606.0,,Urine,,22224
4877,,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,U,A,7766,,,9606.0,,Urine,,22224
4878,,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,U,A,7766,,,9606.0,,Urine,,22224
4879,,Homo sapiens,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,U,A,1916,In vivo,,9606.0,,,,22224
4880,,Homo sapiens,Oral bioavailability in human,U,A,16643,In vivo,,9606.0,,,,22224
4881,,Homo sapiens,Compound was tested for human plasma protein binding,U,A,17248,,,9606.0,,,,22224
4882,,Homo sapiens,Compound was tested for human plasma protein binding; Not determined,U,A,17248,,,9606.0,,,,22224
4883,,Homo sapiens,Protein binding activity of compound in human plasma; % Free,U,A,6241,,,9606.0,,,,22224
4884,,Homo sapiens,Unbound fraction (plasma),U,A,17716,,,9606.0,,,,22224
4885,,Homo sapiens,Half life for the hydrolysis of compound in human blood serum,U,A,17605,,,9606.0,,Plasma,,22224
4886,,Homo sapiens,Half life period in human plasma using phosphate buffer (0.08 M),U,A,17625,,,9606.0,,Plasma,,22224
4887,,Homo sapiens,Half life period in human plasma using phosphate buffer (0.1 M),U,A,17625,,,9606.0,,Plasma,,22224
4888,,Homo sapiens,Half-life in human plasma was determined,U,A,17747,,,9606.0,,Plasma,,22224
4889,,Homo sapiens,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,U,A,15613,,,9606.0,,,,22224
4890,,Homo sapiens,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),U,A,354,,,9606.0,,,,22224
4891,,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",U,A,3741,,,9606.0,,,,22224
4892,,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",U,A,3741,,,9606.0,,,,22224
4893,,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",U,A,3741,,,9606.0,,,,22224
4894,,Homo sapiens,Partition coefficient (logP),U,A,17599,,,9606.0,,,,22224
4895,,Homo sapiens,In vitro metabolic stability in human was measured as pmol/min/mg/protein,U,A,5486,,,9606.0,,,,22224
4896,Microsomes,Homo sapiens,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,U,A,5600,,,9606.0,,,,22224
4897,,Homo sapiens,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),U,A,14294,,,9606.0,,,,22224
4898,,Homo sapiens,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),U,A,14294,,,9606.0,,,,22224
4899,,Homo sapiens,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),U,A,14294,,,9606.0,,,,22224
4900,Microsomes,Homo sapiens,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),U,A,14294,,,9606.0,,,,22224
4901,Microsomes,Homo sapiens,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),U,A,14294,,,9606.0,,,,22224
4902,Microsomes,Homo sapiens,Metabolism of compound in human microsomes; Trace,U,A,14294,,,9606.0,,,,22224
4903,Microsomes,Homo sapiens,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,U,A,6260,,,9606.0,,Liver,,22224
4904,Microsomes,Homo sapiens,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,U,A,6187,,,9606.0,,,,22224
4905,Microsomes,Homo sapiens,In vitro metabolic potential in human liver microsomes,U,A,6251,,,9606.0,,Liver,,22224
4906,,Homo sapiens,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,U,A,3246,,,9606.0,,,,22224
4907,,Homo sapiens,Tested for human plasma protein binding of the compound; Not tested,U,A,17313,,,9606.0,,,,22224
4908,,Homo sapiens,Compound was tested for percent protein binding (PB) in human,U,A,6227,,,9606.0,,,,22224
4909,,Homo sapiens,Protein binding in human plasma,U,A,5530,,,9606.0,,Plasma,,22224
4910,,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,U,A,6108,,,9606.0,,,,22224
4911,,Homo sapiens,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,U,A,6108,,,9606.0,,,,22224
4912,,Homo sapiens,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),U,A,2774,,,9606.0,,,,22224
4913,,Homo sapiens,In vitro rate of absorption observed as Caco-2 permeability in humans,U,A,16643,,,9606.0,,,,22224
4914,,Homo sapiens,Cellular permeability of compound was determined in Caco-2 cells; High,U,A,17582,,,9606.0,,,Caco-2,22224
4915,,Homo sapiens,Permeability in Caco-2 cells of compound,U,A,6838,,,9606.0,,,Caco-2,22224
4916,,Homo sapiens,Permeability coefficient (A to B) in Caco-2 cell,U,A,6108,,,9606.0,,,,22224
4917,,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,U,A,6108,,,9606.0,,,,22224
4918,,Homo sapiens,Permeability coefficient (Papp) (Caco-2 cell monolayer),U,A,6108,,,9606.0,,,,22224
4919,,Homo sapiens,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,U,A,2146,,,9606.0,,,,22224
4920,,Homo sapiens,Compound was tested for protein binding in human plasma,U,A,4514,,,9606.0,,,,22224
4921,,Homo sapiens,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,U,A,6108,,,9606.0,,,,22224
4922,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,U,A,7766,,,9606.0,,Urine,,22224
4923,,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,N,A,5969,In vivo,,10090.0,,,,50594
4924,,Mus musculus,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,A,3277,In vivo,,10090.0,,,,50594
4925,,Mus musculus,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,N,A,3802,In vivo,,10090.0,,,,50594
4926,,Mus musculus,Time taken to reach maximum concentration in plasma upon oral administration in mouse,N,A,2862,In vivo,,10090.0,,Plasma,,50594
4927,,Mus musculus,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,A,6348,In vivo,,10090.0,,Plasma,,50594
4928,,Mus musculus,Tmax after intraperitoneal administration in mice at 23 uM/kg,N,F,17764,In vivo,,10090.0,,,,50594
4929,,Mus musculus,Tmax after oral administration at 30 mg/kg in ICR mouse,N,A,5781,In vivo,,10090.0,,,,50594
4930,,Mus musculus,Tmax after peroral administration in mice at 2.4 uM/kg,N,A,17764,In vivo,,10090.0,,,,50594
4931,,Mus musculus,Tmax at a single subcutaneous administration of 40 mg/kg in mice,N,A,4066,In vivo,,10090.0,,,,50594
4932,,Mus musculus,Tmax in brain of mice at the oral dose of 50 mg/kg,N,A,17641,In vivo,,10090.0,,Brain,,50594
4933,,Mus musculus,Tmax in kidney of mice at the oral dose of 50 mg/kg,N,A,17641,In vivo,,10090.0,,Kidney,,50594
4934,,Mus musculus,Tmax in liver of mice at the oral dose of 50 mg/kg,N,A,17641,In vivo,,10090.0,,Liver,,50594
4935,,Mus musculus,Tmax in lungs of mice at the oral dose of 50 mg/kg,N,A,17641,In vivo,,10090.0,,Lung,,50594
4936,,Mus musculus,Tmax in mice at 18 uM/kg i.p. administration,N,F,17764,In vivo,,10090.0,,,,50594
4937,,Mus musculus,Tmax in mice at 23 uM/kg i.v. administration,N,F,17764,In vivo,,10090.0,,,,50594
4938,,Mus musculus,Tmax in mice at 25 uM/kg i.p. administration,N,F,17764,In vivo,,10090.0,,,,50594
4939,,Mus musculus,Tmax in mice at 26 uM/kg i.p. administration,N,F,17764,In vivo,,10090.0,,,,50594
4940,,Mus musculus,Tmax in spleen of mice at the oral dose of 50 mg/kg,N,A,17641,In vivo,,10090.0,,Spleen,,50594
4941,,Mus musculus,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,N,A,16597,In vivo,,10090.0,,,,50594
4942,,Mus musculus,Tmax value at a dose of 10 mg/kg peroral administration in mice.,N,A,16597,In vivo,,10090.0,,,,50594
4943,,Mus musculus,Tmax value in IRC mice,N,A,5951,,,10090.0,,,,50594
4944,,Mus musculus,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,N,A,5506,In vivo,,10090.0,,,,50594
4945,,Mus musculus,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,N,A,5506,In vivo,,10090.0,,,,50594
4946,,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),N,A,429,,,10090.0,,Urine,,50594
4947,,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),N,A,429,,,10090.0,,Urine,,50594
4948,,Mus musculus,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),N,A,4066,,,10090.0,,Urine,,50594
4949,,Mus musculus,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,A,17734,,,10090.0,,,,50594
4950,,Mus musculus,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,A,17734,,,10090.0,,,,50594
4951,,Mus musculus,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,N,A,6062,In vivo,,10090.0,,,,50594
4952,,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,N,A,5969,In vivo,,10090.0,,,,50594
4953,,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,N,A,5969,In vivo,,10090.0,,,,50594
4954,,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,A,5969,In vivo,,10090.0,,,,50594
4955,,Mus musculus,Vd in mice,N,A,5980,In vivo,,10090.0,,,,50594
4956,,Mus musculus,Volume of distribution in mouse,N,A,17592,In vivo,,10090.0,,,,50594
4957,,Mus musculus,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,A,6348,In vivo,,10090.0,,,,50594
4958,,Mus musculus,Volume of distribution of compound in plasma was determined at 24 mg/Kg,N,A,17753,In vivo,,10090.0,,,,50594
4959,,Mus musculus,Volume of distribution of compound in plasma was determined at 40 mg/Kg,N,A,17753,In vivo,,10090.0,,,,50594
4960,,Mus musculus,Volume of distribution of compound in plasma was determined at 5 mg/Kg,N,A,17753,In vivo,,10090.0,,,,50594
4961,,Mus musculus,Pharmacokinetic property (vdss) was measured in mouse,N,A,4239,In vivo,,10090.0,,,,50594
4962,,Mus musculus,Value distribution upon iv administration in mouse,N,A,2862,In vivo,,10090.0,,,,50594
4963,,Mus musculus,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,A,17734,In vivo,,10090.0,,,,50594
4964,,Mus musculus,Volume of distribution was evaluated in mice after intravenous administration,N,A,2675,In vivo,,10090.0,,,,50594
4965,,Mus musculus,Volume of distribution was evaluated in mice after oral administration,N,A,2675,In vivo,,10090.0,,,,50594
4966,,Mus musculus,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,N,A,17837,In vivo,,10090.0,,,,50594
4967,,Mus musculus,Steady state volume of distribution was determined in mice,N,A,5727,In vivo,,10090.0,,,,50594
4968,,Mus musculus,Volume distribution (steady state) of compound was determined in mouse,N,A,17852,In vivo,,10090.0,,,,50594
4969,,Mus musculus,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,N,A,17764,In vivo,,10090.0,,,,50594
4970,,Mus musculus,Vss value at a dose of 10 mg/kg intravenous administration in mice.,N,A,16597,In vivo,,10090.0,,,,50594
4971,,Mus musculus,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,N,A,6062,In vivo,,10090.0,,,,50594
4972,,Mus musculus,Biodistribution of compound (oxidized form) in in kidney tissue,N,A,16438,In vivo,,10090.0,,Kidney,,50594
4973,,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,A,16438,In vivo,,10090.0,,Blood,,50594
4974,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,A,16438,In vivo,,10090.0,,Blood,,50594
4975,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Blood,,50594
4976,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,N,F,10708,,,9606.0,,,A-427,80019
4977,,Homo sapiens,Inhibition of A431 human squamous cell carcinoma cell proliferation,N,F,16597,,,9606.0,,,A-431,80852
4978,,Homo sapiens,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,N,F,16062,,,9606.0,,,A-431,80852
4979,,Homo sapiens,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,N,F,16062,,,9606.0,,,A-431,80852
4980,,Homo sapiens,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,N,F,16958,,,9606.0,,,A-431,80852
4981,,Homo sapiens,Inhibition of A431 human carcinoma cell proliferation,N,F,6700,,,9606.0,,,A-431,80852
4982,,Homo sapiens,In vitro inhibition of A431 (human carcinoma) cell basal growth.,N,F,17226,,,9606.0,,,A-431,80852
4983,,Homo sapiens,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,N,F,6828,,,9606.0,,,A-431,80852
4984,,Homo sapiens,In vitro cytotoxicity against epidermoid carcinoma cell line,N,F,12314,,,9606.0,,,A-431,80852
4985,,Homo sapiens,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",D,F,13412,,,9606.0,,,A-431,9
4986,,Homo sapiens,Antiproliferative activity of compound was measured on human tumor cell line A431.,N,F,13299,,,9606.0,,,A-431,80852
4987,,Homo sapiens,Antiproliferative effect of compound on A431 cell line expressing mutant p53,N,F,17420,,,9606.0,,,A-431,80852
4988,,Homo sapiens,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,N,F,13678,,,9606.0,,,A-431,80852
4989,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,H,F,14171,,,,,,A-431,9
4990,,Homo sapiens,Tested for antiproliferative activity against human A431 cells,N,F,6333,,,9606.0,,,A-431,80852
4991,,Homo sapiens,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,D,F,2356,,,9606.0,,,A-431,9
4992,,Homo sapiens,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,N,F,15578,,,9606.0,,,A-431,80852
4993,,Homo sapiens,Inhibition of A431 cell proliferation,N,F,5126,,,9606.0,,,A-431,80852
4994,,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells,N,F,6844,,,9606.0,,,A-431,80852
4995,,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),N,F,6844,,,9606.0,,,A-431,80852
4996,,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,N,F,4925,,,9606.0,,,A-431,80852
4997,,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,N,F,4925,,,9606.0,,,A-431,80852
4998,,Homo sapiens,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,N,F,13978,,,9606.0,,,A-431,80852
4999,,Homo sapiens,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,N,F,16786,,,9606.0,,,A-431,80852
5000,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,H,F,13412,,,,,,A-431,9
5001,,Homo sapiens,In vivo antiproliferative activity against A431 cell line,N,F,17824,,,9606.0,,,A-431,80852
5002,,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,D,F,12751,,,9606.0,,,A-431,9
5003,,Homo sapiens,Inhibition of A431 human epidermoid carcinoma cell proliferation,N,F,12380,,,9606.0,,,A-431,80852
5004,,Homo sapiens,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,D,F,4959,,,9606.0,,,A-431,9
5005,,Homo sapiens,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),N,F,6333,,,9606.0,,,A-431,80852
5006,,Homo sapiens,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),N,F,6333,,,9606.0,,,A-431,80852
5007,,Homo sapiens,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),N,F,6333,,,9606.0,,,A-431,80852
5008,,Homo sapiens,Inhibition of EGFR overexpressing A431 cell proliferation,D,F,5296,,,9606.0,,,,9
5009,,Homo sapiens,Inhibition of A431 cell proliferation,N,F,12624,,,9606.0,,,A-431,80852
5010,,Homo sapiens,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,D,F,14926,,,9606.0,,,A-431,9
5011,,Homo sapiens,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",D,F,14926,,,9606.0,,,A-431,9
5012,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),H,F,14926,,,,,,A-431,9
5013,,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,N,F,15144,,,9606.0,,,A-431,80852
5014,,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,N,F,15144,,,9606.0,,,A-431,80852
5015,,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,N,F,5245,,,9606.0,,,A-431,80852
5016,,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,N,F,5245,,,9606.0,,,A-431,80852
5017,,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,N,F,5245,,,9606.0,,,A-431,80852
5018,,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,N,F,5245,,,9606.0,,,A-431,80852
5019,,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,N,F,5245,,,9606.0,,,A-431,80852
5020,,Cercopithecidae,Half-life period in cynomolgus monkey,U,A,5922,,,9527.0,,,,22224
5021,,Cercopithecidae,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",U,A,1116,In vitro,,9527.0,,Plasma,,22224
5022,,Cercopithecidae,Longer half-life in monkey (i.v.) at 0.5 mpk,U,A,17853,In vivo,,9527.0,,,,22224
5023,,Cercopithecidae,Plasma half life in monkey,U,A,993,,,9527.0,,Plasma,,22224
5024,,Cercopithecidae,Plasma half-life in rhesus monkey,U,A,4514,,,9527.0,,Plasma,,22224
5025,,Cercopithecidae,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,A,5334,In vivo,,9527.0,,Plasma,,22224
5026,,Cercopithecidae,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,A,5334,In vivo,,9527.0,,Plasma,,22224
5027,,Cercopithecidae,Tested for half life upon iv administration to african green monkey,U,A,4578,In vivo,,9527.0,,,,22224
5028,,Cercopithecidae,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,A,2661,In vivo,,9527.0,,,,22224
5029,,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,U,A,5355,In vivo,,9527.0,,,,22224
5030,,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,U,A,5355,In vivo,,9527.0,,,,22224
5031,,Cercopithecidae,The time for peak concentration value after oral administration in cynomolgus monkeys,U,A,5355,In vivo,,9527.0,,,,22224
5032,,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5033,,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5034,,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5035,,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5036,,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5037,,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5038,,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5039,,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5040,,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5041,,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5042,,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5043,,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5044,,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5045,,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5046,,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5047,,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,U,A,11271,,,9527.0,,,,22224
5048,,Rattus norvegicus,Bioavailability in rat (cannulated) (dose 2 mg/kg),N,A,5809,In vivo,,10116.0,,,,50597
5049,,Rattus norvegicus,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,N,A,17720,In vivo,,10116.0,,Plasma,,50597
5050,,Rattus norvegicus,AUC value in rat after IV administration at a dose of 10 mg/kg,N,A,3546,,,10116.0,,Plasma,,50597
5051,,Rattus norvegicus,AUC value in rat after oral administration at a dose of 10 mg/kg,N,A,3546,,,10116.0,,Plasma,,50597
5052,,Rattus norvegicus,Cmax value in rat after oral administration at a dose of 10 mg/kg,N,A,3546,In vivo,,10116.0,,,,50597
5053,,Rattus norvegicus,Bioavailability in rat after oral administration at a dose of 10 mg/kg,N,A,3546,In vivo,,10116.0,,,,50597
5054,,Rattus norvegicus,Tmax value in rat after oral administration at a dose of 10 mg/kg,N,A,3546,In vivo,,10116.0,,,,50597
5055,,Rattus norvegicus,Vc value in rat after IV administration at a dose of 10 mg/kg,N,A,3546,,,10116.0,,,,50597
5056,,Rattus norvegicus,Half life period in rat after IV administration at a dose of 10 mg/kg,N,A,3546,In vivo,,10116.0,,,,50597
5057,,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,U,A,10625,,,9557.0,,,,22224
5058,,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),U,A,10625,,,9557.0,,,,22224
5059,,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),U,A,10625,,,9557.0,,,,22224
5060,,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,U,A,10625,,,9557.0,,,,22224
5061,,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,U,A,10625,,,9557.0,,,,22224
5062,,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,U,A,10625,,,9557.0,,,,22224
5063,,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,U,A,10625,,,9557.0,,,,22224
5064,,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,U,A,10625,,,9557.0,,,,22224
5065,,beagle,Area under curve after 1 mpk peroral administration to beagles,U,A,3510,,,9615.0,,,,22224
5066,,beagle,Area under curve after 2 mpk peroral administration to beagles,U,A,3510,,,9615.0,,,,22224
5067,,beagle,Cmax value after 1 mpk peroral administration to beagles,U,A,3510,In vivo,,9615.0,,,,22224
5068,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,U,A,7766,,,9606.0,,Urine,,22224
5069,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,U,A,7766,,,9606.0,,Urine,,22224
5070,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,U,A,7766,,,9606.0,,Urine,,22224
5071,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,U,A,7766,,,9606.0,,Urine,,22224
5072,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,U,A,7766,,,9606.0,,Urine,,22224
5073,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,U,A,7766,,,9606.0,,Urine,,22224
5074,,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,U,A,7766,,,9606.0,,Urine,,22224
5075,Microsomes,Homo sapiens,Metabolic stability observed at 30 min after administration in human liver microsomes,U,A,16643,,,9606.0,,Liver,,22224
5076,,Homo sapiens,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,U,A,6852,,,9606.0,,,,22224
5077,,Homo sapiens,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,U,A,6852,,,9606.0,,,,22224
5078,,Homo sapiens,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,U,A,6852,,,9606.0,,,,22224
5079,Microsomes,Homo sapiens,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",U,A,6567,,,9606.0,,Liver,,22224
5080,,Homo sapiens,Metabolic stability (% remaining at 30 mins) in human S9.,U,A,6570,,,9606.0,,,,22224
5081,,Homo sapiens,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,U,A,6570,,,9606.0,,,,22224
5082,Microsomes,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes,U,A,5237,,,9606.0,,Liver,,22224
5083,Microsomes,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,U,A,5237,,,9606.0,,Liver,,22224
5084,Microsomes,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,U,A,5237,,,9606.0,,Liver,,22224
5085,,Homo sapiens,First pass metabolism and metabolic bioavailability using human hepatic microsomes,U,A,5202,,,9606.0,,,,22224
5086,,Homo sapiens,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,U,A,5481,,,9606.0,,,,22224
5087,,Homo sapiens,Percent remaining in human plasma after incubation for 60 min at 37 C.,U,A,5481,,,9606.0,,,,22224
5088,,Homo sapiens,The percent remaining in human plasma after 30 min was determined,U,A,3956,,,9606.0,,,,22224
5089,,Homo sapiens,Conversion rate of the prodrug in human plasma,U,A,5074,,,9606.0,,Plasma,,22224
5090,,Homo sapiens,Conversion rate of the prodrug in human plasma; ND means no data,U,A,5074,,,9606.0,,Plasma,,22224
5091,,Homo sapiens,Half life of compound was determined in human blood,U,A,4727,,,9606.0,,Blood,,22224
5092,,Homo sapiens,Half life of compound was determined in man with once daily dosing,U,A,5965,,,9606.0,,,,22224
5093,Microsomes,Homo sapiens,Half life in human microsomes,U,A,5732,In vitro,,9606.0,,,,22224
5094,,Homo sapiens,Half life in human plasma,U,A,5819,,,9606.0,,Plasma,,22224
5095,,Homo sapiens,Half life in human plasma; Not detected,U,A,5819,,,9606.0,,Plasma,,22224
5096,,Homo sapiens,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,U,A,1916,In vivo,,9606.0,,,,22224
5097,Microsomes,Homo sapiens,Half-life for oxidative metabolic stability was determined using rat liver microsomes,U,A,6597,In vitro,,9606.0,,Liver,,22224
5098,,Homo sapiens,Half-life in human plasma,U,A,5229,,,9606.0,,Plasma,,22224
5099,,Homo sapiens,Half-life of the parent prodrug in plasma,U,A,5229,,,9606.0,,Plasma,,22224
5100,,Homo sapiens,In vitro half life in human plasma was determined,U,A,2192,In vitro,,9606.0,,Plasma,,22224
5101,Microsomes,Homo sapiens,The compound was tested In Vitro for half life in human liver microsomes.,U,A,3032,In vitro,,9606.0,,Liver,,22224
5102,,Homo sapiens,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,U,A,1916,In vivo,,9606.0,,,,22224
5103,,Homo sapiens,Observed volume of distribution,U,A,17716,In vivo,,9606.0,,,,22224
5104,,Homo sapiens,Oral bioavailability in human,U,A,15778,In vivo,,9606.0,,,,22224
5105,,Homo sapiens,Tested for human plasma protein binding of the compound,U,A,17313,,,9606.0,,,,22224
5106,,Homo sapiens,"First order rate constant, k was determined in human plasma",U,A,4231,,,9606.0,,,,22224
5107,,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,U,A,4755,,,9606.0,,,,22224
5108,,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,U,A,4755,,,9606.0,,,,22224
5109,Microsomes,Homo sapiens,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,U,A,16907,,,9606.0,,Liver,,22224
5110,,Homo sapiens,The compound was tested for the plasma binding in human,U,A,10839,,,9606.0,,,,22224
5111,,Homo sapiens,Plasma protein binding (human),U,A,10839,,,9606.0,,,,22224
5112,Microsomes,Homo sapiens,Compound was evaluated for half-life in human liver microsomes,U,A,3199,In vitro,,9606.0,,Liver,,22224
5113,,Homo sapiens,Half life measured in vitro for its stability in human blood,U,A,1345,In vitro,,9606.0,,Blood,,22224
5114,,Homo sapiens,Half life in human serum,U,A,4297,,,9606.0,,Serum,,22224
5115,,Homo sapiens,Half life in human serum; ND=not determined,U,A,4297,,,9606.0,,Serum,,22224
5116,,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 1,U,A,4297,,,9606.0,,,,22224
5117,,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 2,U,A,4297,,,9606.0,,,,22224
5118,,Homo sapiens,Half life of the in human plasma,U,A,4231,,,9606.0,,Plasma,,22224
5119,S9,Homo sapiens,Half life period in human hepatic S9 fraction was determined,U,A,5633,In vitro,,9606.0,,,,22224
5120,Microsomes,Homo sapiens,Half life period in human liver microsome was determined,U,A,5633,In vitro,,9606.0,,Liver,,22224
5121,,Homo sapiens,Half life period was determined; 6-7,U,A,17791,,,9606.0,,,,22224
5122,,Homo sapiens,Half life period was evaluated in human,U,A,17791,,,9606.0,,,,22224
5123,,Homo sapiens,Half life time in human plasma,U,A,3160,,,9606.0,,Plasma,,22224
5124,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Brain,,50594
5125,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Heart,,50594
5126,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Heart,,50594
5127,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Kidney,,50594
5128,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,A,16438,In vivo,,10090.0,,Kidney,,50594
5129,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Kidney,,50594
5130,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Liver,,50594
5131,,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,A,16438,In vivo,,10090.0,,Liver,,50594
5132,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Liver,,50594
5133,,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,A,16438,In vivo,,10090.0,,Spleen,,50594
5134,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,A,16438,In vivo,,10090.0,,Spleen,,50594
5135,,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Spleen,,50594
5136,,Mus musculus,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,A,16438,In vivo,,10090.0,,Brain,,50594
5137,,Mus musculus,Biodistribution of compound (oxidized form) in blood tissue,N,A,16438,In vivo,,10090.0,,Blood,,50594
5138,,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Blood,,50594
5139,,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,A,16438,In vivo,,10090.0,,Blood,,50594
5140,,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,A,16438,In vivo,,10090.0,,Blood,,50594
5141,,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Blood,,50594
5142,,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,A,16438,In vivo,,10090.0,,Blood,,50594
5143,,Mus musculus,Biodistribution of compound (oxidized form) in brain tissue of mice,N,A,16438,In vivo,,10090.0,,Brain,,50594
5144,,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Brain,,50594
5145,,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,A,16438,In vivo,,10090.0,,Brain,,50594
5146,,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Brain,,50594
5147,,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,A,16438,In vivo,,10090.0,,Brain,,50594
5148,,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,A,16438,In vivo,,10090.0,,Brain,,50594
5149,,Mus musculus,Biodistribution of compound (oxidized form) in heart tissue of mice,N,A,16438,In vivo,,10090.0,,Heart,,50594
5150,,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Heart,,50594
5151,,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Heart,,50594
5152,,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,A,16438,In vivo,,10090.0,,Heart,,50594
5153,,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Heart,,50594
5154,,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,A,16438,In vivo,,10090.0,,Heart,,50594
5155,,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Kidney,,50594
5156,,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,A,16438,In vivo,,10090.0,,Kidney,,50594
5157,,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,A,16438,In vivo,,10090.0,,Kidney,,50594
5158,,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Kidney,,50594
5159,,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,A,16438,In vivo,,10090.0,,Kidney,,50594
5160,,Mus musculus,Biodistribution of compound (oxidized form) in liver tissue,N,A,16438,In vivo,,10090.0,,Liver,,50594
5161,,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,A,16438,In vivo,,10090.0,,Liver,,50594
5162,,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,A,16438,In vivo,,10090.0,,Liver,,50594
5163,,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,N,F,5245,,,9606.0,,,A-431,80852
5164,,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,N,F,5245,,,9606.0,,,A-431,80852
5165,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",N,F,16289,,,,,,A-431,80852
5166,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",N,F,16289,,,,,,A-431,80852
5167,,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,D,F,16093,,,9606.0,,,A-431,9
5168,,Homo sapiens,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",N,F,16825,,,9606.0,,,A-431,80852
5169,,Homo sapiens,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,N,F,4848,,,9606.0,,,A-431,80852
5170,,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,D,F,14827,,,9606.0,,,A-431,9
5171,,Homo sapiens,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,D,F,14827,,,9606.0,,,A-431,9
5172,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",N,F,16289,,,,,,A-431,80852
5173,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",N,F,16289,,,,,,A-431,80852
5174,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",N,F,16289,,,,,,A-431,80852
5175,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",N,F,16289,,,,,,A-431,80852
5176,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",N,F,16289,,,,,,A-431,80852
5177,,Homo sapiens,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",D,F,16289,,,9606.0,,,A-431,9
5178,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,H,F,16289,,,,,,A-431,9
5179,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",N,F,16289,,,,,,A-431,80852
5180,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",N,F,16289,,,,,,A-431,80852
5181,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",N,F,16289,,,,,,A-431,80852
5182,,Mus musculus,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",N,F,14555,,,10090.0,,,A-431,80852
5183,,Mus musculus,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",N,F,14555,,,10090.0,,,A-431,80852
5184,,Mus musculus,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",N,F,14555,,,10090.0,,,A-431,80852
5185,,Mus musculus,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",N,F,14555,,,10090.0,,,A-431,80852
5186,,Homo sapiens,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,N,F,1937,,,9606.0,,,A-431,80852
5187,,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,N,F,13739,,,9606.0,,,A-431,80852
5188,,Homo sapiens,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,N,F,3558,,,9606.0,,,A-431,80852
5189,,Homo sapiens,Dose giving a 50% decrease in the living cell number (A437 cells),N,F,3558,,,9606.0,,,A-431,80852
5190,,Homo sapiens,In vitro inhibitory concentration against proliferation of A459 cell line.,N,F,17686,,,9606.0,,,A549,80682
5191,,Homo sapiens,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,N,F,5305,,,9606.0,,,A549,80682
5192,,Homo sapiens,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,N,F,3614,,,9606.0,,,A549,80682
5193,,Homo sapiens,In vitro antitumor activity against renal A498 tumor cell lines,N,F,17229,,,9606.0,,,A498,80021
5194,,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",N,F,15935,,,9606.0,,,A498,80021
5195,,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",N,F,15935,,,9606.0,,,A498,80021
5196,,Homo sapiens,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,N,F,15560,,,9606.0,,,A498,80021
5197,,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,N,F,13891,,,9606.0,,,A498,80021
5198,,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,N,F,13891,,,9606.0,,,A498,80021
5199,,Homo sapiens,Cytotoxicity on kidney carcinoma (A-498) cell line,N,F,13788,,,9606.0,,,A498,80021
5200,,Homo sapiens,Compound was evaluated against Human cell line renal A498,N,F,15403,,,9606.0,,,A498,80021
5201,,Homo sapiens,Compound was tested for inhibition of A498 human renal cancer cell line,N,F,1009,,,9606.0,,,A498,80021
5202,,Homo sapiens,Growth inhibitory activity against A498 human cancer cell line,N,F,1043,,,9606.0,,,A498,80021
5203,,Homo sapiens,In vitro antitumor activity against human renal A498 cell line,N,F,5858,,,9606.0,,,A498,80021
5204,,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line,N,F,5958,,,9606.0,,,A498,80021
5205,,Homo sapiens,In vitro cytotoxic activity against human renal cancer (A498) cell line,N,F,5506,,,9606.0,,,A498,80021
5206,,Homo sapiens,Tested for cytostatic activity against renal A498 cell line,N,F,12781,,,9606.0,,,A498,80021
5207,,Homo sapiens,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,N,F,14399,,,9606.0,,,A498,80021
5208,,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,N,F,5958,,,9606.0,,,A498,80021
5209,,beagle,Cmax value after 2 mpk peroral administration to beagles,U,A,3510,In vivo,,9615.0,,,,22224
5210,,Canis lupus familiaris,Bioavailability,U,A,3510,In vivo,,9615.0,beagle,,,22224
5211,,Canis lupus familiaris,Bioavailability after 1 mpk peroral administration to beagles,U,A,3510,In vivo,,9615.0,beagle,,,22224
5212,,Canis lupus familiaris,Bioavailability after 2 mpk peroral administration to beagles,U,A,3510,In vivo,,9615.0,beagle,,,22224
5213,,Bos taurus,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,U,A,3085,,,9913.0,,,,22224
5214,,Bos taurus,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,U,A,3085,,,9913.0,,,,22224
5215,,Bos taurus,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,U,A,3085,,,9913.0,,,,22224
5216,,Bos taurus,Solubility against bovine alpha-chymotrypsin,U,A,9372,,,9913.0,,,,22224
5217,,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,U,A,3085,,,9913.0,,,,22224
5218,,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,U,A,3085,,,9913.0,,,,22224
5219,,Bos taurus,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,U,A,1469,,,9913.0,,Spleen,,22224
5220,,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum,U,A,4297,,,9913.0,,,,22224
5221,,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,U,A,4297,,,9913.0,,,,22224
5222,,Bos taurus,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,U,A,17585,,,9913.0,,,,22224
5223,,Bos taurus,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,U,A,1336,,,9913.0,,Spleen,,22224
5224,,Bos taurus,Half life in presence of 2 mg/mL BSA at pH 8.8,U,A,3085,,,9913.0,,,,22224
5225,,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,U,A,2857,,,9913.0,,,,22224
5226,,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,U,A,2857,,,9913.0,,,,22224
5227,,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,U,A,2857,,,9913.0,,,,22224
5228,,Bos taurus,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),U,A,1540,,,9913.0,,,,22224
5229,,Canis lupus familiaris,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,N,A,6316,,,9615.0,,Plasma,,50588
5230,,Canis lupus familiaris,AUC after administration at 100 mg/kg/day in dogs,N,A,17594,,,9615.0,,Plasma,,50588
5231,,Canis lupus familiaris,AUC in dog at 0-24 hr by peroral administration at 3 mpk,N,A,4953,,,9615.0,,Plasma,,50588
5232,,Canis lupus familiaris,AUC value after 15 mg/kg iv dose in Dogs,N,A,16907,,,9615.0,,Plasma,,50588
5233,,Canis lupus familiaris,AUC value after 30 mg/kg po dose in Dogs,N,A,16907,,,9615.0,,Plasma,,50588
5234,,Canis lupus familiaris,AUC value after administration of 4 mg/Kg oral dose in dog,N,A,2959,,,9615.0,,Plasma,,50588
5235,,Canis lupus familiaris,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,N,A,17594,,,9615.0,,Plasma,,50588
5236,,Canis lupus familiaris,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,N,A,5356,,,9615.0,,,,50588
5237,,Canis lupus familiaris,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,N,A,16807,,,9615.0,,,,50588
5238,,Canis lupus familiaris,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,N,A,4527,,,9615.0,,,,50588
5239,,Canis lupus familiaris,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,N,A,4527,,,9615.0,,,,50588
5240,,Canis lupus familiaris,Area under curve determined in dogs after intravenous administration of 3 mg/kg,N,A,15660,,,9615.0,,,,50588
5241,,Canis lupus familiaris,Area under curve determined in dogs after oral administration of 10 mg/kg,N,A,15660,,,9615.0,,,,50588
5242,,Canis lupus familiaris,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,A,5802,,,9615.0,,,,50588
5243,,Canis lupus familiaris,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,N,A,3598,,,9615.0,,,,50588
5244,,Canis lupus familiaris,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,N,A,3598,,,9615.0,,,,50588
5245,,Canis lupus familiaris,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),N,A,5944,,,9615.0,,,,50588
5246,,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,N,A,5944,,,9615.0,,,,50588
5247,,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),N,A,5944,,,9615.0,,,,50588
5248,,Canis lupus familiaris,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,N,A,5944,,,9615.0,,,,50588
5249,,Canis lupus familiaris,Area under curve in dog after administration of 20 mg/kg dose through peroral route,N,A,4186,,,9615.0,,,,50588
5250,,Canis lupus familiaris,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,A,5007,,,9615.0,,,,50588
5251,,Canis lupus familiaris,Area under curve was determine after peroral administration at 10 mpk in dog,N,A,5668,,,9615.0,,,,50588
5252,,Canis lupus familiaris,Area under curve was determine after peroral administration at 5 mpk in dog,N,A,5668,,,9615.0,,,,50588
5253,,Canis lupus familiaris,Area under curve was determined,N,A,5006,,,9615.0,,,,50588
5254,,Canis lupus familiaris,Area under curve in dogs,N,A,5006,,,9615.0,,,,50588
5255,,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration,N,A,3771,,,9615.0,,,,50588
5256,,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),N,A,3771,,,9615.0,,,,50588
5257,,Canis lupus familiaris,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,N,A,3771,,,9615.0,,,,50588
5258,,Canis lupus familiaris,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,A,1916,,,9615.0,,,,50588
5259,,Canis lupus familiaris,Area under curve value in dog at a dose of 5 mg/kg,N,A,5302,,,9615.0,,,,50588
5260,,Canis lupus familiaris,Area under curve was determined after 0.1 mg/kg iv administration in dog,N,A,5600,,,9615.0,,,,50588
5261,,Canis lupus familiaris,Area under curve was determined after 0.3 mg/kg po administration in dog,N,A,5600,,,9615.0,,,,50588
5262,,Canis lupus familiaris,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,N,A,17764,,,9615.0,,,,50588
5263,,Canis lupus familiaris,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,N,A,4368,,,9615.0,,,,50588
5264,,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,U,A,5318,,,9606.0,,,,22224
5265,,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,U,A,5318,,,9606.0,,,,22224
5266,,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,U,A,5318,,,9606.0,,,,22224
5267,,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,U,A,5318,,,9606.0,,,,22224
5268,,Homo sapiens,Time taken to reduce 50% of the concentration of compound in blood plasma,U,A,14518,,,9606.0,,Blood,,22224
5269,,Homo sapiens,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",U,A,2209,,,9606.0,,Plasma,,22224
5270,,Homo sapiens,Half life in human plasma,U,A,6787,,,9606.0,,Plasma,,22224
5271,,Homo sapiens,Half life in human plasma was reported,U,A,4898,,,9606.0,,Plasma,,22224
5272,,Homo sapiens,Half life in human serum,U,A,6072,,,9606.0,,Serum,,22224
5273,,Homo sapiens,Half life upon exposure to human plasma,U,A,16907,,,9606.0,,Plasma,,22224
5274,Microsomes,Homo sapiens,t1/2 in human microsomes,U,A,5656,In vitro,,9606.0,,,,22224
5275,,Homo sapiens,Half life period in 80% human plasma at 37 degree Centigrade,U,A,4755,,,9606.0,,Plasma,,22224
5276,,Homo sapiens,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),U,A,17503,,,9606.0,,Zone of skin,,22224
5277,,Homo sapiens,Half-life measured in in vitro Cathepsin B assay in human plasma,U,A,12357,In vitro,,9606.0,,Plasma,,22224
5278,,Homo sapiens,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,U,A,3076,,,9606.0,,,,22224
5279,Microsomes,Homo sapiens,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,U,A,6410,In vitro,,9606.0,,Liver,,22224
5280,,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",U,A,3741,,,9606.0,,Plasma,,22224
5281,,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",U,A,3741,,,9606.0,,Plasma,,22224
5282,,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",U,A,3741,,,9606.0,,Plasma,,22224
5283,,Homo sapiens,Half-life in the CEM cell extracts,U,A,1540,,,9606.0,,,,22224
5284,,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,U,A,2905,,,9606.0,,Plasma,,22224
5285,,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,U,A,2905,,,9606.0,,Plasma,,22224
5286,,Homo sapiens,Half-life was determined,U,A,5523,,,9606.0,,,,22224
5287,,Homo sapiens,Half-life (human blood stability),U,A,1499,,,9606.0,,Blood,,22224
5288,,Homo sapiens,Half-life (human blood stability); no data,U,A,1499,,,9606.0,,Blood,,22224
5289,,Homo sapiens,Half-life in human plasma,U,A,17065,,,9606.0,,Plasma,,22224
5290,,Homo sapiens,CYP3A4 metabolism half-life (t1/2),U,A,6861,,,9606.0,,,,22224
5291,,Homo sapiens,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),U,A,1499,,,9606.0,,Blood,,22224
5292,,Homo sapiens,In vitro half life in human plasma,U,A,530,In vitro,,9606.0,,Plasma,,22224
5293,,Homo sapiens,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",U,A,1116,In vitro,,9606.0,,Plasma,,22224
5294,,Homo sapiens,In vitro hydrolysis in human plasma,U,A,6695,In vitro,,9606.0,,Plasma,,22224
5295,,Homo sapiens,In vitro hydrolysis in human plasma; no data,U,A,6695,In vitro,,9606.0,,Plasma,,22224
5296,Microsomes,Homo sapiens,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,U,A,10,In vitro,,9606.0,,Liver,,22224
5297,,Homo sapiens,Plasma half life in human,U,A,993,,,9606.0,,Plasma,,22224
5298,,Homo sapiens,Stability after incubation with human plasma (at 37 degree C),U,A,15429,,,9606.0,,Plasma,,22224
5299,,Homo sapiens,T1/2 was evaluated in human plasma,U,A,1675,,,9606.0,,Plasma,,22224
5300,,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",U,A,2209,,,9606.0,,Plasma,,22224
5301,,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",U,A,2209,,,9606.0,,Plasma,,22224
5302,,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,U,A,5318,,,9606.0,,,,22224
5303,,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,U,A,2412,In vitro,,9606.0,,,,22224
5304,,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,U,A,2412,In vitro,,9606.0,,,,22224
5305,,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,U,A,2906,,,9606.0,,Plasma,,22224
5306,,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,U,A,2906,,,9606.0,,Plasma,,22224
5307,,Homo sapiens,Time taken for 50% to be consumed by serum PON1 was determined,U,A,5495,,,9606.0,,,,22224
5308,,Homo sapiens,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,U,A,5495,,,9606.0,,,,22224
5309,Microsomes,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,U,A,4397,,,9606.0,,Liver,,22224
5310,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,A,2413,,,10095.0,,,,22224
5311,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,A,2413,,,10095.0,,,,22224
5312,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,A,2413,,,10095.0,,,,22224
5313,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,A,2413,,,10095.0,,,,22224
5314,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,A,2413,,,10095.0,,,,22224
5315,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,A,2413,,,10095.0,,,,22224
5316,,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line 786-0,N,F,6058,,,9606.0,,,786-0,80640
5317,,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,N,F,17708,,,9606.0,,,786-0,80640
5318,,Homo sapiens,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,N,F,14017,,,9606.0,,,786-0,80640
5319,,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",N,F,16818,,,9606.0,,,786-0,80640
5320,,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",N,F,16818,,,9606.0,,,786-0,80640
5321,,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",N,F,16818,,,9606.0,,,786-0,80640
5322,,Homo sapiens,Tested for cytotoxicity against 786-0 cell lines in renal cancer,N,F,11970,,,9606.0,,,786-0,80640
5323,,Homo sapiens,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,N,F,12400,,,9606.0,,,786-0,80640
5324,,Homo sapiens,Cytotoxic effect on renal cancer line 786-0,N,F,12888,,,9606.0,,,786-0,80640
5325,,Homo sapiens,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,N,F,15300,,,9606.0,,,786-0,80640
5326,,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),N,F,14769,,,9606.0,,,786-0,80640
5327,,Homo sapiens,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",N,F,15895,,,9606.0,,,786-0,80640
5328,,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,N,F,17376,,,9606.0,,,786-0,80640
5329,,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,N,F,14882,,,9606.0,,,786-0,80640
5330,,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),N,F,14882,,,9606.0,,,786-0,80640
5331,,Homo sapiens,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,N,F,15176,,,9606.0,,,786-0,80640
5332,,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,N,F,12696,,,9606.0,,,786-0,80640
5333,,Homo sapiens,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),N,F,2496,,,9606.0,,,786-0,80640
5334,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,N,F,11831,,,9606.0,,,791T cell line,80641
5335,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),N,F,11831,,,9606.0,,,791T cell line,80641
5336,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,N,F,11831,,,9606.0,,,791T cell line,80641
5337,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),N,F,11831,,,9606.0,,,791T cell line,80641
5338,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),N,F,11831,,,9606.0,,,791T cell line,80641
5339,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,N,F,11831,,,9606.0,,,791T cell line,80641
5340,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),N,F,11831,,,9606.0,,,791T cell line,80641
5341,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),N,F,11831,,,9606.0,,,791T cell line,80641
5342,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),N,F,11831,,,9606.0,,,791T cell line,80641
5343,,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,N,F,11831,,,9606.0,,,791T cell line,80641
5344,,Homo sapiens,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,N,F,12782,,,9606.0,,,786-0,80640
5345,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,U,F,1229,,,,,,,22226
5346,,Homo sapiens,Inhibition of cell growth in drug resistant 8226 myeloma cell line,N,F,15313,,,9606.0,,,RPMI-8226,80433
5347,,Homo sapiens,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,N,F,15313,,,9606.0,,,RPMI-8226,80433
5348,,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,N,F,11544,,,9606.0,,,RPMI-8226,80433
5349,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,F,9424,,,9606.0,,,RPMI-8226,80433
5350,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,F,9424,,,9606.0,,,RPMI-8226,80433
5351,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5352,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5353,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5354,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5355,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5356,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5357,,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5358,,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),N,F,14769,,,9606.0,,,A498,80021
5359,,Homo sapiens,Compound was tested for the growth inhibition of A498 renal tumor cell line,N,F,15354,,,9606.0,,,A498,80021
5360,,Homo sapiens,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),N,F,17445,,,9606.0,,,A498,80021
5361,,Homo sapiens,In vitro inhibitory concentration against renal cancer cell line A498,N,F,4337,,,9606.0,,,A498,80021
5362,,Homo sapiens,Cytotoxicity against A 498 tumor cell line,N,F,15277,,,9606.0,,,A498,80021
5363,,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line,N,F,4812,,,9606.0,,,A498,80021
5364,,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),N,F,4812,,,9606.0,,,A498,80021
5365,,Homo sapiens,Inhibitory dose required against A498 human tumor cell lines,N,F,4995,,,9606.0,,,A498,80021
5366,,Homo sapiens,Anticancer activity against one renal cancer (A498 cell line),N,F,5847,,,9606.0,,,A498,80021
5367,,Homo sapiens,In vitro cytotoxicity against melanoma A498 cell line,N,F,6557,,,9606.0,,,A498,80021
5368,,Homo sapiens,Compound was tested for growth inhibitory activity against A498 cell line,N,F,2597,,,9606.0,,,A498,80021
5369,,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line A498,N,F,6058,,,9606.0,,,A498,80021
5370,,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,N,F,17708,,,9606.0,,,A498,80021
5371,,Homo sapiens,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,N,F,15176,,,9606.0,,,A498,80021
5372,,Homo sapiens,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,N,F,15300,,,9606.0,,,A498,80021
5373,,Homo sapiens,Tested for cytotoxicity against A498 cell lines in renal cancer,N,F,11970,,,9606.0,,,A498,80021
5374,,Homo sapiens,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,N,F,12400,,,9606.0,,,A498,80021
5375,,Homo sapiens,Cytotoxic effect on renal cancer lines A498,N,F,12888,,,9606.0,,,A498,80021
5376,,Homo sapiens,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,N,F,3030,,,9606.0,,,A498,80021
5377,,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),N,F,14769,,,9606.0,,,A498,80021
5378,,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,N,F,17376,,,9606.0,,,A498,80021
5379,,Homo sapiens,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,N,F,16558,,,9606.0,,,A498,80021
5380,,Homo sapiens,Cytotoxicity against human kidney carcinoma cell lines A4982LM,N,F,5194,,,9606.0,,,A498,80021
5381,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,N,F,10708,,,9606.0,,,A498,80021
5382,,Homo sapiens,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,N,F,16880,,,9606.0,,,A549,80682
5383,,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line,N,F,10196,,,9606.0,,,A549,80682
5384,,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,N,F,10196,,,9606.0,,,A549,80682
5385,,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,N,F,10196,,,9606.0,,,A549,80682
5386,,Homo sapiens,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",N,F,12083,,,9606.0,,,A549,80682
5387,,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,N,F,16464,,,9606.0,,,A549,80682
5388,,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,F,16464,,,9606.0,,,A549,80682
5389,,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line,N,F,16470,,,9606.0,,,A549,80682
5390,,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),N,F,16470,,,9606.0,,,A549,80682
5391,,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line),N,F,16470,,,9606.0,,,A549,80682
5392,,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,N,F,16470,,,9606.0,,,A549,80682
5393,,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A549.,N,F,16582,,,9606.0,,,A549,80682
5394,,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",N,F,15935,,,9606.0,,,A549,80682
5395,,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",N,F,15935,,,9606.0,,,A549,80682
5396,,Homo sapiens,Inhibition of A549 human lung carcinoma cell proliferation,N,F,16597,,,9606.0,,,A549,80682
5397,,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,N,F,17376,,,9606.0,,,A549,80682
5398,,Homo sapiens,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,N,F,16496,,,9606.0,,,A549,80682
5399,,Homo sapiens,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,N,F,16152,,,9606.0,,,A549,80682
5400,,Homo sapiens,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,N,F,16152,,,9606.0,,,A549,80682
5401,,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,F,16464,,,9606.0,,,A549,80682
5402,,Homo sapiens,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,N,F,2288,,,9606.0,,,A549,80682
5403,,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,N,F,17350,,,9606.0,,,A549,80682
5404,,Homo sapiens,Inhibition of A549 cancer cell proliferation,N,F,4090,,,9606.0,,,A549,80682
5405,,Homo sapiens,Inhibition of A549 cancer cell proliferation (Not tested),N,F,4090,,,9606.0,,,A549,80682
5406,,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,N,F,17350,,,9606.0,,,A549,80682
5407,,Homo sapiens,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,N,F,4197,,,9606.0,,,A549,80682
5408,,Homo sapiens,Antiproliferative potency determined as inhibitory concentration against A549 cells,N,F,17072,,,9606.0,,,A549,80682
5409,,Homo sapiens,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,N,F,17072,,,9606.0,,,A549,80682
5410,,Homo sapiens,Cytotoxicity against Renal cell lines A549 was determined,N,F,5194,,,9606.0,,,A549,80682
5411,,Canis lupus familiaris,Area under curve was determined in dog after a 3 mg/kg of oral dose,N,A,4257,,,9615.0,,,,50588
5412,,Canis lupus familiaris,Area under curve was determined in dog after oral administration at 1 mg/kg,N,A,6123,,,9615.0,,,,50588
5413,,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,A,1337,,,9615.0,,,,50588
5414,,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,A,1337,,,9615.0,,,,50588
5415,,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),N,A,8833,,,9615.0,,,,50588
5416,,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),N,A,8833,,,9615.0,,,,50588
5417,,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),N,A,8833,,,9615.0,,,,50588
5418,,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),N,A,8833,,,9615.0,,,,50588
5419,,Canis lupus familiaris,Area under plasma concentration time curve in dog upon oral administration,N,A,17657,,,9615.0,,Plasma,,50588
5420,,Canis lupus familiaris,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,N,A,17650,,,9615.0,,Plasma,,50588
5421,,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,N,A,1977,,,9615.0,,,,50588
5422,,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,N,A,1977,,,9615.0,,,,50588
5423,,Canis lupus familiaris,Area under the curve for the compound was obtained when tested in dog,N,A,3132,,,9615.0,,,,50588
5424,,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg,N,A,5473,,,9615.0,,,,50588
5425,,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg (oral),N,A,5474,,,9615.0,,,,50588
5426,,Canis lupus familiaris,Area under the curve at i.v. dose of 0.2 mg/kg,N,A,5474,,,9615.0,,,,50588
5427,,Canis lupus familiaris,Area under the curve was measured in dog after an iv dose of 1 mg/kg,N,A,6062,,,9615.0,,,,50588
5428,,Canis lupus familiaris,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,N,A,4709,,,9615.0,,,,50588
5429,,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,N,A,2652,,,9615.0,,,,50588
5430,,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,N,A,2652,,,9615.0,,,,50588
5431,,Canis lupus familiaris,Compound was evaluated for area under the curve in dog blood.,N,A,2877,,,9615.0,,,,50588
5432,,Canis lupus familiaris,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,N,A,5444,,,9615.0,,,,50588
5433,,Canis lupus familiaris,AUC in dog after oral dose (1 mg/kg),N,A,5130,,,9615.0,,Plasma,,50588
5434,,Canis lupus familiaris,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,N,A,6265,,,9615.0,,,,50588
5435,,Canis lupus familiaris,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",N,A,4657,,,9615.0,,,,50588
5436,,Canis lupus familiaris,Pharmacokinetic parameter AUC after intravenous administration to dogs,N,A,16367,,,9615.0,,,,50588
5437,,Canis lupus familiaris,Pharmacokinetic parameter AUC after oral administration to dogs,N,A,16367,,,9615.0,,,,50588
5438,,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,N,A,9579,,,9615.0,,,,50588
5439,,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,N,A,9579,,,9615.0,,,,50588
5440,,Canis lupus familiaris,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,N,A,5983,,,9615.0,,,,50588
5441,,Canis lupus familiaris,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,N,A,6241,,,9615.0,,,,50588
5442,,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",N,A,5313,,,9615.0,,,,50588
5443,,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",N,A,5313,,,9615.0,,,,50588
5444,,Canis lupus familiaris,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,A,6642,,,9615.0,,,,50588
5445,,Canis lupus familiaris,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,A,6642,,,9615.0,,,,50588
5446,,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),N,A,6641,,,9615.0,,,,50588
5447,,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),N,A,6642,,,9615.0,,,,50588
5448,,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dog; 90-100,N,A,17791,,,9615.0,,,,50588
5449,,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,N,A,17655,,,9615.0,,,,50588
5450,,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,N,A,17655,,,9615.0,,,,50588
5451,,Canis lupus familiaris,PAPP (membrane permeability) in dog kidney cell monolayer assay,N,A,6596,,,9615.0,,,,50588
5452,,Canis lupus familiaris,Oral bioavailability in dog,N,A,3880,,,9615.0,,,,50588
5453,,Canis lupus familiaris,Bioavailability administered orally at a dose of 10 mg/kg to dogs,N,A,16367,,,9615.0,,,,50588
5454,,Canis lupus familiaris,Plasma protein binding towards dog plasma at 10 uM,N,A,17409,,,9615.0,,Plasma,,50588
5455,,Canis lupus familiaris,Plasma protein binding towards dog plasma at 100 uM,N,A,17409,,,9615.0,,Plasma,,50588
5456,,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),N,A,2959,In vivo,,9615.0,,,,50588
5457,,Canis lupus familiaris,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,N,A,13501,In vivo,,9615.0,,,,50588
5458,,Canis lupus familiaris,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,N,A,4527,In vivo,,9615.0,,,,50588
5459,,Canis lupus familiaris,Bioavailability in dogs,N,A,15145,In vivo,,9615.0,,,,50588
5460,,Canis lupus familiaris,Bioavailability,N,A,4219,In vivo,,9615.0,,,,50588
5461,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),N,A,17538,In vivo,,9615.0,,,,50588
5462,,Canis lupus familiaris,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,N,A,17538,In vivo,,9615.0,,,,50588
5463,,Canis lupus familiaris,Bioavailability in dog (dose 10.0 mg/kg p.o.),N,A,1466,In vivo,,9615.0,,,,50588
5464,,Canis lupus familiaris,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,N,A,17650,In vivo,,9615.0,,,,50588
5465,,Canis lupus familiaris,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,N,A,3132,In vivo,,9615.0,,,,50588
5466,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,A,2413,,,10095.0,,,,22224
5467,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,A,2413,,,10095.0,,Liver,,22224
5468,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,A,2413,,,10095.0,,Liver,,22224
5469,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,A,2413,,,10095.0,,Liver,,22224
5470,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,A,2413,,,10095.0,,,,22224
5471,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,A,2413,,,10095.0,,,,22224
5472,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,A,2413,,,10095.0,,Muscle tissue,,22224
5473,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,A,2413,,,10095.0,,Muscle tissue,,22224
5474,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,A,2413,,,10095.0,,Muscle tissue,,22224
5475,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,A,2413,,,10095.0,,Spleen,,22224
5476,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,A,2413,,,10095.0,,Spleen,,22224
5477,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,A,2413,,,10095.0,,,,22224
5478,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,A,2413,,,10095.0,,,,22224
5479,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,A,2413,,,10095.0,,,,22224
5480,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,A,2413,,,10095.0,,,,22224
5481,,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,A,2413,,,10095.0,,,,22224
5482,,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),U,A,17827,,,9527.0,,,,22224
5483,,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),U,A,17827,,,9527.0,,Cerebellum,,22224
5484,,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),U,A,17827,,,9527.0,,Frontal cortex,,22224
5485,,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),U,A,17827,,,9527.0,,,,22224
5486,,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),U,A,17827,,,9527.0,,Striatum,,22224
5487,,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),U,A,17827,,,9527.0,,,,22224
5488,,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),U,A,17827,,,9527.0,,Cerebellum,,22224
5489,,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),U,A,17827,,,9527.0,,Frontal cortex,,22224
5490,,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),U,A,17827,,,9527.0,,,,22224
5491,,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),U,A,17827,,,9527.0,,Striatum,,22224
5492,,Cercopithecidae,Compound was evaluated for oral bioavailability in rats,U,A,17791,,,9527.0,,,,22224
5493,,Cercopithecidae,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,U,A,17667,In vivo,,9527.0,,Plasma,,22224
5494,,Cercopithecidae,Half life period was evaluated in monkey,U,A,17791,,,9527.0,,,,22224
5495,,Cercopithecidae,Half-life in rhesus monkeys by intravenous administration of dose,U,A,110,In vivo,,9527.0,,,,22224
5496,,Mus musculus,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,N,A,5781,,,10090.0,,Plasma,,50594
5497,,Mus musculus,AUC after intraperitoneal administration of 100 mg/kg in mice,N,A,17734,,,10090.0,,Plasma,,50594
5498,,Mus musculus,AUC value was determined after oral administration,N,A,17718,,,10090.0,,Plasma,,50594
5499,,Mus musculus,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,N,A,4573,,,10090.0,,,,50594
5500,,Mus musculus,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,A,3277,,,10090.0,,,,50594
5501,,Mus musculus,Area under curve by ioral administration in mouse,N,A,2862,,,10090.0,,,,50594
5502,,Mus musculus,Area under curve by iv administration in mouse,N,A,2862,,,10090.0,,,,50594
5503,,Mus musculus,Area under curve at 0-8 hr in IRC mice after peroral administration,N,A,5951,,,10090.0,,,,50594
5504,,Mus musculus,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,N,A,17729,,,10090.0,,,,50594
5505,,Mus musculus,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,N,A,17728,,,10090.0,,,,50594
5506,,Mus musculus,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,N,A,17728,,,10090.0,,,,50594
5507,,Mus musculus,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,N,A,17729,,,10090.0,,,,50594
5508,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,F,9424,,,9606.0,,,RPMI-8226,80433
5509,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,F,9424,,,9606.0,,,RPMI-8226,80433
5510,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5511,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5512,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5513,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5514,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5515,,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5516,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,F,9424,,,9606.0,,,RPMI-8226,80433
5517,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,F,9424,,,9606.0,,,RPMI-8226,80433
5518,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5519,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5520,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5521,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5522,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5523,,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,F,9424,,,9606.0,,,RPMI-8226,80433
5524,,Homo sapiens,In vitro inhibition of human 8226 myeloma tumor cell line growth.,N,F,9424,,,9606.0,,,RPMI-8226,80433
5525,,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,N,F,11544,,,9606.0,,,RPMI-8226,80433
5526,,Homo sapiens,Cytotoxicity of compound against 8226/DOX1V cells,N,F,17378,,,9606.0,,,RPMI-8226,80433
5527,,Homo sapiens,Cytotoxicity of compound against 8226/S cells,N,F,17378,,,9606.0,,,RPMI-8226,80433
5528,,Homo sapiens,Inhibitory concentration against 8226 myeloma cancer cell line,N,F,17079,,,9606.0,,,RPMI-8226,80433
5529,,Homo sapiens,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,N,F,17079,,,9606.0,,,RPMI-8226,80433
5530,,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K).,N,F,13466,,,9606.0,,,833K,80647
5531,,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',N,F,13466,,,9606.0,,,833K,80647
5532,,Homo sapiens,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,N,F,2392,,,9606.0,,,833K,80647
5533,,Homo sapiens,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,N,F,2392,,,9606.0,,,833K,80647
5534,,,Inhibitory activity against caspase-1,U,B,6608,,,,,,,22226
5535,,Enterococcus faecalis,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,H,B,10199,,,1351.0,,,,45
5536,,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,N,F,17749,,,9606.0,,,8701-BC,80648
5537,,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,N,F,17749,,,9606.0,,,8701-BC,80648
5538,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,U,F,1229,,,,,,,22226
5539,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,U,F,1229,,,,,,,22226
5540,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,U,F,1229,,,,,,,22226
5541,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,U,B,6390,,,,,,,22226
5542,,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,U,F,16219,,,1314.0,,,,22226
5543,,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,U,F,16219,,,1314.0,,,,22226
5544,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,H,B,17043,,,,,,,11922
5545,,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,N,F,6929,,,9606.0,,,KB ,81115
5546,,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,N,A,6929,,,9606.0,,,KB ,81115
5547,,Homo sapiens,In vitro cytotoxicity of compound was tested against 9KB cells.,U,F,7083,,,9606.0,,,,22226
5548,,Rattus norvegicus,Cytotoxic concentration against 9L cells was determined on day 3,N,F,12446,,,10116.0,,,9L,80653
5549,,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells,N,F,15345,,,10116.0,,,9L,80653
5550,,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells; Not determined,N,F,15345,,,10116.0,,,9L,80653
5551,,Homo sapiens,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,N,F,6301,,,9606.0,,,A549,80682
5552,,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,N,F,4833,,,9606.0,,,A549,80682
5553,,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,N,F,4833,,,9606.0,,,A549,80682
5554,,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,N,F,4833,,,9606.0,,,A549,80682
5555,,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line,N,F,13330,,,9606.0,,,A549,80682
5556,,Homo sapiens,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,D,F,17517,,,9606.0,,,A549,25
5557,,Homo sapiens,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",D,F,17517,,,9606.0,,,A549,25
5558,,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma",N,F,14425,,,9606.0,,,A549,80682
5559,,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma.",N,F,14425,,,9606.0,,,A549,80682
5560,,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,F,5228,,,9606.0,,,A549,80682
5561,,Homo sapiens,Cytotoxic activity against human lung cancer A549 cell line was determined,N,F,5351,,,9606.0,,,A549,80682
5562,,Homo sapiens,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,N,F,12198,,,9606.0,,,A549,80682
5563,,Homo sapiens,Cytotoxicity concentration against human lung carcinoma A-549 cell line,N,F,13891,,,9606.0,,,A549,80682
5564,,Homo sapiens,Cytotoxicity in A549 (human carcinoma) cell line.,N,F,5677,,,9606.0,,,A549,80682
5565,,Homo sapiens,Cytotoxicity on lung carcinoma (A-549) cell line,N,F,13788,,,9606.0,,,A549,80682
5566,,Homo sapiens,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,N,F,13384,,,9606.0,,,A549,80682
5567,,Homo sapiens,Effective dose of compound against replication of A549 cell line was evaluated,N,F,6726,,,9606.0,,,A549,80682
5568,,Homo sapiens,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,N,F,3455,,,9606.0,,,A549,80682
5569,,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),N,F,5726,,,9606.0,,,A549,80682
5570,,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,N,F,5726,,,9606.0,,,A549,80682
5571,,Homo sapiens,The compound was evaluated for antiproliferative activity against A549 cell line,N,F,3936,,,9606.0,,,A549,80682
5572,,Homo sapiens,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,N,F,14991,,,9606.0,,,A549,80682
5573,,Homo sapiens,Concentration required for growth inhibition of human lung carcinoma cell line A549,N,F,5243,,,9606.0,,,A549,80682
5574,,Homo sapiens,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,N,F,12858,,,9606.0,,,A549,80682
5575,,Homo sapiens,Growth inhibition against A549 cell line was evaluated,N,F,6776,,,9606.0,,,A549,80682
5576,,Homo sapiens,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,N,F,16558,,,9606.0,,,A549,80682
5577,,Homo sapiens,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,N,F,4583,,,9606.0,,,A549,80682
5578,,Homo sapiens,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,N,F,13514,,,9606.0,,,A549,80682
5579,,Homo sapiens,Chemosensitivity against DT-diaphorase rich A549 cell lines,N,F,15166,,,9606.0,,,A549,80682
5580,,Homo sapiens,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,N,F,13873,,,9606.0,,,A549,80682
5581,,Homo sapiens,In vitro cytotoxicity against human A549 (lung cancer) cell line.,N,F,6447,,,9606.0,,,A549,80682
5582,,Homo sapiens,In vitro antitumor activity against A549 (lung) human tumor cell lines.,N,F,2068,,,9606.0,,,A549,80682
5583,,Homo sapiens,In vitro cytotoxic activity against human lung carcinoma A549 cell line,N,F,1863,,,9606.0,,,A549,80682
5584,,Homo sapiens,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,N,F,13873,,,9606.0,,,A549,80682
5585,,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,N,F,13873,,,9606.0,,,A549,80682
5586,,Homo sapiens,Tested against A549 lung carcinoma in the sulforhodamine B assay.,N,F,13873,,,9606.0,,,A549,80682
5587,,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),N,F,579,,,9606.0,,,A549,80682
5588,,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,N,F,579,,,9606.0,,,A549,80682
5589,,Homo sapiens,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,N,F,4584,,,9606.0,,,A549,80682
5590,,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,N,F,5421,,,9606.0,,,A549,80682
5591,,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,N,F,5421,,,9606.0,,,A549,80682
5592,,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,N,F,5421,,,9606.0,,,A549,80682
5593,,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,N,F,5421,,,9606.0,,,A549,80682
5594,,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,N,F,14188,,,9606.0,,,A549,80682
5595,,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,N,F,14188,,,9606.0,,,A549,80682
5596,,Homo sapiens,Compound was tested for the growth inhibition of A549 lung tumor cell line,N,F,15354,,,9606.0,,,A549,80682
5597,,Homo sapiens,Growth inhibition of human non-small-lung carcinoma (A549) cell line,N,F,14253,,,9606.0,,,A549,80682
5598,,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,N,F,13873,,,9606.0,,,A549,80682
5599,,Canis lupus familiaris,Oral bioavailability in dog (conscious),N,A,3043,In vivo,,9615.0,,,,50588
5600,,Canis lupus familiaris,Compound was evaluated for the oral bioavailability after oral administration in dog.,N,A,3045,In vivo,,9615.0,,,,50588
5601,,Canis lupus familiaris,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,N,A,3022,In vivo,,9615.0,,,,50588
5602,,Canis lupus familiaris,Oral bioavailability in dog,N,A,4453,In vivo,,9615.0,,,,50588
5603,,Canis lupus familiaris,Oral bioavailability in dog,N,A,1696,In vivo,,9615.0,,,,50588
5604,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5045,In vivo,,9615.0,,,,50588
5605,,Canis lupus familiaris,Oral bioavailability in dog (fasted),N,A,5356,In vivo,,9615.0,,,,50588
5606,,Canis lupus familiaris,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,N,A,17764,In vivo,,9615.0,,,,50588
5607,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6448,In vivo,,9615.0,,,,50588
5608,,Canis lupus familiaris,Oral bioavailability in dog,N,A,1475,In vivo,,9615.0,,,,50588
5609,,Canis lupus familiaris,Percent bioavailability in dog,N,A,3788,In vivo,,9615.0,,,,50588
5610,,Canis lupus familiaris,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,N,A,3639,In vivo,,9615.0,,,,50588
5611,,Canis lupus familiaris,Oral bioavailability in dog,N,A,13397,In vivo,,9615.0,,,,50588
5612,,Canis lupus familiaris,The compound was evaluated for bioavailability in dogs; 34-44,N,A,2137,In vivo,,9615.0,,,,50588
5613,,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),N,A,2959,In vivo,,9615.0,,,,50588
5614,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6448,In vivo,,9615.0,,,,50588
5615,,Canis lupus familiaris,8 hour trough Blood level in dog was measured after administration of compound,N,A,6084,,,9615.0,,,,50588
5616,,Canis lupus familiaris,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,N,A,3639,In vivo,,9615.0,,Plasma,,50588
5617,,Canis lupus familiaris,C24 after oral administration at 5 mg/kg,N,A,6316,,,9615.0,,,,50588
5618,,Canis lupus familiaris,Clearance after oral and iv dosing in dogs,N,A,5238,,,9615.0,,,,50588
5619,,Canis lupus familiaris,Clearance of the drug was measured in the plasma of dog,N,A,17796,,,9615.0,,Plasma,,50588
5620,,Canis lupus familiaris,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,N,A,2652,,,9615.0,,,,50588
5621,,Canis lupus familiaris,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,A,5654,In vivo,,9615.0,,,,50588
5622,,Canis lupus familiaris,Clearance of compound was determined in dogs,N,A,6621,In vivo,,9615.0,,,,50588
5623,,Canis lupus familiaris,Clearance on i.v. administration of 2 mg/kg was measured in dog,N,A,6505,In vivo,,9615.0,,,,50588
5624,,Canis lupus familiaris,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,A,5802,In vivo,,9615.0,,,,50588
5625,,Canis lupus familiaris,Plasma clearance in dog was determined,N,A,17267,In vivo,,9615.0,,,,50588
5626,,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,A,4521,In vivo,,9615.0,,,,50588
5627,,Canis lupus familiaris,Plasma clearance in dog after administration of 0.25 mg/kg iv,N,A,6535,In vivo,,9615.0,,,,50588
5628,,Canis lupus familiaris,Plasma clearance in dog after administration of 1 mg/kg iv,N,A,6535,In vivo,,9615.0,,,,50588
5629,,Canis lupus familiaris,Plasma clearance in dogs,N,A,6535,In vivo,,9615.0,,,,50588
5630,,Canis lupus familiaris,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,N,A,5542,In vivo,,9615.0,,,,50588
5631,,Canis lupus familiaris,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,N,A,5199,In vivo,,9615.0,,,,50588
5632,,Canis lupus familiaris,Plasma clearance after 15 mg/kg iv dose in Dogs,N,A,16907,In vivo,,9615.0,,,,50588
5633,,Canis lupus familiaris,Plasma clearance after 30 mg/kg po dose in Dogs,N,A,16907,In vivo,,9615.0,,,,50588
5634,,Canis lupus familiaris,Plasma administration to dogs,N,A,16367,In vivo,,9615.0,,,,50588
5635,,Canis lupus familiaris,Plasma clearance was determined,N,A,5505,In vivo,,9615.0,,,,50588
5636,,Canis lupus familiaris,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,N,A,6215,In vivo,,9615.0,,,,50588
5637,,Canis lupus familiaris,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,N,A,1466,In vivo,,9615.0,,,,50588
5638,Microsomes,Homo sapiens,Intrinsic clearance in human liver microsomes,S,A,5007,In vitro,,9606.0,,Liver,,102164
5639,Microsomes,Homo sapiens,Intrinsic clearance in human liver microsomes,S,A,5007,In vitro,,9606.0,,Liver,,102164
5640,,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,A,16452,In vivo,,9615.0,,,,50588
5641,,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,A,16452,In vivo,,9615.0,,,,50588
5642,,Canis lupus familiaris,Clearance in dog (dose 1 mg/kg i.v.),N,A,16452,In vivo,,9615.0,,,,50588
5643,,Canis lupus familiaris,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,N,A,6221,In vivo,,9615.0,,,,50588
5644,,Canis lupus familiaris,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,A,5007,In vivo,,9615.0,,,,50588
5645,,Canis lupus familiaris,Plasma clearance after peroral administration at 10 mpk in dog,N,A,5668,In vivo,,9615.0,,,,50588
5646,,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mpk in dog,N,A,5668,In vivo,,9615.0,,,,50588
5647,,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mg/kg in dog,N,A,5668,In vivo,,9615.0,,,,50588
5648,,Canis lupus familiaris,Plasma clearance was measured in dog,N,A,15660,In vivo,,9615.0,,,,50588
5649,,Canis lupus familiaris,Plasma clearance was measured in dog,N,A,15660,In vivo,,9615.0,,,,50588
5650,,Canis lupus familiaris,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,N,A,5983,In vivo,,9615.0,,,,50588
5651,,Canis lupus familiaris,Total clearance was determined after 0.1 mg/kg iv administration in dog,N,A,5600,In vivo,,9615.0,,,,50588
5652,,Canis lupus familiaris,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,N,A,17764,In vivo,,9615.0,,,,50588
5653,,Canis lupus familiaris,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,N,A,6039,In vivo,,9615.0,,,,50588
5654,,Canis lupus familiaris,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,N,A,6039,In vivo,,9615.0,,,,50588
5655,,Canis lupus familiaris,Clearance after peroral administration of 0.2 mg/kg in dog was determined,N,A,6039,In vivo,,9615.0,,,,50588
5656,,Canis lupus familiaris,Clearance by intravenous administration of 1.2 mg/kg in dog,N,A,4368,In vivo,,9615.0,,,,50588
5657,,Canis lupus familiaris,Clearance by iv administration in dogs at a dose of 1 mg/kg,N,A,4305,In vivo,,9615.0,,,,50588
5658,,Canis lupus familiaris,Clearance value was evaluated in dog plasma,N,A,1918,In vivo,,9615.0,,Plasma,,50588
5659,,Canis lupus familiaris,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,N,A,6005,In vivo,,9615.0,,,,50588
5660,,Canis lupus familiaris,Compound was tested for plasma clearance in dog,N,A,4839,In vivo,,9615.0,,Plasma,,50588
5661,,Canis lupus familiaris,Pharmacokinetic property (Plasma clearance) was measured in dog,N,A,4239,In vivo,,9615.0,,,,50588
5662,,Mus musculus,Area under curve when injected perorally in mice at a dose of 50 mg/kg,N,A,17729,,,10090.0,,,,50594
5663,,Mus musculus,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,N,A,17728,,,10090.0,,,,50594
5664,,Mus musculus,Area under curve value in mouse at a dose of 10 mg/kg,N,A,5302,,,10090.0,,,,50594
5665,,Mus musculus,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,N,A,5506,,,10090.0,,,,50594
5666,,Mus musculus,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,N,A,5506,,,10090.0,,,,50594
5667,,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,N,F,17764,,,10090.0,,,,50594
5668,,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,N,F,17764,,,10090.0,,,,50594
5669,,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,N,F,17764,,,10090.0,,,,50594
5670,,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,N,F,17764,,,10090.0,,,,50594
5671,,Mus musculus,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,N,A,17764,,,10090.0,,,,50594
5672,,Mus musculus,Area under curve was determined for the compound at 24 mg/Kg,N,A,17753,,,10090.0,,,,50594
5673,,Mus musculus,Area under curve was determined for the compound at 40 mg/Kg,N,A,17753,,,10090.0,,,,50594
5674,,Mus musculus,Area under curve was determined for the compound at 5 mg/Kg,N,A,17753,,,10090.0,,,,50594
5675,,Mus musculus,Area under the curve for the compound is obtained at dose 25 mg/kg,N,A,3132,,,10090.0,,,,50594
5676,,Mus musculus,Area under the curve for the compound was obtained when tested in mouse,N,A,3132,,,10090.0,,,,50594
5677,,Mus musculus,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,N,A,17837,,,10090.0,,,,50594
5678,,Mus musculus,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,N,A,17837,,,10090.0,,,,50594
5679,,Mus musculus,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,N,A,6062,,,10090.0,,,,50594
5680,,Mus musculus,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,N,A,4066,,,10090.0,,,,50594
5681,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),N,A,16597,,,10090.0,,,,50594
5682,,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,N,A,14239,,,10090.0,,,,50594
5683,,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,N,A,14239,,,10090.0,,,,50594
5684,,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, area under curve",N,A,4890,,,10090.0,,,,50594
5685,,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),N,A,429,,,10090.0,,,,50594
5686,,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),N,A,429,,,10090.0,,,,50594
5687,,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,N,A,5969,,,10090.0,,,,50594
5688,,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,N,A,5969,,,10090.0,,,,50594
5689,,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,A,5969,,,10090.0,,,,50594
5690,,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,N,A,6091,,,10090.0,,,,50594
5691,,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,N,A,6091,,,10090.0,,,,50594
5692,,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,N,A,6091,,,10090.0,,,,50594
5693,,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,N,A,6091,,,10090.0,,,,50594
5694,,Mus musculus,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,N,A,6178,,,10090.0,,,,50594
5695,,Mus musculus,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,N,A,6178,,,10090.0,,,,50594
5696,,Mus musculus,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",N,A,6619,,,10090.0,,,,50594
5697,,Mus musculus,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",N,A,6619,,,10090.0,,,,50594
5698,,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",N,A,3760,,,10090.0,,,,50594
5699,,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",N,A,3760,,,10090.0,,,,50594
5700,,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",N,A,3760,,,10090.0,,,,50594
5701,,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",N,A,3760,,,10090.0,,,,50594
5702,,Mus musculus,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,N,A,3192,,,10090.0,,,,50594
5703,,Mus musculus,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,N,A,3192,,,10090.0,,,,50594
5704,,Mus musculus,Area under the curve was evaluated in mice after intravenous administration,N,A,2675,,,10090.0,,,,50594
5705,,Mus musculus,Area under the curve was evaluated in mice after oral administration,N,A,2675,,,10090.0,,,,50594
5706,,Mus musculus,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,N,A,16597,,,10090.0,,Plasma,,50594
5707,,Mus musculus,AUC total value at a dose of 10 mg/kg peroral administration in mice.,N,A,16597,,,10090.0,,Plasma,,50594
5708,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),N,A,16597,,,10090.0,,,,50594
5709,,Mus musculus,AUMC after intraperitoneal administration of 100 mg/kg in mice,N,A,17734,,,10090.0,,,,50594
5710,,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Blood,,50594
5711,,,The compound was tested in vitro for anticancer activity against 9L cells,N,F,15345,,,,,,9L,80653
5712,,Rattus norvegicus,Anti proliferation activity determined; Weak effect,U,F,2181,,,10116.0,,,,22226
5713,,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,U,F,2181,,,10116.0,,,,22226
5714,,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,U,F,2181,,,10116.0,,,,22226
5715,,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,U,F,2181,,,10116.0,,,,22226
5716,,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method,U,F,10486,,,10090.0,,,,22226
5717,,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method.,U,F,10486,,,10090.0,,,,22226
5718,,,Partition coefficient (logD6.5),U,A,15508,,,,,,,22224
5719,,Homo sapiens,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,N,F,5242,,,9606.0,,,A2780,81034
5720,,Homo sapiens,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),N,F,16167,,,9606.0,,,A-375,80018
5721,,Homo sapiens,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,N,F,4782,,,9606.0,,,A-431,80852
5722,,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,D,F,16093,,,9606.0,,,A-431,9
5723,,Homo sapiens,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,N,F,2596,,,9606.0,,,A498,80021
5724,,Homo sapiens,in vitro cytotoxicity against A 498 cancer cell line,N,F,2596,,,9606.0,,,A498,80021
5725,,Homo sapiens,In vitro cytotoxic activity against renal (A 498) cancer cell line.,N,F,3239,,,9606.0,,,A498,80021
5726,,Homo sapiens,Cytotoxic activity against A 498 renal cancer cell lines.,N,F,1847,,,9606.0,,,A498,80021
5727,,Homo sapiens,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,N,F,10553,,,9606.0,,,A498,80021
5728,,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,U,F,16219,,,1280.0,,,,22226
5729,,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,U,F,16219,,,1280.0,,,,22226
5730,,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,U,F,16219,,,1280.0,,,,22226
5731,,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,U,F,16219,,,1280.0,,,,22226
5732,,Homo sapiens,Inhibitory concentration required against A 549 lung cancer cell line,N,F,4782,,,9606.0,,,A549,80682
5733,,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,N,F,11805,,,9606.0,,,A549,80682
5734,,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,N,F,11805,,,9606.0,,,A549,80682
5735,,Homo sapiens,In vitro cytotoxicity against lung cancer A 549 cell lines,N,F,2007,,,9606.0,,,A549,80682
5736,,Homo sapiens,Compound was tested for its cytotoxicity against A 549 cell line,N,F,4594,,,9606.0,,,A549,80682
5737,,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",N,F,6018,,,9606.0,,,A549,80682
5738,,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",N,F,6018,,,9606.0,,,A549,80682
5739,,Homo sapiens,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,N,F,3599,,,9606.0,,,A549,80682
5740,,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,N,F,2551,,,9606.0,,,A549,80682
5741,,Homo sapiens,In vitro inhibition of A549 (human lung cancer) cell growth.,N,F,16132,,,9606.0,,,A549,80682
5742,,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,N,F,16132,,,9606.0,,,A549,80682
5743,,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,N,F,2551,,,9606.0,,,A549,80682
5744,,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),N,F,2551,,,9606.0,,,A549,80682
5745,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,U,F,11913,,,,,,,22226
5746,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,H,F,12621,In vivo,,,,,,104694
5747,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,H,F,12621,In vivo,,,,,,104694
5748,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,H,F,12621,In vivo,,,,,,104694
5749,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,H,F,12621,In vivo,,,,,,104694
5750,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,H,F,12621,In vivo,,,,,,104694
5751,,Homo sapiens,Inhibition of A-498 human Renal cell proliferation,N,F,3600,,,9606.0,,,A498,80021
5752,,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",U,F,1796,,,10116.0,,,,22226
5753,,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",U,F,1796,,,10116.0,,,,22226
5754,,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",U,F,1796,,,10116.0,,,,22226
5755,,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,N,F,16464,,,9606.0,,,A 172,80012
5756,,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,F,16464,,,9606.0,,,A 172,80012
5757,,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,F,16464,,,9606.0,,,A 172,80012
5758,,Homo sapiens,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,N,F,13617,,,9606.0,,,A549,80682
5759,,Homo sapiens,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,N,F,4584,,,9606.0,,,A549,80682
5760,,Homo sapiens,Cytotoxic activity evaluated against A549 tumor cells,N,F,13799,,,9606.0,,,A549,80682
5761,,Homo sapiens,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,N,F,16726,,,9606.0,,,A549,80682
5762,,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,N,F,16109,,,9606.0,,,A549,80682
5763,,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,N,F,16109,,,9606.0,,,A549,80682
5764,,Homo sapiens,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,N,F,15474,,,9606.0,,,A549,80682
5765,,Homo sapiens,Cytotoxicity of compound against A549 cell line,N,F,6851,,,9606.0,,,A549,80682
5766,,Homo sapiens,Cytotoxicity against human lung cell carcinoma A549 cell line,N,F,17534,,,9606.0,,,A549,80682
5767,,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,N,F,2621,,,9606.0,,,A549,80682
5768,,Homo sapiens,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,N,F,830,,,9606.0,,,A549,80682
5769,,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,N,F,14255,,,9606.0,,,A549,80682
5770,,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,N,F,14255,,,9606.0,,,A549,80682
5771,,Homo sapiens,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,N,F,1590,,,9606.0,,,A549,80682
5772,,Homo sapiens,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,N,F,6146,,,9606.0,,,A549,80682
5773,,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,F,17427,,,9606.0,,,A549,80682
5774,,Homo sapiens,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,N,F,5280,,,9606.0,,,A549,80682
5775,,Homo sapiens,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,N,F,16786,,,9606.0,,,A549,80682
5776,,Homo sapiens,In vitro cytotoxicity against A549 (human lung cancer),N,F,5895,,,9606.0,,,A549,80682
5777,,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,N,F,14297,,,9606.0,,,A549,80682
5778,,Homo sapiens,In vivo antiproliferative activity against A549 cell line,N,F,17824,,,9606.0,,,A549,80682
5779,,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549),N,F,14368,,,9606.0,,,A549,80682
5780,,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,N,F,14368,,,9606.0,,,A549,80682
5781,,Homo sapiens,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,N,F,14254,,,9606.0,,,A549,80682
5782,,Homo sapiens,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),N,F,15897,,,9606.0,,,A549,80682
5783,,Homo sapiens,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,N,F,13866,,,9606.0,,,A549,80682
5784,,Homo sapiens,Inhibitory activity of compound against human A549 lung carcinoma cell line.,N,F,13370,,,9606.0,,,A549,80682
5785,,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,N,F,4862,,,9606.0,,,A549,80682
5786,,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,N,F,4862,,,9606.0,,,A549,80682
5787,,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,N,F,4862,,,9606.0,,,A549,80682
5788,,Homo sapiens,Inhibitory concentration against A549 (lung cancer) cell line,N,F,15970,,,9606.0,,,A549,80682
5789,,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,N,F,17713,,,9606.0,,,A549,80682
5790,,Homo sapiens,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,N,F,4833,,,9606.0,,,A549,80682
5791,,Homo sapiens,Activity against A549 cancer cell line.,N,F,13736,,,9606.0,,,A549,80682
5792,,Homo sapiens,The compound was evaluated for cytotoxicity against A549 cell line,N,F,4312,,,9606.0,,,A549,80682
5793,,Homo sapiens,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,N,F,5421,,,9606.0,,,A549,80682
5794,,Homo sapiens,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,N,F,5421,,,9606.0,,,A549,80682
5795,,Homo sapiens,Growth inhibitory activity was measured for human A549 tumor cell line.,N,F,14717,,,9606.0,,,A549,80682
5796,,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,N,F,4634,,,9606.0,,,A549,80682
5797,,Homo sapiens,Inhibitory activity against A549 cell line; inactive,N,F,1149,,,9606.0,,,A549,80682
5798,,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,N,F,5421,,,9606.0,,,A549,80682
5799,,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,N,F,5421,,,9606.0,,,A549,80682
5800,,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,N,F,5421,,,9606.0,,,A549,80682
5801,,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),N,F,3320,,,9606.0,,,A549,80682
5802,,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),N,F,3320,,,9606.0,,,A549,80682
5803,,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),N,F,3320,,,9606.0,,,A549,80682
5804,,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),N,F,3320,,,9606.0,,,A549,80682
5805,,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),N,F,3320,,,9606.0,,,A549,80682
5806,,Homo sapiens,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,N,F,5726,,,9606.0,,,A549,80682
5807,,Canis lupus familiaris,Plasma clearance (in vivo) in mongrel dogs was determined,N,A,17800,In vivo,,9615.0,,,,50588
5808,,Canis lupus familiaris,Plasma clearance was measured in dog,N,A,5985,In vivo,,9615.0,,,,50588
5809,,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,N,A,5530,In vivo,,9615.0,,,,50588
5810,,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,N,A,5530,In vivo,,9615.0,,,,50588
5811,,Canis lupus familiaris,Tested for plasma clearance in dog,N,A,4839,In vivo,,9615.0,,Plasma,,50588
5812,,Canis lupus familiaris,The compound was tested for clearance in dog plasma.,N,A,3639,In vivo,,9615.0,,,,50588
5813,,Canis lupus familiaris,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",N,A,4838,In vivo,,9615.0,,,,50588
5814,,Canis lupus familiaris,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,N,A,4137,In vivo,,9615.0,,,,50588
5815,,Canis lupus familiaris,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),N,A,5017,In vivo,,9615.0,,Plasma,,50588
5816,Microsomes,Canis lupus familiaris,In vitro clearance in dog liver microsomes,N,A,17538,In vitro,,9615.0,,Liver,,50588
5817,,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,N,A,6161,In vivo,,9615.0,,,,50588
5818,,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,N,A,6161,In vivo,,9615.0,,,,50588
5819,,Canis lupus familiaris,Plasma clearance in dog,N,A,1696,In vivo,,9615.0,,,,50588
5820,,Canis lupus familiaris,Clearance rate in dog,N,A,6762,In vivo,,9615.0,,,,50588
5821,,Canis lupus familiaris,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,N,A,5932,In vivo,,9615.0,,Plasma,,50588
5822,,Canis lupus familiaris,Clearance in dogs,N,A,6305,In vivo,,9615.0,,,,50588
5823,,Canis lupus familiaris,Plasma clearance in dogs,N,A,4942,In vivo,,9615.0,,,,50588
5824,,Canis lupus familiaris,Plasma clearance was determined,N,A,4219,In vivo,,9615.0,,,,50588
5825,,Canis lupus familiaris,Lower clearance in dog (i.v.) at 0.5 mpk,N,A,17853,In vivo,,9615.0,,,,50588
5826,,Canis lupus familiaris,Plasma clearance in Beagle dogs,N,A,4514,In vivo,,9615.0,,,,50588
5827,,Canis lupus familiaris,Plasma clearance (Clp) in dog,N,A,6448,In vivo,,9615.0,,,,50588
5828,,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,N,A,6227,In vivo,,9615.0,,,,50588
5829,,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog was determined,N,A,6227,In vivo,,9615.0,,,,50588
5830,,Canis lupus familiaris,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,N,A,6062,In vivo,,9615.0,,,,50588
5831,,Canis lupus familiaris,Plasma clearance of compound was determined in dog,N,A,6821,In vivo,,9615.0,,,,50588
5832,,Canis lupus familiaris,Plasma clearance after intravenous administration of 1 mg/kg in dog,N,A,4709,In vivo,,9615.0,,,,50588
5833,,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,A,4521,In vivo,,9615.0,,,,50588
5834,,Canis lupus familiaris,Plasma clearance in dog was determined,N,A,5374,In vivo,,9615.0,,,,50588
5835,,Canis lupus familiaris,Plasma clearance was calculated in dog,N,A,6057,In vivo,,9615.0,,,,50588
5836,,Canis lupus familiaris,Plasma clearance at the dose of 2 mg/kg in dog,N,A,4727,In vivo,,9615.0,,,,50588
5837,,Canis lupus familiaris,Plasma clearance in dog,N,A,5145,In vivo,,9615.0,,,,50588
5838,,Canis lupus familiaris,Plasma clearance in dog,N,A,17657,In vivo,,9615.0,,,,50588
5839,,Canis lupus familiaris,Plasma clearance in dog; Unable to calculate,N,A,17657,In vivo,,9615.0,,,,50588
5840,,Canis lupus familiaris,Plasma clearance in rhesus monkey,N,A,5145,In vivo,,9615.0,,,,50588
5841,,Canis lupus familiaris,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,A,6642,In vivo,,9615.0,,,,50588
5842,,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,A,6641,In vivo,,9615.0,,,,50588
5843,,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,A,6642,In vivo,,9615.0,,,,50588
5844,,Canis lupus familiaris,Plasma clearance was evaluated in dog,N,A,5472,In vivo,,9615.0,,,,50588
5845,,Canis lupus familiaris,Plasma clearance was evaluated in dog; Not tested,N,A,5472,In vivo,,9615.0,,,,50588
5846,,Canis lupus familiaris,Plasma clearance was evaluated in rhesus,N,A,5472,In vivo,,9615.0,,,,50588
5847,,Canis lupus familiaris,Plasma clearance was evaluated in rhesus; Not tested,N,A,5472,In vivo,,9615.0,,,,50588
5848,,Canis lupus familiaris,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,N,A,4257,In vivo,,9615.0,,,,50588
5849,,Canis lupus familiaris,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,A,6679,In vivo,,9615.0,,,,50588
5850,,Canis lupus familiaris,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,A,5546,In vivo,,9615.0,,,,50588
5851,,Canis lupus familiaris,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,A,6348,In vivo,,9615.0,,,,50588
5852,,Canis lupus familiaris,Clearance value at a dose of 0.2 mg/kg i.v.,N,A,5474,In vivo,,9615.0,,,,50588
5853,,Canis lupus familiaris,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,N,A,6316,In vivo,,9615.0,,Plasma,,50588
5854,,Canis lupus familiaris,Cmax after oral dose of compound at 3 mg/kg in dogs,N,A,17594,In vivo,,9615.0,,,,50588
5855,,Canis lupus familiaris,Cmax after single intravenous bolus of 1 mg/kg in dogs,N,A,17594,In vivo,,9615.0,,,,50588
5856,,Canis lupus familiaris,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,A,5802,In vivo,,9615.0,,,,50588
5857,,Canis lupus familiaris,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,N,A,6535,In vivo,,9615.0,,,,50588
5858,,Canis lupus familiaris,Cmax in dog after administration of 1 mg/kg iv,N,A,6535,In vivo,,9615.0,,,,50588
5859,,Canis lupus familiaris,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,N,A,1466,In vivo,,9615.0,,Plasma,,50588
5860,,Canis lupus familiaris,Cmax on p.o. administration of 10 mg/kg was measured in dog,N,A,6505,In vivo,,9615.0,,,,50588
5861,,Canis lupus familiaris,Cmax was determine after peroral administration at 10 mpk in dog,N,A,5668,In vivo,,9615.0,,,,50588
5862,,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mpk in dog,N,A,5668,In vivo,,9615.0,,,,50588
5863,,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mg/kg in dog,N,A,5668,In vivo,,9615.0,,,,50588
5864,,Canis lupus familiaris,Cmax after 0.3 mg/kg po administration in dog,N,A,5600,In vivo,,9615.0,,,,50588
5865,,Canis lupus familiaris,Cmax after peroral administration in dogs at 2.4 uM/kg,N,A,17764,In vivo,,9615.0,,,,50588
5866,,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg,N,A,6123,In vivo,,9615.0,,,,50588
5867,,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,N,A,6123,In vivo,,9615.0,,,,50588
5868,,Canis lupus familiaris,Cmax upon oral administration in male Beagle dog at 10 mg/kg,N,A,6757,In vivo,,9615.0,,,,50588
5869,,Canis lupus familiaris,Cmax value after 15 mg/kg iv dose in Dogs,N,A,16907,In vivo,,9615.0,,,,50588
5870,,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Blood,,50594
5871,,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Blood,,50594
5872,,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Bone,,50594
5873,,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Bone,,50594
5874,,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Bone,,50594
5875,,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,,,50594
5876,,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,,,50594
5877,,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,,,50594
5878,,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Heart,,50594
5879,,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Heart,,50594
5880,,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Heart,,50594
5881,,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Kidney,,50594
5882,,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Kidney,,50594
5883,,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Kidney,,50594
5884,,Mus musculus,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Intestine,,50594
5885,,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Intestine,,50594
5886,,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Intestine,,50594
5887,,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Liver,,50594
5888,,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Liver,,50594
5889,,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Liver,,50594
5890,,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Lung,,50594
5891,,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Lung,,50594
5892,,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Lung,,50594
5893,,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Muscle tissue,,50594
5894,,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Muscle tissue,,50594
5895,,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Muscle tissue,,50594
5896,,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,,,50594
5897,,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,,,50594
5898,,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,,,50594
5899,,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Intestine,,50594
5900,,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Intestine,,50594
5901,,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Intestine,,50594
5902,,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Spleen,,50594
5903,,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Spleen,,50594
5904,,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Spleen,,50594
5905,,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Stomach,,50594
5906,,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Stomach,,50594
5907,,Homo sapiens,Cytotoxicity against A-172 human tumor cell lines,N,F,2036,,,9606.0,,,A 172,80012
5908,,Homo sapiens,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,N,F,2357,,,9606.0,,,A 172,80012
5909,,Homo sapiens,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,N,F,1457,,,9606.0,,,A204,80014
5910,,Homo sapiens,Tested for antiproliferative activity against A-2780 tumoral cell line,N,F,4379,,,9606.0,,,A2780,81034
5911,,Homo sapiens,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,N,F,1093,,,9606.0,,,A-375,80018
5912,,Homo sapiens,Tested in vitro against A-375 cell line human melanoma,N,F,12152,,,9606.0,,,A-375,80018
5913,,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,N,F,16464,,,9606.0,,,A-427,80019
5914,,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,F,16464,,,9606.0,,,A-427,80019
5915,,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,N,F,16582,,,9606.0,,,A-427,80019
5916,,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,F,16464,,,9606.0,,,A-427,80019
5917,,Homo sapiens,Antitumor activity on A-427 lung carcinoma cell lines,N,F,10413,,,9606.0,,,A-427,80019
5918,,Homo sapiens,Cytotoxic activity against human A-427 lung tumor cell line,N,F,6418,,,9606.0,,,A-427,80019
5919,,Homo sapiens,In vitro antitumor effects against human A-427 cell lines.,N,F,17134,,,9606.0,,,A-427,80019
5920,,Homo sapiens,In vitro inhibition of A-427 (human lung cancer) cell growth.,N,F,16132,,,9606.0,,,A-427,80019
5921,,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,N,F,16132,,,9606.0,,,A-427,80019
5922,,Homo sapiens,Cytotoxic activity of compound against A-427 lung human tumor cell line,N,F,16780,,,9606.0,,,A-427,80019
5923,,Homo sapiens,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,N,F,4085,,,9606.0,,,A-431,80852
5924,,Homo sapiens,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,N,F,1276,,,9606.0,,,A498,80021
5925,,Homo sapiens,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,N,F,3498,,,9606.0,,,A498,80021
5926,,Homo sapiens,Cytotoxicity against human kidney carcinoma A-498cell lines,N,F,1169,,,9606.0,,,A498,80021
5927,,Homo sapiens,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,N,F,4450,,,9606.0,,,A498,80021
5928,,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,N,F,3311,,,9606.0,,,A498,80021
5929,,Homo sapiens,Antitumor cytotoxic activity against A-498 cell line was determined,N,F,4461,,,9606.0,,,A498,80021
5930,,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,N,F,3311,,,9606.0,,,A498,80021
5931,,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,N,F,3311,,,9606.0,,,A498,80021
5932,,Homo sapiens,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,N,F,1457,,,9606.0,,,A498,80021
5933,,Homo sapiens,In vitro inhibitory activity against A-498 ovarian cancer cell lines,N,F,3664,,,9606.0,,,A498,80021
5934,,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",N,F,15895,,,9606.0,,,A498,80021
5935,,Homo sapiens,Inhibition of growth lung non-small cell carcinoma A-549 cell line,N,F,11843,,,9606.0,,,A549,80682
5936,,Homo sapiens,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,N,F,11843,,,9606.0,,,A549,80682
5937,,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line,N,F,17705,,,9606.0,,,A549,80682
5938,,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,N,F,17705,,,9606.0,,,A549,80682
5939,,Homo sapiens,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,N,F,4369,,,9606.0,,,A549,80682
5940,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,N,F,4369,,,9606.0,,,A549,80682
5941,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,N,F,4369,,,9606.0,,,A549,80682
5942,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,N,F,4369,,,9606.0,,,A549,80682
5943,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,N,F,4369,,,9606.0,,,A549,80682
5944,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,N,F,4369,,,9606.0,,,A549,80682
5945,,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,N,F,4369,,,9606.0,,,A549,80682
5946,,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,N,F,4787,,,9606.0,,,A549,80682
5947,,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,N,F,4787,,,9606.0,,,A549,80682
5948,,Homo sapiens,Cytotoxic activity against A-549 cell line,N,F,6513,,,9606.0,,,A549,80682
5949,,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,N,F,6690,,,9606.0,,,A549,80682
5950,,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,N,F,6690,,,9606.0,,,A549,80682
5951,,Homo sapiens,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",N,F,12263,,,9606.0,,,A549,80682
5952,,Homo sapiens,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),N,F,1054,,,9606.0,,,A549,80682
5953,,Homo sapiens,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),N,F,1359,,,9606.0,,,A549,80682
5954,,Homo sapiens,Cytotoxic activity against human lung carcinoma (A-549) cell line,N,F,3547,,,9606.0,,,A549,80682
5955,,Homo sapiens,Cytotoxic activity towards A-549 cells,N,F,5771,,,9606.0,,,A549,80682
5956,,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",N,F,14425,,,9606.0,,,A549,80682
5957,,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma",N,F,14425,,,9606.0,,,A549,80682
5958,,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",N,F,14425,,,9606.0,,,A549,80682
5959,,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",N,F,14425,,,9606.0,,,A549,80682
5960,,Homo sapiens,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,N,F,5280,,,9606.0,,,A549,80682
5961,,Homo sapiens,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,N,F,15176,,,9606.0,,,A549,80682
5962,,Homo sapiens,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,N,F,15300,,,9606.0,,,A549,80682
5963,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,F,17824,,,9606.0,,,A549,80682
5964,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,F,17824,,,9606.0,,,A549,80682
5965,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,F,17824,,,9606.0,,,A549,80682
5966,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,F,17824,,,9606.0,,,A549,80682
5967,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,F,17824,,,9606.0,,,A549,80682
5968,,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",N,F,17824,,,9606.0,,,A549,80682
5969,,Homo sapiens,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),N,F,17528,,,9606.0,,,A549,80682
5970,,Homo sapiens,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,N,F,6870,,,9606.0,,,A549,80682
5971,,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,N,F,6870,,,9606.0,,,A549,80682
5972,,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,N,F,6870,,,9606.0,,,A549,80682
5973,,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,N,F,6870,,,9606.0,,,A549,80682
5974,,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,N,F,16726,,,9606.0,,,A549,80682
5975,,Homo sapiens,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",N,F,6170,,,9606.0,,,A549,80682
5976,,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,N,F,6583,,,9606.0,,,A549,80682
5977,,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,N,F,6583,,,9606.0,,,A549,80682
5978,,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,N,F,6583,,,9606.0,,,A549,80682
5979,,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,N,F,6583,,,9606.0,,,A549,80682
5980,,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,N,F,6583,,,9606.0,,,A549,80682
5981,,Homo sapiens,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,N,F,17321,,,9606.0,,,A549,80682
5982,,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,N,F,17528,,,9606.0,,,A549,80682
5983,,Homo sapiens,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,N,F,12888,,,9606.0,,,A549,80682
5984,,Homo sapiens,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,N,F,4312,,,9606.0,,,A549,80682
5985,,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,N,F,4312,,,9606.0,,,A549,80682
5986,,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,N,F,4312,,,9606.0,,,A549,80682
5987,,Mus musculus,In vitro antiproliferative activity against A549 cell line,N,F,17737,,,10090.0,,,A549,80682
5988,,,Synergism with indomethacin in A549 cells,N,F,6630,,,,,,A549,80682
5989,,,Synergism with tolmetin in A549 cells,N,F,6630,,,,,,A549,80682
5990,,,Synergism with sulindac in A549 cells,N,F,6630,,,,,,A549,80682
5991,,,Antagonism of indomethacin in A549 cells,N,F,6630,,,,,,A549,80682
5992,,,Antagonism of sulindac in A549 cells,N,F,6630,,,,,,A549,80682
5993,,,Antagonism of tolmetin in A549 cells,N,F,6630,,,,,,A549,80682
5994,,,Synergism with indomethacin in A549 cells,N,F,6630,,,,,,A549,80682
5995,,,Synergism with sulindac in A549 cells,N,F,6630,,,,,,A549,80682
5996,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,N,F,6630,,,,,,A549,80682
5997,,Canis lupus familiaris,Cmax value after 30 mg/kg po dose in Dogs,N,A,16907,In vivo,,9615.0,,,,50588
5998,,Canis lupus familiaris,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),N,A,5944,In vivo,,9615.0,,,,50588
5999,,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,N,A,5944,In vivo,,9615.0,,,,50588
6000,,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),N,A,5944,In vivo,,9615.0,,,,50588
6001,,Canis lupus familiaris,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,N,A,5944,In vivo,,9615.0,,,,50588
6002,,Canis lupus familiaris,Cmax value after administration of 4 mg/Kg oral dose in dog,N,A,2959,In vivo,,9615.0,,,,50588
6003,,Canis lupus familiaris,Cmax value in dog,N,A,6241,In vivo,,9615.0,,,,50588
6004,,Canis lupus familiaris,Cmax value in dogs after oral administration at 1 mg/kg,N,A,6241,In vivo,,9615.0,,,,50588
6005,,Canis lupus familiaris,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,N,A,2652,In vivo,,9615.0,,,,50588
6006,,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,N,A,1806,In vivo,,9615.0,,Plasma,,50588
6007,,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,N,A,1806,In vivo,,9615.0,,Plasma,,50588
6008,,Canis lupus familiaris,Concentration maxima after oral dosing in dogs,N,A,1021,In vivo,,9615.0,,,,50588
6009,,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,N,A,1021,In vivo,,9615.0,,,,50588
6010,,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,N,A,1021,In vivo,,9615.0,,,,50588
6011,,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,N,A,5444,In vivo,,9615.0,,,,50588
6012,,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,N,A,5444,In vivo,,9615.0,,,,50588
6013,,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog,N,A,5444,In vivo,,9615.0,,,,50588
6014,,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,N,A,5444,In vivo,,9615.0,,,,50588
6015,,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,N,A,5444,In vivo,,9615.0,,,,50588
6016,,Canis lupus familiaris,Cmax in dog plasma after oral dose (1 mg/kg),N,A,5130,In vivo,,9615.0,,Plasma,,50588
6017,,Canis lupus familiaris,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,N,A,3249,In vivo,,9615.0,,Plasma,,50588
6018,,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg,N,A,5473,In vivo,,9615.0,,Plasma,,50588
6019,,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg (oral),N,A,5474,In vivo,,9615.0,,Plasma,,50588
6020,,Canis lupus familiaris,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,N,A,4657,In vivo,,9615.0,,Plasma,,50588
6021,,Canis lupus familiaris,Maximum concentration of compound in dog was evaluated.,N,A,3031,In vivo,,9615.0,,,,50588
6022,,Canis lupus familiaris,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,N,A,4527,In vivo,,9615.0,,,,50588
6023,,Canis lupus familiaris,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,N,A,4186,In vivo,,9615.0,,,,50588
6024,,Canis lupus familiaris,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,A,5007,In vivo,,9615.0,,,,50588
6025,,Canis lupus familiaris,Maximum concentration obtained in dog plasma was determined,N,A,3132,In vivo,,9615.0,,Plasma,,50588
6026,,Canis lupus familiaris,Maximum concentration was determined,N,A,5006,In vivo,,9615.0,,,,50588
6027,,Canis lupus familiaris,Maximum concentration at the dose of 2 mg/kg in dog,N,A,4727,In vivo,,9615.0,,,,50588
6028,,Canis lupus familiaris,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,A,1916,In vivo,,9615.0,,,,50588
6029,,Canis lupus familiaris,Maximum concentration was evaluated in dog plasma,N,A,1918,In vivo,,9615.0,,Plasma,,50588
6030,,Canis lupus familiaris,Maximum concentration was evaluated after 75 min after administration in dog,N,A,3045,In vivo,,9615.0,,,,50588
6031,,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 17b,N,A,9579,In vivo,,9615.0,,Plasma,,50588
6032,,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 2b,N,A,9579,In vivo,,9615.0,,Plasma,,50588
6033,,Canis lupus familiaris,Maximum plasma concentration in dog,N,A,933,In vivo,,9615.0,,Plasma,,50588
6034,,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,N,A,17839,In vivo,,9615.0,,Plasma,,50588
6035,,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,N,A,17839,In vivo,,9615.0,,Plasma,,50588
6036,,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,N,A,17839,In vivo,,9615.0,,Plasma,,50588
6037,,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,N,A,17839,In vivo,,9615.0,,Plasma,,50588
6038,,Canis lupus familiaris,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,A,6348,In vivo,,9615.0,,Plasma,,50588
6039,,Canis lupus familiaris,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,N,A,16367,In vivo,,9615.0,,Plasma,,50588
6040,,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,A,1337,In vivo,,9615.0,,Plasma,,50588
6041,,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,A,1337,In vivo,,9615.0,,Plasma,,50588
6042,,Canis lupus familiaris,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,N,A,5199,In vivo,,9615.0,,Plasma,,50588
6043,,Canis lupus familiaris,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,N,A,17650,In vivo,,9615.0,,Plasma,,50588
6044,,Canis lupus familiaris,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,N,A,6679,In vivo,,9615.0,,Plasma,,50588
6045,,Canis lupus familiaris,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,N,A,5356,In vivo,,9615.0,,Plasma,,50588
6046,,Canis lupus familiaris,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,N,A,5356,In vivo,,9615.0,,Plasma,,50588
6047,,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,N,A,6227,In vivo,,9615.0,,Plasma,,50588
6048,,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,N,A,6227,In vivo,,9615.0,,Plasma,,50588
6049,,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,N,A,6227,In vivo,,9615.0,,Plasma,,50588
6050,,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,N,A,6227,In vivo,,9615.0,,Plasma,,50588
6051,,Canis lupus familiaris,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,N,A,3598,In vivo,,9615.0,,Plasma,,50588
6052,,Canis lupus familiaris,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,N,A,4368,In vivo,,9615.0,,,,50588
6053,,Canis lupus familiaris,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,N,A,6265,In vivo,,9615.0,,,,50588
6054,,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Stomach,,50594
6055,,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,A,7767,In vivo,,10090.0,,Urine,,50594
6056,,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,N,A,7767,In vivo,,10090.0,,Urine,,50594
6057,,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,N,A,7767,In vivo,,10090.0,,Urine,,50594
6058,,Mus musculus,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,N,A,17811,,,10090.0,,,,50594
6059,,Mus musculus,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,N,A,17811,,,10090.0,,,,50594
6060,,Mus musculus,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),N,A,17827,,,10090.0,,,,50594
6061,,Mus musculus,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),N,A,17827,,,10090.0,,Blood,,50594
6062,,Mus musculus,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),N,A,17827,,,10090.0,,,,50594
6063,,Mus musculus,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),N,A,17827,,,10090.0,,,,50594
6064,,Mus musculus,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),N,A,17827,,,10090.0,,,,50594
6065,,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),N,A,17827,,,10090.0,,Blood,,50594
6066,,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),N,A,17827,,,10090.0,,Blood,,50594
6067,,Mus musculus,Compound was evaluated for washout rate in mice (Radiolabeled compound),N,A,17827,,,10090.0,,,,50594
6068,,Mus musculus,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,N,A,17827,,,10090.0,,,,50594
6069,,Mus musculus,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,A,17827,,,10090.0,,,,50594
6070,,Mus musculus,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,A,17827,,,10090.0,,,,50594
6071,,Mus musculus,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,A,17827,,,10090.0,,,,50594
6072,,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,N,A,17257,,,10090.0,,,,50594
6073,,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,N,A,17257,,,10090.0,,,,50594
6074,,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,N,A,17257,,,10090.0,,,,50594
6075,,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,N,A,17257,,,10090.0,,,,50594
6076,,Mus musculus,Time at maximum activity in mice (Radiolabeled compound),N,A,17827,,,10090.0,,,,50594
6077,,Mus musculus,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,N,A,3760,,,10090.0,,,,50594
6078,,Mus musculus,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,N,A,3760,,,10090.0,,,,50594
6079,,Mus musculus,Binding towards mouse plasma protein at 10 uM,N,A,17409,,,10090.0,,,,50594
6080,,Mus musculus,Binding towards mouse plasma protein at 100 uM,N,A,17409,,,10090.0,,,,50594
6081,,Mus musculus,Bioavailability was evaluated in mice after intravenous administration,N,A,2675,In vivo,,10090.0,,,,50594
6082,,Mus musculus,Bioavailability was evaluated in mice after oral administration,N,A,2675,In vivo,,10090.0,,,,50594
6083,,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,N,A,3132,In vivo,,10090.0,,,,50594
6084,,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,N,A,3132,In vivo,,10090.0,,,,50594
6085,,Mus musculus,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,N,A,16597,In vivo,,10090.0,,,,50594
6086,,Mus musculus,Oral bioavailability in mouse,N,A,2862,In vivo,,10090.0,,,,50594
6087,,Mus musculus,Oral bioavailability after intravenous administration in mice at 24 uM/kg,N,A,17764,In vivo,,10090.0,,,,50594
6088,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Brain,,50594
6089,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Brain,,50594
6090,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Brain,,50594
6091,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Brain,,50594
6092,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Brain,,50594
6093,,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Brain,,50594
6094,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Heart,,50594
6095,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Heart,,50594
6096,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Heart,,50594
6097,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Heart,,50594
6098,,Homo sapiens,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),N,F,1276,,,9606.0,,,A549,80682
6099,,Homo sapiens,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,N,F,3498,,,9606.0,,,A549,80682
6100,,Homo sapiens,Cytotoxicity against human lung carcinoma A-549 cell lines,N,F,1169,,,9606.0,,,A549,80682
6101,,Homo sapiens,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,N,F,4450,,,9606.0,,,A549,80682
6102,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549,N,F,358,,,9606.0,,,A549,80682
6103,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,N,F,358,,,9606.0,,,A549,80682
6104,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,N,F,358,,,9606.0,,,A549,80682
6105,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,N,F,358,,,9606.0,,,A549,80682
6106,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,N,F,358,,,9606.0,,,A549,80682
6107,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,N,F,358,,,9606.0,,,A549,80682
6108,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,N,F,358,,,9606.0,,,A549,80682
6109,,Homo sapiens,In vitro cytotoxicity against A-549 human lung cancer cells,N,F,15167,,,9606.0,,,A549,80682
6110,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,N,F,4139,,,9606.0,,,A549,80682
6111,,Homo sapiens,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,N,F,833,,,9606.0,,,A549,80682
6112,,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,N,F,15718,,,9606.0,,,A549,80682
6113,,Homo sapiens,Tested in vitro for cytotoxicity against A-549 lung cancer cells,N,F,12373,,,9606.0,,,A549,80682
6114,,Homo sapiens,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,N,F,637,,,9606.0,,,A549,80682
6115,,Homo sapiens,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,N,F,14867,,,9606.0,,,A549,80682
6116,,Homo sapiens,Antitumor cytotoxic activity against A-549 cell line was determined,N,F,4461,,,9606.0,,,A549,80682
6117,,Homo sapiens,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",N,F,5406,,,9606.0,,,A549,80682
6118,,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,N,F,4457,,,9606.0,,,A549,80682
6119,,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,N,F,1386,,,9606.0,,,A549,80682
6120,,Homo sapiens,Antitumoral activity was assayed against A-549 cell line,N,F,3265,,,9606.0,,,A549,80682
6121,,Homo sapiens,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,N,F,2359,,,9606.0,,,A549,80682
6122,,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,N,F,4457,,,9606.0,,,A549,80682
6123,,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,F,12454,,,9606.0,,,A549,80682
6124,,Homo sapiens,Compound was tested for inhibition of cell growth of A-549 cells,N,F,1481,,,9606.0,,,A549,80682
6125,,Homo sapiens,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,N,F,1750,,,9606.0,,,A549,80682
6126,,Homo sapiens,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,N,F,5065,,,9606.0,,,A549,80682
6127,,Homo sapiens,In vitro cytotoxicity against A549-human lung carcinoma cells.,N,F,808,,,9606.0,,,A549,80682
6128,,Homo sapiens,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,N,F,16364,,,9606.0,,,A549,80682
6129,,Homo sapiens,Cytotoxic activity against A-549 cell lines.,N,F,1847,,,9606.0,,,A549,80682
6130,,Homo sapiens,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,N,F,1747,,,9606.0,,,A549,80682
6131,,Homo sapiens,Cytotoxicity against human A549 non small cell lung cell lines,N,F,1003,,,9606.0,,,A549,80682
6132,,Homo sapiens,Inhibition of cell growth in (A-549) lung cell line,N,F,15313,,,9606.0,,,A549,80682
6133,,Homo sapiens,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,N,F,3122,,,9606.0,,,A549,80682
6134,,Homo sapiens,In vitro antitumor activity against A-549 tumor cells.,N,F,16049,,,9606.0,,,A549,80682
6135,,Homo sapiens,In vitro antitumor effects against human A-549 cell lines.,N,F,17134,,,9606.0,,,A549,80682
6136,,Homo sapiens,In vitro cytotoxic activity of compound against A-549 cell line,N,F,6406,,,9606.0,,,A549,80682
6137,,Homo sapiens,In vitro cytotoxicity against human lung carcinoma A-549 cell line,N,F,627,,,9606.0,,,A549,80682
6138,,Homo sapiens,In vitro cytotoxicity against human non-small cell lung carcinoma A549,N,F,12307,,,9606.0,,,A549,80682
6139,,Homo sapiens,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,N,F,17861,,,9606.0,,,A549,80682
6140,,Homo sapiens,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,N,F,6682,,,9606.0,,,A549,80682
6141,,Homo sapiens,Inhibitory concentration of compound against A-549 cell line,N,F,6663,,,9606.0,,,A549,80682
6142,,Homo sapiens,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,N,F,2454,,,9606.0,,,A549,80682
6143,,Homo sapiens,cytotoxic activity against leukemia (A-549) cancer cell line,N,F,14709,,,9606.0,,,A549,80682
6144,,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,N,F,15718,,,9606.0,,,A549,80682
6145,,Homo sapiens,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,N,F,15718,,,9606.0,,,A549,80682
6146,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),N,F,17130,,,9606.0,,,A549,80682
6147,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),N,F,17130,,,9606.0,,,A549,80682
6148,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),N,F,17130,,,9606.0,,,A549,80682
6149,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),N,F,17130,,,9606.0,,,A549,80682
6150,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,N,F,6630,,,,,,A549,80682
6151,,Homo sapiens,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,N,F,16726,,,9606.0,,,A549,80682
6152,,Homo sapiens,Cytotoxicity against A549 cells; No cytotoxicity,N,F,17846,,,9606.0,,,A549,80682
6153,,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines,N,F,3415,,,9606.0,,,A549,80682
6154,,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,N,F,3415,,,9606.0,,,A549,80682
6155,,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,N,F,5609,,,9606.0,,,A549,80682
6156,,Homo sapiens,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6157,,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6158,,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6159,,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6160,,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6161,,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6162,,Homo sapiens,Inhibition of A549 human lung tumor cell proliferation,N,F,16295,,,9606.0,,,A549,80682
6163,,Homo sapiens,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",N,F,16825,,,9606.0,,,A549,80682
6164,,Homo sapiens,In vitro cytotoxicity against human tumor cell line A549,N,F,3439,,,9606.0,,,A549,80682
6165,,Homo sapiens,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,N,F,10870,,,9606.0,,,A549,80682
6166,,Homo sapiens,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,N,F,4845,,,9606.0,,,A549,80682
6167,,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,N,F,5822,,,9606.0,,,A549,80682
6168,,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,N,F,5822,,,9606.0,,,A549,80682
6169,,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,N,F,5822,,,9606.0,,,A549,80682
6170,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,N,F,16381,,,9606.0,,,A549,80682
6171,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,N,F,16381,,,9606.0,,,A549,80682
6172,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,N,F,16381,,,9606.0,,,A549,80682
6173,,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,N,F,5609,,,9606.0,,,A549,80682
6174,,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,N,F,4644,,,9606.0,,,A549,80682
6175,,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,N,F,4644,,,9606.0,,,A549,80682
6176,,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,N,F,4644,,,9606.0,,,A549,80682
6177,,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,N,F,4644,,,9606.0,,,A549,80682
6178,,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,N,F,5822,,,9606.0,,,A549,80682
6179,,Homo sapiens,Percentage inhibition of human lung carcinoma (A549) cell lines,N,F,3415,,,9606.0,,,A549,80682
6180,,Homo sapiens,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,N,F,16726,,,9606.0,,,A549,80682
6181,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",N,F,17206,,,9606.0,,,A549,80682
6182,,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,N,F,17206,,,9606.0,,,A549,80682
6183,,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,N,F,17206,,,9606.0,,,A549,80682
6184,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",N,F,17206,,,9606.0,,,A549,80682
6185,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",N,F,17206,,,9606.0,,,A549,80682
6186,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",N,F,17206,,,9606.0,,,A549,80682
6187,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",N,F,17206,,,9606.0,,,A549,80682
6188,,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",N,F,17206,,,9606.0,,,A549,80682
6189,,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6190,,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6191,,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,N,F,16726,,,9606.0,,,A549,80682
6192,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6193,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6194,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6195,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6196,,Canis lupus familiaris,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,N,A,6084,In vivo,,9615.0,,,,50588
6197,,Canis lupus familiaris,Pharmacokinetic activity (Cmax) in dog,N,A,6084,In vivo,,9615.0,,,,50588
6198,,Canis lupus familiaris,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,A,4809,In vivo,,9615.0,,,,50588
6199,,Canis lupus familiaris,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,N,A,5983,In vivo,,9615.0,,,,50588
6200,,Canis lupus familiaris,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,N,A,6251,In vivo,,9615.0,,,,50588
6201,,Canis lupus familiaris,Cmax in dog plasma after 30mg/kg oral dose,N,A,5932,In vivo,,9615.0,,Plasma,,50588
6202,,Canis lupus familiaris,Tested for the peak blood level in dog,N,A,4273,In vivo,,9615.0,,Blood,,50588
6203,,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",N,A,5313,In vivo,,9615.0,,,,50588
6204,,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",N,A,5313,In vivo,,9615.0,,,,50588
6205,,Canis lupus familiaris,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,N,A,6221,In vivo,,9615.0,,Blood,,50588
6206,,Canis lupus familiaris,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,N,A,4709,,,9615.0,,,,50588
6207,,Canis lupus familiaris,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,N,A,167,,,9615.0,,,,50588
6208,,Canis lupus familiaris,Final plasma concentration in dogs after oral administration at 1 mg/kg,N,A,6241,,,9615.0,,Plasma,,50588
6209,,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,N,A,344,,,9615.0,,,,50588
6210,,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,N,A,344,,,9615.0,,,,50588
6211,,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,N,A,344,,,9615.0,,,,50588
6212,,Canis lupus familiaris,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,N,A,2189,,,9615.0,,,,50588
6213,,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,N,A,2189,,,9615.0,,Urine,,50588
6214,,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,N,A,2189,,,9615.0,,Urine,,50588
6215,,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,N,A,2189,,,9615.0,,Urine,,50588
6216,,Canis lupus familiaris,Absolute bioavailability was evaluated in dog,N,A,4257,In vivo,,9615.0,,,,50588
6217,,Canis lupus familiaris,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,N,A,6221,In vivo,,9615.0,,,,50588
6218,,Canis lupus familiaris,Bioavailability after peroral administration (1 mg/kg) was determined in dog,N,A,6215,In vivo,,9615.0,,,,50588
6219,,Canis lupus familiaris,Bioavailability in dog,N,A,17267,In vivo,,9615.0,,,,50588
6220,,Canis lupus familiaris,Bioavailability in dog,N,A,6621,In vivo,,9615.0,,,,50588
6221,,Canis lupus familiaris,Bioavailability after intravenous administration in dogs,N,A,3854,In vivo,,9615.0,,,,50588
6222,,Canis lupus familiaris,Bioavailability after peroral administration in dogs,N,A,3854,In vivo,,9615.0,,,,50588
6223,,Canis lupus familiaris,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),N,A,5007,In vivo,,9615.0,,,,50588
6224,,Canis lupus familiaris,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,N,A,4333,In vivo,,9615.0,,,,50588
6225,,Canis lupus familiaris,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,N,A,4333,In vivo,,9615.0,,Plasma,,50588
6226,,Canis lupus familiaris,Bioavailability,N,A,5006,In vivo,,9615.0,,,,50588
6227,,Canis lupus familiaris,Bioavailability,N,A,5199,In vivo,,9615.0,,,,50588
6228,,Canis lupus familiaris,Bioavailability by intravenous administration of 1.2 mg/kg in dog,N,A,4368,In vivo,,9615.0,,,,50588
6229,,Canis lupus familiaris,Bioavailability in dog,N,A,3771,In vivo,,9615.0,,,,50588
6230,,Canis lupus familiaris,Bioavailability in dog,N,A,4953,In vivo,,9615.0,,,,50588
6231,,Canis lupus familiaris,Bioavailability in dog,N,A,5064,In vivo,,9615.0,,,,50588
6232,,Canis lupus familiaris,Bioavailability in dog,N,A,17657,In vivo,,9615.0,,,,50588
6233,,Canis lupus familiaris,Bioavailability in dog,N,A,17796,In vivo,,9615.0,,,,50588
6234,,Canis lupus familiaris,Bioavailability in dog (p.o.) at 2.0 mpk,N,A,17853,In vivo,,9615.0,,,,50588
6235,,Canis lupus familiaris,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),N,A,4521,In vivo,,9615.0,,,,50588
6236,,Canis lupus familiaris,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,A,4521,In vivo,,9615.0,,,,50588
6237,,Canis lupus familiaris,Bioavailability in dog,N,A,5006,In vivo,,9615.0,,,,50588
6238,,Canis lupus familiaris,Bioavailability was evaluated after oral administration in dog,N,A,16365,In vivo,,9615.0,,,,50588
6239,,Canis lupus familiaris,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,A,1916,In vivo,,9615.0,,,,50588
6240,,Canis lupus familiaris,Bioavailability was evaluated in dog,N,A,1918,In vivo,,9615.0,,,,50588
6241,,Canis lupus familiaris,Bioavailability in dog,N,A,4239,In vivo,,9615.0,,,,50588
6242,,Canis lupus familiaris,Bioavailability in dog,N,A,6505,In vivo,,9615.0,,,,50588
6243,,Canis lupus familiaris,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,A,5334,In vivo,,9615.0,,,,50588
6244,,Canis lupus familiaris,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),N,A,5334,In vivo,,9615.0,,,,50588
6245,,Canis lupus familiaris,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,A,4809,In vivo,,9615.0,,,,50588
6246,,Canis lupus familiaris,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,A,6348,In vivo,,9615.0,,,,50588
6247,,Canis lupus familiaris,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,N,A,6005,In vivo,,9615.0,,,,50588
6248,,Canis lupus familiaris,Bioavailability of compound in dog was determined after peroral administration,N,A,17804,In vivo,,9615.0,,,,50588
6249,,Canis lupus familiaris,Oral bioavailability in dog,N,A,3184,In vivo,,9615.0,,,,50588
6250,,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,N,A,1806,In vivo,,9615.0,,,,50588
6251,,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,N,A,1806,In vivo,,9615.0,,,,50588
6252,,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dogs; 37-38 %,N,A,1806,In vivo,,9615.0,,,,50588
6253,,Canis lupus familiaris,Bioavailability in dog,N,A,4839,In vivo,,9615.0,,,,50588
6254,,Canis lupus familiaris,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),N,A,5017,In vivo,,9615.0,,,,50588
6255,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Heart,,50594
6256,,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Heart,,50594
6257,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Kidney,,50594
6258,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Kidney,,50594
6259,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Kidney,,50594
6260,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Kidney,,50594
6261,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Kidney,,50594
6262,,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Kidney,,50594
6263,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Liver,,50594
6264,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Liver,,50594
6265,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Liver,,50594
6266,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Liver,,50594
6267,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Liver,,50594
6268,,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Liver,,50594
6269,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Lung,,50594
6270,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Lung,,50594
6271,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Lung,,50594
6272,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Lung,,50594
6273,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Lung,,50594
6274,,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,A,846,In vivo,,10090.0,,Lung,,50594
6275,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,,CCRF S-180,50594
6276,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6277,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,,CCRF S-180,50594
6278,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6279,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6280,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,Brain,CCRF S-180,50594
6281,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,Brain,CCRF S-180,50594
6282,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,Brain,CCRF S-180,50594
6283,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,Brain,CCRF S-180,50594
6284,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,Brain,CCRF S-180,50594
6285,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,Heart,CCRF S-180,50594
6286,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,Heart,CCRF S-180,50594
6287,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,Heart,CCRF S-180,50594
6288,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,Heart,CCRF S-180,50594
6289,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,Heart,CCRF S-180,50594
6290,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,Kidney,CCRF S-180,50594
6291,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,Kidney,CCRF S-180,50594
6292,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,Kidney,CCRF S-180,50594
6293,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,N,F,17130,,,9606.0,,,A549,80682
6294,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,N,F,17130,,,9606.0,,,A549,80682
6295,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),N,F,17130,,,9606.0,,,A549,80682
6296,,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),N,F,17130,,,9606.0,,,A549,80682
6297,,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,N,F,3263,,,9606.0,,,A549,80682
6298,,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,N,F,6663,,,9606.0,,,A549,80682
6299,,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,N,F,6663,,,9606.0,,,A549,80682
6300,,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,N,F,6663,,,9606.0,,,A549,80682
6301,,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,N,F,6663,,,9606.0,,,A549,80682
6302,,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,N,F,6663,,,9606.0,,,A549,80682
6303,,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,N,F,6663,,,9606.0,,,A549,80682
6304,,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,N,F,6663,,,9606.0,,,A549,80682
6305,,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,N,F,6663,,,9606.0,,,A549,80682
6306,,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,N,F,6663,,,9606.0,,,A549,80682
6307,,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,N,F,6663,,,9606.0,,,A549,80682
6308,,Homo sapiens,The compound was evaluated for its cytotoxic potency against A-549 cell line,N,F,3983,,,9606.0,,,A549,80682
6309,,Homo sapiens,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,N,F,11141,,,9606.0,,,A549,80682
6310,,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line.,N,F,5076,,,9606.0,,,A549,80682
6311,,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,N,F,3311,,,9606.0,,,A549,80682
6312,,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,N,F,3311,,,9606.0,,,A549,80682
6313,,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,N,F,3311,,,9606.0,,,A549,80682
6314,,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,N,F,5076,,,9606.0,,,A549,80682
6315,,Homo sapiens,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),N,F,4150,,,9606.0,,,A549,80682
6316,,Homo sapiens,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,N,F,2150,,,9606.0,,,A549,80682
6317,,Homo sapiens,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,N,F,4644,,,9606.0,,,A549,80682
6318,,Homo sapiens,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,N,F,263,,,9606.0,,,A549,80682
6319,,Homo sapiens,Cytotoxic concentration against A-549 tumor cells.,N,F,11333,,,9606.0,,,A549,80682
6320,,Homo sapiens,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,N,F,11333,,,9606.0,,,A549,80682
6321,,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",N,F,15895,,,9606.0,,,A549,80682
6322,,Acinetobacter baumannii,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,N,F,16677,,,470.0,,,,50191
6323,,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),N,F,10624,,,471.0,,,,50192
6324,,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,N,F,16717,,,5059.0,,,,50274
6325,,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,N,F,16717,,,5059.0,,,,50274
6326,,Aspergillus fumigatus,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,N,F,5513,,,746128.0,,,,50416
6327,,Aspergillus fumigatus,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),N,F,15962,,,746128.0,,,,50416
6328,,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),N,F,15962,,,746128.0,,,,50416
6329,,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),N,F,15962,,,746128.0,,,,50416
6330,,Aspergillus fumigatus,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),N,F,15962,,,746128.0,,,,50416
6331,,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,N,F,16717,,,746128.0,,,,50416
6332,,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,N,F,16717,,,746128.0,,,,50416
6333,,Actinomyces naeslundii,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,N,F,8117,,,1655.0,,,,50296
6334,,Actinomyces viscosus,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,N,F,8117,,,1656.0,,,,50366
6335,,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),N,F,15472,,,6277.0,,,,50535
6336,,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),N,F,15472,,,6277.0,,,,50535
6337,,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,N,F,16443,,,714.0,,,,50169
6338,,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,N,F,16443,,,714.0,,,,50169
6339,,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,N,F,16443,,,714.0,,,,50169
6340,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6341,,Homo sapiens,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6342,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,N,F,16381,,,9606.0,,,A549,80682
6343,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,N,F,16381,,,9606.0,,,A549,80682
6344,,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,N,F,16381,,,9606.0,,,A549,80682
6345,,Homo sapiens,GI values against A549 cells (lung cancer),N,F,16381,,,9606.0,,,A549,80682
6346,,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,N,F,17206,,,9606.0,,,A549,80682
6347,,Homo sapiens,Inhibitory activity against A549 human adenocarcinoma,N,F,16325,,,9606.0,,,A549,80682
6348,,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,N,F,10708,,,9606.0,,,A549,80682
6349,,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,N,F,10708,,,9606.0,,,A549,80682
6350,,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,N,F,17376,,,9606.0,,,A549,80682
6351,,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,N,F,17376,,,9606.0,,,A549,80682
6352,,Homo sapiens,Cytotoxicity against human A549 lung cells,N,F,17488,,,9606.0,,,A549,80682
6353,,Homo sapiens,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,N,F,17404,,,9606.0,,,A549,80682
6354,,Homo sapiens,Growth inhibition of A549 (human lung carcinoma) cell line.,N,F,10958,,,9606.0,,,A549,80682
6355,,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line.,N,F,17099,,,9606.0,,,A549,80682
6356,,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,N,F,17099,,,9606.0,,,A549,80682
6357,,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,N,F,4096,,,9606.0,,,A549,80682
6358,,Homo sapiens,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,N,F,4096,,,9606.0,,,A549,80682
6359,,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,N,F,4096,,,9606.0,,,A549,80682
6360,,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture,N,F,2525,,,9606.0,,,A549,80682
6361,,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,N,F,2525,,,9606.0,,,A549,80682
6362,,Homo sapiens,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),N,F,5302,,,9606.0,,,A549,80682
6363,,Homo sapiens,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,N,F,16325,,,9606.0,,,A549,80682
6364,,Homo sapiens,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,N,F,16939,,,9606.0,,,A549,80682
6365,,Homo sapiens,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,N,F,17229,,,9606.0,,,A549,80682
6366,,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,N,F,17380,,,9606.0,,,A549,80682
6367,,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,N,F,17380,,,9606.0,,,A549,80682
6368,,Homo sapiens,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,N,F,1903,,,9606.0,,,A549,80682
6369,,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,N,F,3838,,,9606.0,,,A549,80682
6370,,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,N,F,14696,,,9606.0,,,A549,80682
6371,,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,N,F,3838,,,9606.0,,,A549,80682
6372,,Homo sapiens,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,N,F,1522,,,9606.0,,,A549,80682
6373,,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell lines,N,F,12400,,,9606.0,,,A549,80682
6374,,Homo sapiens,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,N,F,14696,,,9606.0,,,A549,80682
6375,,Homo sapiens,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),N,F,14769,,,9606.0,,,A549,80682
6376,,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,N,F,14696,,,9606.0,,,A549,80682
6377,,Homo sapiens,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,N,F,1888,,,9606.0,,,A549,80682
6378,,Homo sapiens,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,N,F,12016,,,9606.0,,,A549,80682
6379,,Homo sapiens,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,N,F,6058,,,9606.0,,,A549,80682
6380,,Homo sapiens,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,N,F,17708,,,9606.0,,,A549,80682
6381,,Homo sapiens,Antitumor activity against A549/ATCC cell line,N,F,12301,,,9606.0,,,A549,80682
6382,,Homo sapiens,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,N,F,11970,,,9606.0,,,A549,80682
6383,,Homo sapiens,In vitro cytotoxicity against A549/ATCC cell line.,N,F,11818,,,9606.0,,,A549,80682
6384,,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,N,F,12400,,,9606.0,,,A549,80682
6385,,Homo sapiens,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,N,F,3381,,,9606.0,,,A549,80682
6386,,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,N,F,17376,,,9606.0,,,A549,80682
6387,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,N,F,10708,,,9606.0,,,A549,80682
6388,,Homo sapiens,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,U,F,2964,,,9606.0,,,,22226
6389,,Canis lupus familiaris,Compound was tested for oral bioavailability in dogs,U,A,5005,In vivo,,9615.0,,,,22224
6390,,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,N,A,6229,In vivo,,9615.0,,,,50588
6391,,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,N,A,6229,In vivo,,9615.0,,,,50588
6392,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5374,In vivo,,9615.0,,,,50588
6393,,Canis lupus familiaris,Compound was tested for the oral bioavailability in dog; No availability,N,A,5374,In vivo,,9615.0,,,,50588
6394,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),N,A,6265,In vivo,,9615.0,,,,50588
6395,,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,N,A,5654,In vivo,,9615.0,,,,50588
6396,,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,N,A,5654,In vivo,,9615.0,,,,50588
6397,,Canis lupus familiaris,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),N,A,16456,In vivo,,9615.0,,,,50588
6398,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),N,A,5302,In vivo,,9615.0,,,,50588
6399,,Canis lupus familiaris,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),N,A,3624,In vivo,,9615.0,,,,50588
6400,,Canis lupus familiaris,Oral bioavailability of active FTIs in dogs,N,A,16452,In vivo,,9615.0,,,,50588
6401,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),N,A,5802,In vivo,,9615.0,,,,50588
6402,,Canis lupus familiaris,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,N,A,3598,In vivo,,9615.0,,,,50588
6403,,Canis lupus familiaris,Oral bioavailability in dog,N,A,17839,In vivo,,9615.0,,,,50588
6404,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6762,In vivo,,9615.0,,,,50588
6405,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6821,In vivo,,9615.0,,,,50588
6406,,Canis lupus familiaris,Oral bioavailability of compound was determined in dog; Not tested,N,A,6821,In vivo,,9615.0,,,,50588
6407,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5210,In vivo,,9615.0,,,,50588
6408,,Canis lupus familiaris,Oral bioavailability (10 mg/kg) was determined in dog,N,A,6227,In vivo,,9615.0,,,,50588
6409,,Canis lupus familiaris,Oral bioavailability,N,A,761,In vivo,,9615.0,,,,50588
6410,,Canis lupus familiaris,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),N,A,761,In vivo,,9615.0,,,,50588
6411,,Canis lupus familiaris,Oral bioavailability administered in solution in rats,N,A,761,In vivo,,9615.0,,,,50588
6412,,Canis lupus familiaris,Oral bioavailability after 30 mg/kg po dose in Dogs,N,A,16907,In vivo,,9615.0,,,,50588
6413,,Canis lupus familiaris,Oral bioavailability at a dose of 1 mg/kg in dogs,N,A,5474,In vivo,,9615.0,,,,50588
6414,,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg p.o.),N,A,6535,In vivo,,9615.0,,,,50588
6415,,Canis lupus familiaris,Oral bioavailability in Dog; ND = not determined,N,A,6535,In vivo,,9615.0,,,,50588
6416,,Canis lupus familiaris,Oral bioavailability in dog,N,A,3352,In vivo,,9615.0,,,,50588
6417,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6168,In vivo,,9615.0,,,,50588
6418,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5988,In vivo,,9615.0,,,,50588
6419,,Canis lupus familiaris,Oral bioavailability in dog,N,A,4942,In vivo,,9615.0,,,,50588
6420,,Canis lupus familiaris,Oral bioavailability in dogs; No data,N,A,4942,In vivo,,9615.0,,,,50588
6421,,Canis lupus familiaris,Oral bioavailability measured in dogs,N,A,14541,In vivo,,9615.0,,,,50588
6422,,Canis lupus familiaris,Oral bioavailability in dog,N,A,4449,In vivo,,9615.0,,,,50588
6423,,Canis lupus familiaris,Oral bioavailability was calculated in dog,N,A,6057,In vivo,,9615.0,,,,50588
6424,,Canis lupus familiaris,Oral bioavailability after 0.3 mg/kg po administration in dog,N,A,5600,In vivo,,9615.0,,,,50588
6425,,Canis lupus familiaris,Oral bioavailability in dog (i.v. dosing),N,A,5542,In vivo,,9615.0,,,,50588
6426,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5542,In vivo,,9615.0,,,,50588
6427,,Canis lupus familiaris,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,N,A,5546,In vivo,,9615.0,,,,50588
6428,,Canis lupus familiaris,Oral bioavailability in Beagle dogs,N,A,4514,In vivo,,9615.0,,,,50588
6429,,Canis lupus familiaris,Oral bioavailability in dog,N,A,3624,In vivo,,9615.0,,,,50588
6430,,Canis lupus familiaris,Oral bioavailability in dog,N,A,3854,In vivo,,9615.0,,,,50588
6431,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5836,In vivo,,9615.0,,,,50588
6432,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5940,In vivo,,9615.0,,,,50588
6433,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6168,In vivo,,9615.0,,,,50588
6434,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6227,In vivo,,9615.0,,,,50588
6435,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6251,In vivo,,9615.0,,,,50588
6436,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6448,In vivo,,9615.0,,,,50588
6437,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6647,In vivo,,9615.0,,,,50588
6438,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5940,In vivo,,9615.0,,,,50588
6439,,Canis lupus familiaris,Oral bioavailability in dog,N,A,933,In vivo,,9615.0,,,,50588
6440,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5210,In vivo,,9615.0,,,,50588
6441,,Canis lupus familiaris,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),N,A,6642,In vivo,,9615.0,,,,50588
6442,,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),N,A,6641,In vivo,,9615.0,,,,50588
6443,,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),N,A,6642,In vivo,,9615.0,,,,50588
6444,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5472,In vivo,,9615.0,,,,50588
6445,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5985,In vivo,,9615.0,,,,50588
6446,,Canis lupus familiaris,Oral bioavailability in dog,N,A,15660,In vivo,,9615.0,,,,50588
6447,,Canis lupus familiaris,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),N,A,5530,In vivo,,9615.0,,,,50588
6448,,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg i.v.),N,A,5530,In vivo,,9615.0,,,,50588
6449,,Canis lupus familiaris,Oral bioavailability (F) in dogs,N,A,6305,In vivo,,9615.0,,,,50588
6450,,Canis lupus familiaris,Oral bioavailability in dog,N,A,5210,In vivo,,9615.0,,,,50588
6451,,Canis lupus familiaris,Bioavailability in dog,N,A,5238,In vivo,,9615.0,,,,50588
6452,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),N,A,5668,In vivo,,9615.0,,,,50588
6453,,Canis lupus familiaris,Oral bioavailability after peroral administration at 5 mpk in Dog,N,A,5668,In vivo,,9615.0,,,,50588
6454,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),N,A,5668,In vivo,,9615.0,,,,50588
6455,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),N,A,6084,In vivo,,9615.0,,,,50588
6456,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,Kidney,CCRF S-180,50594
6457,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,Kidney,CCRF S-180,50594
6458,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,Liver,CCRF S-180,50594
6459,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,Liver,CCRF S-180,50594
6460,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,Liver,CCRF S-180,50594
6461,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,Liver,CCRF S-180,50594
6462,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,Liver,CCRF S-180,50594
6463,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,Lung,CCRF S-180,50594
6464,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,Lung,CCRF S-180,50594
6465,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,Lung,CCRF S-180,50594
6466,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,Lung,CCRF S-180,50594
6467,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,Lung,CCRF S-180,50594
6468,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,,CCRF S-180,50594
6469,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6470,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,,CCRF S-180,50594
6471,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6472,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6473,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,Spleen,CCRF S-180,50594
6474,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,Spleen,CCRF S-180,50594
6475,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,Spleen,CCRF S-180,50594
6476,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,Spleen,CCRF S-180,50594
6477,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,Spleen,CCRF S-180,50594
6478,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,,CCRF S-180,50594
6479,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6480,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,,CCRF S-180,50594
6481,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6482,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6483,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,,CCRF S-180,50594
6484,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6485,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,,CCRF S-180,50594
6486,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6487,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6488,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,Heart,CCRF S-180,50594
6489,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,Heart,CCRF S-180,50594
6490,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,Heart,CCRF S-180,50594
6491,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,Heart,CCRF S-180,50594
6492,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,Heart,CCRF S-180,50594
6493,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,Liver,CCRF S-180,50594
6494,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,Liver,CCRF S-180,50594
6495,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,Liver,CCRF S-180,50594
6496,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,Liver,CCRF S-180,50594
6497,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,Liver,CCRF S-180,50594
6498,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,Lung,CCRF S-180,50594
6499,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,Lung,CCRF S-180,50594
6500,,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,F,12269,,,107673.0,,,,50067
6501,,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,F,12269,,,107673.0,,,,50067
6502,,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,F,12269,,,107673.0,,,,50067
6503,,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,F,12269,,,107673.0,,,,50067
6504,,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),N,F,10624,,,471.0,,,,50192
6505,,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,N,F,17216,,,28377.0,,,,50714
6506,,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,N,F,17216,,,28377.0,,,,50714
6507,,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii 631,N,F,9560,,,1655.0,,,,50296
6508,,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii B74,N,F,9560,,,1655.0,,,,50296
6509,,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/3,N,F,9560,,,1655.0,,,,50296
6510,,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/9,N,F,9560,,,1655.0,,,,50296
6511,,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii 631,N,F,9560,,,1655.0,,,,50296
6512,,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/9,N,F,9560,,,1655.0,,,,50296
6513,,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii B74,N,F,9560,,,1655.0,,,,50296
6514,,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/3,N,F,9560,,,1655.0,,,,50296
6515,,Artemia salina,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,N,F,114,,,85549.0,,,,50056
6516,,Artemia salina,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",N,F,114,,,85549.0,,,,50056
6517,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,N,F,10841,,,6253.0,,,,50532
6518,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,N,F,10841,,,6253.0,,,,50532
6519,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,N,F,10841,,,6253.0,,,,50532
6520,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,N,F,10841,,,6253.0,,,,50532
6521,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,N,F,10841,,,6253.0,,,,50532
6522,,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,N,F,10841,,,6253.0,,,,50532
6523,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,N,F,10841,,,6253.0,,,,50532
6524,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,N,F,10841,,,6253.0,,,,50532
6525,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,N,F,10841,,,6253.0,,,,50532
6526,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,N,F,10841,,,6253.0,,,,50532
6527,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,N,F,10841,,,6253.0,,,,50532
6528,,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,N,F,10841,,,6253.0,,,,50532
6529,,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,N,F,8117,,,1656.0,,,,50366
6530,,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,N,F,8117,,,1656.0,,,,50366
6531,,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus 8A06,N,F,9560,,,1656.0,,,,50366
6532,,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-100,N,F,9560,,,1656.0,,,,50366
6533,,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-626,N,F,9560,,,1656.0,,,,50366
6534,,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus T14V,N,F,9560,,,1656.0,,,,50366
6535,,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 8A06,N,F,9560,,,1656.0,,,,50366
6536,,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100,N,F,9560,,,1656.0,,,,50366
6537,,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,N,F,9560,,,1656.0,,,,50366
6538,,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",N,F,9560,,,1656.0,,,,50366
6539,,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",N,F,9560,,,1656.0,,,,50366
6540,,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 626,N,F,9560,,,1656.0,,,,50366
6541,,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus T14V,N,F,9560,,,1656.0,,,,50366
6542,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,N,F,10986,,,6277.0,,,,50535
6543,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,N,F,10986,,,6277.0,,,,50535
6544,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,N,F,10986,,,6277.0,,,,50535
6545,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,N,F,10986,,,6277.0,,,,50535
6546,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,N,F,10986,,,6277.0,,,,50535
6547,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,N,F,10708,,,9606.0,,,A673,80023
6548,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,N,F,10708,,,9606.0,,,A704,80661
6549,,Rattus norvegicus,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,U,F,416,,,10116.0,,,,22226
6550,,Mus musculus,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,N,F,14354,,,10090.0,,,A9,80024
6551,,Mus musculus,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,N,F,14354,,,10090.0,,,A9,80024
6552,,Homo sapiens,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,N,F,5116,,,9606.0,,,A9,80024
6553,,Homo sapiens,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,N,F,5116,,,9606.0,,,A9,80024
6554,,Homo sapiens,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,N,F,15694,,,9606.0,,,Human ovarian carcinoma cell line,81037
6555,,Mus musculus,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",N,F,13038,,,10090.0,,,A9,80024
6556,,Mus musculus,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,N,F,13038,,,10090.0,,,A9,80024
6557,,Mus musculus,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,N,F,10923,,,10090.0,,,A9,80024
6558,,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,N,F,10923,,,10090.0,,,A9,80024
6559,,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,N,F,10923,,,10090.0,,,A9,80024
6560,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",H,F,10923,,,,,,,10649
6561,,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,N,F,10923,,,10090.0,,,A9,80024
6562,,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,N,F,10923,,,10090.0,,,A9,80024
6563,,Cricetulus griseus,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,N,F,8158,,,10029.0,,,AA6,80663
6564,,Homo sapiens,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,U,F,15494,,,9606.0,,,,22226
6565,,Homo sapiens,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",U,F,15494,,,9606.0,,,,22226
6566,,Homo sapiens,Anti -HIV activity was measured against AA5/HIV-1(IIIB),N,F,12348,,,9606.0,,,AA5,80662
6567,,Homo sapiens,Cytotoxicity was measured against AA5/HIV-1(IIIB),N,F,12348,,,9606.0,,,AA5,80662
6568,,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,N,F,2726,,,9606.0,,,AA5,80662
6569,,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,N,F,2726,,,9606.0,,,U-937,80566
6570,,Cricetulus griseus,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,N,F,10747,,,10029.0,,,UV4,80578
6571,,Cricetulus griseus,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",N,F,11005,,,10029.0,,,CHO-AA8,80089
6572,,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6,N,F,12687,,,10029.0,,,CHO-AA8,80089
6573,,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6.,N,F,12687,,,10029.0,,,CHO-AA8,80089
6574,,Cricetulus griseus,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,N,F,12687,,,10029.0,,,CHO-AA8,80089
6575,,Cricetulus griseus,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,N,F,12687,,,10029.0,,,CHO-AA8,80089
6576,,Cricetulus griseus,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,N,F,12687,,,10029.0,,,CHO-AA8,80089
6577,,Cricetulus griseus,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",N,F,13436,,,10029.0,,,CHO-AA8,80089
6578,,Cricetulus griseus,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",N,F,13435,,,10029.0,,,CHO-AA8,80089
6579,,Cricetulus griseus,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,N,F,13302,,,10029.0,,,CHO-AA8,80089
6580,,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,N,F,12687,,,10029.0,,,CHO-AA8,80089
6581,,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,N,A,12687,,,10029.0,,,CHO-AA8,80089
6582,,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,N,A,12687,,,10029.0,,,CHO-AA8,80089
6583,,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,N,A,12878,,,10029.0,,,CHO-AA8,80089
6584,,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,N,A,12878,,,10029.0,,,CHO-AA8,80089
6585,,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,N,F,14367,,,10029.0,,,CHO-AA8,80089
6586,,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,N,F,14367,,,10029.0,,,CHO-AA8,80089
6587,,hampster,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,N,F,12398,,,36483.0,,,CHO-AA8,80089
6588,,Cricetulus griseus,Aerobic growth inhibition in Chinese hamster cell line AA8,N,F,12878,,,10029.0,,,CHO-AA8,80089
6589,,Cricetulus griseus,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,N,F,13820,,,10029.0,,,CHO-AA8,80089
6590,,Cricetulus griseus,Inhibition of growth under aerobic conditions in AA8 cells,N,F,13436,,,10029.0,,,CHO-AA8,80089
6591,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),N,A,6084,In vivo,,9615.0,,,,50588
6592,,Canis lupus familiaris,Oral bioavailability in dog at 10 mg/kg of the compound,N,A,5711,In vivo,,9615.0,,,,50588
6593,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),N,A,4353,In vivo,,9615.0,,,,50588
6594,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),N,A,4353,In vivo,,9615.0,,,,50588
6595,,Canis lupus familiaris,Oral bioavailability in dog (mongrel),N,A,17800,In vivo,,9615.0,,,,50588
6596,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),N,A,3994,In vivo,,9615.0,,,,50588
6597,,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),N,F,3994,In vivo,,9615.0,,,,50588
6598,,Canis lupus familiaris,Bioavailability in dog,N,A,5145,In vivo,,9615.0,,,,50588
6599,,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),N,A,16452,In vivo,,9615.0,,,,50588
6600,,Canis lupus familiaris,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),N,A,16452,In vivo,,9615.0,,,,50588
6601,,Canis lupus familiaris,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,N,A,5983,In vivo,,9615.0,,,,50588
6602,,Canis lupus familiaris,Bioavailability in dog,N,A,4273,In vivo,,9615.0,,,,50588
6603,,Canis lupus familiaris,Bioavailability in dog (dose 3-10 mg/kg),N,A,12500,In vivo,,9615.0,,,,50588
6604,,Canis lupus familiaris,The compound was tested for bioavailability of compound in plasma of dog; Complete,N,A,12500,In vivo,,9615.0,,Plasma,,50588
6605,,Canis lupus familiaris,Oral bioavailability in dog,N,A,3639,In vivo,,9615.0,,,,50588
6606,,Canis lupus familiaris,Oral bioavailability in dog,N,A,3880,In vivo,,9615.0,,,,50588
6607,,Canis lupus familiaris,Bioavailability in dog,N,A,4838,In vivo,,9615.0,,,,50588
6608,,Canis lupus familiaris,oral bioavailability was measured in dogs,N,A,15600,In vivo,,9615.0,,,,50588
6609,,Canis lupus familiaris,Compound was tested for plasma protein binding in dog; Not determined,N,A,17248,,,9615.0,,,,50588
6610,,Canis lupus familiaris,Compound was tested for plasma protein binding of dog,N,A,17248,,,9615.0,,,,50588
6611,,Canis lupus familiaris,Compound was tested for plasma protein binding of dog; Not determined,N,A,17248,,,9615.0,,,,50588
6612,,Canis lupus familiaris,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,N,A,17443,,,9615.0,,,,50588
6613,,Canis lupus familiaris,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,N,A,4186,In vivo,,9615.0,,,,50588
6614,,Canis lupus familiaris,Half life was determined,N,A,3749,,,9615.0,,,,50588
6615,,Canis lupus familiaris,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,N,A,3249,In vivo,,9615.0,,,,50588
6616,,Canis lupus familiaris,Half life was evaluated in dog,N,A,3022,,,9615.0,,,,50588
6617,,Canis lupus familiaris,Half life was determined,N,A,3749,,,9615.0,,,,50588
6618,,Canis lupus familiaris,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,A,2517,In vivo,,9615.0,,,,50588
6619,,Canis lupus familiaris,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,A,2517,In vivo,,9615.0,,Heart,,50588
6620,,Canis lupus familiaris,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,A,2517,In vivo,,9615.0,,Kidney,,50588
6621,,Canis lupus familiaris,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,A,2517,In vivo,,9615.0,,Liver,,50588
6622,,Canis lupus familiaris,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,A,2517,In vivo,,9615.0,,Lung,,50588
6623,,Canis lupus familiaris,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,A,2517,In vivo,,9615.0,,Spleen,,50588
6624,,Canis lupus familiaris,LogP in dog,N,A,3639,,,9615.0,,,,50588
6625,,Canis lupus familiaris,Partition coefficient (logP),N,A,6227,,,9615.0,,,,50588
6626,,Canis lupus familiaris,Partition coefficient in dog,N,A,6227,,,9615.0,,,,50588
6627,,Canis lupus familiaris,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,N,A,17764,In vivo,,9615.0,,,,50588
6628,,Canis lupus familiaris,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),N,A,4809,In vivo,,9615.0,,,,50588
6629,,Canis lupus familiaris,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,N,A,5600,,,9615.0,,,,50588
6630,,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),N,A,14294,,,9615.0,,,,50588
6631,,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),N,A,14294,,,9615.0,,,,50588
6632,,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes; Trace,N,A,14294,,,9615.0,,,,50588
6633,,Canis lupus familiaris,In vitro metabolic potential in dog liver microsomes,N,A,6251,,,9615.0,,Liver,,50588
6634,,Canis lupus familiaris,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,N,A,3748,In vivo,,9615.0,,,,50588
6635,,Canis lupus familiaris,Oral bioavailability in dog,N,A,2713,In vivo,,9615.0,,,,50588
6636,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6512,In vivo,,9615.0,,,,50588
6637,,Canis lupus familiaris,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,A,6679,In vivo,,9615.0,,,,50588
6638,,Canis lupus familiaris,The compound was tested for bioavailability in dogs,N,A,3749,In vivo,,9615.0,,,,50588
6639,,Canis lupus familiaris,The compound was tested for oral bioavailability in dogs,N,A,3749,In vivo,,9615.0,,,,50588
6640,,Canis lupus familiaris,Oral bioavailability in dog,N,A,6742,In vivo,,9615.0,,,,50588
6641,,Canis lupus familiaris,Compound was tested for percent protein binding (PB) in dog,N,A,6227,,,9615.0,,,,50588
6642,,Canis lupus familiaris,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,N,A,6874,,,9615.0,,,,50588
6643,,Canis lupus familiaris,Compound was evaluated for plasma clearance.,N,A,2877,In vivo,,9615.0,,Plasma,,50588
6644,,Canis lupus familiaris,The compound was tested for plasma clearance in dog,N,A,12500,In vivo,,9615.0,,Plasma,,50588
6645,,Canis lupus familiaris,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,N,A,12500,In vivo,,9615.0,,Plasma,,50588
6646,,Canis lupus familiaris,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,N,A,4709,,,9615.0,,,,50588
6647,,Canis lupus familiaris,In vitro relative rate of metabolism was determined in dog liver microsomes,N,A,5542,,,9615.0,,Liver,,50588
6648,,Canis lupus familiaris,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,N,A,17594,In vivo,,9615.0,,,,50588
6649,,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,N,A,2652,In vivo,,9615.0,,,,50588
6650,,Canis lupus familiaris,Half life after intravenous administration in dogs at 1.2 uM/kg,N,A,17764,In vivo,,9615.0,,,,50588
6651,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,Lung,CCRF S-180,50594
6652,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,Lung,CCRF S-180,50594
6653,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,Lung,CCRF S-180,50594
6654,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,N,A,6599,,,10090.0,,,CCRF S-180,50594
6655,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6656,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,N,A,6599,,,10090.0,,,CCRF S-180,50594
6657,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6658,,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,N,A,6599,,,10090.0,,,CCRF S-180,50594
6659,,Mus musculus,C2 in brain of mice at the oral dose of 50 mg/kg,N,A,17641,,,10090.0,,Brain,,50594
6660,,Mus musculus,C2 in kidney of mice at the oral dose of 50 mg/kg,N,A,17641,,,10090.0,,Kidney,,50594
6661,,Mus musculus,C2 in liver of mice at the oral dose of 50 mg/kg,N,A,17641,,,10090.0,,Liver,,50594
6662,,Mus musculus,C2 in lungs of mice at the oral dose of 50 mg/kg,N,A,17641,,,10090.0,,Lung,,50594
6663,,Mus musculus,C2 in spleen of mice at the oral dose of 50 mg/kg,N,A,17641,,,10090.0,,Spleen,,50594
6664,,Mus musculus,Plasma clearance in mouse,N,A,17852,In vivo,,10090.0,,,,50594
6665,,Mus musculus,Clearance of compound after intravenous administration in mice at 24 uM/kg,N,A,17764,In vivo,,10090.0,,,,50594
6666,,Mus musculus,Clearance from mouse blood following i.v. administration of 10 mg/kg,N,A,17837,In vivo,,10090.0,,,,50594
6667,,Mus musculus,Clearance was evaluated in mice after intravenous administration,N,A,2675,In vivo,,10090.0,,,,50594
6668,,Mus musculus,Clearance was evaluated in mice after oral administration,N,A,2675,In vivo,,10090.0,,,,50594
6669,,Mus musculus,Pharmacokinetic property (Plasma clearance) was measured in mouse,N,A,4239,In vivo,,10090.0,,,,50594
6670,,Mus musculus,Plasma clearance of compound was determined at 40 mg/Kg,N,A,17753,In vivo,,10090.0,,,,50594
6671,,Mus musculus,Plasma clearance of at 24 mg/Kg,N,A,17753,In vivo,,10090.0,,,,50594
6672,,Mus musculus,Plasma clearance at 24 mg/Kg,N,A,17753,In vivo,,10090.0,,,,50594
6673,,Mus musculus,Plasma clearance at 5 mg/Kg,N,A,17753,In vivo,,10090.0,,,,50594
6674,,Mus musculus,Plasma clearance in mice,N,A,5727,In vivo,,10090.0,,,,50594
6675,,Mus musculus,Plasma clearance value upon iv administration in mouse,N,A,2862,In vivo,,10090.0,,,,50594
6676,,Mus musculus,Total plasma clearance in mice,N,A,5980,In vivo,,10090.0,,Plasma,,50594
6677,,Mus musculus,Clearance in mouse,N,A,17592,In vivo,,10090.0,,,,50594
6678,,Mus musculus,Clearance value was determined,N,A,17718,In vivo,,10090.0,,,,50594
6679,,Mus musculus,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,N,A,16597,In vivo,,10090.0,,,,50594
6680,,,Calculated partition coefficient (clogP),U,P,17384,,,,,,,22229
6681,,Mus musculus,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,N,A,6062,In vivo,,10090.0,,,,50594
6682,,Mus musculus,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,N,A,17734,In vivo,,10090.0,,,,50594
6683,,Mus musculus,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,A,6348,In vivo,,10090.0,,,,50594
6684,,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,N,A,5969,In vivo,,10090.0,,,,50594
6685,,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,N,A,5969,In vivo,,10090.0,,,,50594
6686,,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,A,5969,In vivo,,10090.0,,,,50594
6687,,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,N,A,16597,In vivo,,10090.0,,,,50594
6688,,Mus musculus,Cmax after oral administration at 30 mg/kg in ICR mouse,N,A,5781,In vivo,,10090.0,,,,50594
6689,,Mus musculus,Cmax after peroral administration in mice at 2.4 uM/kg,N,A,17764,In vivo,,10090.0,,,,50594
6690,,Mus musculus,Cmax in brain of mice at the oral dose of 50 mg/kg,N,A,17641,In vivo,,10090.0,,Brain,,50594
6691,,Mus musculus,Cmax in kidney of mice at the oral dose of 50 mg/kg,N,A,17641,In vivo,,10090.0,,Kidney,,50594
6692,,Mus musculus,Cmax in liver of mice at the oral dose of 50 mg/kg,N,A,17641,In vivo,,10090.0,,Liver,,50594
6693,,Mus musculus,Cmax in lungs of mice at the oral dose of 50 mg/kg,N,A,17641,In vivo,,10090.0,,Lung,,50594
6694,,Mus musculus,Cmax in mice at 18 uM/kg i.p. administration,N,F,17764,In vivo,,10090.0,,,,50594
6695,,Mus musculus,Cmax in mice at 23 uM/kg i.v. administration,N,F,17764,In vivo,,10090.0,,,,50594
6696,,Mus musculus,Cmax in mice at 24 uM/kg i.p. administration,N,F,17764,In vivo,,10090.0,,,,50594
6697,,Mus musculus,Cmax in mice at 25 uM/kg i.p. administration,N,F,17764,In vivo,,10090.0,,,,50594
6698,,Mus musculus,Cmax in mice at 26 uM/kg i.p. administration,N,F,17764,In vivo,,10090.0,,,,50594
6699,,Mus musculus,Cmax in spleen of mice at the oral dose of 50 mg/kg,N,A,17641,In vivo,,10090.0,,Spleen,,50594
6700,,Mus musculus,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,N,A,16597,In vivo,,10090.0,,,,50594
6701,,Mus musculus,Cmax value at a dose of 10 mg/kg peroral administration in mice.,N,A,16597,In vivo,,10090.0,,,,50594
6702,,Mus musculus,Cmax value was determined,N,A,5727,In vivo,,10090.0,,,,50594
6703,,Mus musculus,Cmax value in IRC mice,N,A,5951,In vivo,,10090.0,,,,50594
6704,,Mus musculus,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,N,A,5506,In vivo,,10090.0,,,,50594
6705,,Mus musculus,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,N,A,5506,In vivo,,10090.0,,,,50594
6706,,Mus musculus,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,N,A,14239,In vivo,,10090.0,,Plasma,,50594
6707,,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",N,A,4890,In vivo,,10090.0,,Plasma,,50594
6708,,Mus musculus,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,N,A,429,In vivo,,10090.0,,,,50594
6709,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,N,F,10986,,,6277.0,,,,50535
6710,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,N,F,10986,,,6277.0,,,,50535
6711,,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,N,F,10986,,,6277.0,,,,50535
6712,,Homo sapiens,Inhibitory activity against human tumor cell line A0375 melanoma.,N,F,13227,,,9606.0,,,A-375,80018
6713,Brain membranes,Rattus norvegicus,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,D,B,4481,,,10116.0,,,,12512
6714,,Homo sapiens,Forskolin-induced cAMP production at human A1 adenosine receptor,D,F,16931,,,9606.0,,,,114
6715,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,H,F,3850,,,,,,CHO,114
6716,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,H,F,3850,,,,,,CHO,114
6717,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,H,F,3850,,,,,,CHO,114
6718,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,H,F,3850,,,,,,CHO,114
6719,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,H,F,3850,,,,,,CHO,114
6720,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,H,F,3850,,,,,,CHO,114
6721,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,H,F,3850,,,,,,CHO,114
6722,,Homo sapiens,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,D,F,3850,,,9606.0,,,CHO,114
6723,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,H,F,3850,,,,,,CHO,114
6724,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,H,F,3850,,,,,,CHO,114
6725,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,H,F,3850,,,,,,CHO,114
6726,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,H,F,3850,,,,,,CHO,114
6727,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,H,F,3850,,,,,,CHO,114
6728,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,H,F,3850,,,,,,CHO,114
6729,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,H,F,3850,,,,,,CHO,114
6730,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,H,F,3850,,,,,,CHO,114
6731,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,H,F,3850,,,,,,CHO,114
6732,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,H,F,3850,,,,,,CHO,114
6733,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,H,F,3850,,,,,,CHO,114
6734,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,H,F,3850,,,,,,CHO,114
6735,,Oryctolagus cuniculus,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,N,F,12680,,,9986.0,,,A10,80013
6736,,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells,U,F,1313,,,10116.0,,,A10,22226
6737,,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,U,F,1313,,,10116.0,,,A10,22226
6738,,Rattus norvegicus,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,N,F,17567,,,10116.0,,,A10,80013
6739,,Rattus norvegicus,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,N,F,17567,,,10116.0,,,A10,80013
6740,,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,N,F,11819,,,10116.0,,,A10,80013
6741,,Cricetulus griseus,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,N,F,13436,,,10029.0,,,CHO-AA8,80089
6742,,Cricetulus griseus,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,N,F,12687,,,10029.0,,,CHO-AA8,80089
6743,,Cricetulus griseus,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,N,F,12651,,,10029.0,,,CHO-AA8,80089
6744,,Cricetulus griseus,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,N,F,13300,,,10029.0,,,CHO-AA8,80089
6745,,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,N,F,15296,,,10029.0,,,CHO-AA8,80089
6746,,Cricetulus griseus,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",N,F,15328,,,10029.0,,,CHO-AA8,80089
6747,,Cricetulus griseus,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),N,F,13302,,,10029.0,,,CHO-AA8,80089
6748,,Cricetulus griseus,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",N,F,14367,,,10029.0,,,CHO-AA8,80089
6749,,Cricetulus griseus,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,N,F,17002,,,10029.0,,,CHO-AA8,80089
6750,,Cricetulus griseus,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,N,F,13436,,,10029.0,,,CHO-AA8,80089
6751,,Cricetulus griseus,Inhibitory activity against aerobic growth of AA8 cells.,N,F,13435,,,10029.0,,,CHO-AA8,80089
6752,,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,A,10503,,,10029.0,,,CHO-AA8,80089
6753,,Cricetulus griseus,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,F,10503,,,10029.0,,,CHO-AA8,80089
6754,,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,F,10503,,,10029.0,,,CHO-AA8,80089
6755,,Cricetulus griseus,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,N,F,15090,,,10029.0,,,CHO-AA8,80089
6756,,Cricetulus griseus,Cytotoxicity against AA8 cell line,N,F,10368,,,10029.0,,,CHO-AA8,80089
6757,,Cricetulus griseus,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),N,F,12651,,,10029.0,,,CHO-AA8,80089
6758,,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,A,12687,,,10029.0,,,CHO-AA8,80089
6759,,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,F,12687,,,10029.0,,,CHO-AA8,80089
6760,,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,A,12687,,,10029.0,,,CHO-AA8,80089
6761,,Cricetulus griseus,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,N,F,1890,,,10029.0,,,CHO-AA8,80089
6762,,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,N,F,10747,,,10029.0,,,CHO-AA8,80089
6763,,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,N,F,10747,,,10029.0,,,CHO-AA8,80089
6764,,Cricetulus griseus,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),U,F,11616,,,10029.0,,,,22224
6765,,Cricetulus griseus,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,N,F,11616,,,10029.0,,,CHO-AA8,80089
6766,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,U,F,3471,,,10029.0,,,CHO-AA8,22224
6767,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,U,F,3471,,,10029.0,,,CHO-AA8,22224
6768,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,U,F,3471,,,10029.0,,,CHO-AA8,22224
6769,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,U,F,3471,,,10029.0,,,CHO-AA8,22224
6770,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,U,F,3471,,,10029.0,,,CHO-AA8,22224
6771,,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,U,F,3471,,,10029.0,,,CHO-AA8,22224
6772,,Cricetulus griseus,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,U,F,3471,,,10029.0,,,CHO-AA8,22224
6773,,Cricetulus griseus,Concentration required to reduce AA8 cell survival by 10%,N,F,11616,,,10029.0,,,CHO-AA8,80089
6774,,Cricetulus griseus,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",U,F,2656,,,10029.0,,,CHO-AA8,22224
6775,,Cricetulus griseus,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,U,F,10518,,,10029.0,,,CHO-AA8,22224
6776,,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,U,F,10518,,,10029.0,,,CHO-AA8,22224
6777,,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,U,F,10518,,,10029.0,,,CHO-AA8,22224
6778,,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,U,F,10518,,,10029.0,,,CHO-AA8,22224
6779,,Cricetulus griseus,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,U,F,16156,,,10029.0,,,CHO-AA8,22224
6780,,Cricetulus griseus,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,U,F,2656,,,10029.0,,,CHO-AA8,22224
6781,,Cricetulus griseus,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",U,F,11005,,,10029.0,,,,22224
6782,,Cricetulus griseus,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,U,F,11942,,,10029.0,,,CHO-AA8,22224
6783,,Cricetulus griseus,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,U,F,2128,,,10029.0,,,CHO-AA8,22224
6784,,Canis lupus familiaris,Half life period after 15 mg/kg iv dose in Dogs,N,A,16907,In vivo,,9615.0,,,,50588
6785,,Canis lupus familiaris,Half life period after 30 mg/kg po dose in Dogs,N,A,16907,In vivo,,9615.0,,,,50588
6786,,Canis lupus familiaris,Half life was measured after oral 2b administration (tested in 6 dogs),N,A,9579,In vivo,,9615.0,,,,50588
6787,,Canis lupus familiaris,Half life was measured in dog after oral 17b administration,N,A,9579,In vivo,,9615.0,,,,50588
6788,,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,N,A,9579,In vivo,,9615.0,,,,50588
6789,,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,N,A,9579,In vivo,,9615.0,,,,50588
6790,,Canis lupus familiaris,Tmax value after 15 mg/kg iv dose in Dogs,N,A,16907,In vivo,,9615.0,,,,50588
6791,,Canis lupus familiaris,Tmax value after 30 mg/kg po dose in Dogs,N,A,16907,In vivo,,9615.0,,,,50588
6792,,Canis lupus familiaris,Compound was evaluated for its half life when administered intravenously in dog,N,A,3184,In vivo,,9615.0,,,,50588
6793,,Canis lupus familiaris,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),N,A,5017,In vivo,,9615.0,,Plasma,,50588
6794,,Canis lupus familiaris,Elimination Half-life of compound was determined in dog,N,A,6821,,,9615.0,,,,50588
6795,,Canis lupus familiaris,Half life of compound in dog following oral administration,N,A,17839,In vivo,,9615.0,,,,50588
6796,,Canis lupus familiaris,Half life of compound was determined in dog,N,A,17267,,,9615.0,,,,50588
6797,,Canis lupus familiaris,Half life of compound was determined in dog blood,N,A,4727,,,9615.0,,Blood,,50588
6798,,Canis lupus familiaris,Half life after oral and iv dosing in dogs,N,A,5238,In vivo,,9615.0,,,,50588
6799,,Canis lupus familiaris,Half life in dogs in hours,N,A,4942,,,9615.0,,,,50588
6800,,Canis lupus familiaris,Half life on i.v. administration of 2 mg/kg was measured in dog,N,A,6505,In vivo,,9615.0,,,,50588
6801,,Canis lupus familiaris,t1/2 in dog after oral dose (1 mg/kg),N,A,5130,In vivo,,9615.0,,,,50588
6802,,Canis lupus familiaris,Half life was evaluated in dog,N,A,1475,,,9615.0,,,,50588
6803,,Canis lupus familiaris,Half life period of compound was determined after intravenous administration at 2 mg/kg,N,A,17804,In vivo,,9615.0,,,,50588
6804,,Canis lupus familiaris,Half life period of compound was determined after peroral administration at 2 mg/kg,N,A,17804,In vivo,,9615.0,,,,50588
6805,,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,N,A,6084,In vivo,,9615.0,,,,50588
6806,,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,N,A,6084,In vivo,,9615.0,,,,50588
6807,,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 0.3 mg/kg,N,A,5542,In vivo,,9615.0,,,,50588
6808,,Canis lupus familiaris,Half life period by po administration in dog at a dose of 0.3 mg/kg,N,A,5542,In vivo,,9615.0,,,,50588
6809,,Canis lupus familiaris,Half life period in dog,N,A,6084,,,9615.0,,,,50588
6810,,Canis lupus familiaris,Half life period in dogs after oral administration at 1 mg/kg,N,A,6241,In vivo,,9615.0,,,,50588
6811,,Canis lupus familiaris,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,A,1916,In vivo,,9615.0,,,,50588
6812,,Canis lupus familiaris,Half-life of compound was determined in dogs,N,A,6621,,,9615.0,,,,50588
6813,,Canis lupus familiaris,Half-life in dog plasma,N,A,1696,,,9615.0,,Plasma,,50588
6814,,Canis lupus familiaris,Half-life in mongrel dogs was determined,N,A,17800,,,9615.0,,,,50588
6815,,Canis lupus familiaris,Half-life in dog upon oral administration,N,A,17657,In vivo,,9615.0,,,,50588
6816,,Canis lupus familiaris,Half-life in dog upon oral administration; Unable to calculate,N,A,17657,In vivo,,9615.0,,,,50588
6817,,Canis lupus familiaris,Half-life was measured in dog,N,A,4239,,,9615.0,,,,50588
6818,,Canis lupus familiaris,Half-life was measured in dog,N,A,5985,,,9615.0,,,,50588
6819,,Canis lupus familiaris,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,N,A,9932,,,9615.0,,,,50588
6820,,Canis lupus familiaris,Oral half life was determined,N,A,5199,In vivo,,9615.0,,,,50588
6821,,Canis lupus familiaris,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,N,A,5199,In vivo,,9615.0,,Plasma,,50588
6822,,Canis lupus familiaris,Plasma half life was evaluated,N,A,1475,,,9615.0,,Plasma,,50588
6823,,Canis lupus familiaris,Plasma half life was evaluated in Dog,N,A,1475,,,9615.0,,Plasma,,50588
6824,,Canis lupus familiaris,Plasma half life was evaluated in dog,N,A,1475,,,9615.0,,Plasma,,50588
6825,,Canis lupus familiaris,T1/2 (Half-life) was after oral administration at 5 mg/kg,N,A,6316,In vivo,,9615.0,,,,50588
6826,,Canis lupus familiaris,Tested for the half life value in dog,N,A,4883,,,9615.0,,,,50588
6827,,Canis lupus familiaris,Maximum time at the dose of 2 mg/kg in dog,N,A,4727,In vivo,,9615.0,,,,50588
6828,,Canis lupus familiaris,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,A,1916,In vivo,,9615.0,,,,50588
6829,,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,A,1337,In vivo,,9615.0,,Blood,,50588
6830,,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,A,1337,In vivo,,9615.0,,Blood,,50588
6831,,Canis lupus familiaris,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,N,A,6265,In vivo,,9615.0,,,,50588
6832,,Canis lupus familiaris,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,A,4809,In vivo,,9615.0,,,,50588
6833,,Canis lupus familiaris,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,N,A,5983,In vivo,,9615.0,,,,50588
6834,,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",N,A,5313,,,9615.0,,,,50588
6835,,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",N,A,5313,In vivo,,9615.0,,,,50588
6836,,Canis lupus familiaris,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,N,A,17650,In vivo,,9615.0,,Plasma,,50588
6837,,Canis lupus familiaris,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,N,A,5199,In vivo,,9615.0,,Plasma,,50588
6838,,Canis lupus familiaris,Time taken for maximum plasma concentration in dog,N,A,933,,,9615.0,,Plasma,,50588
6839,,Canis lupus familiaris,Time to reach Cmax after oral administration to dogs,N,A,16367,In vivo,,9615.0,,,,50588
6840,,Canis lupus familiaris,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,A,6348,In vivo,,9615.0,,Plasma,,50588
6841,,Canis lupus familiaris,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,N,A,6316,In vivo,,9615.0,,,,50588
6842,,Canis lupus familiaris,Tmax after peroral administration (1 mg/kg) was determined in dog,N,A,6215,In vivo,,9615.0,,,,50588
6843,,Canis lupus familiaris,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,N,A,3598,In vivo,,9615.0,,,,50588
6844,,Canis lupus familiaris,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,N,A,4527,In vivo,,9615.0,,,,50588
6845,,Canis lupus familiaris,Tmax after peroral administration in dogs at 2.4 uM/kg,N,A,17764,In vivo,,9615.0,,,,50588
6846,,Mus musculus,In vivo Cmax in mice at dose of 100 mg/kg,N,A,5969,In vivo,,10090.0,,,,50594
6847,,Mus musculus,In vivo Cmax in mice at dose of 50 mg/kg,N,A,5969,In vivo,,10090.0,,,,50594
6848,,Mus musculus,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,N,A,4573,In vivo,,10090.0,,,,50594
6849,,Mus musculus,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,A,3277,In vivo,,10090.0,,Plasma,,50594
6850,,Mus musculus,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,N,A,17734,In vivo,,10090.0,,Plasma,,50594
6851,,Mus musculus,Maximum concentration obtained in mouse plasma was determined,N,A,3132,In vivo,,10090.0,,Plasma,,50594
6852,,Mus musculus,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,N,A,3132,In vivo,,10090.0,,Plasma,,50594
6853,,Mus musculus,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,A,6348,In vivo,,10090.0,,Plasma,,50594
6854,,Mus musculus,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,N,A,17729,In vivo,,10090.0,,Plasma,,50594
6855,,Mus musculus,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,N,A,17729,In vivo,,10090.0,,Plasma,,50594
6856,,Mus musculus,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,N,A,17729,In vivo,,10090.0,,Plasma,,50594
6857,,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,N,A,17728,In vivo,,10090.0,,Plasma,,50594
6858,,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,N,A,17728,In vivo,,10090.0,,Plasma,,50594
6859,,Mus musculus,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,N,A,17728,In vivo,,10090.0,,Plasma,,50594
6860,,Mus musculus,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,N,A,4066,In vivo,,10090.0,,,,50594
6861,,Mus musculus,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,N,A,6178,In vivo,,10090.0,,,,50594
6862,,Mus musculus,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,N,A,6178,In vivo,,10090.0,,,,50594
6863,,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,N,A,3760,In vivo,,10090.0,,,,50594
6864,,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,N,A,3760,In vivo,,10090.0,,,,50594
6865,,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,N,A,3760,In vivo,,10090.0,,,,50594
6866,,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,N,A,3760,In vivo,,10090.0,,,,50594
6868,,Mus musculus,Cmax in male mice after 2 mg/kg oral dose,N,A,5961,In vivo,,10090.0,,,,50594
6869,,Mus musculus,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,N,A,6137,In vivo,,10090.0,,,,50594
6870,,Mus musculus,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,N,A,3802,In vivo,,10090.0,,,,50594
6871,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,N,A,3535,,,10090.0,,,,50594
6872,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,N,A,3535,,,10090.0,,,,50594
6873,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,N,A,3535,,,10090.0,,,,50594
6874,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,N,A,3535,,,10090.0,,,,50594
6875,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,N,A,3535,,,10090.0,,,,50594
6876,,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,N,A,3535,,,10090.0,,,,50594
6877,,Mus musculus,Maximum concentration in plasma upon oral administration in mouse,N,A,2862,,,10090.0,,Plasma,,50594
6878,,Mus musculus,Maximum plasma concentration was evaluated in mice after oral administration,N,A,2675,,,10090.0,,Plasma,,50594
6879,,Mus musculus,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,N,A,2675,In vivo,,10090.0,,Plasma,,50594
6880,,Mus musculus,Dose at which the compound induced fecal excretion in mice,N,A,5399,,,10090.0,,,,50594
6893,,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,N,F,11819,,,10116.0,,,A10,80013
6894,,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,N,F,11819,,,10116.0,,,A10,80013
6895,,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,N,F,11819,,,10116.0,,,A10,80013
6896,,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,N,F,11819,,,10116.0,,,A10,80013
6897,,Rattus norvegicus,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),N,F,16361,,,10116.0,,,A10,80013
6898,,Homo sapiens,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,N,F,2288,,,9606.0,,,A121,80655
6899,,Homo sapiens,Anticancer activity against human ovarian carcinoma A121 cells,N,F,10404,,,9606.0,,,A121,80655
6900,,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,N,F,14790,,,9606.0,,,A121,80655
6901,,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,N,F,14790,,,9606.0,,,A121,80655
6902,,Homo sapiens,Growth inhibition of human ovarian carcinoma (A121) cell line,N,F,14253,,,9606.0,,,A121,80655
6903,,Homo sapiens,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,N,F,13617,,,9606.0,,,A121,80655
6904,,Homo sapiens,Cytotoxicity against human A121 ovarian cells,N,F,1003,,,9606.0,,,A121,80655
6905,,Homo sapiens,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,N,F,830,,,9606.0,,,A121,80655
6906,,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma A21,N,F,12307,,,9606.0,,,A121,80655
6907,,Homo sapiens,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,N,F,14254,,,9606.0,,,A121,80655
6908,,Homo sapiens,Inhibitory activity of compound against human A121 ovarian cell line.,N,F,13370,,,9606.0,,,A121,80655
6909,,Homo sapiens,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,N,F,14790,,,9606.0,,,A121,80655
6910,,Homo sapiens,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,N,F,3614,,,9606.0,,,A121,80655
6911,,Homo sapiens,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,N,F,2664,,,9606.0,,,A 172,80012
6912,,Homo sapiens,In vitro cytotoxicity against A172 human tumor cell lines.,N,F,2037,,,9606.0,,,A 172,80012
6913,,Homo sapiens,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,N,F,14539,,,9606.0,,,A 172,80012
6914,,Homo sapiens,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,N,F,2836,,,9606.0,,,A 172,80012
6915,,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,N,F,10708,,,9606.0,,,A 172,80012
6916,,Canis lupus familiaris,Association constant against A2 adenosine receptor,H,B,8975,,,9615.0,,,,104729
6917,,fish,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,N,F,7645,,,,,,A2,80656
6918,,Rattus norvegicus,Ratio of Ki for adenosine A2 and A1 receptor binding,D,B,11377,,,10116.0,,,,104713
6919,,Homo sapiens,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,N,F,13528,,,9606.0,,,A204,80014
6920,,Homo sapiens,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,N,F,10160,,,9606.0,,,A204,80014
6921,,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,N,F,15144,,,9606.0,,,A2058,80015
6922,,Homo sapiens,Growth inhibition against Human squamous cell line(A 253),N,F,13160,,,9606.0,,,A253 cell line,80657
6923,,Homo sapiens,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,N,F,12898,,,9606.0,,,A253 cell line,80657
6924,,Homo sapiens,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,N,F,13069,,,9606.0,,,A253 cell line,80657
6925,,Homo sapiens,Growth inhibition of A253 cell lines.,N,F,15984,,,9606.0,,,A253 cell line,80657
6926,,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),N,F,15564,,,9606.0,,,A253 cell line,80657
6927,,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,N,F,15564,,,9606.0,,,A253 cell line,80657
6928,,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,N,F,15564,,,9606.0,,,A253 cell line,80657
6929,,Homo sapiens,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,N,F,4720,,,9606.0,,,A2780,81034
6930,,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,N,F,16112,,,9606.0,,,A2780,81034
6931,,Homo sapiens,Cytotoxic activity against A2780 human ovarian carcinoma cell line,N,F,16597,,,9606.0,,,A2780,81034
6932,,Homo sapiens,Cytotoxicity against human cancer cell lines A2780 (ovarian),N,F,16378,,,9606.0,,,A2780,81034
6933,,Homo sapiens,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,N,F,16085,,,9606.0,,,A2780,81034
6934,,Homo sapiens,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,N,F,16317,,,9606.0,,,A2780,81034
6935,,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),N,F,15748,,,9606.0,,,A2780,81034
6936,,Homo sapiens,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,N,F,16597,,,9606.0,,,A2780,81034
6937,,Homo sapiens,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,N,F,16597,,,9606.0,,,A2780,81034
6938,,Homo sapiens,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,N,F,16597,,,9606.0,,,A2780,81034
6939,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,N,F,15608,,,9606.0,,,A2780,81034
6940,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,N,F,15608,,,9606.0,,,A2780,81034
6941,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,N,F,15608,,,9606.0,,,A2780,81034
6942,,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,U,F,15296,,,10029.0,,,,22224
6943,,Cricetulus griseus,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,U,A,10251,,,10029.0,,,CHO-AA8,22224
6944,,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic conditions,U,F,10251,,,10029.0,,,CHO-AA8,22224
6945,,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,U,F,10251,,,10029.0,,,CHO-AA8,22224
6946,,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),U,F,10251,,,10029.0,,,CHO-AA8,22224
6947,,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8,U,F,11858,,,10029.0,,,,22224
6948,,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],U,F,11858,,,10029.0,,,CHO-AA8,22224
6949,,hampster,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,N,F,11616,,,36483.0,,,CHO-AA8,80089
6950,,Cricetulus griseus,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,N,F,11616,,,10029.0,,,CHO-AA8,80089
6951,,Cricetulus griseus,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,U,F,10518,,,10029.0,,,CHO-AA8,22224
6952,,Cricetulus griseus,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,U,F,11396,,,10029.0,,,CHO-AA8,22224
6953,,Cricetulus griseus,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,U,F,10518,,,10029.0,,,CHO-AA8,22224
6954,,Cricetulus griseus,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,N,F,11616,,,10029.0,,,CHO-AA8,80089
6955,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,H,F,14837,,,,,,,12675
6956,,,Number of binding sites (n) of isolated serum protein AAG,H,F,14837,,,,,,,12675
6957,,,Association constant for binding to AATT duplex,M,B,16037,,,,,,,22222
6958,,Homo sapiens,Inhibition of ABAE human fibroblast cell proliferation,N,F,16597,,,9606.0,,,ABAE,100090
6959,,Mus musculus,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",N,F,8831,,,10090.0,,,AC755,80668
6960,,Oryctolagus cuniculus,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,D,F,13419,,,9986.0,,,,102444
6961,,Oryctolagus cuniculus,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,D,F,13419,In vivo,,9986.0,,,,102444
6962,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,H,B,15778,,,,,,,69
6963,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,H,B,15778,,,,,,,69
6964,,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,N,F,12988,,,9606.0,,,ACH-2 cell line,80669
6965,,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),N,F,12988,,,9606.0,,,ACH-2 cell line,80669
6966,,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,U,F,12988,,,11676.0,,,T cell line,22224
6967,,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),U,F,12988,,,11676.0,,,T cell line,22224
6968,,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),U,F,12988,,,11676.0,,,T cell line,22224
6969,,Homo sapiens,Inhibition of growth of renal cancer ACHN cell line,N,F,11843,,,9606.0,,,ACHN,80025
6970,,Homo sapiens,Inhibition of growth of ACHN renal cancer cell line,N,F,16939,,,9606.0,,,ACHN,80025
6971,,Homo sapiens,Inhibitory concentration required against ACHN renal cancer cell line,N,F,4782,,,9606.0,,,ACHN,80025
6972,,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line,N,F,6310,,,9606.0,,,ACHN,80025
6973,,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,N,F,6310,,,9606.0,,,ACHN,80025
6974,,Homo sapiens,Cytotoxic activity against ACHN Renal cancer cell line,N,F,12858,,,9606.0,,,ACHN,80025
6975,,Homo sapiens,Cytotoxicity evaluation against ACHN renal cancer cells,N,F,17380,,,9606.0,,,ACHN,80025
6976,,Homo sapiens,In vitro antitumor activity against human renal ACHN cell line,N,F,5858,,,9606.0,,,ACHN,80025
6977,,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,N,F,3838,,,9606.0,,,ACHN,80025
6978,,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,N,F,3838,,,9606.0,,,ACHN,80025
6979,,Homo sapiens,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",N,F,5406,,,9606.0,,,ACHN,80025
6980,,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,N,F,4071,,,9606.0,,,ACHN,80025
6981,,Homo sapiens,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,N,F,4071,,,9606.0,,,ACHN,80025
6982,,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,N,F,4071,,,9606.0,,,ACHN,80025
6983,,Homo sapiens,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,N,F,15002,,,9606.0,,,ACHN,80025
6984,,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),N,F,14769,,,9606.0,,,ACHN,80025
6985,,Homo sapiens,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",N,F,13958,,,9606.0,,,ACHN,80025
6986,,Homo sapiens,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,N,F,1665,,,9606.0,,,ACHN,80025
6987,,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line,N,F,15354,,,9606.0,,,ACHN,80025
6988,,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,N,F,15354,,,9606.0,,,ACHN,80025
6989,,Homo sapiens,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,N,F,13978,,,9606.0,,,ACHN,80025
6990,,Homo sapiens,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,N,F,6798,,,9606.0,,,ACHN,80025
6991,,Canis lupus familiaris,Tmax value after administration of 4 mg/Kg oral dose in dog,N,A,2959,In vivo,,9615.0,,,,50588
6992,,Canis lupus familiaris,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",N,A,9932,,,9615.0,,,,50588
6993,,Canis lupus familiaris,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,A,5546,,,9615.0,,,,50588
6994,,Canis lupus familiaris,Volume distribution after 15 mg/kg iv dose in Dogs,N,A,16907,In vivo,,9615.0,,,,50588
6995,,Canis lupus familiaris,Volume distribution after 30 mg/kg po dose in Dogs,N,A,16907,In vivo,,9615.0,,,,50588
6996,,Canis lupus familiaris,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,N,A,4257,In vivo,,9615.0,,,,50588
6997,,Canis lupus familiaris,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,N,A,4305,In vivo,,9615.0,,,,50588
6998,,Canis lupus familiaris,Volume of distribution was evaluated in dog,N,A,5472,In vivo,,9615.0,,,,50588
6999,,Canis lupus familiaris,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,N,A,6062,In vivo,,9615.0,,,,50588
7000,,Canis lupus familiaris,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,N,A,3598,,,9615.0,,,,50588
7001,,Canis lupus familiaris,The compound was tested for volume of distribution in dog,N,A,12500,In vivo,,9615.0,,,,50588
7002,,Canis lupus familiaris,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,N,A,12500,In vivo,,9615.0,,,,50588
7003,,Canis lupus familiaris,Vd (1 mg/kg) was determined in dog (in vivo),N,A,6227,In vivo,,9615.0,,,,50588
7004,,Canis lupus familiaris,Vd in dog,N,A,6227,In vivo,,9615.0,,,,50588
7005,,Canis lupus familiaris,Volume distribution was determined,N,A,4219,In vivo,,9615.0,,,,50588
7006,,Canis lupus familiaris,Volume of distribution in dog,N,A,1696,In vivo,,9615.0,,,,50588
7007,,Canis lupus familiaris,Volume of distribution by as 4 fold increase by iv administration in dogs,N,A,5542,In vivo,,9615.0,,,,50588
7008,,Canis lupus familiaris,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,N,A,5199,In vivo,,9615.0,,,,50588
7009,,Canis lupus familiaris,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,A,6348,In vivo,,9615.0,,,,50588
7010,,Canis lupus familiaris,Volume distribution at the dose of 2 mg/kg in dog,N,A,4727,In vivo,,9615.0,,,,50588
7011,,Canis lupus familiaris,Steady state volume of distribution was determined,N,A,16367,In vivo,,9615.0,,,,50588
7012,,Canis lupus familiaris,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,N,A,2652,In vivo,,9615.0,,,,50588
7013,,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,A,16452,In vivo,,9615.0,,,,50588
7014,,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,A,16452,In vivo,,9615.0,,,,50588
7015,,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),N,A,16452,In vivo,,9615.0,,,,50588
7016,,Canis lupus familiaris,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,A,5334,In vivo,,9615.0,,,,50588
7017,,Canis lupus familiaris,Pharmacokinetic property (vdss) was measured in dog,N,A,4239,In vivo,,9615.0,,,,50588
7018,,Canis lupus familiaris,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,N,A,4709,In vivo,,9615.0,,,,50588
7019,,Canis lupus familiaris,Vdss was determined after iv 0.1 mg/kg administration in dog,N,A,5600,In vivo,,9615.0,,,,50588
7020,,Canis lupus familiaris,Volume displacement was calculated in dog,N,A,6057,In vivo,,9615.0,,,,50588
7021,,Canis lupus familiaris,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,A,5654,In vivo,,9615.0,,,,50588
7022,,Canis lupus familiaris,Volume distribution constant was determined,N,A,5505,In vivo,,9615.0,,,,50588
7023,,Canis lupus familiaris,Volume distribution at a dose of 1 uM/kg in dog was determined,N,A,4527,In vivo,,9615.0,,,,50588
7024,,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,A,4521,In vivo,,9615.0,,,,50588
7025,,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,A,4521,In vivo,,9615.0,,,,50588
7026,,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,N,A,15660,In vivo,,9615.0,,,,50588
7027,,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,N,A,15660,In vivo,,9615.0,,,,50588
7028,,Canis lupus familiaris,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,A,6679,In vivo,,9615.0,,,,50588
7029,,Canis lupus familiaris,Volume of distribution in steady state was determined in dog,N,A,5145,In vivo,,9615.0,,,,50588
7030,,Canis lupus familiaris,Volume of distribution of compound was determined in dog,N,A,6821,In vivo,,9615.0,,,,50588
7031,,Canis lupus familiaris,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,N,A,4137,In vivo,,9615.0,,,,50588
7032,,Canis lupus familiaris,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),N,A,5334,In vivo,,9615.0,,,,50588
7033,,Canis lupus familiaris,Volume of distribution (Vdss) was measured in dog,N,A,15660,In vivo,,9615.0,,,,50588
7034,,Canis lupus familiaris,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,A,6642,In vivo,,9615.0,,,,50588
7035,,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,A,6641,In vivo,,9615.0,,,,50588
7036,,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,A,6642,In vivo,,9615.0,,,,50588
7037,,Canis lupus familiaris,Maximum rate of depolarization of the upstroke of the action potential,N,A,11659,,,9615.0,,,,50588
7038,,Canis lupus familiaris,Steady state volume distribution in dog,N,A,6448,In vivo,,9615.0,,,,50588
7039,,Canis lupus familiaris,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,N,A,5474,In vivo,,9615.0,,,,50588
7040,,Canis lupus familiaris,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,N,A,1466,In vivo,,9615.0,,,,50588
7041,,Canis lupus familiaris,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,N,A,6535,In vivo,,9615.0,,,,50588
7042,,Canis lupus familiaris,Volume distribution in dog after administration of 1 mg/kg iv,N,A,6535,In vivo,,9615.0,,,,50588
7043,,Canis lupus familiaris,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,N,A,17764,In vivo,,9615.0,,,,50588
7044,,Canis lupus familiaris,Vss after intravenous administration (0.5 mg/kg) was determined in dog,N,A,6215,In vivo,,9615.0,,,,50588
7045,,Canis lupus familiaris,Vss on i.v. administration of 2 mg/kg was measured in dog,N,A,6505,In vivo,,9615.0,,,,50588
7046,,Canis lupus familiaris,Vss was determined,N,A,3639,,,9615.0,,,,50588
7047,,Canis lupus familiaris,Vss in dog,N,A,3639,,,9615.0,,,,50588
7048,,Canis lupus familiaris,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,N,A,6062,In vivo,,9615.0,,,,50588
7049,,Canis lupus familiaris,Volume distribution in dogs,N,A,4942,In vivo,,9615.0,,,,50588
7050,,Canis lupus familiaris,Volume of distribution in dog,N,A,17796,In vivo,,9615.0,,,,50588
7051,,Canis lupus familiaris,Tested for the oral bioavailability in dog,N,A,4883,In vivo,,9615.0,,,,50588
7060,,Mus musculus,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,N,A,17837,In vivo,,10090.0,,,,50594
7061,,Mus musculus,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,N,A,17729,In vivo,,10090.0,,,,50594
7062,,Mus musculus,Bioavailability after peroral administration of 50 mg/kg of dose in mice,N,A,17729,In vivo,,10090.0,,,,50594
7063,,Mus musculus,Bioavailability was measured in mouse,N,A,4239,In vivo,,10090.0,,,,50594
7064,,Mus musculus,Bioavailability in mouse,N,A,17592,In vivo,,10090.0,,,,50594
7065,,Mus musculus,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,A,6348,In vivo,,10090.0,,,,50594
7066,,Mus musculus,Bioavailability in mouse,N,A,2801,In vivo,,10090.0,,,,50594
7067,,Mus musculus,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,N,A,2801,In vivo,,10090.0,,,,50594
7068,,Mus musculus,Oral bioavailability in mouse,N,A,17718,In vivo,,10090.0,,,,50594
7069,,Mus musculus,Oral availability at 50 mg/kg po in male mice,N,A,5727,In vivo,,10090.0,,,,50594
7070,,Mus musculus,Oral bioavailability in mouse (dose 10 mg/kg),N,A,5302,In vivo,,10090.0,,,,50594
7071,,Mus musculus,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,N,A,3598,In vivo,,10090.0,,,,50594
7072,,Mus musculus,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",N,A,5961,In vivo,,10090.0,,,,50594
7074,,Mus musculus,Oral bioavailability in mouse,N,A,6091,In vivo,,10090.0,,,,50594
7075,,Mus musculus,Oral bioavailability in vivo in mice;ND=Not determined,N,A,6091,In vivo,,10090.0,,,,50594
7076,,Mus musculus,Oral bioavailability in mouse at 10 mg/kg of the compound,N,A,5711,In vivo,,10090.0,,,,50594
7077,,Mus musculus,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),N,A,17728,In vivo,,10090.0,,,,50594
7078,,Mus musculus,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),N,A,17728,In vivo,,10090.0,,,,50594
7079,,Mus musculus,Tested for bioavailability of the compound,N,A,3802,In vivo,,10090.0,,,,50594
7080,,Mus musculus,Tested for half life at the dose of 10 mg/kg when administered intravenously,N,A,3802,In vivo,,10090.0,,,,50594
7081,,Mus musculus,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,N,A,14029,,,10090.0,,Plasma,,50594
7082,,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma. ,N,A,14029,,,10090.0,,Plasma,,50594
7083,,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,N,A,14029,,,10090.0,,Plasma,,50594
7084,,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,N,A,14029,,,10090.0,,Plasma,,50594
7085,,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,N,A,14029,,,10090.0,,Plasma,,50594
7086,,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,N,F,17753,,,10090.0,,,,50594
7087,,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,N,A,17753,,,10090.0,,,,50594
7088,,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,N,A,17753,,,10090.0,,,,50594
7089,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,Blood,,50594
7090,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,A,10107,In vivo,,10090.0,,Blood,,50594
7091,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,Blood,,50594
7092,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,Blood,,50594
7093,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,Blood,,50594
7094,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,A,10107,In vivo,,10090.0,,Blood,,50594
7095,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,Blood,,50594
7096,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,Bone,,50594
7097,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,A,10107,In vivo,,10090.0,,Bone,,50594
7098,,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,N,F,15608,,,9606.0,,,A2780,81034
7099,,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,N,F,3290,,,9606.0,,,A2780,81034
7100,,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,N,F,2859,,,9606.0,,,A2780,81034
7101,,Homo sapiens,Inhibition of A2780 cell clonogenic assay,N,F,15688,,,9606.0,,,A2780,81034
7102,,Homo sapiens,Cytotoxic effect on ovarian cancer cell line (A2780),N,F,5642,,,9606.0,,,A2780,81034
7103,,Homo sapiens,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,N,F,6633,,,9606.0,,,A2780,81034
7104,,Homo sapiens,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",N,F,3906,,,9606.0,,,A2780,81034
7105,,Homo sapiens,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,N,F,6788,,,9606.0,,,A2780,81034
7106,,Homo sapiens,Antiproliferative activity against human A2780 cells,N,F,17582,,,9606.0,,,A2780,81034
7107,,Homo sapiens,Inhibition of human A2780 cell proliferation,N,F,17764,,,9606.0,,,A2780,81034
7108,,Homo sapiens,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,N,F,17764,,,9606.0,,,A2780,81034
7109,,Homo sapiens,Inhibition of human A2780 cell proliferation (No data),N,F,17764,,,9606.0,,,A2780,81034
7110,,Homo sapiens,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,N,F,2815,,,9606.0,,,A2780,81034
7111,,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780,N,F,16930,,,9606.0,,,A2780,81034
7112,,Homo sapiens,Growth inhibition against A2780 wild-type ovarian cell lines,N,F,17777,,,9606.0,,,A2780,81034
7113,,Homo sapiens,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,N,F,17777,,,9606.0,,,A2780,81034
7114,,Homo sapiens,Inhibition of tubulin polymerization in human ovarian cancer cell lines,D,F,16936,,,9606.0,,,,104766
7115,,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,N,F,13759,,,9606.0,,,A2780,81034
7116,,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,N,F,13759,,,9606.0,,,A2780,81034
7117,,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,N,F,13759,,,9606.0,,,A2780,81034
7118,,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,N,F,13759,,,9606.0,,,A2780,81034
7119,,Homo sapiens,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,N,F,15292,,,9606.0,,,A2780,81034
7120,,Homo sapiens,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,N,F,15292,,,9606.0,,,A2780,81034
7121,,Homo sapiens,In vitro inhibition of human ovarian cell line A2780,N,F,15069,,,9606.0,,,A2780,81034
7122,,Homo sapiens,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",N,F,15069,,,9606.0,,,A2780,81034
7123,,Homo sapiens,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),N,F,14073,,,9606.0,,,A2780,81034
7124,,Homo sapiens,Concentration required to inhibit A2780-cell growth by 50%,N,F,14553,,,9606.0,,,A2780,81034
7125,,Homo sapiens,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,N,F,13040,,,9606.0,,,A2780,81034
7126,,Homo sapiens,Cytotoxic effect on human ovarian (A2780) cancer cell line,N,F,6891,,,9606.0,,,A2780,81034
7127,,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,N,F,15569,,,9606.0,,,A2780,81034
7128,,Homo sapiens,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,N,F,14190,,,9606.0,,,A2780,81034
7129,,Homo sapiens,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,N,F,15014,,,9606.0,,,A2780,81034
7130,,Homo sapiens,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,N,F,15014,,,9606.0,,,A2780,81034
7131,,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780 cell line,N,F,17496,,,9606.0,,,A2780,81034
7132,,Homo sapiens,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",N,F,13617,,,9606.0,,,A2780,81034
7133,,Homo sapiens,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",N,F,13617,,,9606.0,,,A2780,81034
7134,,Homo sapiens,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",N,F,13617,,,9606.0,,,A2780,81034
7135,,Homo sapiens,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",N,F,13617,,,9606.0,,,A2780,81034
7136,,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,N,F,17672,,,9606.0,,,A2780,81034
7137,,Homo sapiens,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,N,F,4544,,,9606.0,,,A2780,81034
7138,,Homo sapiens,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,N,F,4544,,,9606.0,,,A2780,81034
7139,,Homo sapiens,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",N,F,16317,,,9606.0,,,A2780,81034
7140,,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,N,F,15099,,,9606.0,,,A2780,81034
7141,,Homo sapiens,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,N,F,13978,,,9606.0,,,A2780,81034
7142,,Homo sapiens,In vitro antitumor activity against A2780 cell line.,N,F,12989,,,9606.0,,,A2780,81034
7143,,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,N,F,5574,,,9606.0,,,A2780,81034
7144,,Homo sapiens,In vitro cytotoxicity against A2780 human ovarian cancer cell line,N,F,13528,,,9606.0,,,A2780,81034
7145,,Homo sapiens,Inhibitory activity against kidney A-CHN tumor cell growth in culture,N,F,12782,,,9606.0,,,ACHN,80025
7146,,Homo sapiens,The IC50 value was measured on ACHN cell line in renal tumor type.,N,F,14255,,,9606.0,,,ACHN,80025
7147,,Homo sapiens,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,N,F,16364,,,9606.0,,,ACHN,80025
7148,,Homo sapiens,In vitro lethal concentration against most sensitive ACHN cell line,N,F,17376,,,9606.0,,,ACHN,80025
7149,,Homo sapiens,Tested for cytotoxic activity against renal cancer ACHN cell line,N,F,12016,,,9606.0,,,ACHN,80025
7150,,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line ACHN,N,F,6058,,,9606.0,,,ACHN,80025
7151,,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,N,F,17708,,,9606.0,,,ACHN,80025
7152,,Homo sapiens,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,N,F,15176,,,9606.0,,,ACHN,80025
7153,,Homo sapiens,In vitro anticancer activity against ACHN renal cancer cell line,N,F,2806,,,9606.0,,,ACHN,80025
7154,,Homo sapiens,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,N,F,15300,,,9606.0,,,ACHN,80025
7155,,Homo sapiens,Percent selectivity was evaluated in renal ACHN cell lines,N,F,16364,,,9606.0,,,ACHN,80025
7156,,Homo sapiens,In vitro inhibitory activity against renal ACHN cancer cell line,N,F,13859,,,9606.0,,,ACHN,80025
7157,,Homo sapiens,Tested for cytotoxicity against ACHN cell lines in renal cancer,N,F,11970,,,9606.0,,,ACHN,80025
7158,,Homo sapiens,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,N,F,2450,,,9606.0,,,ACHN,80025
7159,,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,N,F,12696,,,9606.0,,,ACHN,80025
7160,,Homo sapiens,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,N,F,12400,,,9606.0,,,ACHN,80025
7161,,Homo sapiens,Cytotoxic effect on renal cancer line ACHN,N,F,12888,,,9606.0,,,ACHN,80025
7162,,Homo sapiens,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,N,F,3156,,,9606.0,,,ACHN,80025
7163,,Homo sapiens,In vitro inhibition of Renal Cancer ACHN cell lines,N,F,3381,,,9606.0,,,ACHN,80025
7164,,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells,N,F,16747,,,9606.0,,,ACHN,80025
7165,,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells.,N,F,16748,,,9606.0,,,ACHN,80025
7166,,Homo sapiens,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,N,F,12062,,,9606.0,,,ACHN,80025
7167,,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),N,F,14769,,,9606.0,,,ACHN,80025
7168,,Homo sapiens,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",N,F,15895,,,9606.0,,,ACHN,80025
7169,,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,N,F,17376,,,9606.0,,,ACHN,80025
7170,,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,N,F,14882,,,9606.0,,,ACHN,80025
7171,,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,N,F,14882,,,9606.0,,,ACHN,80025
7172,,Homo sapiens,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,N,F,15661,,,9606.0,,,ACHN,80025
7173,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,U,A,9680,,,,,,,22224
7174,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,H,F,14579,,,,,,,10647
7175,,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,N,F,17290,,,10358.0,,,HEL,50529
7176,,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,N,F,17290,,,10358.0,,,,50529
7177,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),H,B,15891,,,,,,,12159
7178,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),H,B,15890,,,,,,,12159
7179,,Bos taurus,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,N,F,3801,,,9913.0,,,ADDP cell line,80670
7180,,Mus musculus,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,N,F,9222,,,10090.0,,,ADJ/PC6,80671
7181,,Mus musculus,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,N,F,9222,,,10090.0,,,ADJ/PC6,80671
7182,,Mus musculus,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",N,F,7257,,,10090.0,,,ADJ/PC6,80671
7183,,Mus musculus,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,N,F,7257,,,10090.0,,,ADJ/PC6,80671
7184,,Mus musculus,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,N,A,7257,,,10090.0,,,ADJ/PC6,80671
7185,,Mus musculus,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,N,F,8084,,,10090.0,,,ADJ/PC6,80671
7186,,Mus musculus,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,U,F,14943,,,10090.0,,,,22224
7187,,Mus musculus,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,U,F,14943,,,10090.0,,,,22224
7188,,Mus musculus,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,U,F,14943,,,10090.0,,,,22224
7189,,Bacillus subtilis,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),U,A,10524,In vivo,,1423.0,,,,22224
7190,,Canis lupus familiaris,AUC value in dog after IV administration at a dose of 5 mg/kg,N,A,3546,,,9615.0,,Plasma,,50588
7191,,Canis lupus familiaris,AUC value in dog after oral administration at a dose of 5 mg/kg,N,A,3546,,,9615.0,,Plasma,,50588
7192,,Canis lupus familiaris,Cmax value in dog after oral administration at a dose of 5 mg/kg,N,A,3546,In vivo,,9615.0,,,,50588
7193,,Canis lupus familiaris,Bioavailability in dog after oral administration at a dose of 5 mg/kg,N,A,3546,In vivo,,9615.0,,,,50588
7194,,Canis lupus familiaris,Tmax value in dog after oral administration at a dose of 5 mg/kg,N,A,3546,In vivo,,9615.0,,,,50588
7195,,Canis lupus familiaris,Compound was evaluated for its clearance when administered intravenously in dog,N,A,3184,In vivo,,9615.0,,,,50588
7196,,Canis lupus familiaris,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,A,16456,In vivo,,9615.0,,,,50588
7197,,Canis lupus familiaris,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),N,A,4809,In vivo,,9615.0,,,,50588
7198,,,Calculated partition coefficient (clogP),U,P,4219,,,,,,,22229
7199,,Canis lupus familiaris,Half life in dog,N,A,3748,,,9615.0,,,,50588
7200,,Canis lupus familiaris,Time taken for EC90 was determined when tested in dog,N,A,3132,,,9615.0,,,,50588
7201,,Canis lupus familiaris,Half life (iv) was determined,N,A,4219,,,9615.0,,,,50588
7202,,Canis lupus familiaris,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,N,A,16907,,,9615.0,,Liver,,50588
7203,,Canis lupus familiaris,Area under the curve was calculated in dog after iv administration,N,A,6057,,,9615.0,,,,50588
7204,,Canis lupus familiaris,Area under the curve was calculated in dog after peroral administration,N,A,6057,,,9615.0,,,,50588
7205,,Canis lupus familiaris,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,N,A,17853,,,9615.0,,,,50588
7206,,Canis lupus familiaris,pKa was evaluated in dog,N,A,3639,,,9615.0,,,,50588
7207,,Canis lupus familiaris,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,N,A,14541,,,9615.0,,,,50588
7208,,Canis lupus familiaris,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,A,16456,In vivo,,9615.0,,,,50588
7209,,Canis lupus familiaris,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,A,16456,In vivo,,9615.0,,,,50588
7210,,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,N,A,2652,In vivo,,9615.0,,,,50588
7211,,Canis lupus familiaris,Compound was evaluated for the half-life (t 1/2) in hours,N,A,3624,,,9615.0,,,,50588
7212,,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,A,1337,In vivo,,9615.0,,Blood,,50588
7213,,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,A,1337,In vivo,,9615.0,,Blood,,50588
7214,,Canis lupus familiaris,Half life after intravenous administration of 1 mg/kg in dog,N,A,4709,In vivo,,9615.0,,,,50588
7215,,Canis lupus familiaris,Half life was measured in dog,N,A,15660,,,9615.0,,,,50588
7216,,Canis lupus familiaris,Half life period in dog after 5 mg/kg dose,N,A,5302,In vivo,,9615.0,,,,50588
7217,,Canis lupus familiaris,Half life period was evaluated in dog; 4-4.8,N,A,17791,,,9615.0,,,,50588
7218,,Canis lupus familiaris,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,A,6348,In vivo,,9615.0,,,,50588
7219,,Canis lupus familiaris,Half-life was determined in dog after a3 mg/kg of iv dose,N,A,4257,In vivo,,9615.0,,,,50588
7220,,Canis lupus familiaris,Half-life was determined,N,A,3771,,,9615.0,,,,50588
7221,,Canis lupus familiaris,Half life in dogs,N,A,6305,,,9615.0,,,,50588
7222,,Canis lupus familiaris,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,N,A,13501,In vivo,,9615.0,,Plasma,,50588
7223,,Canis lupus familiaris,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,N,A,17594,In vivo,,9615.0,,,,50588
7224,,Canis lupus familiaris,Compound was evaluated for the half life period after iv administration in Beagle dog.,N,A,3045,In vivo,,9615.0,,,,50588
7225,,Canis lupus familiaris,Compound was evaluated for the half life period after oral administration in conscious dog.,N,A,3043,In vivo,,9615.0,,,,50588
7226,,Canis lupus familiaris,Compound was tested for half life in dog,N,A,4839,,,9615.0,,,,50588
7227,,Canis lupus familiaris,Compound was tested for its half life in dog,N,A,4839,,,9615.0,,,,50588
7228,,Canis lupus familiaris,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,A,5802,In vivo,,9615.0,,,,50588
7229,,Canis lupus familiaris,Half life of compound in dog was determined,N,A,17839,,,9615.0,,,,50588
7230,,Canis lupus familiaris,Half life (iv) was determined,N,A,4219,In vivo,,9615.0,,,,50588
7231,,Canis lupus familiaris,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),N,A,13966,,,9615.0,,Blood,,50588
7232,,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,N,A,3994,In vivo,,9615.0,,Plasma,,50588
7233,,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,N,F,3994,In vivo,,9615.0,,Plasma,,50588
7234,,Canis lupus familiaris,Half life in dog,N,A,4453,,,9615.0,,,,50588
7235,,Canis lupus familiaris,Half life in dog plasma,N,A,6535,,,9615.0,,Plasma,,50588
7236,,Canis lupus familiaris,Half life in dog plasma after administration of 0.25 mg/kg iv,N,A,6535,In vivo,,9615.0,,Plasma,,50588
7237,,Canis lupus familiaris,Half life in dog plasma after administration of 1 mg/kg iv,N,A,6535,In vivo,,9615.0,,Plasma,,50588
7238,,Canis lupus familiaris,Half life in dog plasma was determined at dose 10 mg/kg,N,A,3132,In vivo,,9615.0,,Plasma,,50588
7239,,Canis lupus familiaris,Half life in dog was determined,N,A,5374,,,9615.0,,,,50588
7240,,Canis lupus familiaris,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,A,5007,In vivo,,9615.0,,,,50588
7241,,Canis lupus familiaris,Half life upon exposure to human plasma,N,A,16907,,,9615.0,,Plasma,,50588
7242,,Canis lupus familiaris,Half life was calculated in dog,N,A,6057,,,9615.0,,,,50588
7243,,Canis lupus familiaris,Half life was determined,N,A,5006,,,9615.0,,,,50588
7244,,Canis lupus familiaris,Half life was determined,N,A,5473,,,9615.0,,,,50588
7245,,Canis lupus familiaris,Half life by intravenous administration of 1.2 mg/kg in dog,N,A,4368,In vivo,,9615.0,,,,50588
7246,,Canis lupus familiaris,Half life in dog,N,A,6448,,,9615.0,,,,50588
7247,,Canis lupus familiaris,Half life in dog after intra venous administration of the compound,N,A,4353,,,9615.0,,,,50588
7248,,Canis lupus familiaris,Half life in dog after intra venous administration of the compound; ND means Not determined,N,A,4353,,,9615.0,,,,50588
7249,,Canis lupus familiaris,Half life in dog after po administration of the compound,N,A,4353,In vivo,,9615.0,,,,50588
7250,,Canis lupus familiaris,Half life in dog after po administration of the compound; ND means Not determined,N,A,4353,In vivo,,9615.0,,,,50588
7251,,Canis lupus familiaris,Half life in dog at the single oral dose of 1 mg/kg,N,A,6265,In vivo,,9615.0,,,,50588
7252,,Canis lupus familiaris,Half life in dogs,N,A,5006,,,9615.0,,,,50588
7253,,Canis lupus familiaris,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,N,A,5356,In vivo,,9615.0,,,,50588
7254,,Canis lupus familiaris,Half life in rat,N,A,405,,,9615.0,,,,50588
7255,,Canis lupus familiaris,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,A,6642,In vivo,,9615.0,,,,50588
7256,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,Bone,,50594
7257,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,Bone,,50594
7258,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,Bone,,50594
7259,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,A,10107,In vivo,,10090.0,,Bone,,50594
7260,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,Bone,,50594
7261,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,Gut,,50594
7262,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,A,10107,In vivo,,10090.0,,Gut,,50594
7263,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,Gut,,50594
7264,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,Gut,,50594
7265,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,Gut,,50594
7266,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,A,10107,In vivo,,10090.0,,Gut,,50594
7267,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,Gut,,50594
7268,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,Heart,,50594
7269,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,A,10107,In vivo,,10090.0,,Heart,,50594
7270,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,Heart,,50594
7271,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,Heart,,50594
7272,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,Heart,,50594
7273,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,A,10107,In vivo,,10090.0,,Heart,,50594
7274,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,Heart,,50594
7275,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,Kidney,,50594
7276,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,A,10107,In vivo,,10090.0,,Kidney,,50594
7277,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,Kidney,,50594
7278,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,Kidney,,50594
7279,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,Kidney,,50594
7280,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,A,10107,In vivo,,10090.0,,Kidney,,50594
7281,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,Kidney,,50594
7282,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,Liver,,50594
7283,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,A,10107,In vivo,,10090.0,,Liver,,50594
7284,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,Liver,,50594
7285,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,Liver,,50594
7286,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,Liver,,50594
7287,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,A,10107,In vivo,,10090.0,,Liver,,50594
7288,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,Liver,,50594
7289,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,Lung,,50594
7290,,Homo sapiens,In vitro cytotoxicity against A2780 (human ovarian cancer),N,F,5895,,,9606.0,,,A2780,81034
7291,,Homo sapiens,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,N,F,6338,,,9606.0,,,A2780,81034
7292,,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,N,F,15163,,,9606.0,,,A2780,81034
7293,,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,N,F,15163,,,9606.0,,,A2780,81034
7294,,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,N,F,15000,,,9606.0,,,A2780,81034
7295,,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,N,F,15000,,,9606.0,,,A2780,81034
7296,,Homo sapiens,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,N,F,14729,,,9606.0,,,A2780,81034
7297,,Homo sapiens,In vitro cytotoxicity against A2780 cell line,N,F,17270,,,9606.0,,,A2780,81034
7298,,Homo sapiens,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,N,F,5685,,,9606.0,,,A2780,81034
7299,,Homo sapiens,In vitro inhibitory activity against human ovarian cancer A2780 cell line,N,F,3563,,,9606.0,,,A2780,81034
7300,,Homo sapiens,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,N,F,17753,,,9606.0,,,A2780,81034
7301,,Homo sapiens,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",N,F,16317,,,9606.0,,,A2780,81034
7302,,Homo sapiens,Inhibition of tubulin polymerization in analogy of ca.,N,F,16936,,,9606.0,,,A2780,81034
7303,,Homo sapiens,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,N,F,3801,,,9606.0,,,A2780,81034
7304,,Homo sapiens,Cytotoxic effect in ovarian cancer cell line (A2780),N,F,6181,,,9606.0,,,A2780,81034
7305,,Homo sapiens,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,N,F,5318,,,9606.0,,,A2780,81034
7306,,Homo sapiens,Tested for the cytotoxicity in A2780 ovarian cell line,N,F,4840,,,9606.0,,,A2780,81034
7307,,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),N,F,15748,,,9606.0,,,A2780,81034
7308,,Homo sapiens,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,N,F,15748,,,9606.0,,,A2780,81034
7309,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,N,F,15748,,,,,,A2780cisR,80017
7310,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),N,F,15748,,,,,,A2780cisR,80017
7311,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,N,F,15748,,,,,,A2780cisR,80017
7312,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),N,F,15748,,,,,,A2780cisR,80017
7313,,Homo sapiens,In vivo log of cells killed after administration of compound in A2780 cell line,N,F,17753,,,9606.0,,,A2780,81034
7314,,Homo sapiens,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,N,F,17753,In vivo,,9606.0,,,A2780,81034
7315,,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,N,F,16936,,,9606.0,,,A2780,81034
7316,,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,N,F,16936,,,9606.0,,,A2780,81034
7317,,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,N,F,16936,,,9606.0,,,A2780,81034
7318,,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,N,F,16936,,,9606.0,,,A2780,81034
7319,,Homo sapiens,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),N,F,17528,,,9606.0,,,A2780,81034
7320,,Homo sapiens,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,N,F,6633,,,9606.0,,,A2780,81034
7321,,Homo sapiens,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,N,F,15000,,,9606.0,,,A2780,81034
7322,,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,N,F,17528,,,9606.0,,,A2780,81034
7323,,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,N,F,16936,,,9606.0,,,A2780,81034
7324,,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,N,F,16936,,,9606.0,,,A2780,81034
7325,,Homo sapiens,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,N,F,16936,,,9606.0,,,A2780,81034
7326,,Homo sapiens,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",N,F,16936,,,9606.0,,,A2780,81034
7327,,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),N,F,16936,,,9606.0,,,A2780,81034
7328,,Homo sapiens,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",N,F,16936,,,9606.0,,,A2780,81034
7329,,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,F,16936,,,9606.0,,,A2780,81034
7330,,Homo sapiens,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,F,16936,,,9606.0,,,A2780,81034
7331,,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,F,16936,,,9606.0,,,A2780,81034
7332,,Mus musculus,In vitro antiproliferative activity against A2780 cell line,N,F,17737,,,10090.0,,,A2780,81034
7333,,Mus musculus,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,N,F,17764,,,10090.0,,,A2780,81034
7334,,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,N,F,3830,,,9606.0,,,A2780,81034
7335,,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,N,F,3829,,,9606.0,,,A2780,81034
7336,,Canis lupus familiaris,Vc value in dog after IV administration at a dose of 5 mg/kg,N,A,3546,,,9615.0,,,,50588
7337,,Canis lupus familiaris,Half life period in dog after IV administration at a dose of 5 mg/kg,N,A,3546,In vivo,,9615.0,,,,50588
7338,,Cercopithecidae,Area under curve was determine after peroral administration at 10 mpk in Rhesus,U,A,5668,,,9527.0,,,,22224
7339,,Cercopithecidae,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,,,9527.0,,Plasma,,22224
7340,,Cercopithecidae,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,,,9527.0,,Plasma,,22224
7341,,Macaca fascicularis,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,U,A,4256,In vivo,,9541.0,,,,22224
7342,,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,U,A,4256,In vivo,,9541.0,,,,22224
7343,,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,U,A,4256,In vivo,,9541.0,,,,22224
7344,,Rattus norvegicus,Oral Bioavailability in rat,U,A,4256,In vivo,,10116.0,,,,22224
7345,,Cercopithecidae,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,A,1916,,,9527.0,,,,22224
7346,,Cercopithecidae,Area under curve value in monkey at a dose of 5 mg/kg,U,A,5302,,,9527.0,,,,22224
7347,,Cercopithecidae,Area under curve was determined in monkey after a 3 mg/kg of oral dose,U,A,4257,,,9527.0,,,,22224
7348,,Cercopithecidae,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,U,A,5355,,,9527.0,,,,22224
7349,,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,U,A,5355,,,9527.0,,,,22224
7350,,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,U,A,5355,,,9527.0,,,,22224
7351,,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,U,A,6078,,,9527.0,,,,22224
7352,,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,U,A,6078,,,9527.0,,,,22224
7353,,Cercopithecidae,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,U,A,6062,,,9527.0,,,,22224
7354,,Cercopithecidae,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,A,2661,,,9527.0,,,,22224
7355,,Cercopithecidae,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,A,2661,,,9527.0,,,,22224
7356,,Cercopithecidae,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,U,A,5394,,,9527.0,,,,22224
7357,,Cercopithecidae,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,U,A,4397,,,9527.0,,,,22224
7358,,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,U,A,17509,,,9527.0,,,,22224
7359,,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,U,A,17509,,,9527.0,,,,22224
7360,,Cercopithecidae,Oral AUCN in monkey (dosed at 0.5 mpk iv ),U,A,6641,In vivo,,9527.0,,,,22224
7361,,Cercopithecidae,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),U,A,5355,,,9527.0,,,,22224
7362,,Cercopithecidae,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,In vivo,,9527.0,,,,22224
7363,,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,A,3443,In vivo,,9527.0,,,,22224
7364,,Cercopithecidae,Binding towards monkey plasma protein at 10 uM,U,A,17409,,,9527.0,,,,22224
7365,,Cercopithecidae,Binding towards monkey plasma protein at 100 uM,U,A,17409,,,9527.0,,,,22224
7366,,Cercopithecidae,Apparent bioavailability in squirrel monkey was determined,U,A,1052,In vivo,,9527.0,,,,22224
7367,,Cercopithecidae,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,U,A,13501,In vivo,,9527.0,,,,22224
7368,,monkey,Bioavailability in monkey (dose 2 mg/kg),U,A,17509,In vivo,,9443.0,,,,22224
7369,,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,U,A,5394,In vivo,,9527.0,,,,22224
7370,,Cercopithecidae,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,A,2661,In vivo,,9527.0,,,,22224
7371,,monkey,Bioavailability in monkey (i.d. dosing),U,A,11219,In vivo,,9443.0,,,,22224
7372,,Cercopithecidae,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,U,A,3045,In vivo,,9527.0,,,,22224
7373,,Cercopithecidae,Clearance of the drug was measured in cynomolgus,U,A,17796,,,9527.0,,,,22224
7374,,Cercopithecidae,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,U,A,1399,In vivo,,9527.0,,,,22224
7375,,Cercopithecidae,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,A,2661,In vivo,,9527.0,,,,22224
7376,,Macaca mulatta,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,A,5005,In vivo,,9544.0,,Plasma,,22224
7377,,Cercopithecidae,Plasma clearance in rhesus monkey was determined,U,A,17267,In vivo,,9527.0,,,,22224
7378,,Cercopithecidae,Plasma clearance in monkey after administration of 1 mg/kg iv,U,A,6535,In vivo,,9527.0,,,,22224
7379,,Cercopithecidae,Plasma clearance in cynomolgus monkey,U,A,5922,In vivo,,9527.0,,,,22224
7380,,Cercopithecidae,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,U,A,6221,In vivo,,9527.0,,,,22224
7381,,Cercopithecidae,Plasma clearance after peroral administration at 10 mpk in Rhesus,U,A,5668,In vivo,,9527.0,,,,22224
7382,,Cercopithecidae,The total clearance was determined after intravenous administration in cynomolgus monkeys,U,A,5355,In vivo,,9527.0,,,,22224
7383,,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,U,A,5355,In vivo,,9527.0,,,,22224
7384,,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,U,A,5355,In vivo,,9527.0,,,,22224
7385,,Cercopithecidae,Tested for Clearance upon iv administration to african green monkey,U,A,4578,In vivo,,9527.0,,,,22224
7386,,Cercopithecidae,Clearance in monkey,U,A,17592,In vivo,,9527.0,,,,22224
7387,,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,A,6641,In vivo,,9615.0,,,,50588
7388,,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,A,6642,In vivo,,9615.0,,,,50588
7389,,Canis lupus familiaris,Half life was evaluated after intravenous administration to dogs,N,A,16367,In vivo,,9615.0,,,,50588
7390,,Canis lupus familiaris,Half life was evaluated in dog,N,A,5472,,,9615.0,,,,50588
7391,,Canis lupus familiaris,Half life was evaluated in dog,N,A,5474,,,9615.0,,,,50588
7392,,Canis lupus familiaris,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,A,5654,In vivo,,9615.0,,,,50588
7393,,Canis lupus familiaris,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),N,A,6227,In vivo,,9615.0,,,,50588
7394,,Canis lupus familiaris,Half life period after intravenous administration in dog,N,A,6227,In vivo,,9615.0,,,,50588
7395,,Canis lupus familiaris,Half life period after oral administration (2.5 mg/kg) in dog was determined,N,A,6221,In vivo,,9615.0,,,,50588
7396,,Canis lupus familiaris,Half life period at a dose of 1 uM/kg in dog was determined,N,A,4527,,,9615.0,,,,50588
7397,,Canis lupus familiaris,Half life period was determine after peroral administration at 10 mpk in dog,N,A,5668,In vivo,,9615.0,,,,50588
7398,,Canis lupus familiaris,Half life period was determine after peroral administration at 5 mpk in dog,N,A,5668,In vivo,,9615.0,,,,50588
7399,,Canis lupus familiaris,Half life period was determined,N,A,3854,,,9615.0,,,,50588
7400,,Canis lupus familiaris,Half life period was determined,N,A,5505,,,9615.0,,,,50588
7401,,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 6 mg/kg,N,A,6251,In vivo,,9615.0,,,,50588
7402,,Canis lupus familiaris,Half life period was evaluated in dog,N,A,1918,,,9615.0,,,,50588
7403,,Canis lupus familiaris,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,A,5546,In vivo,,9615.0,,,,50588
7404,,Canis lupus familiaris,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),N,A,4809,In vivo,,9615.0,,,,50588
7405,,Canis lupus familiaris,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,N,A,6215,In vivo,,9615.0,,,,50588
7406,,Canis lupus familiaris,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,N,A,4527,In vivo,,9615.0,,,,50588
7407,,Canis lupus familiaris,Half-life after oral dose of compound at 3 mg/kg in dogs,N,A,17594,In vivo,,9615.0,,,,50588
7408,,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,N,A,17839,In vivo,,9615.0,,,,50588
7409,,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,N,A,17839,In vivo,,9615.0,,,,50588
7410,,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,N,A,17839,In vivo,,9615.0,,,,50588
7411,,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 1 mg/kg,N,A,17839,In vivo,,9615.0,,,,50588
7412,,Canis lupus familiaris,Half-life of compound in plasma of dog was determined,N,A,5210,,,9615.0,,Plasma,,50588
7413,,Canis lupus familiaris,Half-life of compound was determined in dogs,N,A,5210,,,9615.0,,,,50588
7414,,Canis lupus familiaris,Half-life after administration of 4 mg/Kg oral dose in dog,N,A,2959,In vivo,,9615.0,,,,50588
7415,,Canis lupus familiaris,Half-life after intravenous administration of 1 mg/kg/h in dog,N,A,4137,In vivo,,9615.0,,,,50588
7416,,Canis lupus familiaris,Half-life in Dog,N,A,5064,,,9615.0,,,,50588
7417,,Canis lupus familiaris,Half-life in Dog,N,A,5147,,,9615.0,,,,50588
7418,,Canis lupus familiaris,Half-life in dog,N,A,5145,,,9615.0,,,,50588
7419,,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg,N,A,6123,In vivo,,9615.0,,,,50588
7420,,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,N,A,6123,In vivo,,9615.0,,,,50588
7421,,Canis lupus familiaris,Half-life in dogs,N,A,4333,,,9615.0,,,,50588
7422,,Canis lupus familiaris,Half-life in dogs; ND indicates not determined,N,A,4333,,,9615.0,,,,50588
7423,,Canis lupus familiaris,Half-life in plasma of dog,N,A,12500,,,9615.0,,Plasma,,50588
7424,,Canis lupus familiaris,Half-life in plasma of dog at dose of 3-10 mgkg,N,A,12500,,,9615.0,,Plasma,,50588
7425,,Canis lupus familiaris,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,N,A,6005,In vivo,,9615.0,,,,50588
7426,,Canis lupus familiaris,Half-life was measured in dog after an iv dose of 1 mg/kg,N,A,6062,In vivo,,9615.0,,,,50588
7427,,Canis lupus familiaris,Half-life was measured in dogs after an oral dose of 10 uM/kg,N,A,17650,In vivo,,9615.0,,,,50588
7428,,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,N,A,5530,In vivo,,9615.0,,,,50588
7429,,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,N,A,5530,In vivo,,9615.0,,,,50588
7430,,Canis lupus familiaris,Half-life of the compound after 0.3 mg/kg po administration in dog,N,A,5600,In vivo,,9615.0,,,,50588
7431,,Canis lupus familiaris,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,N,A,6039,In vivo,,9615.0,,,,50588
7432,,Canis lupus familiaris,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,N,A,6039,In vivo,,9615.0,,,,50588
7433,,Canis lupus familiaris,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,N,A,6039,In vivo,,9615.0,,,,50588
7434,,Canis lupus familiaris,t1/2 in dog,N,A,6227,,,9615.0,,,,50588
7435,,Canis lupus familiaris,Half-life period measured in dogs,N,A,14541,,,9615.0,,,,50588
7436,,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,A,4521,In vivo,,9615.0,,,,50588
7437,,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,A,4521,In vivo,,9615.0,,,,50588
7438,,Canis lupus familiaris,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,A,6679,In vivo,,9615.0,,,,50588
7439,,Canis lupus familiaris,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",N,A,1116,In vitro,,9615.0,,Plasma,,50588
7440,,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog,N,A,5444,In vivo,,9615.0,,,,50588
7441,,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,N,A,5444,In vivo,,9615.0,,,,50588
7442,,Canis lupus familiaris,Longer half-life in dog (i.v.) at 0.5 mpk,N,A,17853,In vivo,,9615.0,,,,50588
7443,,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),N,A,4353,In vivo,,9615.0,,,,50588
7444,,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,A,16452,In vivo,,9615.0,,,,50588
7445,,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,A,16452,In vivo,,9615.0,,,,50588
7446,,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),N,A,16452,In vivo,,9615.0,,,,50588
7447,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,A,10107,In vivo,,10090.0,,Lung,,50594
7448,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,Lung,,50594
7449,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,Lung,,50594
7450,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,Lung,,50594
7451,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,A,10107,In vivo,,10090.0,,Lung,,50594
7452,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,Lung,,50594
7453,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,Muscle tissue,,50594
7454,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,A,10107,In vivo,,10090.0,,Muscle tissue,,50594
7455,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,Muscle tissue,,50594
7456,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,Muscle tissue,,50594
7457,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,Muscle tissue,,50594
7458,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,A,10107,In vivo,,10090.0,,Muscle tissue,,50594
7459,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,Muscle tissue,,50594
7460,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,Zone of skin,,50594
7461,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,A,10107,In vivo,,10090.0,,Zone of skin,,50594
7462,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,Zone of skin,,50594
7463,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,Zone of skin,,50594
7464,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,Zone of skin,,50594
7465,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,A,10107,In vivo,,10090.0,,Zone of skin,,50594
7466,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,Zone of skin,,50594
7467,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,Spleen,,50594
7468,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,A,10107,In vivo,,10090.0,,Spleen,,50594
7469,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,Spleen,,50594
7470,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,Spleen,,50594
7471,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,Spleen,,50594
7472,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,A,10107,In vivo,,10090.0,,Spleen,,50594
7473,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,Spleen,,50594
7474,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,A,10107,In vivo,,10090.0,,Stomach,,50594
7475,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,A,10107,In vivo,,10090.0,,Stomach,,50594
7476,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,A,10107,In vivo,,10090.0,,Stomach,,50594
7477,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,A,10107,In vivo,,10090.0,,Stomach,,50594
7478,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,A,10107,In vivo,,10090.0,,Stomach,,50594
7479,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,A,10107,In vivo,,10090.0,,Stomach,,50594
7480,,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,A,10107,In vivo,,10090.0,,Stomach,,50594
7481,,Rattus norvegicus,Oral bioavailability in rat,N,A,4689,In vivo,,10116.0,,,,50597
7482,,Rattus norvegicus,Tested for the bioavailability in rat,N,A,4950,In vivo,,10116.0,,,,50597
7483,,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,A,5328,In vivo,,10116.0,,,,50597
7484,,Rattus norvegicus,Bioavailability in rat,N,A,406,In vivo,,10116.0,,,,50597
7485,,Rattus norvegicus,Bioavailability in rat,N,A,12500,In vivo,,10116.0,,,,50597
7486,,Rattus norvegicus,Bioavailability in rat (dose 3-10 mg/kg),N,A,12500,In vivo,,10116.0,,,,50597
7487,,Rattus norvegicus,Bioavailability in rat,N,A,5247,In vivo,,10116.0,,,,50597
7488,,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,A,4186,In vivo,,10116.0,,Plasma,,50597
7489,,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,N,A,4186,In vivo,,10116.0,,Plasma,,50597
7490,,Rattus norvegicus,Half life after oral administration was determined in rats at 6 mg/kg,N,A,6647,In vivo,,10116.0,,,,50597
7491,,Rattus norvegicus,Half life was determined,N,A,6484,,,10116.0,,,,50597
7492,,Rattus norvegicus,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,N,A,3249,In vivo,,10116.0,,,,50597
7493,,Rattus norvegicus,Plasma half life in rat at oral dose 2.8 mg/mk body weight,N,A,6281,In vivo,,10116.0,,Plasma,,50597
7494,,Rattus norvegicus,Half life in rats,N,A,3307,,,10116.0,,,,50597
7495,,Rattus norvegicus,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,N,A,12058,In vivo,,10116.0,,Blood,,50597
7496,,Rattus norvegicus,Hill coefficient of the compound,N,A,8833,,,10116.0,,,,50597
7497,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,N,A,3193,,,10116.0,,Blood,,50597
7498,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,N,A,3193,,,10116.0,,Blood,,50597
7499,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,N,A,3193,,,10116.0,,Blood,,50597
7500,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,N,A,3193,,,10116.0,,Blood,,50597
7501,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,N,A,3193,,,10116.0,,Blood,,50597
7502,,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,N,A,3193,,,10116.0,,Blood,,50597
7503,,Rattus norvegicus,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",N,A,3193,,,10116.0,,Blood,,50597
7504,,Rattus norvegicus,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,N,A,5960,,,10116.0,,,,50597
7505,,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,N,A,13950,In vivo,,10116.0,,Brain,,50597
7506,,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,N,A,13950,In vivo,,10116.0,,Brain,,50597
7507,,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,N,A,13950,In vivo,,10116.0,,Brain,,50597
7508,,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,N,A,13950,In vivo,,10116.0,,Brain,,50597
7509,,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,N,A,13950,In vivo,,10116.0,,Brain,,50597
7510,,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,N,A,13950,In vivo,,10116.0,,Thyroid gland,,50597
7511,,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,N,A,13950,In vivo,,10116.0,,Thyroid gland,,50597
7512,,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,N,A,13950,In vivo,,10116.0,,Thyroid gland,,50597
7513,,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,N,A,13950,In vivo,,10116.0,,Thyroid gland,,50597
7514,,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,N,A,13950,In vivo,,10116.0,,Thyroid gland,,50597
7515,,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,A,9866,In vivo,,10116.0,,Blood,,50597
7516,,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,N,A,9866,In vivo,,10116.0,,Blood,,50597
7517,,Rattus norvegicus,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,N,A,9866,In vivo,,10116.0,,Blood,,50597
7518,,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,A,9866,In vivo,,10116.0,,Bone,,50597
7519,,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,N,A,9866,In vivo,,10116.0,,Bone,,50597
7520,,Rattus norvegicus,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,N,A,9866,In vivo,,10116.0,,Bone,,50597
7521,,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,A,9866,In vivo,,10116.0,,Heart,,50597
7522,,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,N,A,9866,In vivo,,10116.0,,Heart,,50597
7523,,Rattus norvegicus,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,N,A,9866,In vivo,,10116.0,,Heart,,50597
